{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyNc94HfH9DtMOxywqabS+yn",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/SanthoshiRavi/Healthcare-Text-Processing-/blob/main/Healthcare1.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "4cxDQn7Im0XA",
        "outputId": "8ea7fe49-354d-4000-ff10-097a9abf9256"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (2.31.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests) (3.7)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests) (2024.2.2)\n"
          ]
        }
      ],
      "source": [
        "pip install requests"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "pip install beautifulsoup4"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "f1AwLaREnQW8",
        "outputId": "835c4966-3b16-41b0-88ad-10aaf9227340"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: beautifulsoup4 in /usr/local/lib/python3.10/dist-packages (4.12.3)\n",
            "Requirement already satisfied: soupsieve>1.2 in /usr/local/lib/python3.10/dist-packages (from beautifulsoup4) (2.5)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "pip install nltk"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Ykol4ABFnYDQ",
        "outputId": "7ac60ad6-5030-44b9-a1b2-b14b72b5fba4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: nltk in /usr/local/lib/python3.10/dist-packages (3.8.1)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.10/dist-packages (from nltk) (8.1.7)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.10/dist-packages (from nltk) (1.4.2)\n",
            "Requirement already satisfied: regex>=2021.8.3 in /usr/local/lib/python3.10/dist-packages (from nltk) (2023.12.25)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from nltk) (4.66.4)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import requests\n",
        "\n",
        "def fetch_pubmed_article_ids(query, api_key, max_results=50):\n",
        "    url = f'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term={query}&retmax={max_results}&api_key={api_key}&retmode=json'\n",
        "    response = requests.get(url)\n",
        "    if response.status_code == 200:\n",
        "        data = response.json()\n",
        "        ids = data['esearchresult']['idlist']\n",
        "        return ids\n",
        "    else:\n",
        "        print(f\"Failed to fetch data: {response.status_code}\")\n",
        "        return None\n",
        "\n",
        "# Your API key\n",
        "api_key = '14b3330cab5a4aabaefc418267dd19492909'\n",
        "# Query term\n",
        "query = 'diabetes treatment'\n",
        "# Fetch article IDs\n",
        "article_ids = fetch_pubmed_article_ids(query, api_key)\n",
        "print(article_ids)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "h10DV-r1nd4j",
        "outputId": "d4ad7152-ac08-4d94-b894-bb3ac05e2f83"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "['38760852', '38760705', '38760678', '38760661', '38760632', '38760595', '38760456', '38760452', '38760427', '38760383', '38760126', '38760125', '38760053', '38760035', '38760033', '38759989', '38759983', '38759874', '38759763', '38759722', '38759707', '38759658', '38759515', '38759430', '38759418', '38759318', '38759315', '38759226', '38759099', '38758937', '38758936', '38758907', '38758866', '38758863', '38758855', '38758848', '38758847', '38758689', '38758687', '38758679', '38758678', '38758675', '38758674', '38758639', '38758517', '38758435', '38758423', '38758248', '38758212', '38758211']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def fetch_pubmed_article_details(article_ids, api_key):\n",
        "    ids = ','.join(article_ids)\n",
        "    url = f'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id={ids}&api_key={api_key}&retmode=xml'\n",
        "    response = requests.get(url)\n",
        "    if response.status_code == 200:\n",
        "        return response.text\n",
        "    else:\n",
        "        print(f\"Failed to fetch data: {response.status_code}\")\n",
        "        return None\n",
        "\n",
        "article_details_xml = fetch_pubmed_article_details(article_ids, api_key)\n",
        "print(article_details_xml)  # This will be in XML format\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ZGTmiVsIn5iM",
        "outputId": "1c209d5f-6028-4285-8f97-d8725a03d6d5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2024//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760852</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Print\">1758-5996</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Diabetology &amp; metabolic syndrome</Title><ISOAbbreviation>Diabetol Metab Syndr</ISOAbbreviation></Journal><ArticleTitle>Response to semaglutide of non-drinker subjects with type 2 diabetes.</ArticleTitle><Pagination><StartPage>103</StartPage><MedlinePgn>103</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s13098-024-01344-6</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) displays a worse prognosis in subjects with type 2 diabetes (T2D); effective treatments are, so far, scanty. Semaglutide showed efficacy in improving steatohepatitis. We longitudinally observed a MASLD cohort of T2D subjects starting semaglutide, to detect an improvement of non-invasive surrogates of steatosis and fibro-inflammatory liver involvement, evaluating the role of mild alcohol consumption.</AbstractText><AbstractText Label=\"PATIENTS AND METHODS\" NlmCategory=\"METHODS\">In 62 overweight/obese T2D subjects with MASLD (36 non-drinker and 26 mild alcohol consumers), anthropometric, bio-humoral and transient elastography (TE) data were collected before (T0) and after an average time of 6.4 month (T1) from injective semaglutide prescription. Circulating levels of hormones (GIP, GLP-1, glucagon, insulin) and inflammatory markers (TNF&#x3b1;, MCP-1, IL-18, IL-10) were measured. Steatotic and necro-inflammatory liver involvement was evaluated with FibroScan controlled attenuation parameter (CAP) and liver stiffness (LS), respectively.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Significant (p&#x2009;&lt;&#x2009;0.006) T0-T1 reductions of BMI, waist circumference, fasting glucose, and HbA1c were observed. AST (-10&#x2009;&#xb1;&#x2009;3 IU/L), ALT (-18&#x2009;&#xb1;&#x2009;5 IU/L), GGT (-33&#x2009;&#xb1;&#x2009;15 IU/L), CAP (-25&#x2009;&#xb1;&#x2009;8 dB/m) and LS (-0.8&#x2009;&#xb1;&#x2009;0.4&#xa0;kPa) were reduced, too. GLP-1 increased (+&#x2009;95.9 pM, p&#x2009;&lt;&#x2009;0.0001) and IL-18 was reduced (-46.6 pg/ml, p&#x2009;=&#x2009;0.0002). After adjustment for confounders, CAP improving was only related to GLP-1 increase (&#xdf;=-0.437, p&#x2009;=&#x2009;0.0122). Mild alcohol intake did not influence these relations.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Use of semaglutide in subjects with T2D and MASLD is associated with a significant decline of liver steatosis and necroinflammation proxies; mild alcohol assumption did not exert any influence. An independent effect of GLP-1 raise was observed on reduction of steatosis, irrespective of alcohol consumption.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Petralli</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Via Roma 67, Pisa, I-56126, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Raggi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Via Roma 67, Pisa, I-56126, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zoppo</LastName><ForeName>Alice Del</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Via Roma 67, Pisa, I-56126, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rovera</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Via Roma 67, Pisa, I-56126, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Salvati</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hepatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Brunetto</LastName><ForeName>Maurizia Rossana</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Solini</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgical Medical, Molecular and Critical Area Pathology, University of Pisa, Via Roma 67, Pisa, I-56126, Italy. anna.solini@unipi.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><GrantID>Fondi Ateneo 2023</GrantID><Agency>University of Pisa</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diabetol Metab Syndr</MedlineTA><NlmUniqueID>101488958</NlmUniqueID><ISSNLinking>1758-5996</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Interleukin-18</Keyword><Keyword MajorTopicYN=\"N\">Liver stiffness</Keyword><Keyword MajorTopicYN=\"N\">Non-drinker</Keyword><Keyword MajorTopicYN=\"N\">Semaglutide</Keyword><Keyword MajorTopicYN=\"N\">Type 2 diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760852</ArticleId><ArticleId IdType=\"doi\">10.1186/s13098-024-01344-6</ArticleId><ArticleId IdType=\"pii\">10.1186/s13098-024-01344-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. Estimating Global Prevalence of Metabolic Dysfunction-Associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20:e573&#x2013;82.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cgh.2021.02.030</ArticleId><ArticleId IdType=\"pubmed\">33618024</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf3;zes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, et al. LITMUS investigators. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:704&#x2013;13.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2468-1253(23)00141-3</ArticleId><ArticleId IdType=\"pubmed\">37290471</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/hep.29302</ArticleId><ArticleId IdType=\"pubmed\">28586172</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan Controlled Attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717&#x2013;30.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1053/j.gastro.2019.01.042</ArticleId><ArticleId IdType=\"pubmed\">30689971</ArticleId></ArticleIdList></Reference><Reference><Citation>European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388&#x2013;402.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jhep.2015.11.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: alcoholic liver disease. Am J Gastroenterol. 2018;113:175&#x2013;94.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ajg.2017.469</ArticleId><ArticleId IdType=\"pubmed\">29336434</ArticleId><ArticleId IdType=\"pmc\">6524956</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Chen J, Li X, Fan R, Arsenault B, Gill D, et al. Lifestyle and metabolic factors for nonalcoholic fatty liver disease: mendelian randomization study. Eur J Epidemiol. 2022;37:723&#x2013;33.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10654-022-00868-3</ArticleId><ArticleId IdType=\"pubmed\">35488966</ArticleId><ArticleId IdType=\"pmc\">9329390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology. 2017;65:2090&#x2013;99.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/hep.29055</ArticleId><ArticleId IdType=\"pubmed\">28100008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972&#x2013;78.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/hep.23527</ArticleId><ArticleId IdType=\"pubmed\">20209604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin Gastroenterol Hepatol. 2018;16:1511&#x2013;20.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cgh.2018.01.026</ArticleId><ArticleId IdType=\"pubmed\">29378307</ArticleId><ArticleId IdType=\"pmc\">6098737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagstr&#xf6;m H, Nasr P, Ekstedt M, Kechagias S, &#xd6;nnerhag K, Nilsson E, et al. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2017;52:159&#x2013;65.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/00365521.2016.1239759</ArticleId><ArticleId IdType=\"pubmed\">27650916</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon HK, Greenson JK, Conjeevaram HS. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int. 2014;34:129&#x2013;35.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/liv.12230</ArticleId><ArticleId IdType=\"pubmed\">23809459</ArticleId></ArticleIdList></Reference><Reference><Citation>Sookoian S, Castano GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut. 2014;63:530&#x2013;32.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/gutjnl-2013-305718</ArticleId><ArticleId IdType=\"pubmed\">24026352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaazouee MS, Hamdallah A, Helmy SK, Hasabo EA, Sayed AK, Gbreel MI, et al. Semaglutide for the treatment of type 2 diabetes Mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes Metab Syndr. 2022;16:102511.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.dsx.2022.102511</ArticleId><ArticleId IdType=\"pubmed\">35623229</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J&#xf3;dar E, Leiter LA, et al. SUSTAIN-6 investigators. Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834&#x2013;44.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1607141</ArticleId><ArticleId IdType=\"pubmed\">27633186</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J, Song L. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. BMC Endocr Disord. 2022;22:125.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12902-022-01036-0</ArticleId><ArticleId IdType=\"pubmed\">35546664</ArticleId><ArticleId IdType=\"pmc\">9097124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay S, Das S, Samajdar SS, Joshi SR. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17:102849.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.dsx.2023.102849</ArticleId><ArticleId IdType=\"pubmed\">37717295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalic AJ, Gozar M, Da BL, Bernstein D, Satapathy SK. Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol. 2023;35:102&#x2013;11.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MEG.0000000000002463</ArticleId><ArticleId IdType=\"pubmed\">36468574</ArticleId></ArticleIdList></Reference><Reference><Citation>Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj&#xe6;r MS, Krarup N, et al. NN9931-4492 investigators. Semaglutide 2&#xb7;4&#xa0;mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511&#x2013;22.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2468-1253(23)00068-7</ArticleId><ArticleId IdType=\"pubmed\">36934740</ArticleId><ArticleId IdType=\"pmc\">10792518</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol Consumption&#x2013;II. Addiction. 1993;88:791&#x2013;804.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1360-0443.1993.tb02093.x</ArticleId><ArticleId IdType=\"pubmed\">8329970</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de L&#xe9;dinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022&#x2013;30.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jhep.2016.12.022</ArticleId><ArticleId IdType=\"pubmed\">28039099</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallet V, Parlati L, Martinino A, Scarano Pereira JP, Jimenez CN, Sakka M, et al. Demosthenes research group. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. J Hepatol. 2022;76:265&#x2013;74.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jhep.2021.09.030</ArticleId><ArticleId IdType=\"pubmed\">34606913</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc5;berg F, Helenius-Hietala J, Puukka P, F&#xe4;rkkil&#xe4; M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology. 2018;67:2141&#x2013;49.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/hep.29631</ArticleId><ArticleId IdType=\"pubmed\">29164643</ArticleId></ArticleIdList></Reference><Reference><Citation>Amonker S, Houshmand A, Hinkson A, Rowe I, Parker R. Prevalence of alcohol-associated liver disease: a systematic review and meta-analysis. Hepatol Commun. 2023;7:e0133.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/HC9.0000000000000133</ArticleId><ArticleId IdType=\"pubmed\">37102767</ArticleId><ArticleId IdType=\"pmc\">10146123</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodoreson MD, Aithal GP, Allison M, Brahmania M, Forrest E, Hagstr&#xf6;m H, et al. Extra-hepatic morbidity and mortality in alcohol-related liver disease: systematic review and meta-analysis. Liver Int. 2023;43:763&#x2013;72.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/liv.15526</ArticleId><ArticleId IdType=\"pubmed\">36694995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta G, Macdonald S, Cronberg A, Rosselli M, Khera-Butler T, Sumpter C, et al. Short-term abstinence from alcohol and changes in cardiovascular risk factors, liver function tests and cancer-related growth factors: a prospective observational study. BMJ Open. 2018;8:e020673.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bmjopen-2017-020673</ArticleId><ArticleId IdType=\"pubmed\">29730627</ArticleId><ArticleId IdType=\"pmc\">5942469</ArticleId></ArticleIdList></Reference><Reference><Citation>Aran&#xe4;s C, Edvardsson CE, Shevchouk OT, Zhang Q, Witley S, Blid Sk&#xf6;ldheden S, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023;93:104642.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ebiom.2023.104642</ArticleId><ArticleId IdType=\"pubmed\">37295046</ArticleId><ArticleId IdType=\"pmc\">10363436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8:12.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1172/jci.insight.170671</ArticleId></ArticleIdList></Reference><Reference><Citation>Quddos F, Hubshman Z, Tegge A, Sane D, Marti E, Kablinger AS, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023;13:20998.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-023-48267-2</ArticleId><ArticleId IdType=\"pubmed\">38017205</ArticleId><ArticleId IdType=\"pmc\">10684505</ArticleId></ArticleIdList></Reference><Reference><Citation>Patti AM, Giglio RV, Allotta A, Bruno A, Di Bella T, Pantea Stoian A, et al. Effect of Semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes. Biomedicines. 2023;11:1362.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/biomedicines11051362</ArticleId><ArticleId IdType=\"pubmed\">37239033</ArticleId><ArticleId IdType=\"pmc\">10216597</ArticleId></ArticleIdList></Reference><Reference><Citation>Pose E, Pera G, Tor&#xe1;n P, Gratac&#xf3;s-Gin&#xe8;s J, Avitabile E, Exp&#xf3;sito C, et al. Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: a population-based study. Liver Int. 2021;41:1556&#x2013;64.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/liv.14830</ArticleId><ArticleId IdType=\"pubmed\">33595176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta D, Kumar M, Shivaprasad KS, Kumar A, Sharma M. Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: a meta-analysis. Diabetes Metab Syndr. 2022;16:102539.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.dsx.2022.102539</ArticleId><ArticleId IdType=\"pubmed\">35709586</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Liu Y, Zhao L, Zhou Y. Effect of 5:2 Fasting Diet on Liver Fat Content in patients with type 2 Diabetic with nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2022;20:459&#x2013;65.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1089/met.2022.0014</ArticleId><ArticleId IdType=\"pubmed\">35925752</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen MN, Skytte MJ, Samkani A, Carl MH, Weber P, Astrup A, et al. Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. Diabetologia. 2022;65:506&#x2013;17.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00125-021-05628-8</ArticleId><ArticleId IdType=\"pubmed\">34993571</ArticleId><ArticleId IdType=\"pmc\">8739348</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan X, Yang L, Wang S, Liu Y, Yue L, Chen S. Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression. Mol Cell Biochem. 2023; Jun 15. https://doi.org/10.1007/s11010-023-04784-2 .</Citation></Reference><Reference><Citation>Martins FF, Marinho TS, Cardoso LEM, Barbosa-da-Silva S, Souza-Mello V, Aguila MB, et al. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice. Cell Biochem Funct. 2022;40:903&#x2013;13.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cbf.3751</ArticleId><ArticleId IdType=\"pubmed\">36169111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontes-da-Silva RM, de Souza Marinho T, de Macedo Cardoso LE, Mandarim-de-Lacerda CA, Aguila MB. Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist. Int J Obes (Lond). 2022;46:21&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41366-021-00955-7</ArticleId><ArticleId IdType=\"pubmed\">34465857</ArticleId></ArticleIdList></Reference><Reference><Citation>Rella S, Onyiah J, Baker C, Singh V, Her A, Rasouli N. Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2023;14:20420188231207348.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/20420188231207348</ArticleId><ArticleId IdType=\"pubmed\">37916028</ArticleId><ArticleId IdType=\"pmc\">10617296</ArticleId></ArticleIdList></Reference><Reference><Citation>Somm E, Jornayvaz FR. Interleukin-18 in metabolism: From mice physiology to human diseases. Front Endocrinol (Lausanne). 2022; 13:971745. Erratum in: Front Endocrinol (Lausanne). 2023; 14:1175361.</Citation></Reference><Reference><Citation>Litwiniuk A, Bik W, Kalisz M, Baranowska-Bik A. Inflammasome NLRP3 potentially links obesity-Associated Low-Grade systemic inflammation and Insulin Resistance with Alzheimer&#x2019;s Disease. Int J Mol Sci. 2021;22:5603.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijms22115603</ArticleId><ArticleId IdType=\"pubmed\">34070553</ArticleId><ArticleId IdType=\"pmc\">8198882</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M, Adiponectin. TNF-&#x3b1; and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. 2016;86:100&#x2013;09.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cyto.2016.06.028</ArticleId><ArticleId IdType=\"pubmed\">27498215</ArticleId></ArticleIdList></Reference><Reference><Citation>Colak Y, Hasan B, Erkalma B, Tandon K, Zervos X, Menzo EL, et al. Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target. Clin Res Hepatol Gastroenterol. 2021;45:101710.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.clinre.2021.101710</ArticleId><ArticleId IdType=\"pubmed\">33930586</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760705</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1471-2180</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>BMC microbiology</Title><ISOAbbreviation>BMC Microbiol</ISOAbbreviation></Journal><ArticleTitle>Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia.</ArticleTitle><Pagination><StartPage>169</StartPage><MedlinePgn>169</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s12866-024-03329-x</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Polycystic ovary syndrome (PCOS) is an endocrinopathy in childbearing-age females which can cause many complications, such as diabetes, obesity, and dyslipidemia. The metabolic disorders in patients with PCOS were linked to gut microbial dysbiosis. However, the correlation between the gut microbial community and dyslipidemia in PCOS remains unillustrated. Our study elucidated the different gut microbiota in patients with PCOS and dyslipidemia (PCOS.D) compared to those with only PCOS and healthy women.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">In total, 18 patients with PCOS, 16 healthy females, and 18 patients with PCOS.D were enrolled. The 16&#xa0;S rRNA sequencing in V3-V4 region was utilized for identifying the gut microbiota, which analyzes species annotation, community diversity, and community functions. Our results showed that the &#x3b2; diversity of gut microbiota did not differ significantly among the three groups. Regarding gut microbiota dysbiosis, patients with PCOS showed a decreased abundance of Proteobacteria, and patients with PCOS.D showed an increased abundance of Bacteroidota compared to other groups. With respect to the gut microbial imbalance at genus level, the PCOS.D group showed a higher abundance of Clostridium_sensu_stricto_1 compared to other two groups. Furthermore, the abundances of Faecalibacterium and Holdemanella were lower in the PCOS.D than those in the PCOS group. Several genera, including Faecalibacterium and Holdemanella, were negatively correlated with the lipid profiles. Pseudomonas was negatively correlated with luteinizing hormone levels. Using PICRUSt analysis, the gut microbiota community functions suggested that certain metabolic pathways (e.g., amino acids, glycolysis, and lipid) were altered in PCOS.D patients as compared to those in PCOS patients.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">The gut microbiota characterizations in patients with PCOS.D differ from those in patients with PCOS and controls, and those might also be related to clinical parameters. This may have the potential to become an alternative therapy to regulate the clinical lipid levels of patients with PCOS in the future.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Yang</LastName><ForeName>Tianjin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Li</LastName><ForeName>Guanjian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Anhui Medical University, Hefei, 230032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Population Health Across Life Cycle, Anhui Medical University, Hefei, 230032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anhui Province Key Laboratory of Reproductive Health and Genetics, Hefei, 230032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, 230032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Xu</LastName><ForeName>Yuping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Anhui Medical University, Hefei, 230032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Population Health Across Life Cycle, Anhui Medical University, Hefei, 230032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anhui Province Key Laboratory of Reproductive Health and Genetics, Hefei, 230032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, 230032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>He</LastName><ForeName>Xiaojin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Anhui Medical University, Hefei, 230032, China. hxj0117@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reproductive Medicine Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. hxj0117@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Song</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China. songbing@ahmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Anhui Medical University, Hefei, 230032, China. songbing@ahmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Population Health Across Life Cycle, Anhui Medical University, Hefei, 230032, China. songbing@ahmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anhui Province Key Laboratory of Reproductive Health and Genetics, Hefei, 230032, China. songbing@ahmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, 230032, China. songbing@ahmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cao</LastName><ForeName>Yunxia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China. caoyunxia6@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Anhui Medical University, Hefei, 230032, China. caoyunxia6@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Population Health Across Life Cycle, Anhui Medical University, Hefei, 230032, China. caoyunxia6@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anhui Province Key Laboratory of Reproductive Health and Genetics, Hefei, 230032, China. caoyunxia6@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, 230032, China. caoyunxia6@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><GrantID>No. 82201777</GrantID><Agency>the National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Microbiol</MedlineTA><NlmUniqueID>100966981</NlmUniqueID><ISSNLinking>1471-2180</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011085\" MajorTopicYN=\"Y\">Polycystic Ovary Syndrome</DescriptorName><QualifierName UI=\"Q000382\" MajorTopicYN=\"N\">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000069196\" MajorTopicYN=\"Y\">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D050171\" MajorTopicYN=\"Y\">Dyslipidemias</DescriptorName><QualifierName UI=\"Q000382\" MajorTopicYN=\"N\">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D064806\" MajorTopicYN=\"Y\">Dysbiosis</DescriptorName><QualifierName UI=\"Q000382\" MajorTopicYN=\"N\">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D001419\" MajorTopicYN=\"Y\">Bacteria</DescriptorName><QualifierName UI=\"Q000145\" MajorTopicYN=\"N\">classification</QualifierName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName><QualifierName UI=\"Q000302\" MajorTopicYN=\"N\">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012336\" MajorTopicYN=\"Y\">RNA, Ribosomal, 16S</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D055815\" MajorTopicYN=\"N\">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005243\" MajorTopicYN=\"N\">Feces</DescriptorName><QualifierName UI=\"Q000382\" MajorTopicYN=\"N\">microbiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Dyslipidemia</Keyword><Keyword MajorTopicYN=\"N\">Gut microbiota</Keyword><Keyword MajorTopicYN=\"N\">Polycystic ovary syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760705</ArticleId><ArticleId IdType=\"doi\">10.1186/s12866-024-03329-x</ArticleId><ArticleId IdType=\"pii\">10.1186/s12866-024-03329-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, et al. Consensus on women&#x2019;s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28&#x2013;38.e25.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22153789</ArticleId><ArticleId IdType=\"doi\">10.1016/j.fertnstert.2011.09.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219&#x2013;31.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21263450</ArticleId><ArticleId IdType=\"doi\">10.1038/nrendo.2010.217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27233760</ArticleId><ArticleId IdType=\"doi\">10.1016/j.fertnstert.2016.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term health. Fertil Steril. 2018;110(5):794&#x2013;809.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30316414</ArticleId><ArticleId IdType=\"doi\">10.1016/j.fertnstert.2018.08.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Li M, Wang Y, Zeng Z, Xie Y, Liu G, Li J, Zhang B, Liang X, Wei L, et al. Overweight and high serum total cholesterol were risk factors for the outcome of IVF/ICSI cycles in PCOS patients and a PCOS-specific predictive model of live birth rate was established. J Endocrinol Invest. 2020;43(9):1221&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32221909</ArticleId><ArticleId IdType=\"doi\">10.1007/s40618-020-01209-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JL, Kar S, Vanky E, Morin-Papunen L, Piltonen T, Puurunen J, Tapanainen JS, Maciel GAR, Hayashida SAY, Soares JM, editors. Jr. : Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: a regional cross-sectional study. Am J Obstet Gynecol. 2017;217(2):189 e181-189 e188.</Citation></Reference><Reference><Citation>Jiang X, Lu X, Cai M, Liu Y, Guo Y. Impact of dyslipidemia on the cumulative pregnancy outcomes after first ovarian stimulation. Front Endocrinol (Lausanne). 2022;13:915424.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36017313</ArticleId><ArticleId IdType=\"doi\">10.3389/fendo.2022.915424</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Liu D, Song X, Qu J, Zheng X, Li J, Yang R, Yang S, Zhang X, Wang H, et al. Lipid metabolism was Associated with oocyte in vitro maturation in women with polycystic ovarian syndrome undergoing unstimulated natural cycle. Front Cell Dev Biol. 2021;9:719173.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34540838</ArticleId><ArticleId IdType=\"pmc\">8446356</ArticleId><ArticleId IdType=\"doi\">10.3389/fcell.2021.719173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes. 2007;56(9):2328&#x2013;38.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">17575085</ArticleId><ArticleId IdType=\"doi\">10.2337/db07-0056</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Si M, Tian T, Shi H, Huang N, Chi H, Yang R, Long X, Qiao J. Adiposity and lipid metabolism indicators mediate the adverse effect of glucose metabolism indicators on oogenesis and embryogenesis in PCOS women undergoing IVF/ICSI cycles. Eur J Med Res 2023:28(1).</Citation></Reference><Reference><Citation>Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716&#x2013;25.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29934437</ArticleId><ArticleId IdType=\"doi\">10.1136/gutjnl-2018-316723</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch SV, Pedersen O. The human intestinal microbiome in Health and Disease. N Engl J Med. 2016;375(24):2369&#x2013;79.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27974040</ArticleId><ArticleId IdType=\"doi\">10.1056/NEJMra1600266</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. 2022;71(5):1020&#x2013;32.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35105664</ArticleId><ArticleId IdType=\"doi\">10.1136/gutjnl-2021-326789</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55&#x2013;71.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32887946</ArticleId><ArticleId IdType=\"doi\">10.1038/s41579-020-0433-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Thackray VG. Sex, microbes, and polycystic ovary syndrome. Trends Endocrinol Metab. 2019;30(1):54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30503354</ArticleId><ArticleId IdType=\"doi\">10.1016/j.tem.2018.11.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R, Zhang C, Shi Y, Zhang F, Li L, Wang X, Ling Y, Fu H, Dong W, Shen J, et al. Dysbiosis of Gut Microbiota Associated with Clinical parameters in Polycystic Ovary Syndrome. Front Microbiol. 2017;8:324.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28293234</ArticleId><ArticleId IdType=\"pmc\">5328957</ArticleId></ArticleIdList></Reference><Reference><Citation>Insenser M, Murri M, Del Campo R, Martinez-Garcia MA, Fernandez-Duran E, Escobar-Morreale HF. Gut microbiota and the polycystic ovary syndrome: influence of sex, sex hormones, and obesity. J Clin Endocrinol Metab. 2018;103(7):2552&#x2013;62.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29897462</ArticleId><ArticleId IdType=\"doi\">10.1210/jc.2017-02799</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X, Yun C, Sun L, Xia J, Wu Q, Wang Y, Wang L, Zhang Y, Liang X, Wang L, et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019;25(8):1225&#x2013;33.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31332392</ArticleId><ArticleId IdType=\"pmc\">7376369</ArticleId><ArticleId IdType=\"doi\">10.1038/s41591-019-0509-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens JA, Brandsma E, Marczynska J, Imhann F, Weersma RK, et al. The gut Microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res. 2015;117(9):817&#x2013;24.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26358192</ArticleId><ArticleId IdType=\"pmc\">4596485</ArticleId><ArticleId IdType=\"doi\">10.1161/CIRCRESAHA.115.306807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalnina I, Gudra D, Silamikelis I, Viksne K, Roga A, Skinderskis E, Fridmanis D, Klovins J. Variations in the relative abundance of gut Bacteria correlate with lipid profiles in healthy adults. Microorganisms 2023;11(11).</Citation></Reference><Reference><Citation>Zhou X, Lian P, Liu H, Wang Y, Zhou M, Feng Z. Causal associations between Gut Microbiota and different types of Dyslipidemia: a two-sample mendelian randomization study. Nutrients 2023;15(20).</Citation></Reference><Reference><Citation>Miyajima Y, Karashima S, Ogai K, Taniguchi K, Ogura K, Kawakami M, Nambo H, Kometani M, Aono D, Demura M, et al. Impact of gut microbiome on dyslipidemia in Japanese adults: Assessment of the Shika-Machi super preventive health examination results for causal inference. Front Cell Infect Microbiol. 2022;12:908997.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36118024</ArticleId><ArticleId IdType=\"pmc\">9479221</ArticleId><ArticleId IdType=\"doi\">10.3389/fcimb.2022.908997</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270&#x2013;84.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29569621</ArticleId><ArticleId IdType=\"doi\">10.1038/nrendo.2018.24</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3(2):103&#x2013;11.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">17237837</ArticleId><ArticleId IdType=\"doi\">10.1038/ncpendmet0400</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26(2):251&#x2013;82.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">15561799</ArticleId><ArticleId IdType=\"doi\">10.1210/er.2004-0004</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres PJ, Siakowska M, Banaszewska B, Pawelczyk L, Duleba AJ, Kelley ST, Thackray VG. Gut Microbial Diversity in Women with Polycystic Ovary Syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2018;103(4):1502&#x2013;11.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29370410</ArticleId><ArticleId IdType=\"pmc\">6276580</ArticleId><ArticleId IdType=\"doi\">10.1210/jc.2017-02153</ArticleId></ArticleIdList></Reference><Reference><Citation>He F, Li Y. The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population. J Ovarian Res. 2021;14(1):50.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33773586</ArticleId><ArticleId IdType=\"pmc\">8005233</ArticleId><ArticleId IdType=\"doi\">10.1186/s13048-021-00799-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowyer RCE, Jackson MA, Le Roy CI, Ni Lochlainn M, Spector TD, Dowd JB, Steves CJ. Socioeconomic status and the gut microbiome: a TwinsUK cohort study. Microorganisms 2019;7(1).</Citation></Reference><Reference><Citation>Wang J, Kurilshikov A, Radjabzadeh D, Turpin W, Croitoru K, Bonder MJ, Jackson MA, Medina-Gomez C, Frost F, Homuth G, et al. Meta-analysis of human genome-microbiome association studies: the MiBioGen consortium initiative. Microbiome. 2018;6(1):101.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29880062</ArticleId><ArticleId IdType=\"pmc\">5992867</ArticleId><ArticleId IdType=\"doi\">10.1186/s40168-018-0479-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominianni C, Sinha R, Goedert JJ, Pei Z, Yang L, Hayes RB, Ahn J. Sex, body mass index, and dietary fiber intake influence the human gut microbiome. PLoS ONE. 2015;10(4):e0124599.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25874569</ArticleId><ArticleId IdType=\"pmc\">4398427</ArticleId><ArticleId IdType=\"doi\">10.1371/journal.pone.0124599</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JJ, Eum SY, Rampersaud E, Daunert S, Abreu MT, Toborek M. Exercise attenuates PCB-induced changes in the mouse gut microbiome. Environ Health Perspect. 2013;121(6):725&#x2013;30.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23632211</ArticleId><ArticleId IdType=\"pmc\">3672930</ArticleId><ArticleId IdType=\"doi\">10.1289/ehp.1306534</ArticleId></ArticleIdList></Reference><Reference><Citation>Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Pedersen HK, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262&#x2013;6.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26633628</ArticleId><ArticleId IdType=\"pmc\">4681099</ArticleId><ArticleId IdType=\"doi\">10.1038/nature15766</ArticleId></ArticleIdList></Reference><Reference><Citation>Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100&#x2013;4.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">16219714</ArticleId><ArticleId IdType=\"doi\">10.1210/jc.2005-1494</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker J, O&#x2019;Brien C, Hawrelak J, Gersh FL. Polycystic ovary syndrome: an evolutionary adaptation to Lifestyle and the Environment. Int J Environ Res Public Health 2022;19(3).</Citation></Reference><Reference><Citation>Holert J, Cardenas E, Bergstrand LH, Zaikova E, Hahn AS, Hallam SJ, Mohn WW, Lindow SE, Tringe S, Garcia J. Metagenomes Reveal Global Distribution of Bacterial Steroid Catabolism in Natural, Engineered, and Host Environments. mBio 2018;9(1).</Citation></Reference><Reference><Citation>Bergstrand LH, Cardenas E, Holert J, Van Hamme JD, Mohn WW. Delineation of Steroid-Degrading microorganisms through comparative genomic analysis. mBio. 2016;7(2):e00166.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26956583</ArticleId><ArticleId IdType=\"pmc\">4810484</ArticleId><ArticleId IdType=\"doi\">10.1128/mBio.00166-16</ArticleId></ArticleIdList></Reference><Reference><Citation>Holert J, Jagmann N, Philipp B. The essential function of genes for a hydratase and an aldehyde dehydrogenase for growth of Pseudomonas sp. strain Chol1 with the steroid compound cholate indicates an aldolytic reaction step for deacetylation of the side chain. J Bacteriol. 2013;195(15):3371&#x2013;80.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23708132</ArticleId><ArticleId IdType=\"pmc\">3719548</ArticleId><ArticleId IdType=\"doi\">10.1128/JB.00410-13</ArticleId></ArticleIdList></Reference><Reference><Citation>Holert J, Kulic Z, Yucel O, Suvekbala V, Suter MJ, Moller HM, Philipp B. Degradation of the acyl side chain of the steroid compound cholate in Pseudomonas sp. strain Chol1 proceeds via an aldehyde intermediate. J Bacteriol. 2013;195(3):585&#x2013;95.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23204454</ArticleId><ArticleId IdType=\"pmc\">3553998</ArticleId><ArticleId IdType=\"doi\">10.1128/JB.01961-12</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramani K, Sekaran G. Production of lipase from Pseudomonas gessardii using blood tissue lipid and thereof for the hydrolysis of blood cholesterol and triglycerides and lysis of red blood cells. Bioprocess Biosyst Eng. 2012;35(6):885&#x2013;96.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22228367</ArticleId><ArticleId IdType=\"doi\">10.1007/s00449-011-0673-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Fu H, Su H, Cai X, Wang Y, Hong Y, Hu J, Xie Z, Wang X. Multi-omics analyses reveal the specific changes in gut metagenome and serum metabolome of patients with polycystic ovary syndrome. Front Microbiol. 2022;13:1017147.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36338055</ArticleId><ArticleId IdType=\"pmc\">9627625</ArticleId><ArticleId IdType=\"doi\">10.3389/fmicb.2022.1017147</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014;74(11):1195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25022952</ArticleId><ArticleId IdType=\"doi\">10.1007/s40265-014-0259-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannone M, Botre F, Martinez-Brito D, Matteucci R, de la Torre X. Development and application of analytical procedures for the GC-MS/MS analysis of the sulfates metabolites of anabolic androgenic steroids: the pivotal role of chemical hydrolysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1155:122280.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32763466</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jchromb.2020.122280</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojinovic D, Radjabzadeh D, Kurilshikov A, Amin N, Wijmenga C, Franke L, Ikram MA, Uitterlinden AG, Zhernakova A, Fu J, et al. Relationship between gut microbiota and circulating metabolites in population-based cohorts. Nat Commun. 2019;10(1):5813.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31862950</ArticleId><ArticleId IdType=\"pmc\">6925111</ArticleId><ArticleId IdType=\"doi\">10.1038/s41467-019-13721-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Tang Z, Hao T, Qiu Z, Zhang B. Simulated digestion and fermentation in Vitro by obese human gut microbiota of sulforaphane from Broccoli seeds. Foods 2022;11(24).</Citation></Reference><Reference><Citation>Burakova I, Smirnova Y, Gryaznova M, Syromyatnikov M, Chizhkov P, Popov E, Popov V. The effect of short-term consumption of lactic acid Bacteria on the gut microbiota in obese people. Nutrients 2022;14(16).</Citation></Reference><Reference><Citation>Rom O, Liu YH, Liu ZP, Zhao Y, Wu JF, Ghrayeb A, Villacorta L, Fan YB, Chang L, Wang L et al. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci Transl Med 2020;12(572).</Citation></Reference><Reference><Citation>Fletcher JR, Pike CM, Parsons RJ, Rivera AJ, Foley MH, McLaren MR, Montgomery SA, Theriot CM. Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota. Nat Commun. 2021;12(1):462.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33469019</ArticleId><ArticleId IdType=\"pmc\">7815924</ArticleId><ArticleId IdType=\"doi\">10.1038/s41467-020-20746-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825&#x2013;34.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25714160</ArticleId><ArticleId IdType=\"pmc\">10966662</ArticleId><ArticleId IdType=\"doi\">10.1056/NEJMoa1408913</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L, Chu H, Du F, Zhu Q, Schnabl B, et al. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol. 2018;175(3):469&#x2013;84.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29139555</ArticleId><ArticleId IdType=\"pmc\">5773980</ArticleId><ArticleId IdType=\"doi\">10.1111/bph.14095</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M, Johnston LJ, Wu C, Ma X. Gut microbiota and its metabolites: Bridge of dietary nutrients and obesity-related diseases. Crit Rev Food Sci Nutr 2021:1&#x2013;18.</Citation></Reference><Reference><Citation>Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, Zhang Y, Shen J, Pang X, Zhang M, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A. 2008;105(6):2117&#x2013;22.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">18252821</ArticleId><ArticleId IdType=\"pmc\">2538887</ArticleId><ArticleId IdType=\"doi\">10.1073/pnas.0712038105</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L, Zhang M, Zhao X, Shen J, Wu S et al. Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. mBio 2018;9(3).</Citation></Reference><Reference><Citation>Min Y, Ma X, Sankaran K, Ru Y, Chen L, Baiocchi M, Zhu S. Sex-specific association between gut microbiome and fat distribution. Nat Commun. 2019;10(1):2408.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31160598</ArticleId><ArticleId IdType=\"pmc\">6546740</ArticleId><ArticleId IdType=\"doi\">10.1038/s41467-019-10440-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Zhao J, Liu F, Li Y. Lipid metabolism and endometrial receptivity. Hum Reprod Update. 2022;28(6):858&#x2013;89.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35639910</ArticleId><ArticleId IdType=\"doi\">10.1093/humupd/dmac026</ArticleId></ArticleIdList></Reference><Reference><Citation>McNaught KJ, Kuatsjah E, Zahn M, Prates ET, Shao H, Bentley GJ, Pickford AR, Gruber JN, Hestmark KV, Jacobson DA, et al. Initiation of fatty acid biosynthesis in Pseudomonas putida KT2440. Metab Eng. 2023;76:193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36796578</ArticleId><ArticleId IdType=\"doi\">10.1016/j.ymben.2023.02.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome. 2019;7(1):91.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31196177</ArticleId><ArticleId IdType=\"pmc\">6567490</ArticleId><ArticleId IdType=\"doi\">10.1186/s40168-019-0704-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189&#x2013;200.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26963409</ArticleId><ArticleId IdType=\"pmc\">4939913</ArticleId><ArticleId IdType=\"doi\">10.1080/19490976.2015.1134082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridgeman SC, Northrop W, Melton PE, Ellison GC, Newsholme P, Mamotte CDS. Butyrate generated by gut microbiota and its therapeutic role in metabolic syndrome. Pharmacol Res. 2020;160:105174.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32860943</ArticleId><ArticleId IdType=\"doi\">10.1016/j.phrs.2020.105174</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotterdam EA-SP. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41&#x2013;7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/humrep/deh098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26(3):575&#x2013;81.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">12610004</ArticleId><ArticleId IdType=\"doi\">10.2337/diacare.26.3.575</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint Committee on the Chinese Guidelines for Lipid M. Chinese guidelines for lipid management (2023). Zhonghua Xin xue guan bing za zhi. 2023;51(3):221&#x2013;55.</Citation></Reference><Reference><Citation>Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, Giannoukos G, Ciulla D, Tabbaa D, Highlander SK, Sodergren E, et al. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 2011;21(3):494&#x2013;504.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21212162</ArticleId><ArticleId IdType=\"pmc\">3044863</ArticleId><ArticleId IdType=\"doi\">10.1101/gr.112730.110</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75(23):7537&#x2013;41.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">19801464</ArticleId><ArticleId IdType=\"pmc\">2786419</ArticleId><ArticleId IdType=\"doi\">10.1128/AEM.01541-09</ArticleId></ArticleIdList></Reference><Reference><Citation>Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21702898</ArticleId><ArticleId IdType=\"pmc\">3218848</ArticleId><ArticleId IdType=\"doi\">10.1186/gb-2011-12-6-r60</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760678</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1528-3658</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Molecular medicine (Cambridge, Mass.)</Title><ISOAbbreviation>Mol Med</ISOAbbreviation></Journal><ArticleTitle>AMPK activation eliminates senescent cells in diabetic wound by inducing NCOA4 mediated ferritinophagy.</ArticleTitle><Pagination><StartPage>63</StartPage><MedlinePgn>63</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s10020-024-00825-8</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Diabetic wounds are one of the long-term complications of diabetes, with a disordered microenvironment, diabetic wounds can easily develop into chronic non-healing wounds, which can impose a significant burden on healthcare. In diabetic condition, senescent cells accumulate in the wound area and suppress the wound healing process. AMPK, as a molecule related to metabolism, has a close relationship with aging and diabetes. The purpose of this study was to investigate the effects of AMPK activation on wound healing and explore the underlying mechanisms.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">AMPK activator A769662 was topically applied in wound models of diabetic mice. Alterations in the wound site were observed and analyzed by immunohistochemistry. The markers related to autophagy and ferritinophagy were analyzed by western blotting and immunofluorescence staining. The role of AMPK activation and ferritinophagy were also analyzed by western blotting.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Our results show that AMPK activation improved diabetic wound healing and reduced the accumulation of senescent cells. Intriguingly, we found that AMPK activation-induced ferroptosis is autophagy-dependent. We detected that the level of ferritin had deceased and NCOA4 was markedly increased after AMPK activation treatment. We further investigated that NCOA4-mediated ferritinophagy was involved in ferroptosis triggered by AMPK activation. Most importantly, AMPK activation can reverse the ferroptosis-insensitive of senescent fibroblast cells in diabetic mice wound area and promote wound healing.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">These results suggest that activating AMPK can promote diabetic wound healing by reversing the ferroptosis-insensitive of senescent fibroblast cells. AMPK may serve as a regulatory factor in senescent cells in the diabetic wound area, therefore AMPK activation can become a promising therapeutic method for diabetic non-healing wounds.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Liu</LastName><ForeName>Mengqian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Burns, Nanfang Hospital, Southern Medical University, Jingxi Street, Guangzhou, 510515, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Wei</LastName><ForeName>Xuerong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Burns, Nanfang Hospital, Southern Medical University, Jingxi Street, Guangzhou, 510515, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zheng</LastName><ForeName>Zijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Burns, Nanfang Hospital, Southern Medical University, Jingxi Street, Guangzhou, 510515, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xie</LastName><ForeName>Erlian</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Burns, Nanfang Hospital, Southern Medical University, Jingxi Street, Guangzhou, 510515, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yu</LastName><ForeName>Qiuyi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Burns, Nanfang Hospital, Southern Medical University, Jingxi Street, Guangzhou, 510515, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gao</LastName><ForeName>Yanbin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Burns, Nanfang Hospital, Southern Medical University, Jingxi Street, Guangzhou, 510515, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ma</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Burns, Nanfang Hospital, Southern Medical University, Jingxi Street, Guangzhou, 510515, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Lei</ForeName><Initials>L</Initials><Identifier Source=\"ORCID\">0000-0003-0259-2479</Identifier><AffiliationInfo><Affiliation>Department of Burns, Nanfang Hospital, Southern Medical University, Jingxi Street, Guangzhou, 510515, Guangdong, China. yuanyang@smu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Med</MedlineTA><NlmUniqueID>9501023</NlmUniqueID><ISSNLinking>1076-1551</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D000818\" MajorTopicYN=\"N\">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D016922\" MajorTopicYN=\"Y\">Cellular Senescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D001343\" MajorTopicYN=\"Y\">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D051379\" MajorTopicYN=\"N\">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005293\" MajorTopicYN=\"Y\">Ferritins</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D014945\" MajorTopicYN=\"Y\">Wound Healing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D055372\" MajorTopicYN=\"Y\">AMP-Activated Protein Kinases</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D003921\" MajorTopicYN=\"Y\">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D056918\" MajorTopicYN=\"Y\">Nuclear Receptor Coactivators</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000079403\" MajorTopicYN=\"N\">Ferroptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D004195\" MajorTopicYN=\"N\">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D004789\" MajorTopicYN=\"N\">Enzyme Activation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">AMPK</Keyword><Keyword MajorTopicYN=\"N\">Autophagy</Keyword><Keyword MajorTopicYN=\"N\">Cellular senescence</Keyword><Keyword MajorTopicYN=\"N\">Diabetic wound</Keyword><Keyword MajorTopicYN=\"N\">Ferroptosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760678</ArticleId><ArticleId IdType=\"doi\">10.1186/s10020-024-00825-8</ArticleId><ArticleId IdType=\"pii\">10.1186/s10020-024-00825-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ajoolabady A, Aslkhodapasandhokmabad H, Libby P, Tuomilehto J, Lip GYH, Penninger JM, et al. Ferritinophagy and ferroptosis in the management of metabolic diseases. Trends Endocrinol Metab. 2021;32(7):444&#x2013;62.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34006412</ArticleId><ArticleId IdType=\"doi\">10.1016/j.tem.2021.04.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeli JPF, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180-U120.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">4894846</ArticleId><ArticleId IdType=\"doi\">10.1038/ncb3064</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltzis D, Eleftheriadou I, Veves A. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther. 2014;31(8):817&#x2013;36.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25069580</ArticleId><ArticleId IdType=\"doi\">10.1007/s12325-014-0140-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellelli R, Federico G, Matte A, Colecchia D, Iolascon A, Chiariello M, et al. NCOA4 deficiency impairs systemic iron homeostasis. Cell Rep. 2016;14(3):411&#x2013;21.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26776506</ArticleId><ArticleId IdType=\"doi\">10.1016/j.celrep.2015.12.065</ArticleId></ArticleIdList></Reference><Reference><Citation>Biran A, Zada L, Abou Karam P, Vadai E, Roitman L, Ovadya Y, et al. Quantitative identification of senescent cells in aging and disease. Aging Cell. 2017;16(4):661&#x2013;71.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28455874</ArticleId><ArticleId IdType=\"pmc\">5506427</ArticleId><ArticleId IdType=\"doi\">10.1111/acel.12592</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair MJ, Jones JD, Woessner AE, Quinn KP. Skin structure-function relationships and the wound healing response to intrinsic aging. Adv Wound Care (new Rochelle). 2020;9(3):127&#x2013;43.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31993254</ArticleId><ArticleId IdType=\"doi\">10.1089/wound.2019.1021</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem Sci. 2016;41(3):274&#x2013;86.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26725301</ArticleId><ArticleId IdType=\"doi\">10.1016/j.tibs.2015.11.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Caulier AL, Sankaran VG. Molecular and cellular mechanisms that regulate human erythropoiesis. Blood. 2022;139(16):2450&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34936695</ArticleId><ArticleId IdType=\"pmc\">9029096</ArticleId><ArticleId IdType=\"doi\">10.1182/blood.2021011044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006;3(6):403&#x2013;16.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">16753576</ArticleId><ArticleId IdType=\"doi\">10.1016/j.cmet.2006.05.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayani PN, Bishop MC, Black K, Zeltzer PM. Desferoxamine (DFO)&#x2013;mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol. 2004;67(3):367&#x2013;77.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">15164994</ArticleId><ArticleId IdType=\"doi\">10.1023/B:NEON.0000024238.21349.37</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060&#x2013;72.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22632970</ArticleId><ArticleId IdType=\"pmc\">3367386</ArticleId><ArticleId IdType=\"doi\">10.1016/j.cell.2012.03.042</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol. 2014;16(11):1069&#x2013;79.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25327288</ArticleId><ArticleId IdType=\"doi\">10.1038/ncb3053</ArticleId></ArticleIdList></Reference><Reference><Citation>Entezari M, Hashemi D, Taheriazam A, Zabolian A, Mohammadi S, Fakhri F, et al. AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: a pre-clinical and clinical investigation. Biomed Pharmacother. 2022;146: 112563.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35062059</ArticleId><ArticleId IdType=\"doi\">10.1016/j.biopha.2021.112563</ArticleId></ArticleIdList></Reference><Reference><Citation>Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005;366(9498):1736&#x2013;43.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">16291068</ArticleId><ArticleId IdType=\"doi\">10.1016/S0140-6736(05)67700-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26(9):1021&#x2013;32.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27514700</ArticleId><ArticleId IdType=\"pmc\">5034113</ArticleId><ArticleId IdType=\"doi\">10.1038/cr.2016.95</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell. 2017;66(6):789&#x2013;800.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28622524</ArticleId><ArticleId IdType=\"pmc\">5553560</ArticleId><ArticleId IdType=\"doi\">10.1016/j.molcel.2017.05.032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Y, Zhou M, Chen C, Wu X, Wang X. Role of AMPK mediated pathways in autophagy and aging. Biochimie. 2022;195:100&#x2013;13.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34838647</ArticleId><ArticleId IdType=\"doi\">10.1016/j.biochi.2021.11.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Han D, Jiang L, Gu X, Huang S, Pang J, Wu Y, et al. SIRT3 deficiency is resistant to autophagy-dependent ferroptosis by inhibiting the AMPK/mTOR pathway and promoting GPX4 levels. J Cell Physiol. 2020;235(11):8839&#x2013;51.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32329068</ArticleId><ArticleId IdType=\"doi\">10.1002/jcp.29727</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding KG, Moore K, Phillips TJ. Wound chronicity and fibroblast senescence&#x2013;implications for treatment. Int Wound J. 2005;2(4):364&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">16618323</ArticleId><ArticleId IdType=\"pmc\">7951708</ArticleId><ArticleId IdType=\"doi\">10.1111/j.1742-4801.2005.00149.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ 3rd, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12(8):1425&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27245739</ArticleId><ArticleId IdType=\"pmc\">4968231</ArticleId><ArticleId IdType=\"doi\">10.1080/15548627.2016.1187366</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016;48(7): e245.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27416781</ArticleId><ArticleId IdType=\"pmc\">4973318</ArticleId><ArticleId IdType=\"doi\">10.1038/emm.2016.81</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266&#x2013;82.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33495651</ArticleId><ArticleId IdType=\"pmc\">8142022</ArticleId><ArticleId IdType=\"doi\">10.1038/s41580-020-00324-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju TC, Chen HM, Lin JT, Chang CP, Chang WC, Kang JJ, et al. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington&#x2019;s disease. J Cell Biol. 2011;194(2):209&#x2013;27.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21768291</ArticleId><ArticleId IdType=\"pmc\">3144412</ArticleId><ArticleId IdType=\"doi\">10.1083/jcb.201105010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandula N, Kumar S, Mandlem VKK, Siddabathuni A, Singh S, Kosuru R. Role of AMPK in myocardial ischemia-reperfusion injury-induced cell death in the presence and absence of diabetes. Oxid Med Cell Longev. 2022;2022:7346699.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36267813</ArticleId><ArticleId IdType=\"pmc\">9578802</ArticleId><ArticleId IdType=\"doi\">10.1155/2022/7346699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132&#x2013;41.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21258367</ArticleId><ArticleId IdType=\"pmc\">3987946</ArticleId><ArticleId IdType=\"doi\">10.1038/ncb2152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura Y, Yanagida T, Onda A, Tsukui D, Hosoyamada M, Kono H. Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation. Arterioscler Thromb Vasc Biol. 2020;40(3):570&#x2013;82.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31996020</ArticleId><ArticleId IdType=\"doi\">10.1161/ATVBAHA.119.313224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari R, Jat P. Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype. Front Cell Dev Biol. 2021;9: 645593.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33855023</ArticleId><ArticleId IdType=\"pmc\">8039141</ArticleId><ArticleId IdType=\"doi\">10.3389/fcell.2021.645593</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Sun S, Tan L, Wang Y, Wang L, Zhang Z, et al. Polystyrene nanoparticles reduced ROS and inhibited ferroptosis by triggering lysosome stress and TFEB nucleus translocation in a size-dependent manner. Nano Lett. 2019;19(11):7781&#x2013;92.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31558022</ArticleId><ArticleId IdType=\"doi\">10.1021/acs.nanolett.9b02795</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Xu C, Xu L, Li X, Sun H, Xue M, et al. Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway. Metabolism. 2020;111: 154334.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32777444</ArticleId><ArticleId IdType=\"doi\">10.1016/j.metabol.2020.154334</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhavi YV, Gaikwad N, Yerra VG, Kalvala AK, Nanduri S, Kumar A. Targeting AMPK in diabetes and diabetic complications: energy homeostasis, autophagy and mitochondrial health. Curr Med Chem. 2019;26(27):5207&#x2013;29.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29623826</ArticleId><ArticleId IdType=\"doi\">10.2174/0929867325666180406120051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancias JD, Wang XX, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509(7498):105.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">24695223</ArticleId><ArticleId IdType=\"pmc\">4180099</ArticleId><ArticleId IdType=\"doi\">10.1038/nature13148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao W, Fan Y, Wang X, Feng G, You Y, Li H, et al. Phloretin ameliorates diabetes-induced endothelial injury through AMPK-dependent anti-EndMT pathway. Pharmacol Res. 2022;179: 106205.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35381340</ArticleId><ArticleId IdType=\"doi\">10.1016/j.phrs.2022.106205</ArticleId></ArticleIdList></Reference><Reference><Citation>Masaldan S, Clatworthy SAS, Gamell C, Meggyesy PM, Rigopoulos AT, Haupt S, et al. Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. Redox Biol. 2018;14:100&#x2013;15.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28888202</ArticleId><ArticleId IdType=\"doi\">10.1016/j.redox.2017.08.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13(9):1016&#x2013;23.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21892142</ArticleId><ArticleId IdType=\"pmc\">3249400</ArticleId><ArticleId IdType=\"doi\">10.1038/ncb2329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogrodnik M. Cellular aging beyond cellular senescence: markers of senescence prior to cell cycle arrest in vitro and in vivo. Aging Cell. 2021;20(4): e13338.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33711211</ArticleId><ArticleId IdType=\"pmc\">8045927</ArticleId><ArticleId IdType=\"doi\">10.1111/acel.13338</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin X, Zhang J, Wang B, Xu G, Yang X, Zou Z, et al. Ferritinophagy is involved in the zinc oxide nanoparticles-induced ferroptosis of vascular endothelial cells. Autophagy. 2021;17(12):4266&#x2013;85.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33843441</ArticleId><ArticleId IdType=\"pmc\">8726675</ArticleId><ArticleId IdType=\"doi\">10.1080/15548627.2021.1911016</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A, Kaarniranta K. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res Rev. 2012;11(2):230&#x2013;41.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22186033</ArticleId><ArticleId IdType=\"doi\">10.1016/j.arr.2011.12.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev. 2008;7(2):83&#x2013;105.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">17964225</ArticleId><ArticleId IdType=\"doi\">10.1016/j.arr.2007.09.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15(7):397&#x2013;408.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26105537</ArticleId><ArticleId IdType=\"doi\">10.1038/nrc3960</ArticleId></ArticleIdList></Reference><Reference><Citation>Song X, Zhu S, Chen P, Hou W, Wen Q, Liu J, et al. AMPK-mediated BECN1 phosphorylation promotes ferroptosis by directly blocking system X(c)(&#x2212;) activity. Curr Biol. 2018;28(15):2388-99 e5.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30057310</ArticleId><ArticleId IdType=\"pmc\">6081251</ArticleId><ArticleId IdType=\"doi\">10.1016/j.cub.2018.05.094</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley A, Osler T. Senescence and the healing rates of venous ulcers. J Vasc Surg. 2001;33(6):1206&#x2013;11.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">11389419</ArticleId><ArticleId IdType=\"doi\">10.1067/mva.2001.115379</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk E, Kulms D. The role of AKT/mTOR pathway in stress response to UV-irradiation: implication in skin carcinogenesis by regulation of apoptosis, autophagy and senescence. Int J Mol Sci. 2013;14(8):15260&#x2013;85.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23887651</ArticleId><ArticleId IdType=\"pmc\">3759859</ArticleId><ArticleId IdType=\"doi\">10.3390/ijms140815260</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomic-Canic M, DiPietro LA. Cellular senescence in diabetic wounds: when too many retirees stress the system. J Invest Dermatol. 2019;139(5):997&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31010531</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jid.2019.02.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Ge J, Tredget EE, Wu Y. The mouse excisional wound splinting model, including applications for stem cell transplantation. Nat Protoc. 2013;8(2):302&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23329003</ArticleId><ArticleId IdType=\"doi\">10.1038/nprot.2013.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei X, Liu M, Zheng Z, Yu S, Huang L, Ma J, et al. Defective NCOA4-dependent ferroptosis in senescent fibroblasts retards diabetic wound healing. Cell Death Discov. 2023;9(1):138.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">37117222</ArticleId><ArticleId IdType=\"pmc\">10147701</ArticleId><ArticleId IdType=\"doi\">10.1038/s41420-023-01437-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson HN, Hardman MJ. Senescence in wound repair: emerging strategies to target chronic healing wounds. Front Cell Dev Biol. 2020;8:773.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32850866</ArticleId><ArticleId IdType=\"pmc\">7431694</ArticleId><ArticleId IdType=\"doi\">10.3389/fcell.2020.00773</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Li Y, Li J, Chen W. Ethyl carbamate triggers ferroptosis in liver through inhibiting GSH synthesis and suppressing Nrf2 activation. Redox Biol. 2022;53: 102349.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35623314</ArticleId><ArticleId IdType=\"pmc\">9142717</ArticleId><ArticleId IdType=\"doi\">10.1016/j.redox.2022.102349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Wang Y, Liu X, Dagda RK, Zhang Y. How AMPK and PKA interplay to regulate mitochondrial function and survival in models of ischemia and diabetes. Oxid Med Cell Longev. 2017;2017:4353510.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29391924</ArticleId><ArticleId IdType=\"pmc\">5748092</ArticleId><ArticleId IdType=\"doi\">10.1155/2017/4353510</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Yao Z, Wang L, Ding H, Shao J, Chen A, et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells. Autophagy. 2018;14(12):2083&#x2013;103.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30081711</ArticleId><ArticleId IdType=\"pmc\">6984765</ArticleId><ArticleId IdType=\"doi\">10.1080/15548627.2018.1503146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T, Guo X, Sun Y. Iron accumulation and lipid peroxidation in the aging retina: implication of ferroptosis in age-related macular degeneration. Aging Dis. 2021;12(2):529&#x2013;51.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33815881</ArticleId><ArticleId IdType=\"pmc\">7990372</ArticleId><ArticleId IdType=\"doi\">10.14336/AD.2020.0912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018;15:335&#x2013;46.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29306791</ArticleId><ArticleId IdType=\"doi\">10.1016/j.redox.2017.12.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou BR, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang DL. Ferroptosis is a type of autophagy-dependent cell death. Semin Cancer Biol. 2020;66:89&#x2013;100.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30880243</ArticleId><ArticleId IdType=\"doi\">10.1016/j.semcancer.2019.03.002</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"In-Process\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760661</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1476-511X</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Lipids in health and disease</Title><ISOAbbreviation>Lipids Health Dis</ISOAbbreviation></Journal><ArticleTitle>Association between lipid accumulation product and psoriasis among adults: a nationally representative cross-sectional study.</ArticleTitle><Pagination><StartPage>143</StartPage><MedlinePgn>143</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s12944-024-02123-y</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Lipid accumulation product (LAP) is an accessible and relatively comprehensive assessment of obesity that represents both anatomical and physiological lipid accumulation. Obesity and psoriasis are potentially related, according to previous research. Investigating the relationship between adult psoriasis and the LAP index was the goal of this study.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">This is a cross-sectional study based on data from the National Health and Nutrition Examination Survey (NHANES) 2003-2006 and 2009-2014. The association between LAP and psoriasis was examined using multivariate logistic regression and smoothed curve fitting. To verify whether this relationship was stable across populations, subgroup analyses and interaction tests were performed.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The LAP index showed a positive correlation with psoriasis in 9,781 adult participants who were 20 years of age or older. A 27% elevated probability of psoriasis was linked to every unit increase in ln LAP in the fully adjusted model (Model 3: OR 1.27, 95% CI 1.06-1.52). In comparison with participants in the lowest ln LAP quartile, those in the highest quartile had an 83% greater likelihood of psoriasis (Model 3: OR 1.83, 95% CI 1.08-3.11). This positive correlation was more pronounced for young males, participants who had never smoked, non-drinkers, participants who exercised little, as well as non-hypertensive and non-diabetic participants.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">This study found that the LAP index and adult psoriasis were positively correlated, especially in young males without comorbidities. Therefore, it is proposed that LAP may serve as a biomarker for early diagnosis of psoriasis and tracking the effectiveness of treatment.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Zhang</LastName><ForeName>Caiyun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Cosmetology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Dong</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210002, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chen</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, 210031, China. springchenjun@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210002, China. liufangndyx@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lipids Health Dis</MedlineTA><NlmUniqueID>101147696</NlmUniqueID><ISSNLinking>1476-511X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Lipid accumulation product</Keyword><Keyword MajorTopicYN=\"N\">NHANES</Keyword><Keyword MajorTopicYN=\"N\">Obesity</Keyword><Keyword MajorTopicYN=\"N\">Psoriasis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760661</ArticleId><ArticleId IdType=\"doi\">10.1186/s12944-024-02123-y</ArticleId><ArticleId IdType=\"pii\">10.1186/s12944-024-02123-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157:940&#x2013;6.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34190957</ArticleId><ArticleId IdType=\"doi\">10.1001/jamadermatol.2021.2007</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945&#x2013;60.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32427307</ArticleId><ArticleId IdType=\"doi\">10.1001/jama.2020.4006</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, Gonz&#xe1;lez-Parra E, Jodar E, Joven B, L&#xe1;zaro P, Olveira A, et al. Position statement for the management of comorbidities in psoriasis. J Eur Acad Dermatol Venereol. 2018;32:2058&#x2013;73.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29992631</ArticleId><ArticleId IdType=\"doi\">10.1111/jdv.15177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Z, Lu T, Chen Y, Yuan M, Yu H, Liu R, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatol. 2022;158:745&#x2013;53.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35612851</ArticleId><ArticleId IdType=\"pmc\">9134040</ArticleId><ArticleId IdType=\"doi\">10.1001/jamadermatol.2022.1609</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, Lebwohl M. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72:961&#x2013;e967965.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25882886</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jaad.2015.02.1099</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JJ, Suryavanshi M, Davidson D, Patel V, Jain A, Seigel L. Economic Burden of Comorbidities in patients with psoriasis in the USA. Dermatol Ther (Heidelb). 2023;13:207&#x2013;19.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36402940</ArticleId><ArticleId IdType=\"doi\">10.1007/s13555-022-00832-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaskin CJ, Cooper K, Stephens LD, Peeters A, Salmon J, Porter J. Clinical practice guidelines for the management of overweight and obesity published internationally: a scoping review. Obes Rev 2024:e13700.</Citation></Reference><Reference><Citation>Rhee EJ. The Influence of Obesity and Metabolic Health on Vascular Health. Endocrinol Metab (Seoul). 2022;37:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35255597</ArticleId><ArticleId IdType=\"doi\">10.3803/EnM.2022.101</ArticleId></ArticleIdList></Reference><Reference><Citation>Donini LM, Pinto A, Giusti AM, Lenzi A, Poggiogalle E. Obesity or BMI Paradox? Beneath the tip of the Iceberg. Front Nutr. 2020;7:53.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32457915</ArticleId><ArticleId IdType=\"pmc\">7221058</ArticleId><ArticleId IdType=\"doi\">10.3389/fnut.2020.00053</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosello O, Donataccio MP, Cuzzolaro M. Obesity or obesities? Controversies on the association between body mass index and premature mortality. Eat Weight Disord. 2016;21:165&#x2013;74.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27043948</ArticleId><ArticleId IdType=\"doi\">10.1007/s40519-016-0278-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchi&#xe9; A, Dallegri F, Carbone F, Bonaventura A, Liberale L, Portincasa P, Fr&#xfc;hbeck G, Montecucco F. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med. 2018;48:6&#x2013;17.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29100895</ArticleId><ArticleId IdType=\"doi\">10.1016/j.ejim.2017.10.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Shi S, Huang Y, Huang H, Zhong VW. Severity of abdominal obesity and cardiometabolic diseases in US adults. Public Health. 2024;227:154&#x2013;62.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">38232563</ArticleId><ArticleId IdType=\"doi\">10.1016/j.puhe.2023.12.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn HS. The lipid accumulation product performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">16150143</ArticleId><ArticleId IdType=\"pmc\">1236917</ArticleId><ArticleId IdType=\"doi\">10.1186/1471-2261-5-26</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi M, Seyedi SA, Nabipoorashrafi SA, Rabizadeh S, Sarzaeim M, Yadegar A, Mohammadi F, Bahri RA, Pakravan P, Shafiekhani P, et al. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Lipids Health Dis. 2023;22:41.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36922815</ArticleId><ArticleId IdType=\"pmc\">10015691</ArticleId><ArticleId IdType=\"doi\">10.1186/s12944-023-01802-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C, Li R, Zhang S, Gong L, Ren W, Wang Z, Li Q. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr. 2012;66:1035&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22781025</ArticleId><ArticleId IdType=\"doi\">10.1038/ejcn.2012.83</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento-Ferreira MV, Rendo-Urteaga T, Vilanova-Campelo RC, Carvalho HB, da Paz Oliveira G, Paes Landim MB, Torres-Leal FL. The lipid accumulation product is a powerful tool to predict metabolic syndrome in undiagnosed Brazilian adults. Clin Nutr. 2017;36:1693&#x2013;700.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28081980</ArticleId><ArticleId IdType=\"doi\">10.1016/j.clnu.2016.12.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguly S, Ray L, Kuruvila S, Nanda SK, Ravichandran K. Lipid accumulation product index as visceral obesity indicator in psoriasis: a case-control study. Indian J Dermatol. 2018;63:136&#x2013;40.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29692455</ArticleId><ArticleId IdType=\"pmc\">5903043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ataseven A, Kutlu R, Uzun L. The relation between visceral fat markers and cardiometabolic disease risks in psoriasis patients. North Clin Istanb. 2021;8:203&#x2013;11.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34222799</ArticleId><ArticleId IdType=\"pmc\">8240228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Parker JD, Clark J, Shin HC, Rammon JR, Burt VL. National Health and Nutrition Examination Survey: estimation procedures, 2011&#x2013;2014. Vital Health Stat 2 2018:1&#x2013;26.</Citation></Reference><Reference><Citation>Phan C, Ezzedine K, Lai C, Le Cleach L, Cogrel O, Fardet L, Wolkenstein P, Chosidow O, Beylot-Barry M, Sbidian E. Agreement between Self-reported inflammatory skin disorders and dermatologists&#x2019; diagnosis: a cross-sectional diagnostic study. Acta Derm Venereol. 2017;97:1243&#x2013;4.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28681066</ArticleId><ArticleId IdType=\"doi\">10.2340/00015555-2749</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American heart Association task force on clinical practice guidelines. Circulation. 2018; 138:e426-e483.</Citation></Reference><Reference><Citation>Shin JI, Wang D, Fernandes G, Daya N, Grams ME, Golden SH, Rajpathak S, Selvin E. Trends in receipt of American Diabetes Association Guideline-recommended care among U.S. adults with diabetes: NHANES 2005&#x2013;2018. Diabetes Care. 2021;44:1300&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33863753</ArticleId><ArticleId IdType=\"pmc\">8247496</ArticleId><ArticleId IdType=\"doi\">10.2337/dc20-2541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Han J, Qureshi AA. Use of aspirin, non-steroidal anti-inflammatory drugs, and acetaminophen (Paracetamol), and risk of psoriasis and psoriatic arthritis: a cohort study. Acta Derm Venereol. 2015;95:217&#x2013;23.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">24691893</ArticleId><ArticleId IdType=\"doi\">10.2340/00015555-1855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#x17e;elj J, Sollner Dolenc M. The role of xenobiotics in triggering psoriasis. Arch Toxicol. 2020;94:3959&#x2013;82.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32833044</ArticleId><ArticleId IdType=\"doi\">10.1007/s00204-020-02870-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33:1163&#x2013;78.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29680995</ArticleId><ArticleId IdType=\"pmc\">6290660</ArticleId><ArticleId IdType=\"doi\">10.1007/s10654-018-0366-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JH, Lee JH, Han KD, Kim HN, Bang CH, Park YM, Lee JY, Kim TY. Increased risk of psoriasis in subjects with abdominal obesity: a nationwide population-based study. J Dermatol. 2019;46:695&#x2013;701.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31149744</ArticleId><ArticleId IdType=\"doi\">10.1111/1346-8138.14939</ArticleId></ArticleIdList></Reference><Reference><Citation>Koebnick C, Black MH, Smith N, Der-Sarkissian JK, Porter AH, Jacobsen SJ, Wu JJ. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159:577&#x2013;83.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21524758</ArticleId><ArticleId IdType=\"pmc\">3168116</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jpeds.2011.03.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Nada H, Elakhrass A, Ahmad N, Refaat M. Psoriasis: is it a risk factor for cardiovascular diseases? J Dermatolog Treat. 2022;33:3154&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35943349</ArticleId><ArticleId IdType=\"doi\">10.1080/09546634.2022.2112137</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2010;76:662&#x2013;5.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21079309</ArticleId><ArticleId IdType=\"doi\">10.4103/0378-6323.72462</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong Y, Nakamizo S, Tan KJ, Kabashima K. An update on the role of adipose tissues in Psoriasis. Front Immunol. 2019;10:1507.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31316526</ArticleId><ArticleId IdType=\"pmc\">6609873</ArticleId><ArticleId IdType=\"doi\">10.3389/fimmu.2019.01507</ArticleId></ArticleIdList></Reference><Reference><Citation>Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001;60:329&#x2013;39.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">11681807</ArticleId><ArticleId IdType=\"doi\">10.1079/PNS200194</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796&#x2013;808.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">14679176</ArticleId><ArticleId IdType=\"pmc\">296995</ArticleId><ArticleId IdType=\"doi\">10.1172/JCI200319246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruglikov IL, Scherer PE, Wollina U. Are dermal adipocytes involved in psoriasis? Exp Dermatol. 2016;25:812&#x2013;3.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26913468</ArticleId><ArticleId IdType=\"doi\">10.1111/exd.12996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">17873860</ArticleId><ArticleId IdType=\"doi\">10.1038/nature06116</ArticleId></ArticleIdList></Reference><Reference><Citation>Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, Collins N, Dzutsev A, Shaik J, Morais da Fonseca D, Harrison OJ, Tamoutounour S, Byrd AL, et al. White Adipose tissue is a Reservoir for Memory T Cells and promotes protective memory responses to infection. Immunity. 2017;47:1154&#x2013;e11681156.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29221731</ArticleId><ArticleId IdType=\"pmc\">5773068</ArticleId><ArticleId IdType=\"doi\">10.1016/j.immuni.2017.11.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk K, Sabat R. Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord. 2016;17:305&#x2013;17.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27554109</ArticleId><ArticleId IdType=\"doi\">10.1007/s11154-016-9381-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911&#x2013;9. quiz 920.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">15867843</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jaci.2005.02.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Serum leptin, Resistin, and adiponectin concentrations in psoriasis: a Meta-analysis of Observational studies. Dermatology. 2017;233:378&#x2013;89.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29232663</ArticleId><ArticleId IdType=\"doi\">10.1159/000481882</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiricozzi A, Raimondo A, Lembo S, Fausti F, Dini V, Costanzo A, Monfrecola G, Balato N, Ayala F, Romanelli M, Balato A. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016;12:1299&#x2013;308.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27322922</ArticleId><ArticleId IdType=\"doi\">10.1080/1744666X.2016.1201423</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Tsuji H, Honma M, Ishida-Yamamoto A, Iizuka H. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res. 2013;305:113&#x2013;6.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23291856</ArticleId><ArticleId IdType=\"doi\">10.1007/s00403-012-1310-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334:1092&#x2013;101.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">16039994</ArticleId><ArticleId IdType=\"doi\">10.1016/j.bbrc.2005.06.202</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch M, Ahern T, Sweeney CM, Malara A, Tobin AM, O&#x2019;Shea D, Kirby B. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int J Dermatol. 2017;56:1103&#x2013;18.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28762474</ArticleId><ArticleId IdType=\"doi\">10.1111/ijd.13699</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci. 2009;55:62&#x2013;3.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">19395243</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jdermsci.2009.02.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007, 157:649&#x2013;655.</Citation></Reference><Reference><Citation>Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol. 2008;159:1207&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">18795929</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata S, Tada Y, Hau CS, Mitsui A, Kamata M, Asano Y, Sugaya M, Kadono T, Masamoto Y, Kurokawa M, et al. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from &#x3b3;&#x3b4;-T cells. Nat Commun. 2015;6:7687.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26173479</ArticleId><ArticleId IdType=\"doi\">10.1038/ncomms8687</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagino T, Saeki H, Fujimoto E, Kanda N. Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis. J Clin Med 2023, 12:1934.</Citation></Reference><Reference><Citation>Piros &#xc9;A, Szab&#xf3; &#xc1;, Rencz F, Brodszky V, Wikonk&#xe1;l N, Miheller P, Horv&#xe1;th M, Holl&#xf3; P. Anti-interleukin-17 therapy of severe psoriatic patients results in an improvement of serum lipid and inflammatory parameters&#x2019; levels, but has no effect on body composition parameters. Life (Basel). 2021;11:535.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34207504</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760632</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1573-7373</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of neuro-oncology</Title><ISOAbbreviation>J Neurooncol</ISOAbbreviation></Journal><ArticleTitle>Medical treatment of functional pituitary adenomas, trials and tribulations.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s11060-024-04670-x</ELocationID><Abstract><AbstractText Label=\"CONTEXT\" NlmCategory=\"BACKGROUND\">Functioning pituitary adenomas (FPAs) include most frequently prolactinomas, somatotroph or corticotroph adenomas, while thyrotroph and gonadotroph adenomas are very rare. Despite their benign histological nature (aggressive tumors are rare and malignant ones exceptional), FPAs could cause significant morbidity and increased mortality due to complications associated with hormonal excess syndromes and/or mass effect leading to compression of adjacent structures. This mini review will focus on the increasing role of medical therapy in the multimodal treatment, which also includes transsphenoidal surgery (TSS) and radiotherapy.</AbstractText><AbstractText Label=\"EVIDENCE SYNTHESIS\" NlmCategory=\"RESULTS\">Most patients with prolactinomas are treated only with medications, but surgery could be considered for some patients in a specialized pituitary center, if higher chances of cure. Dopamine agonists, especially cabergoline, are efficient in reducing tumor size and normalizing prolactin. TSS is the first-line treatment for all other FPAs, but most patients require complex adjuvant treatment, including a combination of therapeutic approaches. Medical therapy is the cornerstone of treatment in all patients after unsuccessful surgery or when surgery cannot be offered and includes somatostatin receptor ligands and dopamine agonists (almost all FPAs), growth hormone receptor antagonists (acromegaly), adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers (Cushing's disease). Novel medical treatments, especially for acromegaly and Cushing's disease are under research.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">An enlarged panel of effective drugs available with increased knowledge of predictive factors for response and/or adverse effects will enhance the possibility to offer a more individualized treatment. This would not only improve disease control and prognosis, but also quality of life.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Capatina</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, University of Medicine and Pharmacy \"Carol Davila\" Bucharest, and Department of Pituitary and Neuroendocrine Pathology, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hanzu</LastName><ForeName>Felicia Alexandra</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Endocrinology Department, Hospital Cl&#xed;nic de Barcelona, Spain, IDIBAPS, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hinojosa-Amaya</LastName><ForeName>Jos&#xe9; Miguel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Endocrinology Division and Department of Medicine, Pituitary Clinic, Hospital Universitario U.A.N.L, Monterrey, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fleseriu</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departments of Medicine (Endocrinology, Diabetes and Clinical Nutrition) and Neurological Surgery, and Pituitary Center, Oregon Health and Science University, Portland, OR, USA. fleseriu@ohsu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurooncol</MedlineTA><NlmUniqueID>8309335</NlmUniqueID><ISSNLinking>0167-594X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Adrenal steroidogenesis inhibitors</Keyword><Keyword MajorTopicYN=\"N\">Dopamine agonists</Keyword><Keyword MajorTopicYN=\"N\">Functional pituitary adenoma</Keyword><Keyword MajorTopicYN=\"N\">Glucocorticoid receptor blockers</Keyword><Keyword MajorTopicYN=\"N\">Growth hormone receptor blocker</Keyword><Keyword MajorTopicYN=\"N\">Somatostatin receptor ligands</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760632</ArticleId><ArticleId IdType=\"doi\">10.1007/s11060-024-04670-x</ArticleId><ArticleId IdType=\"pii\">10.1007/s11060-024-04670-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY (2022) Clinical Biology of the Pituitary Adenoma. Endocr Rev 43:1003&#x2013;1037. https://doi.org/10.1210/endrev/bnac010</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/endrev/bnac010</ArticleId><ArticleId IdType=\"pubmed\">35395078</ArticleId><ArticleId IdType=\"pmc\">9695123</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly AF, Beckers A (2020) The Epidemiology of Pituitary Adenomas. Endocrinol Metab Clin North Am 49:347&#x2013;355. https://doi.org/10.1016/j.ecl.2020.04.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ecl.2020.04.002</ArticleId><ArticleId IdType=\"pubmed\">32741475</ArticleId></ArticleIdList></Reference><Reference><Citation>Tritos NA, Miller KK (2023) Diagnosis and Management of Pituitary Adenomas: A Review. JAMA 329:1386&#x2013;1398. https://doi.org/10.1001/jama.2023.5444</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2023.5444</ArticleId><ArticleId IdType=\"pubmed\">37097352</ArticleId></ArticleIdList></Reference><Reference><Citation>Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R (2015) The epidemiology of pituitary adenomas in Iceland, 1955&#x2013;2012: a nationwide population-based study. Eur J Endocrinol 173:655&#x2013;664. https://doi.org/10.1530/EJE-15-0189</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-15-0189</ArticleId><ArticleId IdType=\"pubmed\">26423473</ArticleId></ArticleIdList></Reference><Reference><Citation>Vroonen L, Daly AF, Beckers A (2019) Epidemiology and Management Challenges in Prolactinomas. Neuroendocrinology 109:20&#x2013;27. https://doi.org/10.1159/000497746</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000497746</ArticleId><ArticleId IdType=\"pubmed\">30731464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 33:101290. https://doi.org/10.1016/j.beem.2019.101290</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.beem.2019.101290</ArticleId><ArticleId IdType=\"pubmed\">31326373</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. https://doi.org/10.1038/s41574-023-00886-5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41574-023-00886-5</ArticleId><ArticleId IdType=\"pubmed\">37670148</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimon I (2019) Giant Prolactinomas. Neuroendocrinology 109:51&#x2013;56. https://doi.org/10.1159/000495184</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000495184</ArticleId><ArticleId IdType=\"pubmed\">30404098</ArticleId></ArticleIdList></Reference><Reference><Citation>Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R (2023) Approach to the Patient With Prolactinoma. J Clin Endocrinol Metab 108:2400&#x2013;2423. https://doi.org/10.1210/clinem/dgad174</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgad174</ArticleId><ArticleId IdType=\"pubmed\">36974474</ArticleId><ArticleId IdType=\"pmc\">10438891</ArticleId></ArticleIdList></Reference><Reference><Citation>Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247&#x2013;2252. https://doi.org/10.1210/jcem.85.6.6657</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jcem.85.6.6657</ArticleId><ArticleId IdType=\"pubmed\">10852458</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, Casulari LA, Cunha Neto MBC, Czepielewski MA, Duarte FHG, Faria MDS, Gadelha MR, Garmes HM, Glezer A, Gurgel MH, Jallad RS, Martins M, Miranda PAC, Montenegro RM, Musolino NRC, Naves LA, Ribeiro-Oliveira Junior A, Silva CMS, Viecceli C, Bronstein MD (2018) Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab 62:236&#x2013;263. https://doi.org/10.20945/2359-3997000000032</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.20945/2359-3997000000032</ArticleId><ArticleId IdType=\"pubmed\">29768629</ArticleId><ArticleId IdType=\"pmc\">10118988</ArticleId></ArticleIdList></Reference><Reference><Citation>Biagetti B, Sarria-Estrada S, Ng-Wong YK, Martinez-Saez E, Casteras A, Cordero Asanza E, Hernandez I, Giralt-Arnaiz M, Simo R (2021) Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. Eur J Endocrinol 185:587&#x2013;595. https://doi.org/10.1530/EJE-21-0561</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-21-0561</ArticleId><ArticleId IdType=\"pubmed\">34374649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Ku CR, Kim EH, Hong JW, Lee EJ, Kim SH (2014) Early prediction of long-term response to cabergoline in patients with macroprolactinomas. Endocrinol Metab (Seoul) 29:280&#x2013;292. https://doi.org/10.3803/EnM.2014.29.3.280</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3803/EnM.2014.29.3.280</ArticleId><ArticleId IdType=\"pubmed\">25309786</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonert V (2020) Do nothing but observe microprolactinomas: when and how to replace sex hormones? Pituitary 23:307&#x2013;313. https://doi.org/10.1007/s11102-020-01039-x</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-020-01039-x</ArticleId><ArticleId IdType=\"pubmed\">32274622</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimon I, Hirsch D, Tsvetov G, Robenshtok E, Akirov A, Fraenkel M, Eizenberg Y, Herzberg D, Barzilay-Yoseph L, Livner A, Friedrich I, Manisterski Y, Ishay A, Yoel U, Masri H (2019) Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years. Endocrine 65:656&#x2013;661. https://doi.org/10.1007/s12020-019-01962-5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12020-019-01962-5</ArticleId><ArticleId IdType=\"pubmed\">31154607</ArticleId></ArticleIdList></Reference><Reference><Citation>Posawetz AS, Trummer C, Pandis M, Aberer F, Pieber TR, Obermayer-Pietsch B, Pilz S, Theiler-Schwetz V (2021) Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr Disord 21:81. https://doi.org/10.1186/s12902-021-00733-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12902-021-00733-6</ArticleId><ArticleId IdType=\"pubmed\">33902531</ArticleId><ArticleId IdType=\"pmc\">8074459</ArticleId></ArticleIdList></Reference><Reference><Citation>Auriemma RS, Galdiero M, Vitale P, Granieri L, Lo Calzo F, Salzano C, Ferreri L, Pivonello C, Cariati F, Coppola G, de Angelis C, Colao A, Pivonello R (2015) Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology 101:66&#x2013;81. https://doi.org/10.1159/000371851</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000371851</ArticleId><ArticleId IdType=\"pubmed\">25592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidianjahromi A, Tritos NA (2022) Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev Endocr Metab Disord 23:1089&#x2013;1099. https://doi.org/10.1007/s11154-022-09753-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11154-022-09753-6</ArticleId><ArticleId IdType=\"pubmed\">36125673</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchfelder M, Zhao Y, Schlaffer SM (2019) Surgery for Prolactinomas to Date. Neuroendocrinology 109:77&#x2013;81. https://doi.org/10.1159/000497331</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000497331</ArticleId><ArticleId IdType=\"pubmed\">30699424</ArticleId></ArticleIdList></Reference><Reference><Citation>Luger A, Broersen LHA, Biermasz NR, Biller BMK, Buchfelder M, Chanson P, Jorgensen JOL, Kelestimur F, Llahana S, Maiter D, Mintziori G, Petraglia F, Verkauskiene R, Webb SM, Dekkers OM (2021) ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol 185:G1&#x2013;G33. https://doi.org/10.1530/EJE-21-0462</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-21-0462</ArticleId><ArticleId IdType=\"pubmed\">34425558</ArticleId></ArticleIdList></Reference><Reference><Citation>Guitelman M (2006) Long-term follow-up of prolactinomas: should dopamine agonist treatment be life-long? Front Horm Res 35:88&#x2013;101. https://doi.org/10.1159/000094312</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000094312</ArticleId><ArticleId IdType=\"pubmed\">16809925</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A, Pituitary Society EGoPT (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary 20:489&#x2013;498. https://doi.org/10.1007/s11102-017-0838-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-017-0838-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara N, Nishiyama M, Iwasaki Y (2022) Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma. Cancers (Basel) 14. https://doi.org/10.3390/cancers14153604</Citation></Reference><Reference><Citation>Maiter D (2019) Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology 109:42&#x2013;50. https://doi.org/10.1159/000495775</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000495775</ArticleId><ArticleId IdType=\"pubmed\">30481756</ArticleId></ArticleIdList></Reference><Reference><Citation>Giese S, Nasi-Kordhishti I, Honegger J (2021) Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases. Exp Clin Endocrinol Diabetes 129:163&#x2013;171. https://doi.org/10.1055/a-1247-4908</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1055/a-1247-4908</ArticleId><ArticleId IdType=\"pubmed\">33461233</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampourlou M, Trifanescu R, Paluzzi A, Ahmed SK, Karavitaki N (2016) Therapy of endocrine disease: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol 175:R89-96. https://doi.org/10.1530/EJE-16-0087</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-16-0087</ArticleId><ArticleId IdType=\"pubmed\">27207245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda H, Watanabe K, Tominaga T, Yoshimoto T (2013) Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg 115:1621&#x2013;1625. https://doi.org/10.1016/j.clineuro.2013.02.016</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.clineuro.2013.02.016</ArticleId><ArticleId IdType=\"pubmed\">23498159</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, Peul WC, Dekkers OM, van Furth WR, Biermasz NR (2020) Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 105:e32-41. https://doi.org/10.1210/clinem/dgz144</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgz144</ArticleId><ArticleId IdType=\"pubmed\">31665485</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10:804&#x2013;826. https://doi.org/10.1016/S2213-8587(22)00244-3</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-8587(22)00244-3</ArticleId><ArticleId IdType=\"pubmed\">36209758</ArticleId></ArticleIdList></Reference><Reference><Citation>Starnoni D, Daniel RT, Marino L, Pitteloud N, Levivier M, Messerer M (2016) Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochir (Wien) 158:2109&#x2013;2121. https://doi.org/10.1007/s00701-016-2903-4</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00701-016-2903-4</ArticleId><ArticleId IdType=\"pubmed\">27586125</ArticleId></ArticleIdList></Reference><Reference><Citation>Varlamov EV, McCartney S, Fleseriu M (2019) Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies. Eur Endocrinol 15:30&#x2013;40. https://doi.org/10.17925/EE.2019.15.1.30</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.17925/EE.2019.15.1.30</ArticleId><ArticleId IdType=\"pubmed\">31244908</ArticleId><ArticleId IdType=\"pmc\">6587904</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical &#x201c;cure.&#x201d; Eur J Endocrinol 152:379&#x2013;387. https://doi.org/10.1530/eje.1.01863</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/eje.1.01863</ArticleId><ArticleId IdType=\"pubmed\">15757854</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez Mateos C, Garcia-Uria M, Morante TL, Garcia-Uria J (2017) Acromegaly: surgical results in 548 patients. Pituitary 20:522&#x2013;528. https://doi.org/10.1007/s11102-017-0813-y</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-017-0813-y</ArticleId><ArticleId IdType=\"pubmed\">28589294</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24:1&#x2013;13. https://doi.org/10.1007/s11102-020-01091-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-020-01091-7</ArticleId><ArticleId IdType=\"pubmed\">33079318</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S (2020) Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord 21:667&#x2013;678. https://doi.org/10.1007/s11154-020-09588-z</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11154-020-09588-z</ArticleId><ArticleId IdType=\"pubmed\">32914330</ArticleId><ArticleId IdType=\"pmc\">7942783</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S, Acromegaly Consensus G (2014) Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10:243&#x2013;248. https://doi.org/10.1038/nrendo.2014.21</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/nrendo.2014.21</ArticleId><ArticleId IdType=\"pubmed\">24566817</ArticleId></ArticleIdList></Reference><Reference><Citation>Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14:552&#x2013;561. https://doi.org/10.1038/s41574-018-0058-5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41574-018-0058-5</ArticleId><ArticleId IdType=\"pubmed\">30050156</ArticleId><ArticleId IdType=\"pmc\">7136157</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael JD, Bonert VS, Nuno M, Ly D, Melmed S (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99:1825&#x2013;1833. https://doi.org/10.1210/jc.2013-3757</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2013-3757</ArticleId><ArticleId IdType=\"pubmed\">24606084</ArticleId><ArticleId IdType=\"pmc\">4010703</ArticleId></ArticleIdList></Reference><Reference><Citation>Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405&#x2013;4410. https://doi.org/10.1210/jc.2004-2466</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2004-2466</ArticleId><ArticleId IdType=\"pubmed\">15827109</ArticleId></ArticleIdList></Reference><Reference><Citation>Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F, Lombardi G, Pivonello R, Ferone D (2009) Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 71:237&#x2013;245. https://doi.org/10.1111/j.1365-2265.2008.03503.x</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1365-2265.2008.03503.x</ArticleId><ArticleId IdType=\"pubmed\">19094074</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G, Maisonobe P, Clermont A, Investigators P (2014) Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99:1282&#x2013;1290. https://doi.org/10.1210/jc.2013-3318</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2013-3318</ArticleId><ArticleId IdType=\"pubmed\">24423301</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM, Group PI (2016) Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 19:149&#x2013;157. https://doi.org/10.1007/s11102-015-0693-y</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-015-0693-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, de Marinis L, Degli Uberti E, Bogazzi F, Mazziotti G, Minuto F, Montini M, Ghigo E (2009) High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161:331&#x2013;338. https://doi.org/10.1530/EJE-09-0372</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-09-0372</ArticleId><ArticleId IdType=\"pubmed\">19465485</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustina A, Mazziotti G, Cannavo S, Castello R, Arnaldi G, Bugari G, Cozzi R, Ferone D, Formenti AM, Gatti E, Grottoli S, Maffei P, Maffezzoni F, Montini M, Terzolo M, Ghigo E (2017) High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. J Clin Endocrinol Metab 102:2454&#x2013;2464. https://doi.org/10.1210/jc.2017-00142</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2017-00142</ArticleId><ArticleId IdType=\"pubmed\">28419317</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Zhang Z, Hanman K, Haria K, Houchard A, Khawaja S, Ribeiro-Oliveira A Jr, Gadelha M (2023) A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly. Pituitary 26:9&#x2013;41. https://doi.org/10.1007/s11102-022-01285-1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-022-01285-1</ArticleId><ArticleId IdType=\"pubmed\">36447058</ArticleId></ArticleIdList></Reference><Reference><Citation>Maione L, Albrici C, Grunenwald S, Mouly C, Cimino V, Lecoq AL, Souberbielle JC, Caron P, Chanson P (2022) IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands. J Clin Endocrinol Metab 107:e3644&#x2013;e3653. https://doi.org/10.1210/clinem/dgac385</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgac385</ArticleId><ArticleId IdType=\"pubmed\">35772775</ArticleId></ArticleIdList></Reference><Reference><Citation>Strasburger CJ, Karavitaki N, Stormann S, Trainer PJ, Kreitschmann-Andermahr I, Droste M, Korbonits M, Feldmann B, Zopf K, Sanderson VF, Schwicker D, Gelbaum D, Haviv A, Bidlingmaier M, Biermasz NR (2016) Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol 174:355&#x2013;362. https://doi.org/10.1530/EJE-15-1042</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-15-1042</ArticleId><ArticleId IdType=\"pubmed\">26744896</ArticleId><ArticleId IdType=\"pmc\">4722610</ArticleId></ArticleIdList></Reference><Reference><Citation>Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D, Liu S, Mathias SD, Shi L (2020) Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary 23:140&#x2013;148. https://doi.org/10.1007/s11102-019-01013-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-019-01013-2</ArticleId><ArticleId IdType=\"pubmed\">31808101</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, Ur E, Molitch M, Ludlam WH, Patou G, Haviv A, Biermasz N, Giustina A, Trainer PJ, Strasburger CJ, Kennedy L, Melmed S (2020) Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. J Clin Endocrinol Metab 105:e3785-3797. https://doi.org/10.1210/clinem/dgaa526</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgaa526</ArticleId><ArticleId IdType=\"pubmed\">32882036</ArticleId><ArticleId IdType=\"pmc\">7470473</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadelha MR, Gordon MB, Doknic M, Mezosi E, Toth M, Randeva H, Marmon T, Jochelson T, Luo R, Monahan M, Madan A, Ferrara-Cook C, Struthers RS, Krasner A (2023) ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly. J Clin Endocrinol Metab 108:e148&#x2013;e159. https://doi.org/10.1210/clinem/dgac643</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgac643</ArticleId><ArticleId IdType=\"pubmed\">36353760</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, Landau I, Karmeli I, Bidlingmaier M, Strasburger CJ, Kleinberg DL, Melmed S, Mamluk R (2012) Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 97:2362&#x2013;2369. https://doi.org/10.1210/jc.2012-1179</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2012-1179</ArticleId><ArticleId IdType=\"pubmed\">22539587</ArticleId></ArticleIdList></Reference><Reference><Citation>Labadzhyan A, Nachtigall LB, Fleseriu M, Gordon MB, Molitch M, Kennedy L, Samson SL, Greenman Y, Biermasz N, Bolanowski M, Haviv A, Ludlam W, Patou G, Strasburger CJ (2021) Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary 24:943&#x2013;953. https://doi.org/10.1007/s11102-021-01163-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-021-01163-2</ArticleId><ArticleId IdType=\"pubmed\">34173129</ArticleId><ArticleId IdType=\"pmc\">8550586</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ (2022) Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 10:102&#x2013;111. https://doi.org/10.1016/S2213-8587(21)00296-5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-8587(21)00296-5</ArticleId><ArticleId IdType=\"pubmed\">34953531</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Molitch M, Dreval A, Pokramovich Y, Bondar I, Poteshkin Y, Macut D, Obermayer-Pietsch B, Gilgun-Sherki Y, Haviv A, Biermasz N, Strasburger CJ (2023) MPOWERED Trial Open-Label Extension: Long-Term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgad365</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgad365</ArticleId><ArticleId IdType=\"pubmed\">37319438</ArticleId><ArticleId IdType=\"pmc\">10655542</ArticleId></ArticleIdList></Reference><Reference><Citation>Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Resendiz K, Ruffin M, Chen Y, Sheppard M, Pasireotide CSG (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791&#x2013;799. https://doi.org/10.1210/jc.2013-2480</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2013-2480</ArticleId><ArticleId IdType=\"pubmed\">24423324</ArticleId><ArticleId IdType=\"pmc\">3965714</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM, Pasireotide Acromegaly Study G (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95:2781&#x2013;2789. https://doi.org/10.1210/jc.2009-2272</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2009-2272</ArticleId></ArticleIdList></Reference><Reference><Citation>Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol 182:583. https://doi.org/10.1530/EJE-19-0762</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-19-0762</ArticleId><ArticleId IdType=\"pubmed\">32217809</ArticleId><ArticleId IdType=\"pmc\">7222286</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A, Pasireotide CSG (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875&#x2013;884. https://doi.org/10.1016/S2213-8587(14)70169-X</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-8587(14)70169-X</ArticleId><ArticleId IdType=\"pubmed\">25260838</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, van der Lely AJ, Ravichandran S, Kandra A, Pedroncelli AM, Colao AAL (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect 9:1178&#x2013;1190. https://doi.org/10.1530/EC-20-0361</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EC-20-0361</ArticleId><ArticleId IdType=\"pubmed\">33434154</ArticleId><ArticleId IdType=\"pmc\">7774766</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiodini PG, Liuzzi A, Botalla L, Cremascoli G, Silvestrini F (1974) Inhibitory effect of dopaminergic stimulation on GH release in acromegaly. J Clin Endocrinol Metab 38:200&#x2013;206. https://doi.org/10.1210/jcem-38-2-200</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jcem-38-2-200</ArticleId><ArticleId IdType=\"pubmed\">4812616</ArticleId></ArticleIdList></Reference><Reference><Citation>Spada A, Sartorio A, Bassetti M, Pezzo G, Giannattasio G (1982) In vitro effect of dopamine on growth hormone (GH) release from human GH-secreting pituitary adenomas. J Clin Endocrinol Metab 55:734&#x2013;740. https://doi.org/10.1210/jcem-55-4-734</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jcem-55-4-734</ArticleId><ArticleId IdType=\"pubmed\">7107817</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96:1327&#x2013;1335. https://doi.org/10.1210/jc.2010-2443</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2010-2443</ArticleId><ArticleId IdType=\"pubmed\">21325455</ArticleId></ArticleIdList></Reference><Reference><Citation>Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933&#x2013;3951. https://doi.org/10.1210/jc.2014-2700</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2014-2700</ArticleId><ArticleId IdType=\"pubmed\">25356808</ArticleId></ArticleIdList></Reference><Reference><Citation>Marazuela M, Ramos-Levi A, Sampedro-Nunez M, Bernabeu I (2014) Cabergoline treatment in acromegaly: pros. Endocrine 46:215&#x2013;219. https://doi.org/10.1007/s12020-014-0206-1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12020-014-0206-1</ArticleId><ArticleId IdType=\"pubmed\">24532103</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasuki L, Vieira Neto L, Gadelha MR (2014) Cabergoline treatment in acromegaly: cons. Endocrine 46:220&#x2013;225. https://doi.org/10.1007/s12020-014-0183-4</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12020-014-0183-4</ArticleId><ArticleId IdType=\"pubmed\">24504766</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonart LP, Tonin FS, Ferreira VL, Fernandez-Llimos F, Pontarolo R (2019) Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine 63:18&#x2013;26. https://doi.org/10.1007/s12020-018-1729-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12020-018-1729-7</ArticleId><ArticleId IdType=\"pubmed\">30145746</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Fuhrer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J, Hey-Hadavi J, Camacho-Hubner C, Wajnrajch MP, Valluri SR, Palladino AA, Gomez R, Salvatori R (2021) More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol 185:525&#x2013;538. https://doi.org/10.1530/EJE-21-0239</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-21-0239</ArticleId><ArticleId IdType=\"pubmed\">34342594</ArticleId><ArticleId IdType=\"pmc\">8428076</ArticleId></ArticleIdList></Reference><Reference><Citation>Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (2015) Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract 21:264&#x2013;274. https://doi.org/10.4158/EP14330.OR</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.4158/EP14330.OR</ArticleId><ArticleId IdType=\"pubmed\">25370326</ArticleId><ArticleId IdType=\"pmc\">4618502</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Barkan A, Brue T, Duquesne E, Houchard A, Del Pilar SM, Ribeiro-Oliveira A Jr, Melmed S (2023) Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis. J Endocr Soc 7:bvad104. https://doi.org/10.1210/jendso/bvad104</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jendso/bvad104</ArticleId><ArticleId IdType=\"pubmed\">37705695</ArticleId><ArticleId IdType=\"pmc\">10496868</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, Angelini F, Liverana L, Gessi M, Carmelo A, Rindi G, Giustina A, Fleseriu M, Pontecorvi A, De Marinis L, Bianchi A (2021) Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol 184:217&#x2013;229. https://doi.org/10.1530/EJE-20-0767</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-20-0767</ArticleId><ArticleId IdType=\"pubmed\">33136550</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S, Giampietro A, Visconti F, Rossi L, Donfrancesco F, Fleseriu CM, Mirra F, Pontecorvi A, Giustina A, Fleseriu M, De Marinis L, Bianchi A (2021) Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine 73:658&#x2013;666. https://doi.org/10.1007/s12020-021-02711-3</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12020-021-02711-3</ArticleId><ArticleId IdType=\"pubmed\">33907985</ArticleId><ArticleId IdType=\"pmc\">8325668</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonert V, Mirocha J, Carmichael J, Yuen KCJ, Araki T, Melmed S (2020) Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial. J Clin Endocrinol Metab 105. https://doi.org/10.1210/clinem/dgaa444</Citation></Reference><Reference><Citation>Muhammad A, van der Lely AJ, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen J, Neggers S (2018) Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). J Clin Endocrinol Metab 103:586&#x2013;595. https://doi.org/10.1210/jc.2017-02017</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2017-02017</ArticleId><ArticleId IdType=\"pubmed\">29155991</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad A, Coopmans EC, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen J, van der Lely AJ, Neggers S (2018) Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study. Eur J Endocrinol 179:269&#x2013;277. https://doi.org/10.1530/EJE-18-0353</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-18-0353</ArticleId><ArticleId IdType=\"pubmed\">30076159</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasso LFS, Auriemma RS, Pivonello R, Colao A (2017) Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly. Expert Rev Endocrinol Metab 12:73&#x2013;85. https://doi.org/10.1080/17446651.2016.1222899</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/17446651.2016.1222899</ArticleId><ArticleId IdType=\"pubmed\">30058878</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernabeu I, Alvarez-Escola C, Paniagua AE, Lucas T, Pavon I, Cabezas-Agricola JM, Casanueva FF, Marazuela M (2013) Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16:101&#x2013;108. https://doi.org/10.1007/s11102-012-0382-z</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-012-0382-z</ArticleId><ArticleId IdType=\"pubmed\">22396133</ArticleId></ArticleIdList></Reference><Reference><Citation>Reincke M, Fleseriu M (2023) Cushing Syndrome: A Review. JAMA 330:170&#x2013;181. https://doi.org/10.1001/jama.2023.11305</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2023.11305</ArticleId><ArticleId IdType=\"pubmed\">37432427</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK (2021) Consensus on diagnosis and management of Cushing&#x2019;s disease: a guideline update. Lancet Diabetes Endocrinol 9:847&#x2013;875. https://doi.org/10.1016/S2213-8587(21)00235-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-8587(21)00235-7</ArticleId><ArticleId IdType=\"pubmed\">34687601</ArticleId><ArticleId IdType=\"pmc\">8743006</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, Langlois F, Melmed S (2023) An individualized approach to the management of Cushing disease. Nat Rev Endocrinol 19:581&#x2013;599. https://doi.org/10.1038/s41574-023-00868-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41574-023-00868-7</ArticleId><ArticleId IdType=\"pubmed\">37537306</ArticleId></ArticleIdList></Reference><Reference><Citation>Melmed S (2020) Pituitary-Tumor Endocrinopathies. N Engl J Med 382:937&#x2013;950. https://doi.org/10.1056/NEJMra1810772</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMra1810772</ArticleId><ArticleId IdType=\"pubmed\">32130815</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A, Endocrine S (2015) Treatment of Cushing&#x2019;s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100:2807&#x2013;2831. https://doi.org/10.1210/jc.2015-1818</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2015-1818</ArticleId><ArticleId IdType=\"pubmed\">26222757</ArticleId><ArticleId IdType=\"pmc\">4525003</ArticleId></ArticleIdList></Reference><Reference><Citation>Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Pasireotide BSG (2012) A 12-month phase 3 study of pasireotide in Cushing&#x2019;s disease. N Engl J Med 366:914&#x2013;924. https://doi.org/10.1056/NEJMoa1105743</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1105743</ArticleId><ArticleId IdType=\"pubmed\">22397653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J, Pasireotide GSG (2018) Efficacy and safety of once-monthly pasireotide in Cushing&#x2019;s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6:17&#x2013;26. https://doi.org/10.1016/S2213-8587(17)30326-1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-8587(17)30326-1</ArticleId><ArticleId IdType=\"pubmed\">29032078</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Petersenn S, Biller BMK, Kadioglu P, De Block C, T&#x2019;Sjoen G, Vantyghem MC, Tauchmanova L, Wojna J, Roughton M, Lacroix A, Newell-Price J (2019) Long-term efficacy and safety of once-monthly pasireotide in Cushing&#x2019;s disease: A Phase III extension study. Clin Endocrinol (Oxf) 91:776&#x2013;785. https://doi.org/10.1111/cen.14081</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/cen.14081</ArticleId><ArticleId IdType=\"pubmed\">31465533</ArticleId></ArticleIdList></Reference><Reference><Citation>Manetti L, Deutschbein T, Schopohl J, Yuen KCJ, Roughton M, Kriemler-Krahn U, Tauchmanova L, Maamari R, Giordano C (2019) Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing&#x2019;s disease: interim results from a long-term real-world evidence study. Pituitary 22:542&#x2013;551. https://doi.org/10.1007/s11102-019-00984-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-019-00984-6</ArticleId><ArticleId IdType=\"pubmed\">31440946</ArticleId><ArticleId IdType=\"pmc\">6728293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix A, Bronstein MD, Schopohl J, Delibasi T, Salvatori R, Li Y, Barkan A, Suzaki N, Tauchmanova L, Ortmann CE, Ravichandran S, Petersenn S, Pivonello R (2020) Long-acting pasireotide improves clinical signs and quality of life in Cushing&#x2019;s disease: results from a phase III study. J Endocrinol Invest 43:1613&#x2013;1622. https://doi.org/10.1007/s40618-020-01246-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s40618-020-01246-0</ArticleId><ArticleId IdType=\"pubmed\">32385851</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha MR, Petersenn S, Tauchmanova L, Ravichandran S, Gupta P, Lacroix A, Biller BMK (2020) Use of late-night salivary cortisol to monitor response to medical treatment in Cushing&#x2019;s disease. Eur J Endocrinol 182:207&#x2013;217. https://doi.org/10.1530/EJE-19-0695</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-19-0695</ArticleId><ArticleId IdType=\"pubmed\">31804965</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM, Pasireotide BSG (2014) Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing&#x2019;s disease: results from a Phase III study. Clin Endocrinol (Oxf) 81:408&#x2013;417. https://doi.org/10.1111/cen.12431</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/cen.12431</ArticleId><ArticleId IdType=\"pubmed\">24533697</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto F, Arvigo M, Ferone D (2020) Somatostatin receptor expression and patients&#x2019; response to targeted medical treatment in pituitary tumors: evidences and controversies. J Endocrinol Invest 43:1543&#x2013;1553. https://doi.org/10.1007/s40618-020-01335-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s40618-020-01335-0</ArticleId><ArticleId IdType=\"pubmed\">32557353</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, Witek P, Kalra P, Pedroncelli AM, Pultar P, Jabbour N, Paul M, Bolanowski M (2021) Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary 24:887&#x2013;903. https://doi.org/10.1007/s11102-021-01161-4</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-021-01161-4</ArticleId><ArticleId IdType=\"pubmed\">34275099</ArticleId><ArticleId IdType=\"pmc\">8550309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O, Reznik Y, Bertherat J, Rohmer V, Briet C, Raingeard I, Castinetti F, Beckers A, Vroonen L, Maiter D, Cephise-Velayoudom FL, Nunes ML, Haissaguerre M, Tabarin A (2017) Cabergoline for Cushing&#x2019;s disease: a large retrospective multicenter study. Eur J Endocrinol 176:305&#x2013;314. https://doi.org/10.1530/EJE-16-0662</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-16-0662</ArticleId><ArticleId IdType=\"pubmed\">28007845</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivonello R, Pivonello C, Simeoli C, De Martino MC, Colao A (2022) The dopaminergic control of Cushing&#x2019;s syndrome. J Endocrinol Invest 45:1297&#x2013;1315. https://doi.org/10.1007/s40618-021-01661-x</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s40618-021-01661-x</ArticleId><ArticleId IdType=\"pubmed\">35460460</ArticleId><ArticleId IdType=\"pmc\">9184412</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoes Correa Galendi J, Correa Neto ANS, Demetres M, Boguszewski CL, Nogueira V (2021) Effectiveness of Medical Treatment of Cushing&#x2019;s Disease: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 12:732240. https://doi.org/10.3389/fendo.2021.732240</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fendo.2021.732240</ArticleId><ArticleId IdType=\"pubmed\">34603209</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinescu SM, Driessens N, Lefebvre A, Furnica RM, Corvilain B, Maiter D (2020) Etomidate infusion at low doses is an effective and safe treatment for severe Cushing&#x2019;s syndrome outside intensive care. Eur J Endocrinol 183:161&#x2013;167. https://doi.org/10.1530/EJE-20-0380</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-20-0380</ArticleId><ArticleId IdType=\"pubmed\">32449698</ArticleId></ArticleIdList></Reference><Reference><Citation>Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, Caron P, Luca F, Donadille B, Vantyghem MC, Bihan H, Delemer B, Raverot G, Motte E, Philippon M, Morange I, Conte-Devolx B, Quinquis L, Martinie M, Vezzosi D, Le Bras M, Baudry C, Christin-Maitre S, Goichot B, Chanson P, Young J, Chabre O, Tabarin A, Bertherat J, Brue T (2014) Ketoconazole in Cushing&#x2019;s disease: is it worth a try? J Clin Endocrinol Metab 99:1623&#x2013;1630. https://doi.org/10.1210/jc.2013-3628</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2013-3628</ArticleId><ArticleId IdType=\"pubmed\">24471573</ArticleId></ArticleIdList></Reference><Reference><Citation>Viecceli C, Mattos ACV, Costa MCB, de Melo RB, Rodrigues TDC, Czepielewski MA (2022) Evaluation of ketoconazole as a treatment for Cushing&#x2019;s disease in a retrospective cohort. Front Endocrinol (Lausanne) 13:1017331. https://doi.org/10.3389/fendo.2022.1017331</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fendo.2022.1017331</ArticleId><ArticleId IdType=\"pubmed\">36277689</ArticleId></ArticleIdList></Reference><Reference><Citation>Young J, Bertherat J, Vantyghem MC, Chabre O, Senoussi S, Chadarevian R, Castinetti F, Compassionalteuse P (2018) Hepatic safety of ketoconazole in Cushing&#x2019;s syndrome: results of a Compassionate Use Programme in France. Eur J Endocrinol 178:447&#x2013;458. https://doi.org/10.1530/EJE-17-0886</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-17-0886</ArticleId><ArticleId IdType=\"pubmed\">29472378</ArticleId></ArticleIdList></Reference><Reference><Citation>Creemers SG, Feelders RA, de Jong FH, Franssen GJH, de Rijke YB, van Koetsveld PM, Hofland LJ (2021) Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing&#x2019;s Syndrome Treatment. J Clin Endocrinol Metab 106:e1618&#x2013;e1630. https://doi.org/10.1210/clinem/dgaa989</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgaa989</ArticleId><ArticleId IdType=\"pubmed\">33399817</ArticleId></ArticleIdList></Reference><Reference><Citation>Varlamov EV, Han AJ, Fleseriu M (2021) Updates in adrenal steroidogenesis inhibitors for Cushing&#x2019;s syndrome - A practical guide. Best Pract Res Clin Endocrinol Metab 35:101490. https://doi.org/10.1016/j.beem.2021.101490</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.beem.2021.101490</ArticleId><ArticleId IdType=\"pubmed\">33707082</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA, Geer EB, Greenman Y, Witek P, Cohen F, Biller BMK (2019) Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing&#x2019;s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol 7:855&#x2013;865. https://doi.org/10.1016/S2213-8587(19)30313-4</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-8587(19)30313-4</ArticleId><ArticleId IdType=\"pubmed\">31542384</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivonello R, Elenkova A, Fleseriu M, Feelders RA, Witek P, Greenman Y, Geer EB, Perotti P, Saiegh L, Cohen F, Arnaldi G (2021) Levoketoconazole in the Treatment of Patients With Cushing&#x2019;s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. Front Endocrinol (Lausanne) 12:595894. https://doi.org/10.3389/fendo.2021.595894</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fendo.2021.595894</ArticleId><ArticleId IdType=\"pubmed\">33897615</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivonello R, Zacharieva S, Elenkova A, Toth M, Shimon I, Stigliano A, Badiu C, Brue T, Georgescu CE, Tsagarakis S, Cohen F, Fleseriu M (2022) Levoketoconazole in the treatment of patients with endogenous Cushing&#x2019;s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary 25:911&#x2013;926. https://doi.org/10.1007/s11102-022-01263-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-022-01263-7</ArticleId><ArticleId IdType=\"pubmed\">36085339</ArticleId><ArticleId IdType=\"pmc\">9675660</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Auchus RJ, Greenman Y, Zacharieva S, Geer EB, Salvatori R, Pivonello R, Feldt-Rasmussen U, Kennedy L, Buchfelder M, Biller BM, Cohen F, Heaney AP (2022) Levoketoconazole treatment in endogenous Cushing&#x2019;s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. Eur J Endocrinol 187:859&#x2013;871. https://doi.org/10.1530/EJE-22-0506</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-22-0506</ArticleId><ArticleId IdType=\"pubmed\">36251618</ArticleId><ArticleId IdType=\"pmc\">9716395</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O&#x2019;Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK, Investigators L (2020) Efficacy and safety of osilodrostat in patients with Cushing&#x2019;s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8:748&#x2013;761. https://doi.org/10.1016/S2213-8587(20)30240-010.1016/S2213-8587(20)30240-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-8587(20)30240-010.1016/S2213-8587(20)30240-0</ArticleId><ArticleId IdType=\"pubmed\">32730798</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, Witek P, Belaya Z, Yu Y, Liao Z, Ku CHC, Carvalho D, Roughton M, Wojna J, Pedroncelli AM, Snyder PJ (2022) Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. J Clin Endocrinol Metab 107:e2882&#x2013;e2895. https://doi.org/10.1210/clinem/dgac178</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgac178</ArticleId><ArticleId IdType=\"pubmed\">35325149</ArticleId><ArticleId IdType=\"pmc\">9202723</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, Arnaldi G, O&#x2019;Connell P, Izquierdo M, Pedroncelli AM, Pivonello R (2022) Long-term efficacy and safety of osilodrostat in Cushing&#x2019;s disease: final results from a Phase II study with an optional extension phase (LINC 2). Pituitary 25:959&#x2013;970. https://doi.org/10.1007/s11102-022-01280-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-022-01280-6</ArticleId><ArticleId IdType=\"pubmed\">36219274</ArticleId><ArticleId IdType=\"pmc\">9675663</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C, Belaya Z, Feelders RA, Vila G, Houde G, Walia R, Izquierdo M, Roughton M, Pedroncelli AM, Biller BMK (2022) Long-term outcomes of osilodrostat in Cushing&#x2019;s disease: LINC 3 study extension. Eur J Endocrinol 187:531&#x2013;541. https://doi.org/10.1530/EJE-22-0317</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-22-0317</ArticleId><ArticleId IdType=\"pubmed\">35980235</ArticleId><ArticleId IdType=\"pmc\">9513654</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Findling JW, Auchus RJ (2022) Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome. Pituitary 25:393&#x2013;403. https://doi.org/10.1007/s11102-022-01218-y</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-022-01218-y</ArticleId><ArticleId IdType=\"pubmed\">35471718</ArticleId><ArticleId IdType=\"pmc\">9170649</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontaine-Sylvestre C, Letourneau-Guillon L, Moumdjian RA, Berthelet F, Lacroix A (2021) Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing&#x2019;s disease. Pituitary 24:207&#x2013;215. https://doi.org/10.1007/s11102-020-01097-1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-020-01097-1</ArticleId><ArticleId IdType=\"pubmed\">33074401</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowotny HF, Braun L, Vogel F, Bidlingmaier M, Reincke M, Tschaidse L, Auer MK, Lottspeich C, Wudy SA, Hartmann MF, Hawley J, Adaway JE, Keevil B, Schilbach K, Reisch N (2022) 11-Oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing&#x2019;s disease. Eur J Endocrinol 187:663&#x2013;673. https://doi.org/10.1530/EJE-22-0320</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-22-0320</ArticleId><ArticleId IdType=\"pubmed\">36074938</ArticleId><ArticleId IdType=\"pmc\">9578081</ArticleId></ArticleIdList></Reference><Reference><Citation>Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 33:6&#x2013;26. https://doi.org/10.1007/s12022-022-09703-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12022-022-09703-7</ArticleId><ArticleId IdType=\"pubmed\">35291028</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieman LBM, Scaroni CM, Deutschbein T, Mezosi E, Driessens N, Georgescu CE, Hubalewska DA, Berker D, Jarzab BM, Maiter DM, Reincke M, Loli P, Zampetti B, Atmaca A, Badiu C, Beckers AM, Bolanowski M, Cavagnini F, Unger N, Giordano RF, Hanzu FA, Terzolo M, Bostnavaron M, Toth M (2021) Metyrapone treatment in endogenous Cushing&#x2019;s syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III/IV study. J Endocr Soc 5:515</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jendso/bvab048.1053</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet-Serrano F, Poirier J, Vaczlavik A, Laguillier-Morizot C, Blanchet B, Baron S, Guignat L, Bessiene L, Bricaire L, Groussin L, Assie G, Guibourdenche J, Bertherat J (2022) Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients. Eur J Endocrinol 187:315&#x2013;322. https://doi.org/10.1530/EJE-22-0208</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-22-0208</ArticleId><ArticleId IdType=\"pubmed\">35699971</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, Investigators SS (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing&#x2019;s syndrome. J Clin Endocrinol Metab 97:2039&#x2013;2049. https://doi.org/10.1210/jc.2011-3350</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2011-3350</ArticleId><ArticleId IdType=\"pubmed\">22466348</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C (2014) Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing&#x2019;s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab 99:3718&#x2013;3727. https://doi.org/10.1210/jc.2014-1843</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2014-1843</ArticleId><ArticleId IdType=\"pubmed\">25013998</ArticleId><ArticleId IdType=\"pmc\">4399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM (2018) Effectiveness of medical treatment for Cushing&#x2019;s syndrome: a systematic review and meta-analysis. Pituitary 21:631&#x2013;641. https://doi.org/10.1007/s11102-018-0897-z</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-018-0897-z</ArticleId><ArticleId IdType=\"pubmed\">29855779</ArticleId><ArticleId IdType=\"pmc\">6244780</ArticleId></ArticleIdList></Reference><Reference><Citation>Feelders RA, Fleseriu M, Kadioglu P, Bex M, Gonzalez-Devia D, Boguszewski CL, Yavuz DG, Patino H, Pedroncelli AM, Maamari R, Chattopadhyay A, Biller BMK, Pivonello R (2023) Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing&#x2019;s disease. Front Endocrinol (Lausanne) 14:1165681. https://doi.org/10.3389/fendo.2023.1165681</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fendo.2023.1165681</ArticleId><ArticleId IdType=\"pubmed\">37876540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadelha MR, Wildemberg LE, Shimon I (2022) Pituitary acting drugs: cabergoline and pasireotide. Pituitary 25:722&#x2013;725. https://doi.org/10.1007/s11102-022-01238-8</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11102-022-01238-8</ArticleId><ArticleId IdType=\"pubmed\">35670988</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenblatt HK, Greenblatt DJ (2014) Liver injury associated with ketoconazole: review of the published evidence. J Clin Pharmacol 54:1321&#x2013;1329. https://doi.org/10.1002/jcph.400</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/jcph.400</ArticleId><ArticleId IdType=\"pubmed\">25216238</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, Pereira AM, Sorensen HT (2013) Multisystem morbidity and mortality in Cushing&#x2019;s syndrome: a cohort study. J Clin Endocrinol Metab 98:2277&#x2013;2284. https://doi.org/10.1210/jc.2012-3582</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jc.2012-3582</ArticleId><ArticleId IdType=\"pubmed\">23533241</ArticleId></ArticleIdList></Reference><Reference><Citation>De Herdt C, Philipse E, De Block C (2021) ENDOCRINE TUMOURS: Thyrotropin-secreting pituitary adenoma: a structured review of 535 adult cases. Eur J Endocrinol 185:R65&#x2013;R74. https://doi.org/10.1530/EJE-21-0162</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-21-0162</ArticleId><ArticleId IdType=\"pubmed\">34132199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N (2014) Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg 121:1462&#x2013;1473. https://doi.org/10.3171/2014.7.JNS1471</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3171/2014.7.JNS1471</ArticleId><ArticleId IdType=\"pubmed\">25237847</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara N, Horiguchi K, Nishioka H, Suzuki H, Takeshita A, Takeuchi Y, Inoshita N, Yamada S (2015) Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma. Endocr J 62:21&#x2013;27. https://doi.org/10.1507/endocrj.EJ14-0118</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1507/endocrj.EJ14-0118</ArticleId><ArticleId IdType=\"pubmed\">25273395</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL (2013) 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2:76&#x2013;82. https://doi.org/10.1159/000351007</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000351007</ArticleId><ArticleId IdType=\"pubmed\">24783044</ArticleId><ArticleId IdType=\"pmc\">3821512</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntali G, Capatina C (2022) Updating the Landscape for Functioning Gonadotroph Tumors. Medicina (Kaunas) 58. https://doi.org/10.3390/medicina58081071</Citation></Reference><Reference><Citation>Zhao J, Wang S, Markison S, Kim SH, Han S, Chen M, Kusnetzow AK, Rico-Bautista E, Johns M, Luo R, Struthers RS, Madan A, Zhu Y, Betz SF (2023) Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist. ACS Med Chem Lett 14:66&#x2013;74. https://doi.org/10.1021/acsmedchemlett.2c00431</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1021/acsmedchemlett.2c00431</ArticleId><ArticleId IdType=\"pubmed\">36655128</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavel M, Borson-Chazot F, Cailleux A, Horsch D, Lahner H, Pivonello R, Tauchmanova L, Darstein C, Olsson H, Tiberg F, Ferone D (2019) Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. Cancer Chemother Pharmacol 83:375&#x2013;385. https://doi.org/10.1007/s00280-018-3734-1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00280-018-3734-1</ArticleId><ArticleId IdType=\"pubmed\">30535537</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu NA, Ben-Shlomo A, Carmichael JD, Wang C, Swerdloff RS, Heaney AP, Barkhoudarian G, Kelly D, Noureddin M, Lu L, Desai M, Stolyarov Y, Yuen K, Mamelak AN, Mirocha J, Tighiouart M, Melmed S (2023) Treatment of Cushing Disease With Pituitary-Targeting Seliciclib. J Clin Endocrinol Metab 108:726&#x2013;735. https://doi.org/10.1210/clinem/dgac588</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgac588</ArticleId><ArticleId IdType=\"pubmed\">36214832</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N, Moraitis AG (2021) Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Front Endocrinol (Lausanne) 12:662865. https://doi.org/10.3389/fendo.2021.662865</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fendo.2021.662865</ArticleId><ArticleId IdType=\"pubmed\">34335465</ArticleId></ArticleIdList></Reference><Reference><Citation>Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM (2023) Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. J Clin Endocrinol Metab 108:1585&#x2013;1601. https://doi.org/10.1210/clinem/dgad098</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgad098</ArticleId><ArticleId IdType=\"pubmed\">36856733</ArticleId><ArticleId IdType=\"pmc\">10271233</ArticleId></ArticleIdList></Reference><Reference><Citation>Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, Theodoropoulou M, Raverot G, Dekkers OM, dagger ESEsc, (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187:593&#x2013;605. https://doi.org/10.1530/EJE-22-0440</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-22-0440</ArticleId><ArticleId IdType=\"pubmed\">36018781</ArticleId><ArticleId IdType=\"pmc\">9513638</ArticleId></ArticleIdList></Reference><Reference><Citation>Das L, Gupta N, Dutta P, Walia R, Vaiphei K, Rai A, Radotra BD, Gupta K, Sreedharanunni S, Ahuja CK, Bhansali A, Tripathi M, Sood R, Dhandapani S (2021) Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. Front Endocrinol (Lausanne) 12:774686. https://doi.org/10.3389/fendo.2021.774686</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fendo.2021.774686</ArticleId><ArticleId IdType=\"pubmed\">34975752</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack A (2022) Temozolomide in aggressive pituitary tumours and pituitary carcinomas. Best Pract Res Clin Endocrinol Metab 36:101713. https://doi.org/10.1016/j.beem.2022.101713</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.beem.2022.101713</ArticleId><ArticleId IdType=\"pubmed\">36274026</ArticleId></ArticleIdList></Reference><Reference><Citation>Das L, Rai A, Salunke P, Ahuja CK, Sood A, Radotra BD, Sood R, Korbonits M, Dutta P (2022) Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes. J Endocr Soc 6:bvab190. https://doi.org/10.1210/jendso/bvab190</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/jendso/bvab190</ArticleId><ArticleId IdType=\"pubmed\">35059545</ArticleId></ArticleIdList></Reference><Reference><Citation>Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, European Society of E (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1&#x2013;G24. https://doi.org/10.1530/EJE-17-0796</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-17-0796</ArticleId></ArticleIdList></Reference><Reference><Citation>Raverot G, Ilie MD (2022) Immunotherapy in pituitary carcinomas and aggressive pituitary tumors. Best Pract Res Clin Endocrinol Metab 36:101712. https://doi.org/10.1016/j.beem.2022.101712</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.beem.2022.101712</ArticleId><ArticleId IdType=\"pubmed\">36274025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper O, Bonert VS, Rudnick J, Pressman BD, Lo J, Salvatori R, Yuen KCJ, Fleseriu M, Melmed S (2021) EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. J Clin Endocrinol Metab 106:e917&#x2013;e925. https://doi.org/10.1210/clinem/dgaa805</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgaa805</ArticleId><ArticleId IdType=\"pubmed\">33150390</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersenn S, Heaney AP (2020) Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas. Rev Endocr Metab Disord 21:277&#x2013;286. https://doi.org/10.1007/s11154-020-09554-9</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11154-020-09554-9</ArticleId><ArticleId IdType=\"pubmed\">32415583</ArticleId></ArticleIdList></Reference><Reference><Citation>Coopmans EC, van Meyel SWF, Pieterman KJ, van Ipenburg JA, Hofland LJ, Donga E, Daly AF, Beckers A, van der Lely AJ, Neggers S (2019) Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. Eur J Endocrinol 181:K21&#x2013;K27. https://doi.org/10.1530/EJE-19-0279</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/EJE-19-0279</ArticleId><ArticleId IdType=\"pubmed\">31167168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Shlomo A, Melmed S (2010) Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 21:123&#x2013;133. https://doi.org/10.1016/j.tem.2009.12.003</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.tem.2009.12.003</ArticleId><ArticleId IdType=\"pubmed\">20149677</ArticleId><ArticleId IdType=\"pmc\">2834886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakuno F, Takahashi SI (2018) IGF1 receptor signaling pathways. J Mol Endocrinol 61:T69&#x2013;T86. https://doi.org/10.1530/JME-17-0311</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/JME-17-0311</ArticleId><ArticleId IdType=\"pubmed\">29535161</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228&#x2013;252. https://doi.org/10.1016/j.yfrne.2013.07.005</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.yfrne.2013.07.005</ArticleId><ArticleId IdType=\"pubmed\">23872332</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760595</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Print\">1869-6953</ISSN><JournalIssue CitedMedium=\"Print\"><PubDate><Year>2024</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Diabetes therapy : research, treatment and education of diabetes and related disorders</Title><ISOAbbreviation>Diabetes Ther</ISOAbbreviation></Journal><ArticleTitle>Therapy-Related Satisfaction and Quality of Life for Japanese People with Diabetes Using Rapid-Acting Insulin Analogs: A Web-Based Survey.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s13300-024-01584-9</ELocationID><Abstract><AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">People with diabetes require insulin to regulate blood glucose (BG); rapid-acting insulin analogs (RAIA) represent one approach for BG management. New fast-acting RAIA administered at the start of a meal suppress postprandial BG better than conventional RAIA. New RAIA are expected to confer higher treatment satisfaction and improved quality of life (QOL) than conventional RAIA.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">This cross-sectional, web-based survey in Japan (November 2022) included people with diabetes (type 1/2), aged&#x2009;&#x2265;&#x2009;18&#xa0;years, registered in the Rakuten Insight Diabetes Panel, using new and/or conventional RAIA. RAIA-specific satisfaction was evaluated by questions on RAIA use (scores: 1 [not at all satisfied]; 7 [very satisfied]) and QOL by the Diabetes Therapy-Related (DTR)-QOL questionnaire (scores: 0-100, 100&#x2009;=&#x2009;best) for the whole population (primary endpoint) and for new versus conventional RAIA users (secondary endpoint). Multiple regression models were used to compare new versus conventional RAIA users.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The analysis population comprised 217 people with diabetes (new RAIA, n&#x2009;=&#x2009;109; conventional RAIA, n&#x2009;=&#x2009;108). Mean (standard deviation) RAIA-specific satisfaction scores ranged from 5.1 (1.2) to 5.4 (1.2); DTR-QOL total score was 51.6 (20.4). RAIA satisfaction scores were numerically higher for new versus conventional RAIA users; no difference in DTR-QOL total score was observed. DTR-QOL satisfaction with treatment domain score was significantly higher in new versus conventional RAIA users (least squares mean difference [standard error]: 7.3 [3.1]; 95% confidence interval: 1.2, 13.4; P&#x2009;=&#x2009;0.0197). RAIA-specific satisfaction was higher among patients who discussed BG sufficiently with their doctor versus those who did not.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">New RAIA users have greater treatment satisfaction than conventional RAIA users. QOL was similar among new and conventional RAIA users, except for satisfaction with treatment, which was significantly higher among new RAIA users. Detailed explanations from the doctor to the person with diabetes about the relationship between new RAIA and BG status are essential. A graphical plain language summary is available with this article.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Ishii</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><Identifier Source=\"ORCID\">0000-0002-6214-0557</Identifier><AffiliationInfo><Affiliation>Department of Doctor-Patient Relationships, Nara Medical University, Nara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Maeda</LastName><ForeName>Yasutaka</ForeName><Initials>Y</Initials><Identifier Source=\"ORCID\">0000-0002-3259-5622</Identifier><AffiliationInfo><Affiliation>Patient Author; Clinic Masae Minami, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sato</LastName><ForeName>Manaka</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0001-7000-4769</Identifier><AffiliationInfo><Affiliation>Japan Drug Development &amp; Medical Affairs, Eli Lilly Japan K.K., Lilly Plaza One Bldg., 5-1-28, Isogamidori, Chuo-ku, Kobe, 651-0086, Japan. sato_manaka@lilly.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cai</LastName><ForeName>Zhihong</ForeName><Initials>Z</Initials><Identifier Source=\"ORCID\">0000-0002-3431-197X</Identifier><AffiliationInfo><Affiliation>Japan Drug Development &amp; Medical Affairs, Eli Lilly Japan K.K., Lilly Plaza One Bldg., 5-1-28, Isogamidori, Chuo-ku, Kobe, 651-0086, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Imori</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Japan Drug Development &amp; Medical Affairs, Eli Lilly Japan K.K., Lilly Plaza One Bldg., 5-1-28, Isogamidori, Chuo-ku, Kobe, 651-0086, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes Ther</MedlineTA><NlmUniqueID>101539025</NlmUniqueID><ISSNLinking>1869-6961</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Diabetes Therapy-Related Quality of Life questionnaire</Keyword><Keyword MajorTopicYN=\"N\">Diabetes mellitus</Keyword><Keyword MajorTopicYN=\"N\">Insulin aspart</Keyword><Keyword MajorTopicYN=\"N\">Insulin glulisine</Keyword><Keyword MajorTopicYN=\"N\">Insulin lispro</Keyword><Keyword MajorTopicYN=\"N\">Japan</Keyword><Keyword MajorTopicYN=\"N\">Quality of life</Keyword><Keyword MajorTopicYN=\"N\">Rapid-acting insulin analog</Keyword><Keyword MajorTopicYN=\"N\">Treatment satisfaction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760595</ArticleId><ArticleId IdType=\"doi\">10.1007/s13300-024-01584-9</ArticleId><ArticleId IdType=\"pii\">10.1007/s13300-024-01584-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization: Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes (2023). Accessed 18 July 2023.</Citation></Reference><Reference><Citation>International Diabetes Federation: IDF Diabetes Atlas, 10th edn. Brussels, Belgium, 2021. https://www.diabetesatlas.org (2022). Accessed 18 July 2023.</Citation></Reference><Reference><Citation>Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753&#x2013;86. https://doi.org/10.2337/dci22-0034 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2337/dci22-0034</ArticleId><ArticleId IdType=\"pubmed\">36148880</ArticleId><ArticleId IdType=\"pmc\">10008140</ArticleId></ArticleIdList></Reference><Reference><Citation>ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Introduction and methodology: standards of care in diabetes&#x2014;2023. Diabetes Care. 2022;46(Suppl 1):S1&#x2013;4. https://doi.org/10.2337/dc23-Sint .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2337/dc23-Sint</ArticleId><ArticleId IdType=\"pmc\">9810461</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2021;64(12):2609&#x2013;52. https://doi.org/10.1007/s00125-021-05568-3 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00125-021-05568-3</ArticleId><ArticleId IdType=\"pubmed\">34590174</ArticleId><ArticleId IdType=\"pmc\">8481000</ArticleId></ArticleIdList></Reference><Reference><Citation>Eli Lilly and Company: HUMALOG (insulin lispro injection). Prescribing information. https://uspl.lilly.com/humalog/humalog.html#pi (2023). Accessed 20 July 2023.</Citation></Reference><Reference><Citation>Novo Nordisk Inc.: NovoRapid<sup>&#xae;</sup> (insulin aspart). Package information. https://media.mycme.com/documents/42/novorapid_pi_august_2012_10451.pdf (2012). Accessed 20 July 2023.</Citation></Reference><Reference><Citation>Sanofi-Aventis U.S. LLC.: APIDRA<sup>&#xae;</sup> (insulin glulisine injection). https://products.sanofi.us/apidra/apidra.html (2019). Accessed 20 July 2023.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Devices Agency: Apidra<sup>&#xae;</sup> vial S.C. Injection [package insert] [Japanese]. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/780069_2492418A1024_1_10 (2020). Accessed 24 Aug 2023.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Devices Agency: NovoRapid<sup>&#xae;</sup> Injection 100 U/mL [package insert] [Japanese]. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/620023_2492415A3031_1_10 (2020). Accessed 24 Aug 2023.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Devices Agency: Humalog<sup>&#xae;</sup> Injection [package insert] [Japanese]. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/530471_2492414A2030_1_17 (2020). Accessed 24 Aug 2023.</Citation></Reference><Reference><Citation>Rassam AG, Zeise TM, Burge MR, Schade DS. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. Diabetes Care. 1999;22(1):133&#x2013;6. https://doi.org/10.2337/diacare.22.1.133 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2337/diacare.22.1.133</ArticleId><ArticleId IdType=\"pubmed\">10333914</ArticleId></ArticleIdList></Reference><Reference><Citation>Blevins T, Zhang Q, Frias JP, Jinnouchi H, Chang AM, PRONTO-T2D Investigators. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care. 2020;43(12):2991&#x2013;8. https://doi.org/10.2337/dc19-2550 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2337/dc19-2550</ArticleId><ArticleId IdType=\"pubmed\">32616612</ArticleId><ArticleId IdType=\"pmc\">7770265</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaff L, Cao D, Dellva MA, Tobian J, Miura J, Dahl D, et al. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020;22(10):1799&#x2013;807. https://doi.org/10.1111/dom.14100 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/dom.14100</ArticleId><ArticleId IdType=\"pubmed\">32488923</ArticleId><ArticleId IdType=\"pmc\">7539952</ArticleId></ArticleIdList></Reference><Reference><Citation>Heise T, Linnebjerg H, Coutant D, LaBell E, Zijlstra E, Kapitza C, et al. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: a phase 1 randomized, crossover study. Diabetes Obes Metab. 2020;22(10):1789&#x2013;98. https://doi.org/10.1111/dom.14094 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/dom.14094</ArticleId><ArticleId IdType=\"pubmed\">32436641</ArticleId><ArticleId IdType=\"pmc\">7540588</ArticleId></ArticleIdList></Reference><Reference><Citation>Eli Lilly and Company: LYUMJEV (insulin lispro-aabc) injection. Prescribing information. https://uspl.lilly.com/lyumjev/lyumjev.html#pi (2022). Accessed 20 July 2023.</Citation></Reference><Reference><Citation>Novo Nordisk Inc.: FIASP<sup>&#xae;</sup> (insulin aspart) injection. Prescribing information. https://www.novo-pi.com/fiasp.pdf (2023). Accessed 20 July 2023.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Devices Agency: Fiasp<sup>&#xae;</sup> Injection 100 U/mL [package insert] [Japanese]. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/620023_2492415A5026_1_05 (2023). Accessed 24 Aug 2023.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Devices Agency: LYUMJEV<sup>&#x24c7;</sup> Injection [package insert] [Japanese]. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/530471_2492414A7024_1_05 (2022). Accessed 24 Aug 2023.</Citation></Reference><Reference><Citation>Masuda H, Sakamoto M, Irie J, Kitaoka A, Shiono K, Inoue G, et al. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-na&#xef;ve type 2 diabetic patients. Diabetes Obes Metab. 2008;10(12):1261&#x2013;5. https://doi.org/10.1111/j.1463-1326.2008.00897.x .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1463-1326.2008.00897.x</ArticleId><ArticleId IdType=\"pubmed\">18494811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura T, Urakami T, Sugihara S, Kim HS, Mochizuki M, Amamiya S. Changes in glycemic control and quality of life in pediatric type 1 diabetics with continuous subcutaneous insulin infusion of insulin aspart following multiple daily injection therapy. Clin Pediatr Endocrinol. 2008;17(2):39&#x2013;47. https://doi.org/10.1297/cpe.17.39 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1297/cpe.17.39</ArticleId><ArticleId IdType=\"pubmed\">24790361</ArticleId><ArticleId IdType=\"pmc\">4004922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii H, Anderson JH Jr, Yamamura A, Takeuchi M, Ikeda I. Improvement of glycemic control and quality-of-life by insulin lispro therapy: assessing benefits by ITR-QOL questionnaires. Diabetes Res Clin Pract. 2008;81(2):169&#x2013;78. https://doi.org/10.1016/j.diabres.2008.03.020 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.diabres.2008.03.020</ArticleId><ArticleId IdType=\"pubmed\">18495289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care. 2008;31(6):1112&#x2013;7. https://doi.org/10.2337/dc07-1183 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2337/dc07-1183</ArticleId><ArticleId IdType=\"pubmed\">18339977</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamoi K, Miyakoshi M, Maruyama R. A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 2004;64(1):19&#x2013;25. https://doi.org/10.1016/j.diabres.2003.10.005 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.diabres.2003.10.005</ArticleId><ArticleId IdType=\"pubmed\">15036823</ArticleId></ArticleIdList></Reference><Reference><Citation>Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med. 2003;20(8):626&#x2013;34. https://doi.org/10.1046/j.1464-5491.2003.01010.x .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1046/j.1464-5491.2003.01010.x</ArticleId><ArticleId IdType=\"pubmed\">12873289</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray M, Boland EA, Tamborlane WV. Use of lispro insulin and quality of life in adolescents on intensive therapy. Diabetes Educ. 1999;25(6):934&#x2013;41. https://doi.org/10.1177/014572179902500611 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/014572179902500611</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell RK, Sclar DA, Robison LM, Stowers JK, Ferguson JC, Trippe BS, et al. Impact on clinical status and quality of life of switching from regular insulin to insulin lispro among patients using insulin pumps. Diabetes Educ. 1998;24(1):95&#x2013;9. https://doi.org/10.1177/014572179802400113 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/014572179802400113</ArticleId><ArticleId IdType=\"pubmed\">9526330</ArticleId></ArticleIdList></Reference><Reference><Citation>Tubiana-Rufi N, Munz-Licha G. [Lispro analog and quality of life] [French]. Diabetes Metab. 1997;23(Suppl 3):58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">9410554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotsanos JG, Vignati L, Huster W, Andrejasich C, Boggs MB, Jacobson AM, et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care. 1997;20(6):948&#x2013;58. https://doi.org/10.2337/diacare.20.6.948 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2337/diacare.20.6.948</ArticleId><ArticleId IdType=\"pubmed\">9167105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii H. Development and psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire. J Med Econ. 2012;15(3):556&#x2013;63. https://doi.org/10.3111/13696998.2012.665111 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3111/13696998.2012.665111</ArticleId><ArticleId IdType=\"pubmed\">22313327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii H, Takamura H, Nishioka Y, Langer J, Watanabe M, Kim HR, et al. Quality of life and utility values for cost-effectiveness modeling in Japanese patients with type 2 diabetes. Diabetes Ther. 2020;11(12):2931&#x2013;43. https://doi.org/10.1007/s13300-020-00938-3 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s13300-020-00938-3</ArticleId><ArticleId IdType=\"pubmed\">33052536</ArticleId><ArticleId IdType=\"pmc\">7644660</ArticleId></ArticleIdList></Reference><Reference><Citation>Shilo S, Godneva A, Rachmiel M, Korem T, Kolobkov D, Karady T, et al. Prediction of personal glycemic responses to food for individuals with type 1 diabetes through integration of clinical and microbial data. Diabetes Care. 2022;45(3):502&#x2013;11. https://doi.org/10.2337/dc21-1048 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2337/dc21-1048</ArticleId><ArticleId IdType=\"pubmed\">34711639</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, et al. Japanese clinical practice guideline for diabetes 2019. J Diabetes Investig. 2020;11(4):1020&#x2013;76. https://doi.org/10.1111/jdi.13306 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/jdi.13306</ArticleId><ArticleId IdType=\"pubmed\">33021749</ArticleId><ArticleId IdType=\"pmc\">7378414</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Nutrition Study Group of the Spanish Diabetes Association. Diabetes Nutrition and Complications Trial (DNCT): food intake and targets of diabetes treatment in a sample of Spanish people with diabetes. Diabetes Care. 1997;20(7):1078&#x2013;80. https://doi.org/10.2337/diacare.20.7.1078 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2337/diacare.20.7.1078</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760456</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2045-2322</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Association of OPRM1 rs1799971, HTR1B rs6296 and COMT rs4680 polymorphisms with clinical phenotype among women with fibromyalgia.</ArticleTitle><Pagination><StartPage>11273</StartPage><MedlinePgn>11273</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1038/s41598-024-62240-7</ELocationID><Abstract><AbstractText>To investigate the association between three selected pain polymorphisms and clinical, functional, sensory-related, psychophysical, psychological or cognitive variables in a sample of women with fibromyalgia (FMS). One hundred twenty-three (n&#x2009;=&#x2009;123) women with FMS completed demographic (age, height, weight), clinical (years with pain, intensity of pain at rest and during daily living activities), functional (quality of life, physical function), sensory-related (sensitization-associated and neuropathic-associated symptoms), psychophysical (pressure pain thresholds), psychological (sleep quality, depressive and anxiety level) and cognitive (pain catastrophizing, kinesiophobia) variables. Those three genotypes of the OPRM1 rs1799971, HTR1B rs6296 and COMT rs4680 single nucleotide polymorphisms were obtained by polymerase chain reactions from no-stimulated whole saliva collection. No significant differences in demographic, clinical, functional, sensory-related, psychophysical, psychological and cognitive variables according to OPRM1 rs1799971, HTR1B rs6296 or COMT rs4680 genotype were identified in our sample of women with FMS. A multilevel analysis did not either reveal any significant gene-to-gene interaction between OPRM1 rs1799971 x HTR1B rs6296, OPRM1 rs1799971 x COMT rs4680 and HTR1B rs6296 x COMT rs4680 for any of the investigated outcomes. This study revealed that three single nucleotide polymorphisms, OPRM1 rs1799971, HTR1B rs6296 or COMT rs4680, mostly associated with chronic pain were not involved in phenotyping features of FMS. Potential gene-to-gene interaction and their association with clinical phenotype in women with FMS should be further investigated in future studies including large sample sizes.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Fern&#xe1;ndez-de-Las-Pe&#xf1;as</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, Av. de Atenas S/N, 28922, Alcorc&#xf3;n, Madrid, Spain. cesar.fernandez@urjc.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), Department of Health Science and Technology, Faculty of Medicine, SMI, Aalborg University, Aalborg, Denmark. cesar.fernandez@urjc.es.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ambite-Quesada</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, Av. de Atenas S/N, 28922, Alcorc&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fern&#xe1;ndez-M&#xe9;ndez</LastName><ForeName>Luis M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, Av. de Atenas S/N, 28922, Alcorc&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jim&#xe9;nez-Antona</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, Av. de Atenas S/N, 28922, Alcorc&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>G&#xf3;mez-Calero</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, Av. de Atenas S/N, 28922, Alcorc&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pocinho</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CICS.NOVA. Ipleiria, Instituto Polit&#xe9;cnico de Leiria, Leiria, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Valera-Calero</LastName><ForeName>Juan Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Rehabilitation and Physiotherapy, Faculty of Nursery, Physiotherapy and Podiatry, Complutense University of Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo InPhysio, Instituto de Investigaci&#xf3;n Sanitaria del Hospital Cl&#xed;nico San Carlos (IdISSC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cigar&#xe1;n-M&#xe9;ndez</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Arendt-Nielsen</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), Department of Health Science and Technology, Faculty of Medicine, SMI, Aalborg University, Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology &amp; Hepatology, Mech-Sense, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Steno Diabetes Center North Denmark, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"C485764\">OPRM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"C588010\">COMT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"C470302\">HTR1B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005356\" MajorTopicYN=\"Y\">Fibromyalgia</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002394\" MajorTopicYN=\"Y\">Catechol O-Methyltransferase</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D017450\" MajorTopicYN=\"Y\">Receptors, Opioid, mu</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D020641\" MajorTopicYN=\"Y\">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D044302\" MajorTopicYN=\"Y\">Receptor, Serotonin, 5-HT1B</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D010641\" MajorTopicYN=\"N\">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005838\" MajorTopicYN=\"N\">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D020022\" MajorTopicYN=\"N\">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011788\" MajorTopicYN=\"N\">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Fibromyalgia</Keyword><Keyword MajorTopicYN=\"N\">Pain genes</Keyword><Keyword MajorTopicYN=\"N\">Single nucleotide polymorphism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760456</ArticleId><ArticleId IdType=\"doi\">10.1038/s41598-024-62240-7</ArticleId><ArticleId IdType=\"pii\">10.1038/s41598-024-62240-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marques, A. P., Santo, A. S. D. E., Berssaneti, A. A., Matsutani, L. A. &amp; Yuan, S. L. K. Prevalence of fibromyalgia: Literature review update. Rev. Bras. Reumatol. Engl. Ed. 57(4), 356&#x2013;363. https://doi.org/10.1016/j.rbre.2017.01.005 (2017).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.rbre.2017.01.005</ArticleId><ArticleId IdType=\"pubmed\">28743363</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarzi-Puttini, P., Giorgi, V., Marotto, D. &amp; Atzeni, F. Fibromyalgia: an update on clinical characteristics, etiopathogenesis and treatment. Nat. Rev. Rheumatol. 16(11), 645&#x2013;660. https://doi.org/10.1038/s41584-020-00506-w (2020).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41584-020-00506-w</ArticleId><ArticleId IdType=\"pubmed\">33024295</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;user, W., Sarzi-Puttini, P. &amp; Fitzcharles, M. A. Fibromyalgia syndrome: under-, over- and misdiagnosis. Clin. Exp. Rheumatol. 37(Suppl 116), 90&#x2013;97 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30747096</ArticleId></ArticleIdList></Reference><Reference><Citation>Berwick, R., Barker, C. &amp; Goebel, A. Guideline development group. The diagnosis of fibromyalgia syndrome. Clin. Med. 22(6), 570&#x2013;574. https://doi.org/10.7861/clinmed.2022-0402 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.7861/clinmed.2022-0402</ArticleId></ArticleIdList></Reference><Reference><Citation>Valera-Calero, J. A. et al. Convergent validity of the central sensitization inventory in women with fibromyalgia: Association with clinical, psychological and psychophysical outcomes. Eur J Pain. 26(10), 2141&#x2013;2151. https://doi.org/10.1002/ejp.2026 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ejp.2026</ArticleId><ArticleId IdType=\"pubmed\">35979630</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew, B. X. W. et al. Distress and sensitization as main mediators of severity in women with fibromyalgia: A structural equation model. Biomedicines. 10(5), 1188. https://doi.org/10.3390/biomedicines10051188 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/biomedicines10051188</ArticleId><ArticleId IdType=\"pubmed\">35625923</ArticleId><ArticleId IdType=\"pmc\">9138673</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xda;beda-D&#x2019;Ocasar, E. et al. Association of neuropathic pain symptoms with sensitization related symptomatology in women with fibromyalgia. Biomedicines. 10(3), 612 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/biomedicines10030612</ArticleId><ArticleId IdType=\"pubmed\">35327414</ArticleId><ArticleId IdType=\"pmc\">8945759</ArticleId></ArticleIdList></Reference><Reference><Citation>Valera-Calero, J. A., Arendt-Nielsen, L., Cigar&#xe1;n-M&#xe9;ndez, M., Fern&#xe1;ndez-de-las-Pe&#xf1;as, C. &amp; Varol, U. Network analysis for better understanding the complex psycho-biological mechanisms behind fibromyalgia syndrome. Diagnostics 12(8), 1845. https://doi.org/10.3390/diagnostics12081845 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/diagnostics12081845</ArticleId><ArticleId IdType=\"pubmed\">36010196</ArticleId><ArticleId IdType=\"pmc\">9406816</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusa, R., Paola, R. D., Cuzzocrea, S. &amp; Impellizzeri, D. Fibromyalgia: Pathogenesis, mechanisms, diagnosis and treatment options update. Int. J. Mol. Sci. 22(8), 3891. https://doi.org/10.3390/ijms22083891 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijms22083891</ArticleId><ArticleId IdType=\"pubmed\">33918736</ArticleId><ArticleId IdType=\"pmc\">8068842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouraki, A. et al. Different genes may be involved in distal and local sensitization: A genome-wide gene-based association study and meta-analysis. Eur. J. Pain. 26(3), 740&#x2013;753. https://doi.org/10.1002/ejp.1902 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ejp.1902</ArticleId><ArticleId IdType=\"pubmed\">34958702</ArticleId><ArticleId IdType=\"pmc\">9303629</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablin, J. N. Buskila D Update on the genetics of the fibromyalgia syndrome. Best Pract. Res. Clin. Rheumatol. 29(1), 20&#x2013;28. https://doi.org/10.1016/j.berh.2015.04.018 (2015).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.berh.2015.04.018</ArticleId><ArticleId IdType=\"pubmed\">26266996</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agnelli, S. et al. Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers. Mol. Pain. 15, 1744806918819944 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30486733</ArticleId></ArticleIdList></Reference><Reference><Citation>Haerian, B. S. &amp; Haerian, M. S. OPRM1 rs1799971 polymorphism and opioid dependence: Evidence from a meta-analysis. Pharmacogenomics. 14(7), 813&#x2013;824. https://doi.org/10.2217/pgs.13.57 (2013).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2217/pgs.13.57</ArticleId><ArticleId IdType=\"pubmed\">23651028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellerbrock, I. et al. Polymorphisms of the &#x3bc;-opioid receptor gene influence cerebral pain processing in fibromyalgia. Eur. J. Pain. 25(2), 398&#x2013;414. https://doi.org/10.1002/ejp.1680 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ejp.1680</ArticleId><ArticleId IdType=\"pubmed\">33064887</ArticleId></ArticleIdList></Reference><Reference><Citation>Solak, &#xd6;. et al. Assessment of opiod receptor &#x3bc;1 gene A118G polymorphism and its association with pain intensity in patients with fibromyalgia. Rheumatol. Int. 34(9), 1257&#x2013;1261. https://doi.org/10.1007/s00296-014-2995-1 (2014).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00296-014-2995-1</ArticleId><ArticleId IdType=\"pubmed\">24671502</ArticleId></ArticleIdList></Reference><Reference><Citation>Tour, J., Sandstr&#xf6;m, A., Kadetoff, D., Schalling, M. &amp; Kosek, E. The OPRM1 gene and interactions with the 5-HT1a gene regulate conditioned pain modulation in fibromyalgia patients and healthy controls. PLoS One. 17(11), e0277427. https://doi.org/10.1371/journal.pone.0277427 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1371/journal.pone.0277427</ArticleId><ArticleId IdType=\"pubmed\">36342939</ArticleId><ArticleId IdType=\"pmc\">9639841</ArticleId></ArticleIdList></Reference><Reference><Citation>Tour, J. et al. Gene-to-gene interactions regulate endogenous pain modulation in fibromyalgia patients and healthy controls-antagonistic effects between opioid and serotonin-related genes. Pain. 158(7), 1194&#x2013;1203. https://doi.org/10.1097/j.pain.0000000000000896 (2017).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/j.pain.0000000000000896</ArticleId><ArticleId IdType=\"pubmed\">28282362</ArticleId><ArticleId IdType=\"pmc\">5472004</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, X. et al. Effects of HTR1B 3&#x2019; region polymorphisms and functional regions on gene expression regulation. BMC Genet. 21, 79. https://doi.org/10.1186/s12863-020-00886-8 (2020).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12863-020-00886-8</ArticleId><ArticleId IdType=\"pubmed\">32689951</ArticleId><ArticleId IdType=\"pmc\">7372893</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammim&#xe4;ki, A. &amp; M&#xe4;nnist&#xf6;, P. T. Catechol-O-methyltransferase gene polymorphism and chronic human pain: A systematic review and meta-analysis. Pharmacogenet. Genomics. 22(9), 673&#x2013;691. https://doi.org/10.1097/FPC.0b013e3283560c46 (2012).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/FPC.0b013e3283560c46</ArticleId><ArticleId IdType=\"pubmed\">22722321</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetterlein, A., Monzel, M. &amp; Reuter, M. Are catechol-O-methyltransferase gene polymorphisms genetic markers for pain sensitivity after all? A review and meta-analysis. Neurosci. Biobehav. Rev. 148, 105112. https://doi.org/10.1016/j.neubiorev.2023.105112 (2023).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.neubiorev.2023.105112</ArticleId><ArticleId IdType=\"pubmed\">36842714</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Y. H., Kim, J. H. &amp; Song, G. G. Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score: A meta-analysis. Rheumatol. Int. 35(1), 159&#x2013;166. https://doi.org/10.1007/s00296-014-3075-2 (2015).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00296-014-3075-2</ArticleId><ArticleId IdType=\"pubmed\">24951880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L., Zhu, J., Chen, Y. &amp; Zhao, J. Meta-analysis reveals a lack of association between a common catechol-O-methyltransferase (COMT) polymorphism Val158Met and fibromyalgia. Int. J. Clin. Exp. Pathol. 7(12), 8489&#x2013;8497 (2014).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25674213</ArticleId><ArticleId IdType=\"pmc\">4314034</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatami, M. et al. Association of catechol-O-methyltranferase 472G&gt;A (Val158Met) polymorphism with susceptibility to fibromyalgia syndrome. J. Orthop. 20, 257&#x2013;260. https://doi.org/10.1016/j.jor.2020.01.013 (2020).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jor.2020.01.013</ArticleId><ArticleId IdType=\"pubmed\">32127730</ArticleId><ArticleId IdType=\"pmc\">7042409</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, C., Liptan, G., Kantorovich, S., Sharma, M. &amp; Brenton, A. Association of Catechol-O-methyltransferase single nucleotide polymorphisms, ethnicity, and sex in a large cohort of fibromyalgia patients. BMC Rheumatol. 2, 38. https://doi.org/10.1186/s41927-018-0045-4 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s41927-018-0045-4</ArticleId><ArticleId IdType=\"pubmed\">30886988</ArticleId><ArticleId IdType=\"pmc\">6390547</ArticleId></ArticleIdList></Reference><Reference><Citation>Est&#xe9;vez-L&#xf3;pez, F. et al. Interplay between genetics and lifestyle on pain susceptibility in women with fibromyalgia: The al-&#xc1;ndalus project. Rheumatology 61(8), 3180&#x2013;3191. https://doi.org/10.1093/rheumatology/keab911 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/rheumatology/keab911</ArticleId><ArticleId IdType=\"pubmed\">34875034</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmeules, J. et al. Central pain sensitization, COMT Val158Met polymorphism, and emotional factors in fibromyalgia. J. Pain. 15(2), 129&#x2013;135. https://doi.org/10.1016/j.jpain.2013.10.004 (2014).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jpain.2013.10.004</ArticleId><ArticleId IdType=\"pubmed\">24342707</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Jauand, M. et al. Pain sensitivity in fibromyalgia is associated with catechol-O-methyltransferase (COMT) gene. Eur. J. Pain. 17(1), 16&#x2013;27. https://doi.org/10.1002/j.1532-2149.2012.00153.x (2013).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/j.1532-2149.2012.00153.x</ArticleId><ArticleId IdType=\"pubmed\">22528689</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as, C., Ambite-Quesada, S., Gil-Crujera, A., Cigar&#xe1;n-M&#xe9;ndez, M. &amp; Pe&#xf1;acoba-Puente, C. Catechol-O-methyltransferase Val158Met polymorphism influences anxiety, depression, and disability, but not pressure pain sensitivity, in women with fibromyalgia syndrome. J. Pain. 13(11), 1068&#x2013;1074. https://doi.org/10.1016/j.jpain.2012.08.001 (2012).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jpain.2012.08.001</ArticleId><ArticleId IdType=\"pubmed\">23025981</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe, F. et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin. Arthritis Rheum. 46(3), 319&#x2013;329. https://doi.org/10.1016/j.semarthrit.2016.08.012 (2016).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.semarthrit.2016.08.012</ArticleId><ArticleId IdType=\"pubmed\">27916278</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri, S. The STROBE guidelines. Saudi J Anaesth. 13(Suppl 1), S31&#x2013;S34. https://doi.org/10.4103/sja.SJA_543_18 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.4103/sja.SJA_543_18</ArticleId><ArticleId IdType=\"pubmed\">30930717</ArticleId><ArticleId IdType=\"pmc\">6398292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheatham, S. W., Kolber, M. J., Mokha, M. &amp; Hanney, W. J. Concurrent validity of pain scales in individuals with myofascial pain and fibromyalgia. J. Bodyw. Mov. Ther. 22(2), 355&#x2013;360. https://doi.org/10.1016/j.jbmt.2017.04.009 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jbmt.2017.04.009</ArticleId><ArticleId IdType=\"pubmed\">29861234</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera, J. &amp; Gonz&#xe1;lez, T. The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin. Exp. Rheumatol. 22, 554&#x2013;560 (2004).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">15485007</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman, M. et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life. Res. 20, 1727&#x2013;1736. https://doi.org/10.1007/s11136-011-9903-x (2011).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType=\"pubmed\">21479777</ArticleId><ArticleId IdType=\"pmc\">3220807</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuesta-Vargas, A. I., Roldan-Jimenez, C. &amp; Neblett, R. Gatchel RJ Cross-cultural adaptation and validity of the Spanish Central Sensitization Inventory. Springerplus. 5(1), 1837. https://doi.org/10.1186/s40064-016-3515-4 (2016).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s40064-016-3515-4</ArticleId><ArticleId IdType=\"pubmed\">27818875</ArticleId><ArticleId IdType=\"pmc\">5074937</ArticleId></ArticleIdList></Reference><Reference><Citation>Neblett, R. et al. The Central Sensitization Inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. J Pain 14(5), 438&#x2013;445. https://doi.org/10.1016/j.jpain.2012.11.012 (2013).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jpain.2012.11.012</ArticleId><ArticleId IdType=\"pubmed\">23490634</ArticleId><ArticleId IdType=\"pmc\">3644381</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-de-Uralde-Villanueva, I. et al. Validity and reliability of the Spanish-language version of the self-administered leeds assessment of neuropathic symptoms and signs (S-LANSS) pain scale. Neurologia (Engl Ed). 33(8), 505&#x2013;514. https://doi.org/10.1016/j.nrl.2016.10.009 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.nrl.2016.10.009</ArticleId><ArticleId IdType=\"pubmed\">27939112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjelland, I., Dahl, A. A., Haug, T. T. &amp; Neckelmann, D. The validity of the hospital anxiety and depression scale. An updated literature review. J. Psychosom. Res. 52(2), 69&#x2013;77. https://doi.org/10.1016/s0022-3999(01)00296-3 (2002).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s0022-3999(01)00296-3</ArticleId><ArticleId IdType=\"pubmed\">11832252</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbri, M. et al. Measuring subjective sleep quality: A Review. Int. J. Environ. Res. Public Health. 18(3), 1082. https://doi.org/10.3390/ijerph18031082 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijerph18031082</ArticleId><ArticleId IdType=\"pubmed\">33530453</ArticleId><ArticleId IdType=\"pmc\">7908437</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a Campayo, J. et al. Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia. Med. Clin. (Barc). 131(13), 487&#x2013;492. https://doi.org/10.1157/13127277 (2008).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1157/13127277</ArticleId><ArticleId IdType=\"pubmed\">19007576</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-P&#xe9;rez, L., L&#xf3;pez-Mart&#xed;nez, A. E. &amp; Ruiz-P&#xe1;rraga, G. T. Psychometric properties of the Spanish Version of the Tampa Scale for Kinesiophobia (TSK). J Pain. 12(4), 425&#x2013;435. https://doi.org/10.1016/j.jpain.2010.08.004 (2011).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jpain.2010.08.004</ArticleId><ArticleId IdType=\"pubmed\">20926355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheatham, S. W., Kolber, M. J., Mokha, G. M. &amp; Hanney, W. J. Concurrent validation of a pressure pain threshold scale for individuals with myofascial pain syndrome and fibromyalgia. J. Man. Manip. Ther. 26, 25&#x2013;35. https://doi.org/10.1080/10669817.2017.1349592 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/10669817.2017.1349592</ArticleId><ArticleId IdType=\"pubmed\">29456445</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as, C. et al. Are pain polymorphisms associated with the risk and phenotype of post-COVID pain in previously hospitalized COVID-19 survivors?. Genes (Basel). 13(8), 1336. https://doi.org/10.3390/genes13081336 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/genes13081336</ArticleId><ArticleId IdType=\"pubmed\">35893072</ArticleId><ArticleId IdType=\"pmc\">9394327</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillingim, R. B. et al. The A118G single nucleotide polymorphism of the &#x3bc;-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 6(3), 159&#x2013;167. https://doi.org/10.1016/j.jpain.2004.11.008 (2005).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jpain.2004.11.008</ArticleId><ArticleId IdType=\"pubmed\">15772909</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, P. et al. A meta-analysis of 5-Hydroxytryptamine receptor 1B polymorphisms with risk of major depressive disorder and suicidal behavior. Front Psychiatry. 12, 696655. https://doi.org/10.3389/fpsyt.2021.69665 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fpsyt.2021.69665</ArticleId><ArticleId IdType=\"pubmed\">34322042</ArticleId><ArticleId IdType=\"pmc\">8311000</ArticleId></ArticleIdList></Reference><Reference><Citation>Adawi, M. et al. Suicidal behavior in fibromyalgia patients: rates and determinants of suicide ideation, risk, suicide, and suicidal attempts: A systematic review of the literature and meta-analysis of over 390,000 fibromyalgia patients. Front Psychiatry. 12, 629417. https://doi.org/10.3389/fpsyt.2021.629417 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fpsyt.2021.629417</ArticleId><ArticleId IdType=\"pubmed\">34867495</ArticleId><ArticleId IdType=\"pmc\">8640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaleycheva, N. et al. The role of lifetime stressors in adult fibromyalgia: systematic review and meta-analysis of case-control studies. Psychol Med. 51(2), 177&#x2013;193. https://doi.org/10.1017/S0033291720004547 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1017/S0033291720004547</ArticleId><ArticleId IdType=\"pubmed\">33602373</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold, L. M. et al. The fibromyalgia family study: a genome-wide linkage scan study. Arthritis Rheum. 65(4), 1122&#x2013;1128. https://doi.org/10.1002/art.37842 (2013).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/art.37842</ArticleId><ArticleId IdType=\"pubmed\">23280346</ArticleId><ArticleId IdType=\"pmc\">3618544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mergener, M., Becker, R. M., dos Santos, A. F., dos Santos, G. A. &amp; de Andrade, F. M. Influence of the interaction between environmental quality and T102C SNP in the HTR2A gene on fibromyalgia susceptibility. Rev Bras Reumatol. 51(6), 594&#x2013;602 (2011).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1590/S0482-50042011000600006</ArticleId><ArticleId IdType=\"pubmed\">22124593</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerra, M. C. et al. DNA methylation changes in fibromyalgia suggest the role of the immune-inflammatory response and central sensitization. J. Clin. Med. 10, 4992. https://doi.org/10.3390/jcm10214992 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/jcm10214992</ArticleId><ArticleId IdType=\"pubmed\">34768513</ArticleId><ArticleId IdType=\"pmc\">8584620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760452</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2045-2322</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Comparison of HIIT and MICT and further detraining on metabolic syndrome and asprosin signaling pathway in metabolic syndrome model of rats.</ArticleTitle><Pagination><StartPage>11313</StartPage><MedlinePgn>11313</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1038/s41598-024-61842-5</ELocationID><Abstract><AbstractText>Physical activity promotes various metabolic benefits by balancing pro and anti-inflammatory adipokines. Recent studies suggest that asprosin might be involved in progression of metabolic syndrome (MetS), however, the underlying mechanisms have not been understood yet. This study aimed to evaluate the effects of high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), and further detraining on MetS indices, insulin resistance, serum and the liver levels of asprosin, and AMP-activated protein kinase (AMPK) pathway in menopause-induced MetS model of rats. A total of 64 Wistar rats were used in this study and divided into eight groups: Sham1, OVX1 (ovariectomized), Sham2, OVX2, OVX&#x2009;+&#x2009;HIIT, OVX&#x2009;+&#x2009;MICT, OVX&#x2009;+&#x2009;HIIT&#x2009;+&#x2009;Det (detraining), and OVX&#x2009;+&#x2009;MICT&#x2009;+&#x2009;Det. Animals performed the protocols, and then serum concentrations of asprosin, TNF-&#x3b1;, insulin, fasting blood glucose, and lipid profiles (TC, LDL, TG, and HDL) were assessed. Additionally, the liver expression of asprosin, AMPK, and P-AMPK was measured by western blotting.&#xa0;Both HIIT and MICT caused a significant decrease in weight, waist circumference, BMI (P&#x2009;=&#x2009;0.001), and serum levels of glucose, insulin, asprosin (P&#x2009;=&#x2009;0.001), triglyceride, total cholesterol, low-density lipoprotein (LDL), and TNF-&#x3b1; (P&#x2009;=&#x2009;0.001), but an increase in the liver AMPK, P-AMPK, and P-AMPK/AMPK (P&#x2009;=&#x2009;0.001), compared with OVX2 noexercised group. MICT was superior to HIIT in reducing serum asprosin, TNF-a, TG, LDL (P&#x2009;=&#x2009;0.001), insulin, fasting blood glucose, HOMA-IR, and QUEKI index (P&#x2009;=&#x2009;0.001), but an increase in the liver AMPK, and p-AMPK (P&#x2009;=&#x2009;0.001). Although after two months of de-training almost all indices returned to the pre exercise values (P&#x2009;&lt;&#x2009;0.05). The findings suggest that MICT effectively alleviates MetS induced by menopause, at least partly through the activation of liver signaling of P-AMPK and the reduction of asprosin and TNF-&#x3b1;. These results have practical implications for the development of exercise interventions targeting MetS in menopausal individuals, emphasizing the potential benefits of MICT in mitigating MetS-related complications.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Rahim</LastName><ForeName>Hiwa Ahmed</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Exercise Physiology, Faculty of Sport Sciences, University of Guilan, Rasht, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Physical Education and Sports Sciences, University of Halabja, Halabja, Iraq.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cellular &amp; Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Damirchi</LastName><ForeName>Arsalan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Exercise Physiology, Faculty of Sport Sciences, University of Guilan, Rasht, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Babaei</LastName><ForeName>Parvin</ForeName><Initials>P</Initials><Identifier Source=\"ORCID\">0000-0003-4870-8182</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Center, Trauma Institute, Guilan University of Medical Sciences, Rasht, Iran. p_babaei@gums.ac.ir.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cellular &amp; Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran. p_babaei@gums.ac.ir.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran. p_babaei@gums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D003160\">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D000818\" MajorTopicYN=\"N\">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000071838\" MajorTopicYN=\"Y\">Fibrillin-1</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D024821\" MajorTopicYN=\"Y\">Metabolic Syndrome</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D051381\" MajorTopicYN=\"N\">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D015398\" MajorTopicYN=\"Y\">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D017208\" MajorTopicYN=\"Y\">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D010805\" MajorTopicYN=\"Y\">Physical Conditioning, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D004195\" MajorTopicYN=\"Y\">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D055372\" MajorTopicYN=\"Y\">AMP-Activated Protein Kinases</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000072696\" MajorTopicYN=\"N\">High-Intensity Interval Training</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008099\" MajorTopicYN=\"N\">Liver</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D007333\" MajorTopicYN=\"N\">Insulin Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D001786\" MajorTopicYN=\"N\">Blood Glucose</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D007328\" MajorTopicYN=\"N\">Insulin</DescriptorName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D010446\" MajorTopicYN=\"N\">Peptide Fragments</DescriptorName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">(MICT) moderate-intensity continuous training</Keyword><Keyword MajorTopicYN=\"N\">Asprosin</Keyword><Keyword MajorTopicYN=\"N\">Diabetes</Keyword><Keyword MajorTopicYN=\"N\">High-intensity interval training (HIIT)</Keyword><Keyword MajorTopicYN=\"N\">Insulin resistance</Keyword><Keyword MajorTopicYN=\"N\">Metabolic syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760452</ArticleId><ArticleId IdType=\"doi\">10.1038/s41598-024-61842-5</ArticleId><ArticleId IdType=\"pii\">10.1038/s41598-024-61842-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Karvinen, S. et al. Menopausal status and physical activity are independently associated with cardiovascular risk factors of healthy middle-aged women: Cross-sectional and longitudinal evidence. Front. Endocrinol. 10, 589. https://doi.org/10.3389/fendo.2019.00589 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fendo.2019.00589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovejoy, J. C., Champagne, C., De Jonge, L., Xie, H. &amp; Smith, S. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int. J. Obes. 32(6), 949&#x2013;958. https://doi.org/10.1038/ijo.2008.25 (2008).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ijo.2008.25</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, Y. et al. The prevalence and characteristics of metabolic syndrome according to different definitions in China: A nationwide cross-sectional study, 2012&#x2013;2015. BMC Public Health 22(1), 1&#x2013;11. https://doi.org/10.1186/s12889-022-14263-w (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12889-022-14263-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Bovolini, A., Garcia, J., Andrade, M. A. &amp; Duarte, J. A. Metabolic syndrome pathophysiology and predisposing factors. Int. J. Sports Med. 42(03), 199&#x2013;214. https://doi.org/10.1055/a-1263-0898 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1055/a-1263-0898</ArticleId><ArticleId IdType=\"pubmed\">33075830</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabir, K. et al. Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence. Cytokine Growth Factor Rev. 60, 120&#x2013;132. https://doi.org/10.1016/j.cytogfr.2021.05.002 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cytogfr.2021.05.002</ArticleId><ArticleId IdType=\"pubmed\">34108103</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaei, P. &amp; Hoseini, R. Exercise training modulates adipokine dysregulations in metabolic syndrome. Sports Med. Health Sci. 4(1), 18&#x2013;28. https://doi.org/10.1016/j.smhs.2022.01.001 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.smhs.2022.01.001</ArticleId><ArticleId IdType=\"pubmed\">35782776</ArticleId><ArticleId IdType=\"pmc\">9219261</ArticleId></ArticleIdList></Reference><Reference><Citation>Romere, C. et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell 165(3), 566&#x2013;579. https://doi.org/10.1016/j.cell.2016.02.063 (2016).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cell.2016.02.063</ArticleId><ArticleId IdType=\"pubmed\">27087445</ArticleId><ArticleId IdType=\"pmc\">4852710</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, H., Hu, W. &amp; Zhang, G. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease. Int. Urol. Nephrol. 52, 1517&#x2013;1522. https://doi.org/10.1007/s11255-020-02509-8 (2020).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11255-020-02509-8</ArticleId><ArticleId IdType=\"pubmed\">32458209</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung, T. W. et al. Asprosin attenuates insulin signaling pathway through PKC&#x3b4;-activated ER stress and inflammation in skeletal muscle. J. Cell. Physiol. 234(11), 20888&#x2013;20899. https://doi.org/10.1002/jcp.28694 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/jcp.28694</ArticleId><ArticleId IdType=\"pubmed\">30997682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, T., Yun, S., Jeong, J. H. &amp; Jung, T. W. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol. Cell. Endocrinol. 486, 96&#x2013;104. https://doi.org/10.1016/j.mce.2019.03.001 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.mce.2019.03.001</ArticleId><ArticleId IdType=\"pubmed\">30853600</ArticleId></ArticleIdList></Reference><Reference><Citation>Beavers, K. M. et al. Effect of exercise modality during weight loss on bone health in older adults with obesity and cardiovascular disease or metabolic syndrome: A randomized controlled trial. J. Bone Min. Res. 33(12), 2140&#x2013;2149. https://doi.org/10.1002/jbmr.3555 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/jbmr.3555</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevellin, E. et al. Exercise training induces mitochondrial biogenesis and glucose uptake in subcutaneous adipose tissue through eNOS-dependent mechanisms. Diabetes 63(8), 2800&#x2013;2811. https://doi.org/10.2337/db13-1234 (2014).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2337/db13-1234</ArticleId><ArticleId IdType=\"pubmed\">24622799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoseini, R., Rahim, H. A. &amp; Ahmed, J. K. Decreased inflammatory gene expression accompanies the improvement of liver enzyme and lipid profile following aerobic training and vitamin D supplementation in T2DM patients. BMC Endocr. Disorders 22(1), 1&#x2013;10. https://doi.org/10.1186/s12902-022-01152-x (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12902-022-01152-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedewa, M. V., Hathaway, E. D. &amp; Ward-Ritacco, C. L. Effect of exercise training on C reactive protein: A systematic review and meta-analysis of randomised and non-randomised controlled trials. Br. J. Sports Med. 51(8), 670&#x2013;676. https://doi.org/10.1136/bjsports-2016-095999 (2017).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bjsports-2016-095999</ArticleId><ArticleId IdType=\"pubmed\">27445361</ArticleId></ArticleIdList></Reference><Reference><Citation>Biteli, P., Barbalho, S. M., Detregiachi, C. R. P., dos Santos Haber, J. F. &amp; Chagas, E. F. B. Dyslipidemia influences the effect of physical exercise on inflammatory markers on obese women in post-menopause: A randomized clinical trial. Exp. Gerontol. 150, 111355. https://doi.org/10.1016/j.exger.2021.111355 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.exger.2021.111355</ArticleId><ArticleId IdType=\"pubmed\">33865923</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueno-Notivol, J. et al. Effect of programmed exercise on insulin sensitivity in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials. Menopause 24(12), 1404&#x2013;1413. https://doi.org/10.1097/GME.0000000000000936 (2017).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/GME.0000000000000936</ArticleId><ArticleId IdType=\"pubmed\">28654627</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo, M. et al. International exercise recommendations in older adults (ICFSR): Expert consensus guidelines. J. Nutr Health Aging 25(7), 824&#x2013;853. https://doi.org/10.1007/s12603-021-1665-8 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12603-021-1665-8</ArticleId><ArticleId IdType=\"pubmed\">34409961</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuddy, T. F., Ramos, J. S. &amp; Dalleck, L. C. Reduced exertion high-intensity interval training is more effective at improving cardiorespiratory fitness and cardiometabolic health than traditional moderate-intensity continuous training. Int. J. Environ. Res. Public Health 16(3), 483. https://doi.org/10.3390/ijerph16030483 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijerph16030483</ArticleId><ArticleId IdType=\"pubmed\">30736402</ArticleId><ArticleId IdType=\"pmc\">6388288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrup, C. M. et al. Effects of high-intensity training on cardiovascular risk factors in premenopausal and postmenopausal women. Am. J. Obstet. Gynecol. 216(4), 384e1-e11. https://doi.org/10.1016/j.ajog.2016.12.017 (2017).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ajog.2016.12.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Steckling, F. et al. High intensity interval training reduces the levels of serum inflammatory cytokine on women with metabolic syndrome. Exp. Clin. Endocrinol. Diabetes 124(10), 597&#x2013;601. https://doi.org/10.1055/s-0042-111044 (2016).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1055/s-0042-111044</ArticleId><ArticleId IdType=\"pubmed\">27657999</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino, D., Yoshida, Y., Kitaoka, Y., Hatta, H. &amp; Bonen, A. High-intensity interval training increases intrinsic rates of mitochondrial fatty acid oxidation in rat red and white skeletal muscle. Appl. Physiol. Nutr. Metab. 38(3), 326&#x2013;333. https://doi.org/10.1139/apnm-2012-0257 (2013).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1139/apnm-2012-0257</ArticleId><ArticleId IdType=\"pubmed\">23537026</ArticleId></ArticleIdList></Reference><Reference><Citation>Way, K. L., Sultana, R. N., Sabag, A., Baker, M. K. &amp; Johnson, N. A. The effect of high Intensity interval training versus moderate intensity continuous training on arterial stiffness and 24 h blood pressure responses: A systematic review and meta-analysis. J. Sci. Med. Sport 22(4), 385&#x2013;391. https://doi.org/10.1016/j.jsams.2018.09.228 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jsams.2018.09.228</ArticleId><ArticleId IdType=\"pubmed\">30803498</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo-Villegas, J. et al. Efficacy of high-intensity, low-volume interval training compared to continuous aerobic training on insulin resistance, skeletal muscle structure and function in adults with metabolic syndrome: Study protocol for a randomized controlled clinical trial (Intraining-MET). Trials 19, 1&#x2013;10. https://doi.org/10.1186/s13063-018-2541-7 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13063-018-2541-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain, S. R., Macaluso, A. &amp; Pearson, S. J. High-intensity interval training versus moderate-intensity continuous training in the prevention/management of cardiovascular disease. Cardiol. Rev. 24(6), 273&#x2013;281. https://doi.org/10.1097/CRD.0000000000000124 (2016).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/CRD.0000000000000124</ArticleId><ArticleId IdType=\"pubmed\">27548688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan, B. J. et al. Moderate-intensity exercise and high-intensity interval training affect insulin sensitivity similarly in obese adults. J. Clin. Endocrinol. Metab. 105(8), e2941&#x2013;e2959. https://doi.org/10.1210/clinem/dgaa345 (2020).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1210/clinem/dgaa345</ArticleId><ArticleId IdType=\"pubmed\">32492705</ArticleId><ArticleId IdType=\"pmc\">7347288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton, R. E. et al. Effects of short-term, medium-term and long-term resistance exercise training on cardiometabolic health outcomes in adults: Systematic review with meta-analysis. Br. J. Sports Med. 54(6), 341&#x2013;348. https://doi.org/10.1136/bjsports-2017-098970 (2020).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bjsports-2017-098970</ArticleId><ArticleId IdType=\"pubmed\">29934430</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgomaster, K. A. et al. Similar metabolic adaptations during exercise after low volume sprint interval and traditional endurance training in humans. J. Physiol. 586(1), 151&#x2013;160. https://doi.org/10.1113/jphysiol.2007.142109 (2008).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1113/jphysiol.2007.142109</ArticleId><ArticleId IdType=\"pubmed\">17991697</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichberg, S. &amp; Rott, C. Sportverhalten im mittleren und h&#xf6;heren Erwachsenenalter. J. Public Health (09431853) 12(2), 93&#x2013;104. https://doi.org/10.1007/s10389-004-0020-y (2004).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10389-004-0020-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemmler, W., Schoene, D., Kohl, M. &amp; von Stengel, S. Changes in body composition and cardiometabolic health after detraining in older men with osteosarcopenia: 6-month follow-up of the randomized controlled franconian osteopenia and sarcopenia trial (FrOST) study. Clin. Interv. Aging 16, 571&#x2013;582. https://doi.org/10.2147/cia.s299867 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/cia.s299867</ArticleId><ArticleId IdType=\"pubmed\">33854307</ArticleId><ArticleId IdType=\"pmc\">8039436</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaei, P., Pourrahim Ghouroghchi, A., Damirchi, A. &amp; Soltani, T. B. The interactive effect of aerobic-resistance training and estrogen therapy on metabolic syndrome indices and omentin-1. Physiol. Pharmacol. 19(3), 200&#x2013;207. http://ppj.phypha.ir/article-1-1120-en.html (2015).</Citation></Reference><Reference><Citation>Fayaz, E., Damirchi, A., Zebardast, N. &amp; Babaei, P. Cinnamon extract combined with high-intensity endurance training alleviates metabolic syndrome via non-canonical WNT signaling. Nutrition 65, 173&#x2013;178. https://doi.org/10.1016/j.nut.2019.03.009 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.nut.2019.03.009</ArticleId><ArticleId IdType=\"pubmed\">31170681</ArticleId></ArticleIdList></Reference><Reference><Citation>Tawfik, S. H. et al. Similar and additive effects of ovariectomy and diabetes on insulin resistance and lipid metabolism. Biochem. Res. Int. 2015, 1&#x2013;8. https://doi.org/10.1155/2015/567945 (2015).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1155/2015/567945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L., Chen, C., Zhou, N., Fu, Y. &amp; Cheng, X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin. Chim. Acta 489, 183&#x2013;188. https://doi.org/10.1016/j.cca.2017.10.034 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cca.2017.10.034</ArticleId><ArticleId IdType=\"pubmed\">29104036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiecek, M., Szymura, J., Maciejczyk, M., Kantorowicz, M. &amp; Szygula, Z. Acute anaerobic exercise affects the secretion of asprosin, irisin, and other cytokines&#x2014;A comparison between sexes. Front. Physiol. 9, 1782. https://doi.org/10.3389/fphys.2018.01782 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fphys.2018.01782</ArticleId><ArticleId IdType=\"pubmed\">30618797</ArticleId><ArticleId IdType=\"pmc\">6295572</ArticleId></ArticleIdList></Reference><Reference><Citation>Alan, M. et al. Asprosin: A novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol. Endocrinol. 35(3), 220&#x2013;223. https://doi.org/10.1080/09513590.2018.1512967 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/09513590.2018.1512967</ArticleId><ArticleId IdType=\"pubmed\">30325247</ArticleId></ArticleIdList></Reference><Reference><Citation>Naiemian, S. et al. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol. Metab. Syndr. 12, 1&#x2013;8. https://doi.org/10.1186/s13098-020-00564-w (2020).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13098-020-00564-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceylan, H. &#x130;, Sayg&#x131;n, &#xd6;. &amp; &#xd6;zel, T. &#xdc;. Assessment of acute aerobic exercise in the morning versus evening on asprosin, spexin, lipocalin-2, and insulin level in overweight/obese versus normal weight adult men. Chronobiol. Int. 37(8), 1252&#x2013;1268. https://doi.org/10.1080/07420528.2020.1792482 (2020).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/07420528.2020.1792482</ArticleId><ArticleId IdType=\"pubmed\">32741294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko, J. R. et al. Aerobic exercise training decreases hepatic asprosin in diabetic rats. J. Clin. Med. 8(5), 666. https://doi.org/10.3390/jcm8050666 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/jcm8050666</ArticleId><ArticleId IdType=\"pubmed\">31083617</ArticleId><ArticleId IdType=\"pmc\">6572469</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, M., Li, W., Zhu, Y., Yu, B. &amp; Wu, J. Asprosin: A novel player in metabolic diseases. Front. Endocrinol. 11, 64. https://doi.org/10.3389/fendo.2020.00064 (2020).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fendo.2020.00064</ArticleId></ArticleIdList></Reference><Reference><Citation>Donath, M. Y. &amp; Shoelson, S. E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11(2), 98&#x2013;107. https://doi.org/10.1038/nri2925 (2011).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/nri2925</ArticleId><ArticleId IdType=\"pubmed\">21233852</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaikhosravi, F., Daryanoosh, F., Koushki Jahromi, M. &amp; Neamati, J. Psycho-physiologic effects of high intensity interval trainings in aged ovariectomized rats: A pilot study. Report Health Care 5(3), 1&#x2013;7 (2019).</Citation></Reference><Reference><Citation>Hannan, A. L. et al. High-intensity interval training versus moderate-intensity continuous training within cardiac rehabilitation: A systematic review and meta-analysis. Open Access J. Sports Med. 9, 1&#x2013;17. https://doi.org/10.2147/oajsm.s150596 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/oajsm.s150596</ArticleId><ArticleId IdType=\"pubmed\">29416382</ArticleId><ArticleId IdType=\"pmc\">5790162</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer, B. J. et al. Effects of high-intensity interval training and moderate-intensity continuous training on endothelial function and cardiometabolic risk markers in obese adults. J. Appl. Physiol. 121(1), 279&#x2013;288. https://doi.org/10.1152/japplphysiol.00024.2016 (2016).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/japplphysiol.00024.2016</ArticleId><ArticleId IdType=\"pubmed\">27255523</ArticleId><ArticleId IdType=\"pmc\">4967258</ArticleId></ArticleIdList></Reference><Reference><Citation>Achten, J. &amp; Jeukendrup, A. E. Optimizing fat oxidation through exercise and diet. Nutrition 20(7&#x2013;8), 716&#x2013;727. https://doi.org/10.1016/j.nut.2004.04.005 (2004).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.nut.2004.04.005</ArticleId><ArticleId IdType=\"pubmed\">15212756</ArticleId></ArticleIdList></Reference><Reference><Citation>Balady, G. J. et al. Recommendations for cardiovascular screening, staffing, and emergency policies at health/fitness facilities. Circulation 97(22), 2283&#x2013;2293. https://doi.org/10.1161/01.CIR.97.22.2283 (1998).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/01.CIR.97.22.2283</ArticleId><ArticleId IdType=\"pubmed\">9631884</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber, C. E. et al. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for prescribing exercise. Med. Sci. Sports Exerc. 43, 1334&#x2013;1359. https://doi.org/10.7916/D8CR5T2R (2011).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.7916/D8CR5T2R</ArticleId><ArticleId IdType=\"pubmed\">21694556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen, B. K. &amp; Saltin, B. Exercise as medicine&#x2013;evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand. J. Med. Sci. Sports 25, 1&#x2013;72. https://doi.org/10.1111/sms.12581 (2015).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/sms.12581</ArticleId><ArticleId IdType=\"pubmed\">26606383</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott, A. D., Rajopadhyaya, K., Bentley, D. J., Beltrame, J. F. &amp; Aromataris, E. C. Interval training versus continuous exercise in patients with coronary artery disease: A meta-analysis. Heart Lung Circ. 24(2), 149&#x2013;157. https://doi.org/10.1016/j.hlc.2014.09.001 (2015).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.hlc.2014.09.001</ArticleId><ArticleId IdType=\"pubmed\">25306500</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou, K., Ho, S., Fildes, J. &amp; Ooi, S.-Y. High intensity interval versus moderate intensity continuous training in patients with coronary artery disease: A meta-analysis of physiological and clinical parameters. Heart Lung Circ. 25(2), 166&#x2013;174. https://doi.org/10.1016/j.hlc.2015.06.828 (2016).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.hlc.2015.06.828</ArticleId><ArticleId IdType=\"pubmed\">26375499</ArticleId></ArticleIdList></Reference><Reference><Citation>Madden, K. M. Evidence for the benefit of exercise therapy in patients with type 2 diabetes. Diabetes Metab. Syndr. Obes. Targets Ther. https://doi.org/10.2147/DMSO.S32951 (2013).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/DMSO.S32951</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, S. R. et al. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity 22(10), 2137&#x2013;2146. https://doi.org/10.1002/oby.20841 (2014).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/oby.20841</ArticleId><ArticleId IdType=\"pubmed\">25044799</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan, S., Gustafson, M. B., Campbell, C., Gaikwad, N. W. &amp; Keim, N. L. Association between circulating endogenous androgens and insulin sensitivity changes with exercise training in midlife women. Menopause 21(9), 967&#x2013;974. https://doi.org/10.1097/GME.0000000000000198 (2014).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/GME.0000000000000198</ArticleId><ArticleId IdType=\"pubmed\">24496084</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashti, B., Mehrabani, J., Damirchi, A. &amp; Babaei, P. The influence of concurrent training intensity on serum irisin and abdominal fat in postmenopausal women. Menopause Review/Przegl&#x105;d Menopauzalny 18(3), 166&#x2013;173. https://doi.org/10.5114/pm.2019.90810 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5114/pm.2019.90810</ArticleId><ArticleId IdType=\"pubmed\">31975984</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira, S. G., dos Santos, N. V., de Oliveira Fraga, S. R., Souza-Mello, V. &amp; Barbosa-da-Silva, S. High-intensity interval training has beneficial effects on cardiac remodeling through local renin-angiotensin system modulation in mice fed high-fat or high-fructose diets. Life Sci. 189, 8&#x2013;17. https://doi.org/10.1016/j.lfs.2017.09.012 (2017).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lfs.2017.09.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, Y., Wiltshire, H. D., Baker, J. S. &amp; Wang, Q. Effects of high intensity exercise on oxidative stress and antioxidant status in untrained humans: A systematic review. Biology 10(12), 1272. https://doi.org/10.3390/biology10121272 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/biology10121272</ArticleId><ArticleId IdType=\"pubmed\">34943187</ArticleId><ArticleId IdType=\"pmc\">8698973</ArticleId></ArticleIdList></Reference><Reference><Citation>Radak, Z., Zhao, Z., Koltai, E., Ohno, H. &amp; Atalay, M. Oxygen consumption and usage during physical exercise: the balance between oxidative stress and ROS-dependent adaptive signaling. Antioxid. Redox Signal. 18(10), 1208&#x2013;1246. https://doi.org/10.1089/ars.2011.4498 (2013).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1089/ars.2011.4498</ArticleId><ArticleId IdType=\"pubmed\">22978553</ArticleId><ArticleId IdType=\"pmc\">3579386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobari, H. et al. An overview on how exercise with green tea consumption can prevent the production of reactive oxygen species and improve sports performance. Int. J. Environ. Res. Public Health 19(1), 218. https://doi.org/10.3390/ijerph19010218 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijerph19010218</ArticleId><ArticleId IdType=\"pubmed\">35010479</ArticleId><ArticleId IdType=\"pmc\">8750450</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider, C. D. &amp; Oliveira, A. R. Oxygen free radicals and exercise: Mechanisms of synthesis and adaptation to the physical training. Revista Bras. Med. Esporte 10, 308&#x2013;313. https://doi.org/10.1590/S1517-86922004000400008 (2004).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1590/S1517-86922004000400008</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr&#xf3;n-Cabrera, E. et al. Epigenetic modifications as outcomes of exercise interventions related to specific metabolic alterations: A systematic review. Lifestyle Genomics 12(1&#x2013;6), 25&#x2013;44. https://doi.org/10.1159/000503289 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000503289</ArticleId><ArticleId IdType=\"pubmed\">31546245</ArticleId><ArticleId IdType=\"pmc\">6921698</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, A. et al. Effects of exercise training on metabolic syndrome risk factors in post-menopausal women&#x2014;A systematic review and meta-analysis of randomised controlled trials. Clin. Nutr. 42, 337&#x2013;351. https://doi.org/10.1016/j.clnu.2023.01.008 (2023).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.clnu.2023.01.008</ArticleId><ArticleId IdType=\"pubmed\">36736057</ArticleId></ArticleIdList></Reference><Reference><Citation>Damirchi, A., Tehrani, B. S., Alamdari, K. A. &amp; Babaei, P. Influence of aerobic training and detraining on serum BDNF, insulin resistance, and metabolic risk factors in middle-aged men diagnosed with metabolic syndrome. Clin. J. Sport Med. 24(6), 513&#x2013;518. https://doi.org/10.1097/JSM.0000000000000082 (2014).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/JSM.0000000000000082</ArticleId><ArticleId IdType=\"pubmed\">24662570</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf8;ydal, M. A., Wisl&#xf8;ff, U., Kemi, O. J. &amp; Ellingsen, &#xd8;. Running speed and maximal oxygen uptake in rats and mice: Practical implications for exercise training. Eur. J. Prev. Cardiol. 14(6), 753&#x2013;760. https://doi.org/10.1097/HJR.0b013e3281eacef1 (2007).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/HJR.0b013e3281eacef1</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafstad, A. D. et al. High-and moderate-intensity training normalizes ventricular function and mechanoenergetics in mice with diet-induced obesity. Diabetes 62(7), 2287&#x2013;2294. https://doi.org/10.2337/db12-1580 (2013).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2337/db12-1580</ArticleId><ArticleId IdType=\"pubmed\">23493573</ArticleId><ArticleId IdType=\"pmc\">3712042</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf3;sa, A. et al. Exercise training and calorie restriction influence the metabolic parameters in ovariectomized female rats. Oxid. Med. Cell. Longev. https://doi.org/10.1155/2015/787063 (2015).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1155/2015/787063</ArticleId><ArticleId IdType=\"pubmed\">26064421</ArticleId><ArticleId IdType=\"pmc\">4438186</ArticleId></ArticleIdList></Reference><Reference><Citation>Sena, C. M. et al. Metformin restores endothelial function in aorta of diabetic rats. Br. J. Pharmacol. 163(2), 424&#x2013;437. https://doi.org/10.1111/j.1476-5381.2011.01230.x (2011).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1476-5381.2011.01230.x</ArticleId><ArticleId IdType=\"pubmed\">21250975</ArticleId><ArticleId IdType=\"pmc\">3087142</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehdipoor, M., Damirchi, A., Razavi Tousi, S. M. T. &amp; Babaei, P. Concurrent vitamin D supplementation and exercise training improve cardiac fibrosis via TGF-&#x3b2;/Smad signaling in myocardial infarction model of rats. J. Physiol. Biochem. 77, 75&#x2013;84. https://doi.org/10.1007/s13105-020-00778-6 (2021).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s13105-020-00778-6</ArticleId><ArticleId IdType=\"pubmed\">33428175</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760427</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Print\">2397-768X</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>NPJ precision oncology</Title><ISOAbbreviation>NPJ Precis Oncol</ISOAbbreviation></Journal><ArticleTitle>Extracellular vesicles in glioblastoma: a challenge and an opportunity.</ArticleTitle><Pagination><StartPage>103</StartPage><MedlinePgn>103</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1038/s41698-024-00600-2</ELocationID><Abstract><AbstractText>Glioblastoma is a highly heterogeneous tumor whose pathophysiological complexities dictate both the diagnosis of disease severity as well as response to therapy. Conventional diagnostic tools and standard treatment regimens have only managed to achieve limited success in the management of patients suspected of glioblastoma. Extracellular vesicles are an emerging liquid biopsy tool that has shown great promise in resolving the limitations presented by the heterogeneous nature of glioblastoma. Here we discuss the contrasting yet interdependent dual role of extracellular vesicles as communication agents that contribute to the progression of glioblastoma by creating a heterogeneous microenvironment and as a liquid biopsy tool providing an opportunity to accurately identify the disease severity and progression.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Indira Chandran</LastName><ForeName>Vineesh</ForeName><Initials>V</Initials><Identifier Source=\"ORCID\">0000-0003-2160-9379</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. vin@clin.au.dk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark. vin@clin.au.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gopala</LastName><ForeName>Srinivas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Venkat</LastName><ForeName>Easwer Hariharan</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kjolby</LastName><ForeName>Mads</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0002-1043-6137</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Steno Diabetes Centre, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nejsum</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Precis Oncol</MedlineTA><NlmUniqueID>101708166</NlmUniqueID><ISSNLinking>2397-768X</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760427</ArticleId><ArticleId IdType=\"doi\">10.1038/s41698-024-00600-2</ArticleId><ArticleId IdType=\"pii\">10.1038/s41698-024-00600-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D. &amp; Wrensch, M. Epidemiology and molecular pathology of glioma. Nat. Clin. Pr. Neurol. 2, 494&#x2013;503 (2006).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ncpneuro0289</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M. &amp; Simjee Sh, U. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac. J. Cancer Prev. 18, 3&#x2013;9 (2017).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28239999</ArticleId><ArticleId IdType=\"pmc\">5563115</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, D. R. et al. A Radiologist&#x2019;s Guide to the 2021 WHO Central Nervous System Tumor Classification: Part I&#x2014;Key Concepts and the Spectrum of Diffuse Gliomas. Radiology 304, 494&#x2013;508 (2022).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35880978</ArticleId><ArticleId IdType=\"doi\">10.1148/radiol.213063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertler, C. et al. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders&#x2019; Collaborative Consortium (EORTC 1419). Eur. J. Cancer 189, https://doi.org/10.1016/j.ejca.2023.05.002 (2023).</Citation></Reference><Reference><Citation>Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C. &amp; Barnholtz-Sloan, J. S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 23, iii1&#x2013;iii105 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34608945</ArticleId><ArticleId IdType=\"pmc\">8491279</ArticleId><ArticleId IdType=\"doi\">10.1093/neuonc/noab200</ArticleId></ArticleIdList></Reference><Reference><Citation>Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987&#x2013;996 (2005).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">15758009</ArticleId><ArticleId IdType=\"doi\">10.1056/NEJMoa043330</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, K. D. et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J. Clin. 71, 381&#x2013;406 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34427324</ArticleId><ArticleId IdType=\"doi\">10.3322/caac.21693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, J., F.G. Stevens, M. &amp; D. Bradshaw, T. Temozolomide: Mechanisms of Action, Repair and Resistance. Curr. Mol. Pharmacol. 5, 102&#x2013;114 (2012).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22122467</ArticleId><ArticleId IdType=\"doi\">10.2174/1874467211205010102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim, M., Xia, Y., Bettegowda, C. &amp; Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422&#x2013;442 (2018).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29643471</ArticleId><ArticleId IdType=\"doi\">10.1038/s41571-018-0003-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Stupp, R., Brada, M., van den Bent, M. J., Tonn, J. C. &amp; Pentheroudakis, G. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25, iii93&#x2013;iii101 (2014).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">24782454</ArticleId><ArticleId IdType=\"doi\">10.1093/annonc/mdu050</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. &amp; Bettegowda, C. Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms. J. Mol. Diagn. 19, 24&#x2013;34 (2017).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27863260</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jmoldx.2016.08.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, J. K. et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat. Genet 49, 594&#x2013;599 (2017).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28263318</ArticleId><ArticleId IdType=\"pmc\">5627771</ArticleId><ArticleId IdType=\"doi\">10.1038/ng.3806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesseling, P., Kros, J. M. &amp; Jeuken, J. W. M. The pathological diagnosis of diffuse gliomas: towards a smart synthesis of microscopic and molecular information in a multidisciplinary context. Diagnostic Histopathol. 17, 486&#x2013;494 (2011).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.mpdhp.2011.08.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosque, A. &amp; Friedmann-Morvinski, D. Drivers of heterogeneity in the glioblastoma immune microenvironment. Curr. Opin. Cell Biol. 85, 102279 (2023).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">37984008</ArticleId><ArticleId IdType=\"doi\">10.1016/j.ceb.2023.102279</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan, X. et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature 549, 227&#x2013;232 (2017).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28854171</ArticleId><ArticleId IdType=\"pmc\">5608080</ArticleId><ArticleId IdType=\"doi\">10.1038/nature23666</ArticleId></ArticleIdList></Reference><Reference><Citation>Puchalski, R. B. et al. An anatomic transcriptional atlas of human glioblastoma. Science 360, 660&#x2013;663 (2018).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29748285</ArticleId><ArticleId IdType=\"pmc\">6414061</ArticleId><ArticleId IdType=\"doi\">10.1126/science.aaf2666</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756&#x2013;760 (2006).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">17051156</ArticleId><ArticleId IdType=\"doi\">10.1038/nature05236</ArticleId></ArticleIdList></Reference><Reference><Citation>Soeda, A. et al. The evidence of glioblastoma heterogeneity. Sci. Rep. 5, 7979 (2015).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25623281</ArticleId><ArticleId IdType=\"pmc\">4306917</ArticleId><ArticleId IdType=\"doi\">10.1038/srep07979</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98&#x2013;110 (2010).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">20129251</ArticleId><ArticleId IdType=\"pmc\">2818769</ArticleId><ArticleId IdType=\"doi\">10.1016/j.ccr.2009.12.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolic, A. et al. Copy-scAT: Deconvoluting single-cell chromatin accessibility of genetic subclones in cancer. Sci. Adv. 7, eabg6045 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34644115</ArticleId><ArticleId IdType=\"pmc\">8514091</ArticleId><ArticleId IdType=\"doi\">10.1126/sciadv.abg6045</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 32, 42&#x2013;56.e46 (2017).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28697342</ArticleId><ArticleId IdType=\"pmc\">5599156</ArticleId><ArticleId IdType=\"doi\">10.1016/j.ccell.2017.06.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl Acad. Sci. USA 110, 4009&#x2013;4014 (2013).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23412337</ArticleId><ArticleId IdType=\"pmc\">3593922</ArticleId><ArticleId IdType=\"doi\">10.1073/pnas.1219747110</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, E., Dickerson, K. L., Connolly, I. D. &amp; Hayden Gephart, M. Single-Cell RNA-Sequencing in Glioma. Curr. Oncol. Rep. 20, 42 (2018).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29637300</ArticleId><ArticleId IdType=\"pmc\">8403493</ArticleId><ArticleId IdType=\"doi\">10.1007/s11912-018-0673-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522&#x2013;526 (2012).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22854781</ArticleId><ArticleId IdType=\"pmc\">3427400</ArticleId><ArticleId IdType=\"doi\">10.1038/nature11287</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson, M., Hassiotou, F. &amp; Nowak, A. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis 36, 177&#x2013;185 (2014).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25504149</ArticleId><ArticleId IdType=\"doi\">10.1093/carcin/bgu243</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Carmona, E. et al. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas. Cell Rep. Med. 101249 https://doi.org/10.1016/j.xcrm.2023.101249 (2023).</Citation></Reference><Reference><Citation>Zhang, L. et al. Genomic analysis of primary and recurrent gliomas reveals clinical outcome related molecular features. Sci. Rep. 9, 16058 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31690770</ArticleId><ArticleId IdType=\"pmc\">6831607</ArticleId><ArticleId IdType=\"doi\">10.1038/s41598-019-52515-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson, I. et al. Modeling glioblastoma heterogeneity as a dynamic network of cell states. Mol. Syst. Biol. 17, e10105 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34528760</ArticleId><ArticleId IdType=\"pmc\">8444284</ArticleId><ArticleId IdType=\"doi\">10.15252/msb.202010105</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelfattah, N. et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat. Commun. 13, 767 (2022).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35140215</ArticleId><ArticleId IdType=\"pmc\">8828877</ArticleId><ArticleId IdType=\"doi\">10.1038/s41467-022-28372-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med 25, 462&#x2013;469 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30742119</ArticleId><ArticleId IdType=\"pmc\">6810613</ArticleId><ArticleId IdType=\"doi\">10.1038/s41591-019-0349-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Franson, A. et al. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment. Front. Med. 9, 966458 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fmed.2022.966458</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto, L. et al. Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. Oncologist 26, 865&#x2013;878 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34105205</ArticleId><ArticleId IdType=\"pmc\">8488799</ArticleId><ArticleId IdType=\"doi\">10.1002/onco.13858</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenbarth, D. &amp; Wang, Y. A. Glioblastoma heterogeneity at single cell resolution. Oncogene 42, 2155&#x2013;2165 (2023).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">37277603</ArticleId><ArticleId IdType=\"pmc\">10913075</ArticleId><ArticleId IdType=\"doi\">10.1038/s41388-023-02738-y</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Bent, M. J. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician&#x2019;s perspective. Acta Neuropathol. 120, 297&#x2013;304 (2010).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">20644945</ArticleId><ArticleId IdType=\"pmc\">2910894</ArticleId><ArticleId IdType=\"doi\">10.1007/s00401-010-0725-7</ArticleId></ArticleIdList></Reference><Reference><Citation>van Niel, G., D&#x2019;Angelo, G. &amp; Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213&#x2013;228 (2018).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29339798</ArticleId><ArticleId IdType=\"doi\">10.1038/nrm.2017.125</ArticleId></ArticleIdList></Reference><Reference><Citation>Indira Chandran, V. et al. Global extracellular vesicle proteomic signature defines U87-MG glioma cell hypoxic status with potential implications for non-invasive diagnostics. J. Neurooncol. 144, 477&#x2013;488 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31414377</ArticleId><ArticleId IdType=\"pmc\">6764937</ArticleId><ArticleId IdType=\"doi\">10.1007/s11060-019-03262-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowal, J. et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc. Natl Acad. Sci. USA 113, E968&#x2013;E977 (2016).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26858453</ArticleId><ArticleId IdType=\"pmc\">4776515</ArticleId><ArticleId IdType=\"doi\">10.1073/pnas.1521230113</ArticleId></ArticleIdList></Reference><Reference><Citation>Willms, E., Caba&#xf1;as, C., M&#xe4;ger, I., Wood, M. J. A. &amp; Vader, P. Extracellular Vesicle Heterogeneity: Subpopulations, Isolation Techniques, and Diverse Functions in Cancer Progression. Front. Immunol. 9, 738 (2018).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29760691</ArticleId><ArticleId IdType=\"pmc\">5936763</ArticleId><ArticleId IdType=\"doi\">10.3389/fimmu.2018.00738</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeppesen, D. K., Zhang, Q., Franklin, J. L. &amp; Coffey, R. J. Extracellular vesicles and nanoparticles: emerging complexities. Trends Cell Biol. 33, 667&#x2013;681 (2023).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36737375</ArticleId><ArticleId IdType=\"doi\">10.1016/j.tcb.2023.01.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma, J. et al. MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res. 40, 9125&#x2013;9138 (2012).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22772984</ArticleId><ArticleId IdType=\"pmc\">3467054</ArticleId><ArticleId IdType=\"doi\">10.1093/nar/gks656</ArticleId></ArticleIdList></Reference><Reference><Citation>Musatova, O. E. &amp; Rubtsov, Y. P. Effects of glioblastoma-derived extracellular vesicles on the functions of immune cells. Front. Cell Dev. Biol. 11, 1060000 (2023).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36960410</ArticleId><ArticleId IdType=\"pmc\">10028257</ArticleId><ArticleId IdType=\"doi\">10.3389/fcell.2023.1060000</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito, H. et al. Analysis of extracellular vesicles as a potential index for monitoring differentiation of neural lineage cells from induced pluripotent stem cells. J. Biosci. Bioeng. 132, 381&#x2013;389 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34284947</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jbiosc.2021.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli, C. et al. Molecular subtypes and differentiation programmes of glioma stem cells as determinants of extracellular vesicle profiles and endothelial cell-stimulating activities. J. Extracell. Vesicles 7, 1490144 (2018).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30034643</ArticleId><ArticleId IdType=\"pmc\">6052423</ArticleId><ArticleId IdType=\"doi\">10.1080/20013078.2018.1490144</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricklefs, F. L. et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci. Adv. 4, eaar2766 (2018).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29532035</ArticleId><ArticleId IdType=\"pmc\">5842038</ArticleId><ArticleId IdType=\"doi\">10.1126/sciadv.aar2766</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, Z. et al. Glioblastoma Stem Cell-Derived Exosomes Enhance Stemness and Tumorigenicity of Glioma Cells by Transferring Notch1 Protein. Cell Mol. Neurobiol. 40, 767&#x2013;784 (2020).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31853695</ArticleId><ArticleId IdType=\"doi\">10.1007/s10571-019-00771-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Treps, L., Perret, R., Edmond, S., Ricard, D. &amp; Gavard, J. Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J. Extracell. Vesicles 6, 1359479 (2017).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28815003</ArticleId><ArticleId IdType=\"pmc\">5549846</ArticleId><ArticleId IdType=\"doi\">10.1080/20013078.2017.1359479</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnier, D. et al. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Neuro Oncol. 20, 236&#x2013;248 (2018).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29016925</ArticleId><ArticleId IdType=\"doi\">10.1093/neuonc/nox142</ArticleId></ArticleIdList></Reference><Reference><Citation>Yekula, A. et al. Extracellular Vesicles in Glioblastoma Tumor Microenvironment. Front. Immunol. 10, 3137 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32038644</ArticleId><ArticleId IdType=\"doi\">10.3389/fimmu.2019.03137</ArticleId></ArticleIdList></Reference><Reference><Citation>Abels, E. R., Broekman, M. L. D., Breakefield, X. O. &amp; Maas, S. L. N. Glioma EVs Contribute to Immune Privilege in the Brain. Trends Cancer 5, 393&#x2013;396 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31311653</ArticleId><ArticleId IdType=\"pmc\">8237701</ArticleId><ArticleId IdType=\"doi\">10.1016/j.trecan.2019.05.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Broekman, M. L. et al. Multidimensional communication in the microenvirons of glioblastoma. Nat. Rev. Neurol. 14, 482&#x2013;495 (2018).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29985475</ArticleId><ArticleId IdType=\"pmc\">6425928</ArticleId><ArticleId IdType=\"doi\">10.1038/s41582-018-0025-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Graner, M. W. Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence. Annu. Rev. Genomics Hum. Genet 20, 331&#x2013;357 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30978305</ArticleId><ArticleId IdType=\"pmc\">6717010</ArticleId><ArticleId IdType=\"doi\">10.1146/annurev-genom-083118-015324</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnier, D., Jabado, N. &amp; Rak, J. Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours. Proteomics 13, 1595&#x2013;1607 (2013).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23505048</ArticleId><ArticleId IdType=\"doi\">10.1002/pmic.201200360</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Nedawi, K. et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619&#x2013;624 (2008).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">18425114</ArticleId><ArticleId IdType=\"doi\">10.1038/ncb1725</ArticleId></ArticleIdList></Reference><Reference><Citation>Caponnetto, F. et al. The miRNA Content of Exosomes Released from the Glioma Microenvironment Can Affect Malignant Progression. Biomedicines 8, https://doi.org/10.3390/biomedicines8120564 (2020).</Citation></Reference><Reference><Citation>Tan, S. et al. Exosomal miRNAs in tumor microenvironment. J. Exp. Clin. Cancer Res. 39, 67 (2020).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32299469</ArticleId><ArticleId IdType=\"pmc\">7164281</ArticleId><ArticleId IdType=\"doi\">10.1186/s13046-020-01570-6</ArticleId></ArticleIdList></Reference><Reference><Citation>He, X. et al. Current landscape of tumor-derived exosomal ncRNAs in glioma progression, detection, and drug resistance. Cell Death Dis. 12, 1145 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34887381</ArticleId><ArticleId IdType=\"pmc\">8660802</ArticleId><ArticleId IdType=\"doi\">10.1038/s41419-021-04430-z</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Asti, E., Chennakrishnaiah, S., Lee, T. H. &amp; Rak, J. Extracellular Vesicles in Brain Tumor Progression. Cell Mol. Neurobiol. 36, 383&#x2013;407 (2016).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26993504</ArticleId><ArticleId IdType=\"doi\">10.1007/s10571-015-0296-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Godlewski, J. et al. MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. Stem Cell Rep. 8, 1497&#x2013;1505 (2017).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.stemcr.2017.04.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396&#x2013;1401 (2014).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">24925914</ArticleId><ArticleId IdType=\"pmc\">4123637</ArticleId><ArticleId IdType=\"doi\">10.1126/science.1254257</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer, M. et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc. Natl Acad. Sci. USA 112, 851&#x2013;856 (2015).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25561528</ArticleId><ArticleId IdType=\"pmc\">4311802</ArticleId><ArticleId IdType=\"doi\">10.1073/pnas.1320611111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucharzewska, P. et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl Acad. Sci. USA 110, 7312&#x2013;7317 (2013).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23589885</ArticleId><ArticleId IdType=\"pmc\">3645587</ArticleId><ArticleId IdType=\"doi\">10.1073/pnas.1220998110</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, G. et al. CD133 positive U87 glioblastoma cells-derived exosomal microRNAs in hypoxia- versus normoxia-microenviroment. J. Neurooncol 135, 37&#x2013;46 (2017).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28948499</ArticleId><ArticleId IdType=\"doi\">10.1007/s11060-017-2566-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu, B. &amp; Ghosh, M. K. Extracellular Vesicles in Glioma: From Diagnosis to Therapy. Bioessays 41, e1800245 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31188499</ArticleId><ArticleId IdType=\"doi\">10.1002/bies.201800245</ArticleId></ArticleIdList></Reference><Reference><Citation>Westphal, M. &amp; Lamszus, K. Circulating biomarkers for gliomas. Nat. Rev. Neurol. 11, 556&#x2013;566 (2015).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26369507</ArticleId><ArticleId IdType=\"doi\">10.1038/nrneurol.2015.171</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen, P. Y. et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J. Clin. Oncol. https://doi.org/10.1200/jco.23.01059 (2023).</Citation></Reference><Reference><Citation>M&#xfc;ller Bark, J., Kulasinghe, A., Chua, B., Day, B. W. &amp; Punyadeera, C. Circulating biomarkers in patients with glioblastoma. Br. J. Cancer 122, 295&#x2013;305 (2020).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31666668</ArticleId><ArticleId IdType=\"doi\">10.1038/s41416-019-0603-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane, R. et al. Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping. Commun. Biol. 2, 315 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31453379</ArticleId><ArticleId IdType=\"pmc\">6700082</ArticleId><ArticleId IdType=\"doi\">10.1038/s42003-019-0560-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Osti, D. et al. Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients. Clin. Cancer Res. 25, 266&#x2013;276 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30287549</ArticleId><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-18-1941</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai, C. P. et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 8, 483&#x2013;494 (2014).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">24383518</ArticleId><ArticleId IdType=\"pmc\">3934350</ArticleId><ArticleId IdType=\"doi\">10.1021/nn404945r</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno, S. et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21, 185&#x2013;191 (2013).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23032975</ArticleId><ArticleId IdType=\"doi\">10.1038/mt.2012.180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooijmans, S. A. A. et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J. Controlled Rel. 224, 77&#x2013;85 (2016).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jconrel.2016.01.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Badosa, C., Rold&#xe1;n, M., Fern&#xe1;ndez-Irigoyen, J., Santamaria, E. &amp; Jimenez-Mallebrera, C. Proteomic and functional characterisation of extracellular vesicles from collagen VI deficient human fibroblasts reveals a role in cell motility. Sci. Rep. 13, 14622 (2023).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">37670049</ArticleId><ArticleId IdType=\"pmc\">10480450</ArticleId><ArticleId IdType=\"doi\">10.1038/s41598-023-41632-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead, C. A. et al. Extracellular vesicles and their role in glioblastoma. Crit. Rev. Clin. Lab Sci. 57, 227&#x2013;252 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31865806</ArticleId><ArticleId IdType=\"doi\">10.1080/10408363.2019.1700208</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bene, M. et al. Extracellular vesicles: The key for precision medicine in glioblastoma. Neuro Oncol. 24, 184&#x2013;196 (2022).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34581817</ArticleId><ArticleId IdType=\"doi\">10.1093/neuonc/noab229</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q., Jeppesen, D. K., Higginbotham, J. N., Franklin, J. L. &amp; Coffey, R. J. Comprehensive isolation of extracellular vesicles and nanoparticles. Nat. Protoc. 18, 1462&#x2013;1487 (2023).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36914899</ArticleId><ArticleId IdType=\"pmc\">10445291</ArticleId><ArticleId IdType=\"doi\">10.1038/s41596-023-00811-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon, D. A. &amp; Wen, P. Y. Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat. Rev. Clin. Oncol. 12, 69&#x2013;70 (2015).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25560529</ArticleId><ArticleId IdType=\"doi\">10.1038/nrclinonc.2014.223</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18, 170&#x2013;186 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33293629</ArticleId><ArticleId IdType=\"doi\">10.1038/s41571-020-00447-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Grech, N. et al. Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population. Cureus 12, e8195 (2020).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32572354</ArticleId><ArticleId IdType=\"pmc\">7302718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kebir, S. et al. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. Clin. Cancer Res. 22, 2190&#x2013;2196 (2016).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26673798</ArticleId><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-15-1334</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramesh, C. S. et al. Priorities for cancer research in low- and middle-income countries: a global perspective. Nat. Med. 28, 649&#x2013;657 (2022).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35440716</ArticleId><ArticleId IdType=\"pmc\">9108683</ArticleId><ArticleId IdType=\"doi\">10.1038/s41591-022-01738-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Youngblood, M. W., Stupp, R. &amp; Sonabend, A. M. Role of Resection in Glioblastoma Management. Neurosurg. Clin. N. Am. 32, 9&#x2013;22 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33223030</ArticleId><ArticleId IdType=\"doi\">10.1016/j.nec.2020.08.002</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijken, B. R. J., van Laar, P. J., Holtman, G. A. &amp; van der Hoorn, A. Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur. Radio. 27, 4129&#x2013;4144 (2017).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00330-017-4789-9</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit, M. C., de Bruin, H. G., Eijkenboom, W., Sillevis Smitt, P. A. &amp; van den Bent, M. J. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63, 535&#x2013;537 (2004).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">15304589</ArticleId><ArticleId IdType=\"doi\">10.1212/01.WNL.0000133398.11870.9A</ArticleId></ArticleIdList></Reference><Reference><Citation>Taal, W. et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113, 405&#x2013;410 (2008).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">18484594</ArticleId><ArticleId IdType=\"doi\">10.1002/cncr.23562</ArticleId></ArticleIdList></Reference><Reference><Citation>Indira Chandran, V. et al. Ultrasensitive Immunoprofiling of Plasma Extracellular Vesicles Identifies Syndecan-1 as a Potential Tool for Minimally Invasive Diagnosis of Glioma. Clin. Cancer Res. 25, 3115&#x2013;3127 (2019).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30679164</ArticleId><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-18-2946</ArticleId></ArticleIdList></Reference><Reference><Citation>Maire, C. L. et al. Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification. Neuro Oncol. 23, 1087&#x2013;1099 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33508126</ArticleId><ArticleId IdType=\"pmc\">8673443</ArticleId><ArticleId IdType=\"doi\">10.1093/neuonc/noab012</ArticleId></ArticleIdList></Reference><Reference><Citation>Batool, S. M. et al. Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients. Clin. Cancer Res. 28, 4070&#x2013;4082 (2022).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35849415</ArticleId><ArticleId IdType=\"pmc\">9475243</ArticleId><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-22-0444</ArticleId></ArticleIdList></Reference><Reference><Citation>Stella, M. et al. Serum Extracellular Vesicle-Derived circHIPK3 and circSMARCA5 Are Two Novel Diagnostic Biomarkers for Glioblastoma Multiforme. Pharmaceuticals 14, https://doi.org/10.3390/ph14070618 (2021).</Citation></Reference><Reference><Citation>Huang, S. W., Ali, N. D., Zhong, L. &amp; Shi, J. MicroRNAs as biomarkers for human glioblastoma: progress and potential. Acta Pharm. Sin. 39, 1405&#x2013;1413 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/aps.2017.173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallal, S. et al. Deep Sequencing of Small RNAs from Neurosurgical Extracellular Vesicles Substantiates miR-486-3p as a Circulating Biomarker that Distinguishes Glioblastoma from Lower-Grade Astrocytoma Patients. Int. J. Mol. Sci. 21, https://doi.org/10.3390/ijms21144954 (2020).</Citation></Reference><Reference><Citation>Arrieta, V. A. et al. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J. Clin. Invest. 133, https://doi.org/10.1172/jci163447 (2023).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760383</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2045-2322</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Development of a nomogram for identifying periodontitis cases in Denmark.</ArticleTitle><Pagination><StartPage>11280</StartPage><MedlinePgn>11280</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1038/s41598-024-60624-3</ELocationID><Abstract><AbstractText>Although self-reported health outcomes are of importance, attempts to validate a clinical applicable instrument (e.g., nomogram) combining sociodemographic and self-reported information on periodontitis have yet to be performed to identify periodontitis cases. Clinical and self-reported periodontitis, along with sociodemographic data, were collected from 197 adults. Akaike information criterion models were developed to identify periodontitis, and nomograms developed based on its regression coefficients. The discriminatory capability was evaluated by receiver-operating characteristic curves. Decision curve analysis was performed. Smoking [OR 3.69 (95%CI 1.89, 7.21)], poor/fair self-rated oral health [OR 6.62 (95%CI 3.23, 13.56)], previous periodontal treatment [OR 9.47 (95%CI 4.02, 22.25)], and tooth loss [OR 4.96 (95%CI 2.47, 9.97)], determined higher probability of having \"Moderate/Severe Periodontitis\". Age [OR 1.08 (95%CI 1.05, 1.12)], low educational level [OR 1.65 (95%CI 1.34, 2.23)], poor/fair self-rated oral health [OR 3.57 (95%CI 1.82, 6.99)], and previous periodontal treatment [OR 6.66 (95%CI 2.83, 15.68)] determined higher probability for \"Any Periodontitis\". Both nomograms showed excellent discriminatory capability (AUC of 0.83 (95%CI 0.75, 0.91) and 0.81 (95% CI 0.74, 0.88), good calibration, and slight overestimation of high risk and underestimation of low risk. Hence, our nomograms could help identify periodontitis among adults in Denmark.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Cassiano</LastName><ForeName>Luisa Schertel</ForeName><Initials>LS</Initials><Identifier Source=\"ORCID\">0000-0002-2976-1386</Identifier><AffiliationInfo><Affiliation>Section for Oral Ecology, Department of Dentistry and Oral Health, Aarhus University, Vennelyst Boulevard 9, 8000, Aarhus, Denmark. lscassiano@dent.au.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jensen</LastName><ForeName>Anne B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Section for Oral Ecology, Department of Dentistry and Oral Health, Aarhus University, Vennelyst Boulevard 9, 8000, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pajaniaye</LastName><ForeName>Julie B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Section for Oral Ecology, Department of Dentistry and Oral Health, Aarhus University, Vennelyst Boulevard 9, 8000, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Leite</LastName><ForeName>F&#xe1;bio R M</ForeName><Initials>FRM</Initials><AffiliationInfo><Affiliation>National Dental Research Institute Singapore, National Dental Centre Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oral Health Academic Clinical Programme, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Li</LastName><ForeName>Huihua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Dental Research Institute Singapore, National Dental Centre Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oral Health Academic Clinical Programme, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Andersen</LastName><ForeName>Anette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bitencourt</LastName><ForeName>Fernando V</ForeName><Initials>FV</Initials><AffiliationInfo><Affiliation>Section for Oral Ecology, Department of Dentistry and Oral Health, Aarhus University, Vennelyst Boulevard 9, 8000, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nascimento</LastName><ForeName>Gustavo G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>National Dental Research Institute Singapore, National Dental Centre Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oral Health Academic Clinical Programme, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><GrantID>AUFF-E 2019-7-3</GrantID><Agency>Aarhus Universitets Forskningsfond</Agency><Country/></Grant><Grant><GrantID>AUFF-E 2019-7-3</GrantID><Agency>Aarhus Universitets Forskningsfond</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D010518\" MajorTopicYN=\"Y\">Periodontitis</DescriptorName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D049451\" MajorTopicYN=\"Y\">Nomograms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D003718\" MajorTopicYN=\"N\" Type=\"Geographic\">Denmark</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012372\" MajorTopicYN=\"N\">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D057566\" MajorTopicYN=\"N\">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D009909\" MajorTopicYN=\"N\">Oral Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012307\" MajorTopicYN=\"N\">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760383</ArticleId><ArticleId IdType=\"doi\">10.1038/s41598-024-60624-3</ArticleId><ArticleId IdType=\"pii\">10.1038/s41598-024-60624-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jylha, M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model. Soc. Sci. Med. 69(3), 307&#x2013;316 (2009).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.socscimed.2009.05.013</ArticleId><ArticleId IdType=\"pubmed\">19520474</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimbux, N. et al. Measuring patient experience of oral health care: A call to action. J. Evid. Based Dent. Pract. 23(1S), 101788 (2023).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jebdp.2022.101788</ArticleId><ArticleId IdType=\"pubmed\">36707167</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento, G. G., Raittio, E., Machado, V., Leite, F. R. M. &amp; Botelho, J. Advancing universal oral health coverage via person-centred outcomes. Int. Dent. J. 73(6), 793&#x2013;799. https://doi.org/10.1016/j.identj.2023.06.006 (2023).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.identj.2023.06.006</ArticleId><ArticleId IdType=\"pubmed\">37684172</ArticleId><ArticleId IdType=\"pmc\">10658430</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento, G. G. et al. Validity of self-reported oral conditions among Brazilian older women: Do socio-economic factors matter?. Int. J. Dent. Hyg. https://doi.org/10.1111/idh.12680 (2023).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/idh.12680</ArticleId><ArticleId IdType=\"pubmed\">37183553</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsson, G. &amp; Helgadottir, S. Comparison of oral health data from self-administered questionnaire and clinical examination. Community Dent. Oral Epidemiol. 23(6), 365&#x2013;368 (1995).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1600-0528.1995.tb00264.x</ArticleId><ArticleId IdType=\"pubmed\">8681520</ArticleId></ArticleIdList></Reference><Reference><Citation>Margozzini, P., Berr&#xed;os, R., Cantarutti, C., Veliz, C. &amp; Ortuno, D. Validity of the self-reported number of teeth in Chilean adults. BMC Oral Health 19(1), 99 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12903-019-0794-5</ArticleId><ArticleId IdType=\"pubmed\">31164110</ArticleId><ArticleId IdType=\"pmc\">6549282</ArticleId></ArticleIdList></Reference><Reference><Citation>Reissmann, D. R. Dental patient-reported outcome measures are essential for evidence-based prosthetic dentistry. J. Evid. Based Dent. Pract. 19(1), 1&#x2013;6 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jebdp.2019.01.003</ArticleId><ArticleId IdType=\"pubmed\">30926098</ArticleId></ArticleIdList></Reference><Reference><Citation>John, M. T. Health outcomes reported by dental patients. J. Evid. Based Dent. Pract. 18(4), 332&#x2013;335 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jebdp.2018.09.001</ArticleId><ArticleId IdType=\"pubmed\">30514446</ArticleId></ArticleIdList></Reference><Reference><Citation>Eke, P. I., Dye, B. A., Wei, L., Thornton-Evans, G. O. &amp; Genco, R. J. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J. Dent. Res. 91(10), 914&#x2013;920 (2012).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/0022034512457373</ArticleId><ArticleId IdType=\"pubmed\">22935673</ArticleId></ArticleIdList></Reference><Reference><Citation>Botelho, J. et al. Economic burden of periodontitis in the United States and Europe: An updated estimation. J. Periodontol. 93(3), 373&#x2013;379 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/JPER.21-0111</ArticleId><ArticleId IdType=\"pubmed\">34053082</ArticleId></ArticleIdList></Reference><Reference><Citation>Eke, P. I. et al. Self-reported measures for surveillance of periodontitis. J. Dent. Res. 92(11), 1041&#x2013;1047 (2013).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/0022034513505621</ArticleId><ArticleId IdType=\"pubmed\">24065636</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite, F. R. M., Peres, K. G., Do, L. G., Demarco, F. F. &amp; Peres, M. A. A. Prediction of periodontitis occurrence: Influence of classification and sociodemographic and general health information. J. Periodontol. 88(8), 731&#x2013;743. https://doi.org/10.1902/jop.2017.160607 (2017).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1902/jop.2017.160607</ArticleId><ArticleId IdType=\"pubmed\">28362224</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, D. Build prognostic nomograms for risk assessment using SAS. In Proceedings of SAS Global Forum Vol. 2013 (2013).</Citation></Reference><Reference><Citation>Iasonos, A., Schrag, D., Raj, G. V. &amp; Panageas, K. S. How to build and interpret a nomogram for cancer prognosis. J. Clin. Oncol. 26(8), 1364&#x2013;1370. https://doi.org/10.1200/JCO.2007.12.9791 (2008).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2007.12.9791</ArticleId><ArticleId IdType=\"pubmed\">18323559</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim, C. P. C., Li, H. &amp; Peres, M. A. Who to be treated: Nomogram using self-reported periodontal screening instrument among English-speaking adults in multi-ethnic Singapore. J. Pers. Med. 12(6), 931 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/jpm12060931</ArticleId><ArticleId IdType=\"pubmed\">35743716</ArticleId><ArticleId IdType=\"pmc\">9225178</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf8;vik, H. et al. The validity of self-reported number of teeth and edentulousness among Norwegian older adults, the HUNT Study. BMC Oral Health 22(1), 82. https://doi.org/10.1186/s12903-022-02116-2 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12903-022-02116-2</ArticleId><ArticleId IdType=\"pubmed\">35313882</ArticleId><ArticleId IdType=\"pmc\">8935783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekundo, C., Stock, C., J&#xfc;rges, H. &amp; Listl, S. Patients&#x2019; self-reported measures of oral health-A validation study on basis of oral health questions used in a large multi-country survey for populations aged 50. Gerodontology 36(2), 171&#x2013;179. https://doi.org/10.1111/ger.12398.E (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/ger.12398.E</ArticleId><ArticleId IdType=\"pubmed\">30821850</ArticleId></ArticleIdList></Reference><Reference><Citation>Simila, T., Nieminen, P. &amp; Virtanen, J. I. Validity of self-reported number of teeth in middle-aged Finnish adults: The Northern Finland Birth Cohort Study 1966. BMC Oral Health 18(1), 210 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12903-018-0666-4</ArticleId><ArticleId IdType=\"pubmed\">30538003</ArticleId><ArticleId IdType=\"pmc\">6290517</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno, M., Shimazu, T., Sawada, N., Tsugane, S. &amp; Kawaguchi, Y. Validity of self-reported tooth counts and masticatory status study of a Japanese adult population. J. Oral Rehabil. 45(5), 393&#x2013;398. https://doi.org/10.1111/joor.12615 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/joor.12615</ArticleId><ArticleId IdType=\"pubmed\">29420835</ArticleId></ArticleIdList></Reference><Reference><Citation>Schertel Cassiano, L. et al. Self-reported periodontitis association with impaired smell and taste: A multicenter survey. Oral Dis. https://doi.org/10.1111/odi.14601 (2023).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/odi.14601</ArticleId><ArticleId IdType=\"pubmed\">37114436</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertl, K. et al. Periodontitis prevalence in patients with ulcerative colitis and Crohn&#x2019;s disease&#x2014;PPCC: A case-control study. J. Clin. Periodontol. 49(12), 1262&#x2013;1274. https://doi.org/10.1111/jcpe.13615 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/jcpe.13615</ArticleId><ArticleId IdType=\"pubmed\">35781889</ArticleId><ArticleId IdType=\"pmc\">9804609</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich, T. et al. The accuracy of individual self-reported items to determine periodontal disease history. Eur. J. Oral Sci. 113(2), 135&#x2013;140. https://doi.org/10.1111/j.1600-0722.2004.00196.x (2005).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1600-0722.2004.00196.x</ArticleId><ArticleId IdType=\"pubmed\">15819819</ArticleId></ArticleIdList></Reference><Reference><Citation>Cyrino, R. M., Miranda Cota, L. O., Pereira Lages, E. J., Bastos Lages, E. M. &amp; Costa, F. O. Evaluation of self-reported measures for prediction of periodontitis in a sample of Brazilians. J. Periodontol. 82(12), 1693&#x2013;1704. https://doi.org/10.1902/jop.2011.110015 (2011).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1902/jop.2011.110015</ArticleId><ArticleId IdType=\"pubmed\">21563951</ArticleId></ArticleIdList></Reference><Reference><Citation>AlJehani, Y. A. Risk factors of periodontal disease: Review of the literature. Int. J. Dent. 2014, 182513 (2014).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1155/2014/182513</ArticleId><ArticleId IdType=\"pubmed\">24963294</ArticleId><ArticleId IdType=\"pmc\">4055151</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuch, H. S., Peres, K. G., Singh, A., Peres, M. A. &amp; Do, L. G. Socioeconomic position during life and periodontitis in adulthood: A systematic review. Community Dent. Oral Epidemiol. 45(3), 201&#x2013;208. https://doi.org/10.1111/cdoe.12278 (2017).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/cdoe.12278</ArticleId><ArticleId IdType=\"pubmed\">28032355</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuch, H. S. et al. The controlled direct effect of early-life socioeconomic position on periodontitis in a birth cohort. Am. J. Epidemiol. 188(6), 1101&#x2013;1108. https://doi.org/10.1093/aje/kwz054 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/aje/kwz054</ArticleId><ArticleId IdType=\"pubmed\">30834447</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite, F. R. M., Nascimento, G. G., Scheutz, F. &amp; L&#xf3;pez, R. Effect of smoking on periodontitis: A systematic review and meta-regression. Am. J. Prev. Med. 54(6), 831&#x2013;841. https://doi.org/10.1016/j.amepre.2018.02.014 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amepre.2018.02.014</ArticleId><ArticleId IdType=\"pubmed\">29656920</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite, F. R. M., L&#xf3;pez, R., Pajaniaye, J. B. &amp; Nascimento, G. G. Effect of smoking exposure on nonsurgical periodontal therapy: 1-year follow-up. J. Dent. Res. 102(3), 280&#x2013;286. https://doi.org/10.1177/00220345221135100 (2023).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/00220345221135100</ArticleId><ArticleId IdType=\"pubmed\">36333874</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., He, J., He, B., Huang, R. &amp; Li, M. Effect of tobacco on periodontal disease and oral cancer. Tob. Induc. Dis. 17, 40. https://doi.org/10.18332/tid/106187 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18332/tid/106187</ArticleId><ArticleId IdType=\"pubmed\">31516483</ArticleId><ArticleId IdType=\"pmc\">6662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Papapanou, P. N. et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J. Clin. Periodontol. 45, S162&#x2013;S170 (2018).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/jcpe.12946</ArticleId><ArticleId IdType=\"pubmed\">29926490</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris, P. A. et al. Research electronic data capture (REDCap)&#x2014;A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42(2), 377&#x2013;381 (2009).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType=\"pubmed\">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris, P. A. et al. REDCap Consortium, The REDCap consortium: Building an international community of software partners. J. Biomed. Inform. https://doi.org/10.1016/j.jbi.2019.103208 (2019).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType=\"pubmed\">31078660</ArticleId><ArticleId IdType=\"pmc\">7254481</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez, R., Frydenberg, M. &amp; Baelum, V. Clinical features of early periodontitis. J. Periodontol. 80(5), 749&#x2013;758. https://doi.org/10.1902/jop.2009.080463 (2009).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1902/jop.2009.080463</ArticleId><ArticleId IdType=\"pubmed\">19405828</ArticleId></ArticleIdList></Reference><Reference><Citation>Eke, P. I., Page, R. C., Wei, L., Thornton-Evans, G. &amp; Genco, R. J. Update of the case definitions for population-based surveillance of periodontitis. J. Periodontol. 83(12), 1449&#x2013;1454. https://doi.org/10.1902/jop.2012.110664 (2012).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1902/jop.2012.110664</ArticleId><ArticleId IdType=\"pubmed\">22420873</ArticleId><ArticleId IdType=\"pmc\">6005373</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales, A. et al. Performance of the 2017 AAP/EFP case definition compared with the CDC/AAP definition in population-based studies. J. Periodontol. 93(7), 1003&#x2013;1013. https://doi.org/10.1002/JPER.21-0276 (2022).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/JPER.21-0276</ArticleId><ArticleId IdType=\"pubmed\">34625960</ArticleId></ArticleIdList></Reference><Reference><Citation>Eke, P. I., Borgnakke, W. S. &amp; Genco, R. J. Recent epidemiologic trends in periodontitis in the USA. Periodontol. 2000 82(1), 257&#x2013;267. https://doi.org/10.1111/prd.12323 (2002).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/prd.12323</ArticleId></ArticleIdList></Reference><Reference><Citation>Eke, P. I. et al. Self-reported measures for surveillance of periodontitis. J. Dent. Res. 92(11), 1041&#x2013;1047. https://doi.org/10.1177/0022034513505621 (2013).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/0022034513505621</ArticleId><ArticleId IdType=\"pubmed\">24065636</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauerbrei, W., Royston, P. &amp; Binder, H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat. Med. 26(30), 5512&#x2013;5528. https://doi.org/10.1002/sim.3148 (2007).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/sim.3148</ArticleId><ArticleId IdType=\"pubmed\">18058845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosmer, D. W. &amp; Lemeshow, S. Applied Logistic Regression 2nd edn, 160&#x2013;164 (John Wiley and Sons, 2000).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/0471722146</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg, E. W. &amp; Vergouwe, Y. Towards better clinical prediction models: Seven steps for development and an ABCD for validation. Eur. Heart J. 35(29), 1925&#x2013;1931 (2014).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/eurheartj/ehu207</ArticleId><ArticleId IdType=\"pubmed\">24898551</ArticleId><ArticleId IdType=\"pmc\">4155437</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers, A. J. &amp; Elkin, E. B. Decision curve analysis: A novel method for evaluating prediction models. Med. Decis. Making 26(6), 565&#x2013;574 (2006).</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/0272989X06295361</ArticleId><ArticleId IdType=\"pubmed\">17099194</ArticleId><ArticleId IdType=\"pmc\">2577036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760126</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1873-7145</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>183</Volume><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Food research international (Ottawa, Ont.)</Title><ISOAbbreviation>Food Res Int</ISOAbbreviation></Journal><ArticleTitle>Are novel plant-based meat alternatives the healthier choice?</ArticleTitle><Pagination><StartPage>114184</StartPage><MedlinePgn>114184</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.foodres.2024.114184</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0963-9969(24)00254-0</ELocationID><Abstract><AbstractText>The global market for plant-based meat alternatives (PBMAs) is expanding quickly. In this narrative review, analysis of the most recent scientific literature was achieved to understand the nutritional profile, health implications, and the challenges faced by PBMAs. On the positive side, most PBMAs are good sources of dietary fiber, contain phytochemicals, have comparable levels of iron, and are lower in calories, saturated fat, and cholesterol than meat. However, PBMAs frequently contain anti-nutrients, have less protein, iron, and vitamin B<sub>12</sub>, are lower in protein quality, and also have higher amounts of sodium. Substituting PBMAs for meats may cause iron, vitamin B<sub>12</sub>, and less likely protein deficiency for these vulnerable population such as women, older adults, and individuals with disorders. PBMAs fall into the category of ultra-processed foods, indicating a need to develop minimally processed, clean-label products. Replacing red meat with healthy plant-based foods is associated with lower risks of cardiovascular diseases, type 2 diabetes, and total mortality. There is a lack of robust, long-term evidence on the role of PBMAs consumption in health. As the nutrient contents of PBMAs can vary, consumers must read nutrition facts labels and ingredient lists to select a product that best fits their nutritional and health objectives.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>El Sadig</LastName><ForeName>Rowan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Agricultural, Food and Nutritional Science, University of Alberta, 4-10 Agriculture/Forestry Centre, Edmonton, Alberta T6G 2P5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wu</LastName><ForeName>Jianping</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Agricultural, Food and Nutritional Science, University of Alberta, 4-10 Agriculture/Forestry Centre, Edmonton, Alberta T6G 2P5, Canada. Electronic address: Jianping.wu@ualberta.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Food Res Int</MedlineTA><NlmUniqueID>9210143</NlmUniqueID><ISSNLinking>0963-9969</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D009753\" MajorTopicYN=\"Y\">Nutritive Value</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D014676\" MajorTopicYN=\"Y\">Diet, Vegetarian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000072001\" MajorTopicYN=\"N\">Diet, Healthy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008460\" MajorTopicYN=\"N\">Meat</DescriptorName><QualifierName UI=\"Q000032\" MajorTopicYN=\"N\">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000095866\" MajorTopicYN=\"N\">Meat Substitutes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Health considerations</Keyword><Keyword MajorTopicYN=\"N\">Nutrition profile</Keyword><Keyword MajorTopicYN=\"N\">Plant-based meat alternatives</Keyword><Keyword MajorTopicYN=\"N\">Sustainability</Keyword><Keyword MajorTopicYN=\"N\">Ultra-processed foods</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>21</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760126</ArticleId><ArticleId IdType=\"doi\">10.1016/j.foodres.2024.114184</ArticleId><ArticleId IdType=\"pii\">S0963-9969(24)00254-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760125</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1873-7145</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>183</Volume><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Food research international (Ottawa, Ont.)</Title><ISOAbbreviation>Food Res Int</ISOAbbreviation></Journal><ArticleTitle>The impact of addition of pearl millet starch-germ complex in white bread on nutritional, textural, structural, and glycaemic response: Single blinded randomized controlled trial in healthy and pre-diabetic participants.</ArticleTitle><Pagination><StartPage>114186</StartPage><MedlinePgn>114186</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.foodres.2024.114186</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0963-9969(24)00256-4</ELocationID><Abstract><AbstractText>The rise of pre-diabetes at the global level has created a significant interest in developing low glycaemic index food products. The pearl millet is a cheaper source of starch and its germ contains significant amount of protein and fat. The complexing of pearl millet starch and germ by dry heat treatment (PMSGH) resulted an increase in the resistant starch content upto 45.09&#xa0;% due to formation of amylose-glutelin-linoleic acid complex. The resulting pearl millet starch germ complex was incorporated into wheat bread at 20, 25, and 30&#xa0;%. The PMSGH incorporated into bread at 30&#xa0;% reduced the glycaemic index to 52.31. The PMSGH incorporated bread had significantly (p&#xa0;&lt;&#xa0;0.05)increased in the hardness with a reduction in springiness and cohesiveness. The structural attributes of the 30&#xa0;% PMSGH incorporated bread revealed a significant (p&#xa0;&lt;&#xa0;0.05)increase in 1040/1020&#xa0;cm<sup>-1</sup> ratio and relative crystallinity. The consumption of functional bread incorporated with pearl millet starch germ complex reduced blood glucose levels and in vivo glycaemic index in healthy and pre-diabetic participants when compared to white bread. Hence, the study showed that the incorporation of pearl millet starch-germ complex into food products could be a potential new and healthier approach for improving dietary options in pre-diabetes care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Vidhyalakshmi</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Grain Science and Technology, CSIR-Central Food Technological Research Institute, Mysore, Karnataka 570020, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Prabhasankar</LastName><ForeName>Pichan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Flour Milling, Baking, and Confectionery Technology, CSIR-Central Food Technological Research Institute, Mysore, Karnataka 570020, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Muthukumar</LastName><ForeName>S P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, CSIR-Central Food Technological Research Institute, Mysore, Karnataka 570020, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Prathima</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, Karnataka 570015, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Meera</LastName><ForeName>M S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Grain Science and Technology, CSIR-Central Food Technological Research Institute, Mysore, Karnataka 570020, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address: meera@cftri.res.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016449\">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Food Res Int</MedlineTA><NlmUniqueID>9210143</NlmUniqueID><ISSNLinking>0963-9969</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D001939\" MajorTopicYN=\"Y\">Bread</DescriptorName><QualifierName UI=\"Q000032\" MajorTopicYN=\"N\">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D031782\" MajorTopicYN=\"Y\">Pennisetum</DescriptorName><QualifierName UI=\"Q000737\" MajorTopicYN=\"N\">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D001786\" MajorTopicYN=\"Y\">Blood Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D013213\" MajorTopicYN=\"Y\">Starch</DescriptorName><QualifierName UI=\"Q000737\" MajorTopicYN=\"N\">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D038321\" MajorTopicYN=\"Y\">Glycemic Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011236\" MajorTopicYN=\"Y\">Prediabetic State</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D009753\" MajorTopicYN=\"N\">Nutritive Value</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D016037\" MajorTopicYN=\"N\">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D055815\" MajorTopicYN=\"N\">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000688\" MajorTopicYN=\"N\">Amylose</DescriptorName><QualifierName UI=\"Q000737\" MajorTopicYN=\"N\">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Bread matrix interactions</Keyword><Keyword MajorTopicYN=\"N\">Glycaemic index</Keyword><Keyword MajorTopicYN=\"N\">Pearl millet</Keyword><Keyword MajorTopicYN=\"N\">Pre-diabetes</Keyword><Keyword MajorTopicYN=\"N\">Resistant starch</Keyword><Keyword MajorTopicYN=\"N\">Ternary complex</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>21</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760125</ArticleId><ArticleId IdType=\"doi\">10.1016/j.foodres.2024.114186</ArticleId><ArticleId IdType=\"pii\">S0963-9969(24)00256-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760053</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2044-6055</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Feasibility and acceptability of a tailored health coaching intervention to improve type 2 diabetes self-management in Saudi Arabia: a mixed-methods randomised feasibility trial.</ArticleTitle><Pagination><StartPage>e078631</StartPage><MedlinePgn>e078631</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1136/bmjopen-2023-078631</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Around one-third of the population of Saudi Arabia have been diagnosed with type 2 diabetes, a condition often requiring lifestyle changes. Personalised health coaching, a strategy developed to assist individuals in overcoming challenges to adopt healthy behaviours, has not yet been widely applied in the country.</AbstractText><AbstractText Label=\"AIMS\" NlmCategory=\"OBJECTIVE\">We aim to explore the feasibility and acceptability of tailored health coaching in Saudi Arabia, in order to help those with type 2 diabetes to more effectively manage their condition.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">Using a mixed-methods approach, this research involved a randomised controlled trial with 30 Saudi adults who have type 2 diabetes. They were randomly allocated into either the intervention or control arm for 12 weeks. The Capability, Opportunity, Motivation and Behaviour framework was used to guide the intervention implementation along with the Behaviour Change Techniques Taxonomy V.1. The primary goal was to assess the suitability and duration of the intervention, recruitment, retention and completion rates. The secondary outcome focused on the preliminary efficacy of the health coaching measured by the glycaemic index, blood pressure, body mass index (BMI), waist circumference, weight, patient self-efficacy and diabetes self-management.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The results showed high rates of eligibility, recruitment and retention (a screening rate of 90%, a recruiting rate of 79% and a retention rate of 97%). Notable improvements were observed in the health coaching group across five outcomes: haemoglobin A1c, BMI, waist circumference, patient self-efficacy and diabetes self-care. Qualitative findings highlighted the participants' perceived benefits from the intervention, including enhanced motivation, better understanding of diabetes management and a supportive coaching relationship. Participants expressed high satisfaction with the intervention and advocated for its expansion.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">The findings demonstrated positive outcomes, supporting the need for a larger randomised controlled trial to evaluate the efficacy of health coaching in improving diabetes self-management among individuals with type 2 diabetes in Saudi Arabia.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Almulhim</LastName><ForeName>Abdullah N</ForeName><Initials>AN</Initials><Identifier Source=\"ORCID\">0000-0003-1745-7528</Identifier><AffiliationInfo><Affiliation>School of Medicine and Population Health, The University of Sheffield, Sheffield, UK aalmulhim@seu.edu.sa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Department, College of Health Sciences, Saudi Electronic University, Riyadh, 13316, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Alhowaish</LastName><ForeName>Atheer</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Education Administration, King Fahad Medical City, Riyadh, 12231, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Madani</LastName><ForeName>Alaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Education Administration, King Fahad Medical City, Riyadh, 12231, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>AlQaddan</LastName><ForeName>Munirah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Education Administration, King Fahad Medical City, Riyadh, 12231, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Altuwalah</LastName><ForeName>Abdulaziz S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Health Education Administration, King Fahad Medical City, Riyadh, 12231, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Goyder</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016449\">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D003924\" MajorTopicYN=\"Y\">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName><QualifierName UI=\"Q000523\" MajorTopicYN=\"N\">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012529\" MajorTopicYN=\"N\" Type=\"Geographic\">Saudi Arabia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005240\" MajorTopicYN=\"Y\">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000073278\" MajorTopicYN=\"Y\">Self-Management</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000071252\" MajorTopicYN=\"Y\">Mentoring</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D020377\" MajorTopicYN=\"N\">Self Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D010342\" MajorTopicYN=\"N\">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D015992\" MajorTopicYN=\"N\">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D015438\" MajorTopicYN=\"N\">Health Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D009042\" MajorTopicYN=\"N\">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012648\" MajorTopicYN=\"N\">Self Care</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Behavior</Keyword><Keyword MajorTopicYN=\"N\">DIABETES &amp; ENDOCRINOLOGY</Keyword><Keyword MajorTopicYN=\"N\">PUBLIC HEALTH</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760053</ArticleId><ArticleId IdType=\"doi\">10.1136/bmjopen-2023-078631</ArticleId><ArticleId IdType=\"pii\">bmjopen-2023-078631</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760035</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2044-6055</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Preferred sources of information on diabetes prevention programmes: a population-based cross-sectional study in Poland.</ArticleTitle><Pagination><StartPage>e083362</StartPage><MedlinePgn>e083362</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1136/bmjopen-2023-083362</ELocationID><Abstract><AbstractText Label=\"OBJECTIVE\" NlmCategory=\"OBJECTIVE\">This study aimed to analyse preferred sources of information on diabetes prevention programmes and to identify sociodemographic determinants influencing these preferences among adults in Poland.</AbstractText><AbstractText Label=\"DESIGN\" NlmCategory=\"METHODS\">A cross-sectional survey was carried out between 15 and 18 September 2023 using a computer-assisted web interview. A self-prepared questionnaire included 10 questions on sources of information on type 2 diabetes prevention.</AbstractText><AbstractText Label=\"PARTICIPANTS\" NlmCategory=\"METHODS\">Data were obtained from 1046 adults (18-82 years); 53.4% were females.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Most respondents preferred email communication (46.4%), followed by a doctor or nurse (33.5%), and a letter or leaflet directly delivered to the mailbox (25.8%) for type 2 diabetes mellitus (DM2) prevention information. Younger respondents were more likely to indicate mass media (OR=1.81, 95% CI=1.12 to 2.95, p=0.01) and digital media (OR=1.65, 95% CI=1.02 to 2.67, p=0.04) as a source of information on DM2 prevention. Those who had higher education (OR=1.51, 95% CI=1.16 to 1.96, p=0.002), as well as those with chronic diseases (OR=1.50, 95% CI=1.14 to 1.97, p=0.004), were more likely to indicate digital media. Out of 10 different variables analysed in this study, passive occupational status (OR=1.43, 95% CI=1.04 to 1.96, p=0.03) as well as having chronic diseases (OR=1.51, 95% CI=1.16 to 1.96, p=0.002) were associated with higher odds of indicating healthcare workers as a preferred source of information. Marital status, having children, place of residence, household characteristics and financial status do not significantly decide communication preferences.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Communication on DM2 prevention should be adjusted to public preferences and expectations. Tailoring interventions to different demographic groups can enhance outreach and engagement. Email emerged as a popular choice, suggesting the potential of digital communication in preventive health programmes.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Grudzi&#x105;&#x17c;-S&#x119;kowska</LastName><ForeName>Justyna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, Centrum Medyczne Ksztalcenia Podyplomowego, Warsaw, Poland jgrudziaz@cmkp.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>S&#x119;kowski</LastName><ForeName>Kuba</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Public Health, Centrum Medyczne Ksztalcenia Podyplomowego, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pinkas</LastName><ForeName>Jaros&#x142;aw</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, Centrum Medyczne Ksztalcenia Podyplomowego, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jankowski</LastName><ForeName>Mateusz</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0002-7142-5167</Identifier><AffiliationInfo><Affiliation>School of Public Health, Centrum Medyczne Ksztalcenia Podyplomowego, Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D003430\" MajorTopicYN=\"N\">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D003924\" MajorTopicYN=\"Y\">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI=\"Q000517\" MajorTopicYN=\"N\">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011044\" MajorTopicYN=\"N\" Type=\"Geographic\">Poland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D055815\" MajorTopicYN=\"N\">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000293\" MajorTopicYN=\"N\">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000369\" MajorTopicYN=\"N\">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011795\" MajorTopicYN=\"N\">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008402\" MajorTopicYN=\"N\">Mass Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000093983\" MajorTopicYN=\"N\">Information Sources</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">diabetes &amp; endocrinology</Keyword><Keyword MajorTopicYN=\"N\">health education</Keyword><Keyword MajorTopicYN=\"N\">preventive medicine</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760035</ArticleId><ArticleId IdType=\"doi\">10.1136/bmjopen-2023-083362</ArticleId><ArticleId IdType=\"pii\">bmjopen-2023-083362</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38760033</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2044-6055</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Effect of metformin use on graft and patient survival in kidney transplant recipients with type 2 diabetes: a systematic review protocol.</ArticleTitle><Pagination><StartPage>e078393</StartPage><MedlinePgn>e078393</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1136/bmjopen-2023-078393</ELocationID><Abstract><AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Metformin is a first-line antihyperglycaemic agent for type 2 diabetes (T2DM). In addition to glycaemic control, it offers benefits related to cardiovascular health, weight neutrality and metabolic syndrome. However, its benefits in kidney transplant recipients remain unclear as metformin use is controversial in this population due to a lack of evidence and there are recommendations against its use in patients with poor kidney function. Hence, we seek to describe a protocol for a systematic review, which will assess the impact of metformin use on graft survival and mortality in kidney transplant recipients.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">This protocol was guided by the standards of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols 2015. We will search empirical databases such as MEDLINE, Embase, Cochrane Library, CINAHL and Web of Science Core Collection for relevant studies conducted in kidney transplant recipients using metformin, which report outcomes related to graft and patient survival. All studies meeting these criteria in adults and published in English from inception to 2023 will be included in our review. We will employ the Cochrane Risk of Bias Tool 2 for randomised controlled trials and the Risk of Bias in Non-randomised Studies of Intervention for non-randomised studies. We will present our data and study characteristics in a table format and determine if a meta-analysis can be performed by clinical and methodological heterogeneity, using the I<sup>2</sup> statistics. If a meta-analysis cannot be performed, we will provide a narrative synthesis of included studies using the Synthesis Without Meta-Analysis Reporting Guideline.</AbstractText><AbstractText Label=\"ETHICS AND DISSEMINATION\" NlmCategory=\"BACKGROUND\">Ethical approval will not be required for this review as the data used will be extracted from already published studies with publicly accessible data. As this study will assess the impact of metformin use on graft and patient survival in kidney transplant recipients, evidence gathered through it will be disseminated using traditional approaches that include open-access peer-reviewed publication, scientific presentations and a report. We will also disseminate our findings to appropriate academic bodies in charge of publishing guidelines related to T2DM and transplantation, as well as patient and research centred groups.</AbstractText><AbstractText Label=\"PROSPERO REGISTRATION NUMBER\" NlmCategory=\"UNASSIGNED\">CRD42023421799.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Shamshad</LastName><ForeName>Farooq</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0009-0003-9407-2266</Identifier><AffiliationInfo><Affiliation>Division of Nephrology and Immunology, University of Alberta Faculty of Medicine &amp; Dentistry, Edmonton, Alberta, Canada shamshad@ualberta.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tungsanga</LastName><ForeName>Somkanya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Immunology, University of Alberta Faculty of Medicine &amp; Dentistry, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Senior</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Endocrinology &amp; Metabolism, University of Alberta Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shojai</LastName><ForeName>Soroush</ForeName><Initials>S</Initials><Identifier Source=\"ORCID\">0000-0002-2969-9121</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, University of Alberta Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ghimire</LastName><ForeName>Anukul</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0001-9165-4920</Identifier><AffiliationInfo><Affiliation>Division of Nephrology and Immunology, University of Alberta Faculty of Medicine &amp; Dentistry, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nephrology, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ye</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kung</LastName><ForeName>Janice Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>John W. Scott Health Sciences Library, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hariramani</LastName><ForeName>Vinash K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Immunology, University of Alberta Faculty of Medicine &amp; Dentistry, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Abdulrahman</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0002-4863-1181</Identifier><AffiliationInfo><Affiliation>Division of Nephrology and Immunology, University of Alberta Faculty of Medicine &amp; Dentistry, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Penney</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Immunology, University of Alberta Faculty of Medicine &amp; Dentistry, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sultana</LastName><ForeName>Naima</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Immunology, University of Alberta Faculty of Medicine &amp; Dentistry, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Muneer</LastName><ForeName>Shezel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Immunology, University of Alberta Faculty of Medicine &amp; Dentistry, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Okpechi</LastName><ForeName>Ikechi</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bello</LastName><ForeName>Aminu K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Immunology, University of Alberta Faculty of Medicine &amp; Dentistry, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D016030\" MajorTopicYN=\"Y\">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000078202\" MajorTopicYN=\"Y\">Systematic Reviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D003924\" MajorTopicYN=\"Y\">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000401\" MajorTopicYN=\"N\">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008687\" MajorTopicYN=\"Y\">Metformin</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D006085\" MajorTopicYN=\"Y\">Graft Survival</DescriptorName><QualifierName UI=\"Q000187\" MajorTopicYN=\"N\">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D007004\" MajorTopicYN=\"Y\">Hypoglycemic Agents</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012107\" MajorTopicYN=\"N\">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D066027\" MajorTopicYN=\"N\">Transplant Recipients</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Adult nephrology</Keyword><Keyword MajorTopicYN=\"N\">Diabetic nephropathy &amp; vascular disease</Keyword><Keyword MajorTopicYN=\"N\">Renal transplantation</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38760033</ArticleId><ArticleId IdType=\"doi\">10.1136/bmjopen-2023-078393</ArticleId><ArticleId IdType=\"pii\">bmjopen-2023-078393</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759989</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">2583-150X</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>36</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>The National medical journal of India</Title><ISOAbbreviation>Natl Med J India</ISOAbbreviation></Journal><ArticleTitle>Recommendations from 'Improving health outcomes of people with diabetes: Target setting for the WHO Global Diabetes Compact' for the Indian context: Laudable but are they achievable?</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>282</EndPage><MedlinePgn>281-282</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.25259/NMJI_713_2023</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">10.25259/NMJI_713_2023</ELocationID><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Sathanapally</LastName><ForeName>Harini</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester LE5 4PW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Khunti</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Applied Research Collaboration East Midlands, University of Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016421\">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Natl Med J India</MedlineTA><NlmUniqueID>8809315</NlmUniqueID><ISSNLinking>0970-258X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D007194\" MajorTopicYN=\"N\" Type=\"Geographic\">India</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D014944\" MajorTopicYN=\"Y\">World Health Organization</DescriptorName><QualifierName UI=\"Q000458\" MajorTopicYN=\"N\">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D003920\" MajorTopicYN=\"Y\">Diabetes Mellitus</DescriptorName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>19</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759989</ArticleId><ArticleId IdType=\"doi\">10.25259/NMJI_713_2023</ArticleId><ArticleId IdType=\"pii\">10.25259/NMJI_713_2023</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hunt D, Hemmingsen B, Matzke A, Varghese C, Hammerich A, Luciani S, et al. The WHO Global Diabetes Compact: A new initiative to support people living with diabetes. Lancet Diabetes Endocrinol. 2021; 9:325-7</Citation></Reference><Reference><Citation>Gregg EW, Buckley J, Ali MK, Davies J, Flood D, Mehta R, et al. Improving health outcomes of people with diabetes: Target setting for the WHO Global Diabetes Compact. Lancet. 2023; 401:1302-12</Citation></Reference><Reference><Citation>Anjana RM, Unnikrishnan R, Deepa M, Venkatesan U, Pradeepa R, Joshi S, et al. Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMRINDIAB-13): A national cross-sectional study. Lancet Diabetes Endocrinol. 2022; 10:430-41</Citation></Reference><Reference><Citation>Chow CK, Ramasundarahettige C, Hu W, AlHabib KF, Jr AA, Cheng X, et al. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: A prospective epidemiological study. Lancet Diabetes Endocrinol. 2018; 6:798-808</Citation></Reference><Reference><Citation>Brewer-Lowry AN, Arcury TA, Bell RA, Quandt SA,. Differentiating approaches to diabetes self-management of multi-ethnic rural older adults at the extremes of glycemic control. Gerontologist. 2010; 50:657-67</Citation></Reference><Reference><Citation>Garc&#xed;a-P&#xe9;rez L, &#xc1;lvarez M, Dilla T, Gil-Guillen Orozco-Beltran,. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013; 4:175-94</Citation></Reference><Reference><Citation>Greenhalgh T, Collard A, Campbell-Richards D, Vijayaraghavan S, Malik F, Morries J, et al. Storylines of self-management: Narratives of people with diabetes from a multiethnic inner city population. J Health Serv Res Policy. 2011; 16:37-43</Citation></Reference><Reference><Citation>Sridharan SG, Chittem M, Muppavaram N,. A review of literature on diabetes self-management: Scope for research and practice in India. J Soc Health Diabetes. 2016; 4:108-14</Citation></Reference><Reference><Citation>Maruthur NM, Ma Y, Delahanty LM, Nelson JA, Vanita Aroda V, White NH, et al. Early response to preventive strategies in the Diabetes Prevention Program. J Gen Intern Med. 2013; 28:1629-36</Citation></Reference><Reference><Citation>Aziz Z, Absetz P, Oldroyd J, Pronk NP, Oldenburg B,. A systematic review of real-world diabetes prevention programs: Learnings from the last 15 years. Implement Sci. 2015; 10:1-17</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759983</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">2583-150X</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>36</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>The National medical journal of India</Title><ISOAbbreviation>Natl Med J India</ISOAbbreviation></Journal><ArticleTitle>Thiamine-responsive megaloblastic anaemia.</ArticleTitle><Pagination><StartPage>314</StartPage><EndPage>315</EndPage><MedlinePgn>314-315</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.25259/NMJI_20_21</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">10.25259/NMJI_20_21</ELocationID><Abstract><AbstractText>We report a 26-year-old girl who was diagnosed with diabetes mellitus in her childhood and was treated with insulin. With a history of visual disturbances during her childhood and anaemia, which was partially evaluated; the possibility of syndromic diabetes was considered. Genetic analysis was done and revealed a mutation in the SLC19A2 gene, confirming the diagnosis of thiamine-responsive megaloblastic anaemia. She was supplemented with thiamine, which dramatically improved her haemoglobin levels and glucose control. However, her vision could not be salvaged as the rod-cone dystrophy is a permanent damage.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Veetil</LastName><ForeName>Vimal Mavila</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Aster MIMS, Kozhikode, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pachat</LastName><ForeName>Divya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Aster MIMS, Kozhikode, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nikitha</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Aster MIMS, Kozhikode, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kutty</LastName><ForeName>Jesheera Mohammed</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Aster MIMS, Kozhikode, Kerala, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D002363\">Case Reports</PublicationType><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Natl Med J India</MedlineTA><NlmUniqueID>8809315</NlmUniqueID><ISSNLinking>0970-258X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"C120043\">SLC19A2 protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type=\"Disease\" UI=\"C536510\">Thiamine responsive megaloblastic anemia syndrome</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000749\" MajorTopicYN=\"Y\">Anemia, Megaloblastic</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D013831\" MajorTopicYN=\"Y\">Thiamine</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D013832\" MajorTopicYN=\"Y\">Thiamine Deficiency</DescriptorName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000151\" MajorTopicYN=\"N\">congenital</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D026901\" MajorTopicYN=\"N\">Membrane Transport Proteins</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D009154\" MajorTopicYN=\"N\">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D014803\" MajorTopicYN=\"N\">Vitamin B Complex</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D003920\" MajorTopicYN=\"N\">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006319\" MajorTopicYN=\"N\">Hearing Loss, Sensorineural</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>19</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759983</ArticleId><ArticleId IdType=\"doi\">10.25259/NMJI_20_21</ArticleId><ArticleId IdType=\"pii\">10.25259/NMJI_20_21</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bergmann AK, Sahai I, Falcone JF, Fleming J, Bagg A, Borgna-Pignati C, et al. Thiamine-responsive megaloblastic anemia: Identification of novel compound heterozygotes and mutation update. J Pediatr. 2009; 155:888-920</Citation></Reference><Reference><Citation>Bay A, Keskin M, Hizli S, Uygun H, Dai A, Gumruk F,. Thiamine-responsive megaloblastic anemia syndrome. Int J Hematol. 2010; 92:524-6</Citation></Reference><Reference><Citation>Boros LG, Steinkamp MP, Fleming JC, Lee WN, Cascante M, Neufeld EJ,. Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood. 2003; 102:3556-61</Citation></Reference><Reference><Citation>Meire FM, Van Genderen MM, Lemmens K, Ens-Dokkum MH,. Thiamine-responsive megaloblastic anemia syndrome (TRMA) with cone-rod dystrophy. Ophthalmic Genet. 2000; 21:243-50</Citation></Reference><Reference><Citation>Borgna-Pignatti C, Marradi P, Pinelli L, Monetti N, Patrini C,. Thiamine-responsive anemia in DIDMOAD syndrome. J Pediatr. 1989; 114:405-10</Citation></Reference><Reference><Citation>Mathews L, Narayanadas K, Sunil G,. Thiamine responsive megaloblastic anemia. Indian Pediatr. 2009; 46:172-4</Citation></Reference><Reference><Citation>Potter K, Wu J, Lauzon J, Ho J,. Beta cell function and clinical course in three siblings with thiamine-responsive megaloblastic anemia (TRMA) treated with thiamine supplementation. J Pediatr Endocrinol Metab. 2017; 30:241-6</Citation></Reference><Reference><Citation>Ak&#xfd;n L, Kurto&#xf0;lu S, Kendirci M, Ak&#xfd;n MA, Karak&#xfc;k&#xe7;&#xfc; M,. Does early treatment prevent deafness in thiamine-responsive megaloblastic anaemia syndrome?. J Clin Res Pediatr Endocrinol. 2011; 3:36-9</Citation></Reference><Reference><Citation>Porter FS, Rogers LE, Sidbury JB, Jr. Thiamine-responsive megaloblastic anemia. J Pediatr. 1969; 74:494-504</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759874</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1532-3064</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Respiratory medicine</Title><ISOAbbreviation>Respir Med</ISOAbbreviation></Journal><ArticleTitle>Long-Term therapy with CFTR modulators consistently improves glucose metabolism in adolescents and adults with Cystic Fibrosis.</ArticleTitle><Pagination><StartPage>107664</StartPage><MedlinePgn>107664</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.rmed.2024.107664</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0954-6111(24)00138-0</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Impaired glycemic control and the subsequent development of Cystic fibrosis Related Diabetes (CFRD) are prevalent complications, affecting up to 50% of adults with cystic fibrosis (CF). CFTR modulator (CFTRm) therapies improve pulmonary functions, reduce exacerbation rates, increase survival in people with CF (pwCF) and appear to have a positive effect on extrapulmonary manifestations, such as nutritional state, improvements in upper respiratory symptoms, and quality of life. Initial findings indicate that CFTRm may have a positive impact on short-term glycemic control; however, long-term effects remain uncertain at present.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">In this retrospective study, data were collected and analyzed on 15 pwCF, ages 13-37 years, started on CFTRm therapy. Oral Glucose Tolerance Test (OGTT) results were compared pre- and post-CFTRm therapy.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The 120-minute OGTT value decreased from 159.7 to 130.4 post-CFTRm (p = 0.047). The average time elapsed between the two OGTT tests was 49.87 months (ranging 9-157 months, median 38 months). Glycemic status improved in six pwCF (two CFRD to normal (NGT)/indeterminate (INDET) glucose tolerance; two impaired glucose tolerance (IGT) to INDET; two INDET to NGT) and worsened in one (IGT to CFRD). Six pwCF and NGT remained stable with no changes in glycemic statues throughout the follow-up period.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">CFTRm therapy may decelerate the glycemic control deterioration in pwCF over an extended period. These findings indicate the need for periodic OGTTs following the initiation of CFTRm therapy to appropriately adjust insulin requirements and prevent hypoglycemia. Further larger cohorts are required to authenticate and substantiate these findings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Cohen</LastName><ForeName>Amitay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mass</LastName><ForeName>Alon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Hebrew University of Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Reiter</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Hebrew University of Jerusalem, Israel; Pediatric Pulmonary Unit and Cystic fibrosis Center, Hadassah Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zangen</LastName><ForeName>David Haim</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cohen-Cymberknoh</LastName><ForeName>Malena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Hebrew University of Jerusalem, Israel; Pediatric Pulmonary Unit and Cystic fibrosis Center, Hadassah Medical Center, Jerusalem, Israel. Electronic address: malena@hadassah.org.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Respir Med</MedlineTA><NlmUniqueID>8908438</NlmUniqueID><ISSNLinking>0954-6111</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">CFRD</Keyword><Keyword MajorTopicYN=\"N\">CFTR modulators</Keyword><Keyword MajorTopicYN=\"N\">INDET</Keyword><Keyword MajorTopicYN=\"N\">NGT</Keyword><Keyword MajorTopicYN=\"N\">impaired OGTT</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest &#x2612; The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. &#x2610; The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759874</ArticleId><ArticleId IdType=\"doi\">10.1016/j.rmed.2024.107664</ArticleId><ArticleId IdType=\"pii\">S0954-6111(24)00138-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759763</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1872-7573</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of ethnopharmacology</Title><ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation></Journal><ArticleTitle>Chemo-profiling and exploring Therapeutic Potential of Momordica dioica Roxb. ex Willd. for Managing Metabolic Related Disorders: In-vitro Studies, and Docking based Approach.</ArticleTitle><Pagination><StartPage>118351</StartPage><MedlinePgn>118351</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.jep.2024.118351</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0378-8741(24)00650-0</ELocationID><Abstract><AbstractText Label=\"ETHNOPHARMACOLOGICAL RELEVANCE\" NlmCategory=\"BACKGROUND\">Momordica dioica Roxb. ex Willd. (M. dioica Roxb.) a nutritious and therapeutic property rich crop of Cucurbitaceae plant family. In various folklore medicine including Ayurveda fruits are used to treat several metabolic related disorders i.e., hyperglycemia, hyperlipidemia, diabetes, obesity etc. Furthermore, traditionally it is used to treat fever, inflammation, ulcer, skin diseases, haemorrhoids, hypertension and also employed as cardioprotective, hepatoprotective, analgesic, diuretic.</AbstractText><AbstractText Label=\"AIM OF THE STUDY\" NlmCategory=\"OBJECTIVE\">This study focuses to explore the therapeutic potential of Momordica dioica Roxb. ex Willd. through in-vitro and in-silico approach for managing hyperlipidemia, hyperglycemia and related metabolic disorders along with its phytochemical profiling for quality evaluation and validation of traditional claim.</AbstractText><AbstractText Label=\"MATERIALS AND METHODS\" NlmCategory=\"METHODS\">The present study was carried out on hydroalcohol extract of dried leaf and fruit of Momordica dioica. In-vitro antioxidant potential using DPPH and Nitric oxide scavenging assay along with in-vitro enzyme inhibitory potential against &#x3b1;-amylase, &#x3b1;-glucosidase, and pancreatic lipase enzymes was studied. The bioactive metabolites were identified from the most potent bioactive extract by analysis with LC-QTOF-MS and also studied their role to lessen the metabolic related disorder through in-silico approaches.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The results confirmed that the fruit extract is more active to possess antioxidant and prominent enzyme inhibition potential compared to the leaf. Sixteen identified metabolites in M. dioica Roxb. fruits may be responsible for the therapeutic potential related to metabolic related disorder. The in-silico study of the identified phytomolecules against &#x3b1;-amylase, &#x3b1;-glucosidase and pancreatic lipase showed significant docking scores ranging from -9.8 to -5.5, -8.3 to -4.8 and -8.3 to -6 respectively.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">The current study illustrated that M. dioica Roxb., a traditionally important plant is potential against metabolic related disorders. Phytocomponents present in the fruit extract may be responsible for antioxidant as well as the enzymes' inhibitory potential. Thus, fruits of M. dioica Roxb. will be useful as alternative therapeutics for treatment of hyperlipidemia, hyperglycemia and related metabolic disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Singha</LastName><ForeName>Seha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Natural Product Studies, Jadavpur University, Kolkata -700 032, India. Electronic address: seha.singha1@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gupta</LastName><ForeName>Barun Das</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>School of Natural Product Studies, Jadavpur University, Kolkata -700 032, India. Electronic address: barun.dg@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sarkar</LastName><ForeName>Arnab</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Jadavpur University, Kolkata -700 032, India. Electronic address: sarkar.arnab54@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jana</LastName><ForeName>Sandipan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Natural Product Studies, Jadavpur University, Kolkata -700 032, India. Electronic address: sandipan.jana95@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bharadwaj</LastName><ForeName>Pardeep K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Institute of Bioresources and Sustainable Development, Dept. of Biotechnology, Govt. of India, Imphal - 795001, Manipur, India. Electronic address: pardeep2128@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sharma</LastName><ForeName>Nanaocha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Bioresources and Sustainable Development, Dept. of Biotechnology, Govt. of India, Imphal - 795001, Manipur, India. Electronic address: sharma.nanaocha@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Haldar</LastName><ForeName>Pallab K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>School of Natural Product Studies, Jadavpur University, Kolkata -700 032, India. Electronic address: pallab.haldar@jadavpuruniversity.in.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mukherjee</LastName><ForeName>Pulok Kumar</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>School of Natural Product Studies, Jadavpur University, Kolkata -700 032, India; Institute of Bioresources and Sustainable Development, Dept. of Biotechnology, Govt. of India, Imphal - 795001, Manipur, India. Electronic address: naturalproductm@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kar</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Bioresources and Sustainable Development, Dept. of Biotechnology, Govt. of India, Imphal - 795001, Manipur, India. Electronic address: amit.kar2@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>J Ethnopharmacol</MedlineTA><NlmUniqueID>7903310</NlmUniqueID><ISSNLinking>0378-8741</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Metabolite Profiling</Keyword><Keyword MajorTopicYN=\"N\">Molecular docking</Keyword><Keyword MajorTopicYN=\"N\">Momordica dioica Roxb. ex Wild.</Keyword><Keyword MajorTopicYN=\"N\">Pancreatic Lipase</Keyword><Keyword MajorTopicYN=\"N\">&#x3b1;-amylase</Keyword><Keyword MajorTopicYN=\"N\">&#x3b1;-glucosidase</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759763</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jep.2024.118351</ArticleId><ArticleId IdType=\"pii\">S0378-8741(24)00650-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759722</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1532-8600</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Metabolism: clinical and experimental</Title><ISOAbbreviation>Metabolism</ISOAbbreviation></Journal><ArticleTitle>Resmetirom for MASH patients with diabetes: challenges and opportunities in the real world.</ArticleTitle><Pagination><StartPage>155935</StartPage><MedlinePgn>155935</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.metabol.2024.155935</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0026-0495(24)00162-8</ELocationID><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Lian</LastName><ForeName>Li-You</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China; Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou 325000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Targher</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Verona, Verona, Italy; Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Byrne</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Wen-Yue</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. Electronic address: liuwenyue@wmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zheng</LastName><ForeName>Ming-Hua</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China; Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou 325000, China. Electronic address: zhengmh@wmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016422\">Letter</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Metabolism</MedlineTA><NlmUniqueID>0375267</NlmUniqueID><ISSNLinking>0026-0495</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest Ming-Hua Zheng has received honoraria for lectures from AstraZeneca, Hisky Medical Technologies and Novo Nordisk, consulting fees from Boehringer Ingelheim, and serves as a consultant for Eieling Technology. Christopher D Byrne has received independent research grant support from Echosens, France. Li-You Lian, Giovanni Targher and Wen-Yue Liu declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759722</ArticleId><ArticleId IdType=\"doi\">10.1016/j.metabol.2024.155935</ArticleId><ArticleId IdType=\"pii\">S0026-0495(24)00162-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759707</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1879-0712</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>European journal of pharmacology</Title><ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Healing the Diabetic Wound: Unlocking the Secrets of Genes and Pathways.</ArticleTitle><Pagination><StartPage>176645</StartPage><MedlinePgn>176645</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.ejphar.2024.176645</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0014-2999(24)00333-9</ELocationID><Abstract><AbstractText>Diabetic wounds (DWs) are open sores that can occur anywhere on a diabetic patient's body. They are often complicated by infections, hypoxia, oxidative stress, hyperglycemia, and reduced growth factors and nucleic acids. The healing process involves four phases: homeostasis, inflammation, proliferation, and remodeling, regulated by various cellular and molecular events. Numerous genes and signaling pathways such as VEGF, TGF-&#x3b2;, NF-&#x3ba;B, PPAR-&#x3b3;, MMPs, IGF, FGF, PDGF, EGF, NOX, TLR, JAK-STAT, PI3K-Akt, MAPK, ERK, JNK, p38, Wnt/&#x3b2;-catenin, Hedgehog, Notch, Hippo, FAK, Integrin, and Src pathways are involved in these events. These pathways and genes are often dysregulated in DWs leading to impaired healing. The present review sheds light on the pathogenesis, healing process, signaling pathways, and genes involved in DW. Further, various therapeutic strategies that target these pathways and genes via nanotechnology are also discussed. Additionally, clinical trials on DW related to gene therapy are also covered in the present review.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Kamal</LastName><ForeName>Raj</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Quality Assurance, ISF College of Pharmacy, Moga, Punjab 142001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Awasthi</LastName><ForeName>Ankit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab 142001, India. Electronic address: awasthiankit458@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pundir</LastName><ForeName>Mandeep</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, RIMT University, Punjab 142001, India; Chitkara College of Pharmacy, Chitkara University, Punjab 142001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Thakur</LastName><ForeName>Shubham</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab 142001, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharmacol</MedlineTA><NlmUniqueID>1254354</NlmUniqueID><ISSNLinking>0014-2999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Diabetic wound</Keyword><Keyword MajorTopicYN=\"N\">clinical trials</Keyword><Keyword MajorTopicYN=\"N\">gene therapy</Keyword><Keyword MajorTopicYN=\"N\">healing process</Keyword><Keyword MajorTopicYN=\"N\">signaling pathways</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759707</ArticleId><ArticleId IdType=\"doi\">10.1016/j.ejphar.2024.176645</ArticleId><ArticleId IdType=\"pii\">S0014-2999(24)00333-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759658</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2352-4650</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>14</Day></PubDate></JournalIssue><Title>The Lancet. Child &amp; adolescent health</Title><ISOAbbreviation>Lancet Child Adolesc Health</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S2352-4642(24)00073-7</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/S2352-4642(24)00073-7</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised by extremely high plasma LDL cholesterol from birth, causing atherosclerotic cardiovascular disease at a young age. Lipoprotein apheresis in combination with lipid-lowering drugs effectively reduce LDL cholesterol, but long-term health outcomes of such treatment are unknown. We aimed to investigate the long-term cardiovascular outcomes associated with lipoprotein apheresis initiated in childhood or adolescence.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">In this cohort study, data were drawn from the HoFH International Clinical Collaboration (HICC) and the international registry for Children with Homozygous Hypercholesterolemia on Lipoprotein Apheresis (CHAIN). An overall cohort included patients diagnosed with HoFH aged 0-18 years who were alive and in follow-up between Jan 1, 2010, and Nov 8, 2021, and whose high plasma LDL cholesterol concentrations made them eligible for lipoprotein apheresis. To compare cardiovascular outcomes, patients who initiated lipoprotein apheresis in childhood (lipoprotein apheresis group) and patients who only received lipid-lowering drugs (pharmacotherapy-only group) were matched by sex and untreated plasma LDL cholesterol concentrations. The primary outcome was a composite of cardiovascular death, myocardial infarction, ischaemic stroke, percutaneous coronary intervention, coronary artery bypass grafting, aortic valve replacement, peripheral artery disease, carotid endarterectomy, angina pectoris, and supra-aortic or aortic stenosis (collectively referred to as atherosclerotic cardiovascular disease), for which survival analyses were performed in the matched cohort. Cox regression analyses were used to compare disease-free survival between cohorts and to calculate hazard ratio (HR) and 95% CI adjusted for sex, age at diagnosis, untreated plasma LDL cholesterol concentration, and number of lipid-lowering therapies other than lipoprotein apheresis.</AbstractText><AbstractText Label=\"FINDINGS\" NlmCategory=\"RESULTS\">The overall cohort included 404 patients with a median age at diagnosis of 6&#xb7;0 years (IQR 3&#xb7;0-9&#xb7;5) and median untreated plasma LDL cholesterol of 17&#xb7;8 mmol/L (14&#xb7;7-20&#xb7;8). The matched cohorts included 250 patients (125 patients per group), with a median untreated LDL cholesterol of 17&#xb7;2 mmol/L (14&#xb7;8-19&#xb7;7). Mean reduction in plasma LDL cholesterol concentrations between baseline and final follow-up was greater in the lipoprotein apheresis group (-55% [95% CI -60 to -51] vs -31% [-36 to -25]; p&lt;0&#xb7;0001). Patients in the lipoprotein apheresis group had longer atherosclerotic cardiovascular disease-free survival (adjusted HR 0&#xb7;52 [95% CI 0&#xb7;32-0&#xb7;85]) and longer cardiovascular death-free survival (0&#xb7;0301 [0&#xb7;0021-0&#xb7;4295]). Cardiovascular death was more common in the pharmacotherapy-only group than in the lipoprotein apheresis group (ten [8%] vs one [1%]; p=0&#xb7;010), whereas median age at coronary artery bypass grafting was lower in the lipoprotein apheresis group than in the pharmacotherapy-only group (15&#xb7;0 years [IQR 12&#xb7;0-24&#xb7;0] vs 30&#xb7;5 years [19&#xb7;0-33&#xb7;8]; p=0&#xb7;037).</AbstractText><AbstractText Label=\"INTERPRETATION\" NlmCategory=\"CONCLUSIONS\">Among patients with HoFH, lipoprotein apheresis initiated during childhood and adolescence is associated with reduced long-term risk of atherosclerotic cardiovascular disease and death, and clear benefits of early initiation of high-frequency treatment on reducing plasma cholesterol were found. Consensus recommendations are now needed to guide more widespread and timely use of lipoprotein apheresis for children with HoFH, and research is required to further optimise treatment and ensure benefits of early and aggressive treatment delivery are balanced against effects on quality of life.</AbstractText><AbstractText Label=\"FUNDING\" NlmCategory=\"BACKGROUND\">Amsterdam University Medical Centers, Location Academic Medical Center; Perelman School of Medicine at the University of Pennsylvania; European Atherosclerosis Society; and the US National Heart, Lung, and Blood Institute, National Institutes of Health.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Reijman</LastName><ForeName>M Doortje</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tromp</LastName><ForeName>Tycho R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hutten</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Amsterdam Cardiovascular Sciences, Diabetes and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hovingh</LastName><ForeName>G Kees</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Novo Nordisk, S&#xf8;borg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Blom</LastName><ForeName>Dirk J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Lipidology, Department of Medicine and the Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Catapano</LastName><ForeName>Alberico L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>IRCCS Multimedica, Milan, Italy; University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cuchel</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Dann</LastName><ForeName>Eldad J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Blood Bank and Apheresis Unit, Rambam Health Care Campus, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gallo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, UMR 1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, APHP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hudgins</LastName><ForeName>Lisa C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>The Rogosin Institute, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Raal</LastName><ForeName>Frederick J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ray</LastName><ForeName>Kausik K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sadiq</LastName><ForeName>Fouzia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Shifa Tameer-e-Millat University, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Soran</LastName><ForeName>Handrean</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Diabetes, Endocrinology and Metabolism, Manchester University NHS Foundation Trust and National Institute of Health Research/Wellcome Trust Clinical Research Facility, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Groothoff</LastName><ForeName>Jaap W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wiegman</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. Electronic address: a.wiegman@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kusters</LastName><ForeName>D Meeike</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><CollectiveName>Homozygous Familial Hypercholesterolaemia International Clinical Collaborators (HICC)</CollectiveName></Author><Author ValidYN=\"Y\"><CollectiveName>Children with Homozygous Hypercholesterolemia on Lipoprotein Apheresis: an International Registry (CHAIN) consortia</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Child Adolesc Health</MedlineTA><NlmUniqueID>101712925</NlmUniqueID><ISSNLinking>2352-4642</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of interests BAH received a research grant from Silence Therapeutics. GKH reports research grants from the Klinkerpad fonds, and part-time employment at Novo Nordisk (S&#xf8;borg, Denmark) since April, 2019. GKH is shareholder of Novo Nordisk. DJB reports clinical trial fees paid to their institution from LIB Therapeutics, Novartis, Silence Therapeutics, and IONIS; speaker fees from Amgen, Sanofi, Organon, MSD, Amryt, and Novartis; and consulting fees from Amryt. ALC has received research grants or support from Amarin, Amgen, Menarini, Mylan, Sanofi, and Sanofi Regeneron, and served as a consultant for or received honoraria from Akcea, Amarin, Amgen, Daiichi Sankyo, Esperion Therapeutics, Ionis, Kowa, Medco, Menarini, MSD, Mylan, Novartis, Recordati, Regeneron, Sanofi, and The Corpus. MC reports institutional support for the conduction of clinical trials from Regeneron Pharmaceuticals and Regenxbio, and consulting fees from Amryt Pharma. AG received grants and personal fees from Amgen, Sanofi&#x2013;Regeneron, Mylan Viatris, MSD, Akcea Therapeutics, Amryt, Servier, Novartis, and Ultragenyx. FJR reports receiving advisory board fees and lecture fees from Amgen, Sanofi-Aventis, Regeneron Pharmaceuticals, Novartis, and LIB Therapeutics. KKR reports grants from Amgen, Sanofi&#x2013;Regeneron, Pfizer, Merck Sharp &amp; Dohme, Daiichi Sankyo, and Ultragenyx; consulting fees from AstraZeneca, Kowa, Novartis, Sanofi, Amgen, Eli Lilly, Algorithm, Boehringer Ingelheim, Novo Nordisk, Silence Therapeutics, Bayer, Esperion, Daiichi Sankyo, Abbott, New Amsterdam, SCRIBE, CRISPR, VAXXINITY, EMENDOBIO, Cargene, Viatris, Amarin, Nodthera, and Resverlogix; honoraria for lectures from AstraZeneca, Novartis, Sanofi, Amgen, Algorithm, Boehringer Ingelheim, Novo Nordisk, Esperion, Daiichi Sankyo, and Amarin; and stock options in New Amsterdam, PEMI 31, and SCRIBE. HS reports research grants from Amgen, MSD, Synageva, Amryt, Alexion, and Akcea; consulting fees from Amgen, Alexion, Daiichi-Sankyo, Novartis, Pfizer, and Akcea; and speaker fees from Amgen, Daiichi-Sankyo, Sanofi, and Akcea. AW reports research grants from Amgen, Esperion, Novartis, Regeneron, Sanofi, Silence Therapeutics, and Ultragenyx; consulting fees from Chiesi and Novartis; and speaker fees from Algorithm, Sanofi, and Ultragenyx. All other authors declare no competing interests. The declaration of interests of individual collaborators are listed in the appendix (p 27).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759658</ArticleId><ArticleId IdType=\"doi\">10.1016/S2352-4642(24)00073-7</ArticleId><ArticleId IdType=\"pii\">S2352-4642(24)00073-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759515</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1618-1298</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>103</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>European journal of cell biology</Title><ISOAbbreviation>Eur J Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Mechanoresponsive ETS1 causes endothelial dysfunction and arterialization in varicose veins via NOTCH4/DLL4 signaling.</ArticleTitle><Pagination><StartPage>151420</StartPage><MedlinePgn>151420</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.ejcb.2024.151420</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0171-9335(24)00037-2</ELocationID><Abstract><AbstractText>Varicose veins are the most common venous disorder in humans and are characterized by hemodynamic instability due to valvular insufficiency and orthostatic lifestyle factors. It is unclear how changes in biomechanical signals cause aberrant remodeling of the vein wall. Our previous studies suggest that Notch signaling is implicated in varicose vein arterialization. In the arterial system, mechanoresponsive ETS1 is a transcriptional activator of the endothelial Notch, but its involvement in sensing disrupted venous flow and varicose vein formation has not been investigated. Here, we use human varicose veins and cultured human venous endothelial cells to show that disturbed venous shear stress activates ETS1-NOTCH4/DLL4 signaling. Notch components were highly expressed in the neointima, whereas ETS1 was upregulated in all histological layers of varicose veins. In vitro microfluidic flow-based studies demonstrate that even minute changes in venous flow patterns enhance ETS1-NOTCH4/DLL4 signaling. Uniform venous shear stress, albeit an inherently low-flow system, does not induce ETS1 and Notch proteins. ETS1 activation under altered flow was mediated primarily by MEK1/2 and, to a lesser extent, by MEK5 but was independent of p38&#xa0;MAP kinase. Endothelial cell-specific ETS1 knockdown prevented disturbed flow-induced NOTCH4/DLL4 expression. TK216, an inhibitor of ETS-family, prevented the acquisition of arterial molecular identity and loss of endothelial integrity in cells exposed to the ensuing altered shear stress. We conclude that ETS1 senses blood flow disturbances and may promote venous remodeling by inducing endothelial dysfunction. Targeting ETS1 rather than downstream Notch proteins could be an effective and safe strategy to develop varicose vein therapies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Sreelakshmi</LastName><ForeName>B J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Cardiovascular Diseases and Diabetes Biology, Rajiv Gandhi Centre for Biotechnology (RGCB),&#xa0;Thiruvananthapuram,&#xa0;Kerala 695014,&#xa0;India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Karthika</LastName><ForeName>C L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Cardiovascular Diseases and Diabetes Biology, Rajiv Gandhi Centre for Biotechnology (RGCB),&#xa0;Thiruvananthapuram,&#xa0;Kerala 695014,&#xa0;India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ahalya</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiovascular Diseases and Diabetes Biology, Rajiv Gandhi Centre for Biotechnology (RGCB),&#xa0;Thiruvananthapuram,&#xa0;Kerala 695014,&#xa0;India; Manipal Academy of Higher Education,&#xa0;Manipal,&#xa0;Karnataka 576104,&#xa0;India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kalpana</LastName><ForeName>S R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Sri Jayadeva Institute for Cardiovascular Sciences &amp; Research,&#xa0;Bangalore 570016,&#xa0;India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kartha</LastName><ForeName>C C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Cardiovascular Diseases and Diabetes Biology, Rajiv Gandhi Centre for Biotechnology (RGCB),&#xa0;Thiruvananthapuram,&#xa0;Kerala 695014,&#xa0;India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sumi</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiovascular Diseases and Diabetes Biology, Rajiv Gandhi Centre for Biotechnology (RGCB),&#xa0;Thiruvananthapuram,&#xa0;Kerala 695014,&#xa0;India. Electronic address: sumis@rgcb.res.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cell Biol</MedlineTA><NlmUniqueID>7906240</NlmUniqueID><ISSNLinking>0171-9335</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">ETS</Keyword><Keyword MajorTopicYN=\"N\">Endothelium</Keyword><Keyword MajorTopicYN=\"N\">Notch</Keyword><Keyword MajorTopicYN=\"N\">Shear stress</Keyword><Keyword MajorTopicYN=\"N\">Therapeutics</Keyword><Keyword MajorTopicYN=\"N\">Varicose veins</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759515</ArticleId><ArticleId IdType=\"doi\">10.1016/j.ejcb.2024.151420</ArticleId><ArticleId IdType=\"pii\">S0171-9335(24)00037-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759430</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1471-4973</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>76</Volume><PubDate><Year>2024</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Current opinion in pharmacology</Title><ISOAbbreviation>Curr Opin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>In the heart and beyond: Mitochondrial dysfunction in heart failure with preserved ejection fraction (HFpEF).</ArticleTitle><Pagination><StartPage>102461</StartPage><MedlinePgn>102461</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.coph.2024.102461</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S1471-4892(24)00031-6</ELocationID><Abstract><AbstractText>Heart failure with preserved ejection fraction (HFpEF) is a major cardiovascular disorder with increasing prevalence and a limited range of targeted treatment options. While HFpEF can be derived from several different etiologies, much of the current growth in the disease is being driven by metabolic dysfunction (e.g. obesity, diabetes, hypertension). Deleterious changes in mitochondrial energy metabolism are a common feature of HFpEF, and may help to drive the progression of the disease. In this brief article we aim to review various aspects of cardiac mitochondrial dysfunction in HFpEF, discuss the emerging topic of HFpEF-driven mitochondrial dysfunction in tissues beyond the heart, and examine whether supporting mitochondrial function may be a therapeutic approach to arrest or reverse disease development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Bhattarai</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA; Center for Metabolism and Mitochondrial Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA; Division of Cardiology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Scott</LastName><ForeName>Iain</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA; Center for Metabolism and Mitochondrial Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA; Division of Cardiology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA. Electronic address: iain.scott@pitt.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Pharmacol</MedlineTA><NlmUniqueID>100966133</NlmUniqueID><ISSNLinking>1471-4892</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest The authors declared that there are no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759430</ArticleId><ArticleId IdType=\"doi\">10.1016/j.coph.2024.102461</ArticleId><ArticleId IdType=\"pii\">S1471-4892(24)00031-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759418</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2213-2317</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>73</Volume><PubDate><Year>2024</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>Redox biology</Title><ISOAbbreviation>Redox Biol</ISOAbbreviation></Journal><ArticleTitle>Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming.</ArticleTitle><Pagination><StartPage>103183</StartPage><MedlinePgn>103183</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.redox.2024.103183</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S2213-2317(24)00161-7</ELocationID><Abstract><AbstractText Label=\"AIMS\" NlmCategory=\"OBJECTIVE\">Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved.</AbstractText><AbstractText Label=\"METHODS AND RESULTS\" NlmCategory=\"RESULTS\">A computed tomography angiography investigation of coronary arteries from 1554 patients with type 2 diabetes revealed that SGLT2 inhibitor use was correlated with a lower Agatston calcification score. In the vitamin D3 overdose, 5/6 nephrectomy chronic kidney disease-induced medial calcification and Western diet-induced atherosclerotic intimal calcification models, dapagliflozin (DAPA) substantially alleviated vascular calcification in the aorta. Furthermore, we showed that DAPA reduced vascular calcification via Runx2-dependent osteogenic transdifferentiation in vascular smooth muscle cells (VSMCs). Transcriptome profiling revealed that thioredoxin domain containing 5 (TXNDC5) was involved in the attenuation of vascular calcification by DAPA. Rescue experiments showed that DAPA-induced TXNDC5 downregulation in VSMCs blocked the protective effect on vascular calcification. Furthermore, TXNDC5 downregulation disrupted protein folding-dependent Runx2 stability and promoted subsequent proteasomal degradation. Moreover, DAPA downregulated TXNDC5 expression via amelioration of oxidative stress and ATF6-dependent endoplasmic reticulum stress. Consistently, the class effects of SGLT2 inhibitors on vascular calcification were validated with empagliflozin in intimal and medial calcification models.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">SGLT2 inhibitors ameliorate vascular calcification through blocking endoplasmic reticulum stress-dependent TXNDC5 upregulation and promoting subsequent Runx2 proteasomal degradation, suggesting that SGLT2 inhibitors are potentially beneficial for vascular calcification treatment and prevention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Wu</LastName><ForeName>Shaofa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China; Department of Nephrology, Youyang Hospital, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 409800, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Luo</LastName><ForeName>Xiaolin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chen</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Zelan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Youyang Hospital, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 409800, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sun</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhao</LastName><ForeName>Junyong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Luo</LastName><ForeName>Wenjian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhang</LastName><ForeName>Jiawen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tong</LastName><ForeName>Xiaoyong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Innovative Drug Research Centre, Chongqing University, Chongqing, 401331, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Huang</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China. Electronic address: huanglan260@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Chuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China. Electronic address: liuchuan19821207@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Qin</LastName><ForeName>Zhexue</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China. Electronic address: zhexueqin@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Redox Biol</MedlineTA><NlmUniqueID>101605639</NlmUniqueID><ISSNLinking>2213-2317</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Endoplasmic reticulum stress</Keyword><Keyword MajorTopicYN=\"N\">Runx2</Keyword><Keyword MajorTopicYN=\"N\">Sodium-glucose cotransporter 2 inhibitors</Keyword><Keyword MajorTopicYN=\"N\">Thioredoxin domain containing 5</Keyword><Keyword MajorTopicYN=\"N\">Vascular calcification</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759418</ArticleId><ArticleId IdType=\"doi\">10.1016/j.redox.2024.103183</ArticleId><ArticleId IdType=\"pii\">S2213-2317(24)00161-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759318</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1618-095X</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>130</Volume><PubDate><Year>2024</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title><ISOAbbreviation>Phytomedicine</ISOAbbreviation></Journal><ArticleTitle>JinLiDa granules alleviates cardiac hypertrophy and inflammation in diabetic cardiomyopathy by regulating TP53.</ArticleTitle><Pagination><StartPage>155659</StartPage><MedlinePgn>155659</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.phymed.2024.155659</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0944-7113(24)00318-0</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">JinLiDa granules (JLD) is a traditional Chinese medicine (TCM) used to treat type 2 diabetes mellitus with Qi and Yin deficiency. Clinical evidence has shown that JLD can alleviate diabetic cardiomyopathy, but the exact mechanism is not yet clear.</AbstractText><AbstractText Label=\"PURPOSE\" NlmCategory=\"OBJECTIVE\">The purpose of this study was to examine the potential role and mechanism of JLD in the treatment of diabetic cardiomyopathy through network pharmacological analysis and basic experiments.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">The targets of JLD associated with diabetic cardiomyopathy were examined by network pharmacology. Protein interaction analysis was performed on the targets, and the associated pathways were searched by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Diabetic mice were treated with low or high doses of JLD by gavage, and AC16 and H9C2 cardiomyocytes exposed to high-glucose conditions were treated with JLD. The analysis results were verified by various experimental techniques to examine molecular mechanisms.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Network pharmacological analysis revealed that JLD acted on the tumor suppressor p53 (TP53) during inflammation and fibrosis associated with diabetic cardiomyopathy. The results of basic experiments showed that after JLD treatment, ventricular wall thickening in diabetic mouse hearts was attenuated, cardiac hypertrophy and myocardial inflammation were alleviated, and the expression of cardiac hypertrophy- and inflammation-related factors in cardiomyocytes exposed to a high-glucose environment was decreased. Cardiomyocyte morphology also improved after JLD treatment. TP53 expression and the tumor necrosis factor (TNF) and transforming growth factor beta-1 (TGF&#x3b2;1) signaling pathways were significantly altered, and inhibiting TP53 expression effectively alleviated the activation of the TNF and TGF&#x3b2;1 signaling pathways under high glucose conditions. Overexpression of TP53 activated these signaling pathways.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">JLD acted on TP53 to regulate the TNF and TGF&#x3b2;1 signaling pathways, effectively alleviating cardiomyocyte hypertrophy and inflammation in high glucose and diabetic conditions. Our study provides a solid foundation for the future treatment of diabetic cardiomyopathy with JLD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Fang</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital &amp; Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Jingyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital &amp; Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sun</LastName><ForeName>Shengnan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital &amp; Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Deng</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital &amp; Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xue</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Zhongnan Hospital of Wuhan University, 430071 Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Han</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital &amp; Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sun</LastName><ForeName>Bei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital &amp; Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China. Electronic address: sun_peipei220@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chen</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital &amp; Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China. Electronic address: xfx22081@vip.163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Phytomedicine</MedlineTA><NlmUniqueID>9438794</NlmUniqueID><ISSNLinking>0944-7113</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Diabetic cardiomyopathy</Keyword><Keyword MajorTopicYN=\"N\">JinLiDa granules</Keyword><Keyword MajorTopicYN=\"N\">Network pharmacology</Keyword><Keyword MajorTopicYN=\"N\">TNF and TGF&#x3b2;1 signaling pathway</Keyword><Keyword MajorTopicYN=\"N\">Tumor suppressor p53</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759318</ArticleId><ArticleId IdType=\"doi\">10.1016/j.phymed.2024.155659</ArticleId><ArticleId IdType=\"pii\">S0944-7113(24)00318-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759315</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1618-095X</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>130</Volume><PubDate><Year>2024</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title><ISOAbbreviation>Phytomedicine</ISOAbbreviation></Journal><ArticleTitle>A single-cell profile reveals the transcriptional regulation responded for Abelmoschus manihot (L.) treatment in diabetic kidney disease.</ArticleTitle><Pagination><StartPage>155642</StartPage><MedlinePgn>155642</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.phymed.2024.155642</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0944-7113(24)00301-5</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Huangkui capsule (HKC), as an ethanol extract of Abelmoschus manihot (L.), has a significant efficacy in treatment of the patients with diabetic kidney disease (DKD). The bioactive ingredients of HKC mainly include the flavonoids such as rutin, hyperoside, hibifolin, isoquercetin, myricetin, quercetin and quercetin-3-O-robinobioside.</AbstractText><AbstractText Label=\"PURPOSE\" NlmCategory=\"OBJECTIVE\">To explore the molecular mechanisms of A. manihot in treatment of DKD.</AbstractText><AbstractText Label=\"STUDY DESIGN\" NlmCategory=\"METHODS\">A single-cell RNA sequencing analysis of kidneys in db/db mice with and without HKC administration.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">Urinary biochemical and histopathological examination in C57BL/6 and db/db mice of DKD and HKC groups was done. Single-cell RNA sequencing pipeline was then performed. The regulatory mechanisms of seven flavonoids in HKC were revealed by cell communication, prediction of transcription factor regulatory network, and molecular docking.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">By constructing ligand-receptor regulatory network and performing molecular docking between 75 receptors with different activities and seven flavonoids. 11 key receptors in 4 cell types (segment 3 proximal convoluted tubular cell, ascending limbs of the loop of Henle, distal convoluted tubule, and T cell) in kidneys were found to be directly interacted with HKC. The interactions regulated 8 downstream regulons. The docking receptors in T cell led to transcriptional event differences in the regulons such as Cebpb, Rel, Tbx21 and Klf2 and consequently affected the activation, differentiation, and infiltration of T cell, while the receptors Tgfbr1 and Ldlr in stromal cells of kidneys were closely associated with the downstream transcriptional events of renal injury and proteinuria in DKD.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">The current study provides novel information of the key receptors and regulons in renal cells for a better understanding of the cell type specific molecular mechanisms of A. manihot in treatment of DKD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Wu</LastName><ForeName>Chenhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 210009, China; Laboratory of Minigene Pharmacy, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Suzhong Pharmaceutical Research Institute, Nanjing, Jiangsu Province, 210018, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cui</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Li</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, 210029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fei</LastName><ForeName>Jingjin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Minigene Pharmacy, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ge</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Suzhong Pharmaceutical Research Institute, Nanjing, Jiangsu Province, 210018, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wu</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Jiangsu Key Laboratory of Drug Screening, Institute of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing, Jiangsu Province, 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Minigene Pharmacy, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China. Electronic address: wujie@cpu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gu</LastName><ForeName>Harvest F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 210009, China. Electronic address: feng.gu@cpu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Phytomedicine</MedlineTA><NlmUniqueID>9438794</NlmUniqueID><ISSNLinking>0944-7113</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Abelmoschus manihot</Keyword><Keyword MajorTopicYN=\"N\">Diabetic kidney disease</Keyword><Keyword MajorTopicYN=\"N\">Huangkui capsule</Keyword><Keyword MajorTopicYN=\"N\">Single-cell RNA sequencing</Keyword><Keyword MajorTopicYN=\"N\">Transcriptional regulation</Keyword></KeywordList><CoiStatement>Declaration of competing interest There are no potential conflicts of interest relevant to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759315</ArticleId><ArticleId IdType=\"doi\">10.1016/j.phymed.2024.155642</ArticleId><ArticleId IdType=\"pii\">S0944-7113(24)00301-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759226</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1940-5480</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>The Journal of the American Academy of Orthopaedic Surgeons</Title><ISOAbbreviation>J Am Acad Orthop Surg</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and Management of Periprosthetic Joint Infections After Total Ankle Arthroplasty.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.5435/JAAOS-D-23-01266</ELocationID><Abstract><AbstractText>Periprosthetic joint infection (PJI) after total ankle arthroplasty (TAA) is a dreaded complication that may lead to catastrophic outcomes. Risk factors include a history of surgery on the operated ankle, low preoperative function scores, diabetes, extended surgical time, and postoperative wound-healing problems. Clinical presentation varies and may include increasing ankle pain and swelling, high temperature, local erythema, wound drainage, and dehiscence. The initial diagnostic evaluation should include plain radiographs, erythrocyte sedimentation rate, C-reactive protein levels, and leukocyte count. In suspected cases with elevated erythrocyte sedimentation rate and C-reactive protein, aspiration of the ankle joint for synovial fluid analysis, Gram staining, and culture should be performed. Antibiotic therapy should be based on the pathogen identified, and the surgical strategy should be determined based on the time lines of PJI. Early PJI can be treated with irrigation and d&#xe9;bridement with polyethylene exchange. The surgical treatment of choice for late PJI is two-stage revision arthroplasty, which includes removal of the implant, insertion of an antibiotic spacer, and reimplantation of a TAA. In certain chronic PJI cases, permanent articulating antibiotic spacers can be left in place or an ankle arthrodesis can be performed. Below-knee amputation is considered as the final option after limb-sparing procedures have failed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 by the American Academy of Orthopaedic Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Atesok</LastName><ForeName>Kivanc</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Orthopaedics and Physical Medicine, Medical University of South Carolina, Charleston, SC (Atesok, Scott, and Gross), Department of Orthopaedic Surgery, University of Virginia, Charlottesville, VA (Hurwitz).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Scott</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials></Author><Author ValidYN=\"Y\"><LastName>Hurwitz</LastName><ForeName>Shepard</ForeName><Initials>S</Initials></Author><Author ValidYN=\"Y\"><LastName>Gross</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><Identifier Source=\"ORCID\">0000-0002-4740-3902</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Orthop Surg</MedlineTA><NlmUniqueID>9417468</NlmUniqueID><ISSNLinking>1067-151X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759226</ArticleId><ArticleId IdType=\"doi\">10.5435/JAAOS-D-23-01266</ArticleId><ArticleId IdType=\"pii\">00124635-990000000-00989</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lachman JR, Ramos JA, DeOrio JK, Easley ME, Nunley JA, Adams SB: Outcomes of acute hematogenous periprosthetic joint infection in total ankle arthroplasty treated with irrigation, debridement, and polyethylene exchange. Foot Ankle Int 2018;39:1266-1271.</Citation></Reference><Reference><Citation>Shah JA, Schwartz AM, Farley KX, et al.: Projections and epidemiology of total ankle and revision total ankle arthroplasty in the United States to 2030. Foot Ankle Specialist 2022;14:193864002211094.</Citation></Reference><Reference><Citation>Althoff A, Cancienne JM, Cooper MT, Werner BC: Patient-related risk factors for periprosthetic ankle joint infection: An analysis of 6977 total ankle arthroplasties. J Foot Ankle Surg 2018;57:269-272.</Citation></Reference><Reference><Citation>Kessler B, Sendi P, Graber P, et al.: Risk factors for periprosthetic ankle joint infection: A case-control study. J Bone Joint Surg Am 2012;94:1871-1876.</Citation></Reference><Reference><Citation>Myerson MS, Shariff R, Zonno AJ: The management of infection following total ankle replacement: Demographics and treatment. Foot Ankle Int 2014;35:855-862.</Citation></Reference><Reference><Citation>Smyth NA, Kennedy JG, Parvizi J, Schon LC, Aiyer AA: Risk factors for periprosthetic joint infection following total ankle replacement. Foot Ankle Surg 2020;26:591-595.</Citation></Reference><Reference><Citation>Patton D, Kiewiet N, Brage M: Infected total ankle arthroplasty: Risk factors and treatment options. Foot Ankle Int 2015;36:626-634.</Citation></Reference><Reference><Citation>Heidari N, Oh I, Malagelada F: What is the diagnostic \"algorithm\" for infected total ankle arthroplasty (TAA)?. Foot Ankle Int 2019;40:21S-22S.</Citation></Reference><Reference><Citation>Aynardi MC, Pl&#xf6;ger MM, Walley KC, Arena CB: What is the definition of acute and chronic periprosthetic joint infection (PJI) of total ankle arthroplasty (TAA)?. Foot Ankle Int 2019;40:19S-21S.</Citation></Reference><Reference><Citation>Alrashidi Y, Galhoum AE, Wiewiorski M, et al.: How to diagnose and treat infection in total ankle arthroplasty. Foot Ankle Clin 2017;22:405-423.</Citation></Reference><Reference><Citation>Gazendam A, Wood TJ, Tushinski D, Bali K: Diagnosing periprosthetic joint infection: A scoping review. Curr Rev Musculoskelet Med 2022;15:219-229.</Citation></Reference><Reference><Citation>Tarabichi S, Goh GS, Baker CM, Chisari E, Shahi A, Parvizi J: Plasma D-dimer is noninferior to serum C-reactive protein in the diagnosis of periprosthetic joint infection. J Bone Joint Surg Am 2023;105:501-508.</Citation></Reference><Reference><Citation>Shahi A, Kheir MM, Tarabichi M, Hosseinzadeh HRS, Tan TL, Parvizi J: Serum D-dimer test is promising for the diagnosis of periprosthetic joint infection and timing of reimplantation. J Bone Joint Surg Am 2017;99:1419-1427.</Citation></Reference><Reference><Citation>Yu JS, Bornes TD, Youssef MP, et al.: Which combination is the best? A comparison of the predictive potential of serum biomarker combinations to diagnose periprosthetic joint infection. J Arthroplasty 2023;38:S381-S388, doi.</Citation></Reference><Reference><Citation>Kaufman MG, Meaike JD, Izaddoost SA: Orthopedic prosthetic infections: Diagnosis and orthopedic salvage. Semin Plast Surg 2016;30:66-72.</Citation></Reference><Reference><Citation>Colvin OC, Kransdorf MJ, Roberts CC, et al.: Leukocyte esterase analysis in the diagnosis of joint infection: Can we make a diagnosis using a simple urine dipstick?. Skeletal Radiol 2015;44:673-677, doi.</Citation></Reference><Reference><Citation>De Vecchi E, Roman&#xf2; CL, De Grandi R, Cappelletti L, Villa F, Drago L: Alpha defensin, leukocyte esterase, C-reactive protein, and leukocyte count in synovial fluid for pre-operative diagnosis of periprosthetic infection. Int J Immunopathol Pharmacol 2018;32:2058738418806072.</Citation></Reference><Reference><Citation>Wang C, Li R, Wang Q, Wang C: Synovial fluid leukocyte esterase in the diagnosis of peri-prosthetic joint infection: A systematic review and meta-analysis. Surg Infect (Larchmt) 2018;19:245-253.</Citation></Reference><Reference><Citation>Thiesen DM, Koniker A, Gehrke T, et al.: The impact of &#x3b1;-defensin test in diagnosing periprosthetic infection after total ankle arthroplasty. J Foot Ankle Surg 2019;58:1125-1128.</Citation></Reference><Reference><Citation>Kuiper JWP, Verberne SJ, Vos SJ, van Egmond PW: Does the alpha defensin ELISA test perform better than the alpha defensin lateral flow test for PJI diagnosis? A systematic review and meta-analysis of prospective studies. Clin Orthop Relat Res 2020;478:1333-1344.</Citation></Reference><Reference><Citation>Deirmengian C, Kardos K, Kilmartin P, Gulati S, Citrano P, Booth RE Jr: The alpha-defensin test for periprosthetic joint infection responds to a wide spectrum of organisms. Clin Orthop Relat Res 2015;473:2229-2235.</Citation></Reference><Reference><Citation>Salari P, Grassi M, Cinti B, Onori N, Gigante A: Synovial fluid calprotectin for the preoperative diagnosis of chronic periprosthetic joint infection. J Arthroplasty 2020;35:534-537.</Citation></Reference><Reference><Citation>Karbysheva S, Yermak K, Grigoricheva L, Renz N, Perka C, Trampuz A: Synovial fluid d-lactate-A novel pathogen-specific biomarker for the diagnosis of periprosthetic joint infection. J Arthroplasty 2020;35:2223-2229.e2.</Citation></Reference><Reference><Citation>Mason LW, Wyatt J, Butcher C, Wieshmann H, Molloy AP: Single-photon-emission computed tomography in painful total ankle replacements. Foot Ankle Int 2015;36:635-640.</Citation></Reference><Reference><Citation>Richter A, Stukenborg-Colsman C, Plaass C: SPECT/CT of total ankle arthroplasty. Foot Ankle Clin 2023;28:493-507.</Citation></Reference><Reference><Citation>Lin J, Sofka CM, Demetracopoulos CA, Potter HG: The utility of isotropic 3D magnetic resonance imaging in assessing painful total ankle replacements. Foot Ankle Orthop 2022;7:24730114221094840.</Citation></Reference><Reference><Citation>Fritz J, Rashidi A, de Cesar Netto C: Magnetic resonance imaging of total ankle arthroplasty: State-of-The-Art assessment of implant-related pain and dysfunction. Foot Ankle Clin 2023;28:463-492.</Citation></Reference><Reference><Citation>Parvizi J, Zmistowski B, Berbari EF, et al.: New definition for periprosthetic joint infection: From the workgroup of the musculoskeletal infection society. Clin Orthop Relat Res 2011;469:2992-2994.</Citation></Reference><Reference><Citation>Pfahl K, R&#xf6;ser A, Gottschalk O, et al.: Common bacteria and treatment options for the acute and chronic infection of the total ankle arthroplasty. Foot Ankle Surg 2022;28:1008-1013.</Citation></Reference><Reference><Citation>Mercurio M, Castioni D, Porco E, Familiari F, Gasparini G, Galasso O: Periprosthetic ankle infection: Eradication rate, complications, and limb salvage. A systematic review. Foot Ankle Surg 2022;28:550-556.</Citation></Reference><Reference><Citation>Sousa R, Pereira A, Massada M, da Silva MV, Lemos R, Costa e Castro J: Empirical antibiotic therapy in prosthetic joint infections. Acta Orthop Belg 2010;76:254-259.</Citation></Reference><Reference><Citation>Conti MS, Irwin TA, Ford SE, Jones CP, Anderson RB, Davis WH: Complications, reoperations, and patient-reported outcomes following a 2-stage revision total ankle arthroplasty for chronic periprosthetic joint infections. Foot Ankle Int 2022;43:1614-1621.</Citation></Reference><Reference><Citation>Miner SA, Martucci JA, Brigido SA, DiDomenico L: Time to revision after periprosthetic joint infection in total ankle arthroplasty: A systematic review. J Foot Ankle Surg 2023;62:186-190.</Citation></Reference><Reference><Citation>Wolf CF, Gu NY, Doctor JN, Manner PA, Leopold SS: Comparison of one and two-stage revision of total hip arthroplasty complicated by infection: A markov expected-utility decision analysis. J Bone Joint Surg Am 2011;93:631-639.</Citation></Reference><Reference><Citation>Goud AL, Harlianto NI, Ezzafzafi S, Veltman ES, Bekkers JEJ, van der Wal BCH: Reinfection rates after one- and two-stage revision surgery for hip and knee arthroplasty: A systematic review and meta-analysis. Arch Orthop Trauma Surg 2023;143:829-838.</Citation></Reference><Reference><Citation>Kunutsor SK, Whitehouse MR, Lenguerrand E, Blom AW, Beswick AD, INFORM Team: Re-infection outcomes following one- and two-stage surgical revision of infected knee prosthesis: A systematic review and meta-analysis. PLoS One 2016;11:e0151537.</Citation></Reference><Reference><Citation>Ferrao P, Myerson MS, Schuberth JM, McCourt MJ: Cement spacer as definitive management for postoperative ankle infection. Foot Ankle Int 2012;33:173-178.</Citation></Reference><Reference><Citation>Lee HS, Ahn JY, Lee JS, Lee JY, Jeong JJ, Choi YR: Cement arthroplasty for ankle joint destruction. J Bone Joint Surg Am 2014;96:1468-1475.</Citation></Reference><Reference><Citation>Gross C, Erickson BJ, Adams SB, Parekh SG: Ankle arthrodesis after failed total ankle replacement: A systematic review of the literature. Foot &amp; Ankle Specialist 2015;8:143-151.</Citation></Reference><Reference><Citation>Culpan P, Le Strat V, Piriou P, Judet T: Arthrodesis after failed total ankle replacement. J Bone Joint Surg Br 2007;89:1178-1183.</Citation></Reference><Reference><Citation>Gross CE, Hamid KS, Green C, Easley ME, DeOrio JK, Nunley JA: Operative wound complications following total ankle arthroplasty. Foot Ankle Int 2017;38:360-366.</Citation></Reference><Reference><Citation>Wukich DK, Ahn J, Raspovic KM, La Fontaine J, Lavery LA: Improved quality of life after transtibial amputation in patients with diabetes-related foot complications. Int J Lower Extremity Wounds 2017;16:114-121.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38759099</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1537-6591</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Clinical presentation, antimicrobial resistance, and treatment outcomes of Aeromonas human infections: A 14-year retrospective study and comparative genomics of two isolates from fatal cases.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">ciae272</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1093/cid/ciae272</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Aeromonas virulence may not be entirely dependent on the host immune status. Pathophysiologic determinants of disease progression and severity remain unclear.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">One hundred five patients with Aeromonas infections and 112 isolates were identified, their clinical presentations and outcomes analyzed, and their antimicrobial resistance (AMR) patterns assessed. Two isolates (A and B) from fatal cases of Aeromonas dhakensis bacteremia were characterized using whole genome sequence analysis. Virulence factor- and AMR-encoding genes from these isolates were compared with a well-characterized diarrheal isolate A. dhakensis SSU, and environmental isolate A. hydrophila ATCC_7966T.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Skin and soft tissue infections, traumatic wound infections, sepsis, burns, and intraabdominal infections were common. Diabetes, malignancy, and cirrhosis were frequent comorbidities. Male sex, age&#x2009;&#x2265;&#x2009;65 years, hospitalization, burns, and intensive care were associated with complicated disease. High rates of AMR to carbapenems and piperacillin-tazobactam were found. Treatment failure was observed in 25.7% of cases. Septic shock and hospital-acquired infections were predictors of treatment failure. All four isolates harbored assorted broad-spectrum AMR genes including blaOXA, ampC, cphA, and efflux pumps. Only clinical isolates possessed both polar and lateral flagellar genes, genes for various surface adhesion proteins, type 3- and -6 secretion systems and their effectors, and toxin genes, including exotoxin A. Both isolates A and B were resistant to colistin and harbored the mobile colistin resistance-3 (mcr-3) gene.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Empirical therapy tailored to local Aeromonas antibiograms may facilitate more favorable outcomes, while advanced diagnostic methods may aid in identifying correct Aeromonas spp. of significant clinical importance.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Pineda-Reyes</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source=\"ORCID\">0000-0001-6242-2952</Identifier><AffiliationInfo><Affiliation>Infectious Disease Division, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Neil</LastName><ForeName>Blake H</ForeName><Initials>BH</Initials><Identifier Source=\"ORCID\">0009-0002-8091-0604</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Orndorff</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Williams-Bouyer</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Netherland</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>EzBiome, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hasan</LastName><ForeName>Nur A</ForeName><Initials>NA</Initials><Identifier Source=\"ORCID\">0000-0003-0175-8879</Identifier><AffiliationInfo><Affiliation>EzBiome, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tahashilder</LastName><ForeName>Md Ibrahim</ForeName><Initials>MI</Initials><Identifier Source=\"ORCID\">0000-0001-8521-1461</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics and Data Science, School of Public and Population Health, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sha</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chopra</LastName><ForeName>Ashok K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Reynoso</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source=\"ORCID\">0000-0002-2639-4197</Identifier><AffiliationInfo><Affiliation>Infectious Disease Division, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Aeromonas</Keyword><Keyword MajorTopicYN=\"N\">antimicrobial resistance</Keyword><Keyword MajorTopicYN=\"N\">genomics</Keyword><Keyword MajorTopicYN=\"N\">retrospective study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38759099</ArticleId><ArticleId IdType=\"doi\">10.1093/cid/ciae272</ArticleId><ArticleId IdType=\"pii\">7676121</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758937</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Electronic\">1932-6203</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>The effect of calcaneus and metatarsal head offloading insoles on healthy subjects' gait kinematics, kinetics, asymmetry, and the implications for plantar pressure management: A pilot study.</ArticleTitle><Pagination><StartPage>e0303826</StartPage><MedlinePgn>e0303826</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1371/journal.pone.0303826</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">The global number of people with diabetes is estimated to reach 643 million by 2030 of whom 19-34% will present with diabetic foot ulceration. Insoles which offload high-risk ulcerative regions on the foot, by removing insole material, are the main contemporary conservative treatment to maintain mobility and reduce the likelihood of ulceration. However, their effect on the rest of the foot and relationship with key gait propulsive and balance kinematics and kinetics has not been well researched.</AbstractText><AbstractText Label=\"PURPOSE\" NlmCategory=\"OBJECTIVE\">The aim of this study is to investigate the effect of offloading insoles on gait kinematics, kinetics, and plantar pressure throughout the gait cycle.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">10 healthy subjects were recruited for this experiment to walk in 6 different insole conditions. Subjects walked at three speeds on a treadmill for 10 minutes while both plantar pressure and gait kinematics, kinetics were measured using an in-shoe pressure measurement insole and motion capture system/force plates. Average peak plantar pressure, pressure time integrals, gait kinematics and centre of force were analysed.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The average peak plantar pressure and pressure time integrals changed by -30% (-68% to 3%) and -36% (-75% to -1%) at the region of interest when applying offloading insoles, whereas the heel strike and toe-off velocity changed by 15% (-6% to 32%) and 12% (-2% to 19%) whilst walking at three speeds.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">The study found that offloading insoles reduced plantar pressure in the region of interest with loading transferred to surrounding regions increasing the risk of higher pressure time integrals in these locations. Heel strike and toe-off velocities were increased under certain configurations of offloading insoles which may explain the higher plantar pressures and supporting the potential of integrating kinematic gait variables within a more optimal therapeutic approach. However, there was inter-individual variability in responses for all variables measured supporting individualised prescription.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Shuang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Shuang</LastName><ForeName>Jiawei</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0009-0007-3106-5471</Identifier><AffiliationInfo><Affiliation>School of Engineering, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Haron</LastName><ForeName>Athia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Engineering, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Massey</LastName><ForeName>Garry</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NIHR Exeter BRC, Exeter, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mansoubi</LastName><ForeName>Maedeh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NIHR Exeter BRC, Exeter, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Dawes</LastName><ForeName>Helen</ForeName><Initials>H</Initials><Identifier Source=\"ORCID\">0000-0002-2933-5213</Identifier><AffiliationInfo><Affiliation>NIHR Exeter BRC, Exeter, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bowling</LastName><ForeName>Frank L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Faculty of Biology, School of Medical Sciences, Medicine and Health, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Reeves</LastName><ForeName>Neil D</ForeName><Initials>ND</Initials><Identifier Source=\"ORCID\">0000-0001-9213-4580</Identifier><AffiliationInfo><Affiliation>Faculty of Science and Engineering, Department of Life Sciences, Manchester Metropolitan University, Manchester, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manchester Metropolitan University Institute of Sport, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Weightman</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Engineering, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cooper</LastName><ForeName>Glen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Engineering, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005684\" MajorTopicYN=\"Y\">Gait</DescriptorName><QualifierName UI=\"Q000502\" MajorTopicYN=\"N\">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D001696\" MajorTopicYN=\"N\">Biomechanical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D010865\" MajorTopicYN=\"N\">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011312\" MajorTopicYN=\"Y\">Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D061826\" MajorTopicYN=\"Y\">Foot Orthoses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002111\" MajorTopicYN=\"Y\">Calcaneus</DescriptorName><QualifierName UI=\"Q000502\" MajorTopicYN=\"N\">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D064368\" MajorTopicYN=\"N\">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012775\" MajorTopicYN=\"N\">Shoes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D007700\" MajorTopicYN=\"N\">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D016138\" MajorTopicYN=\"N\">Walking</DescriptorName><QualifierName UI=\"Q000502\" MajorTopicYN=\"N\">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008684\" MajorTopicYN=\"N\">Metatarsus</DescriptorName><QualifierName UI=\"Q000502\" MajorTopicYN=\"N\">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D005528\" MajorTopicYN=\"N\">Foot</DescriptorName><QualifierName UI=\"Q000502\" MajorTopicYN=\"N\">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>14</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758937</ArticleId><ArticleId IdType=\"doi\">10.1371/journal.pone.0303826</ArticleId><ArticleId IdType=\"pii\">PONE-D-23-30055</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758936</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Electronic\">1932-6203</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Bacteriological analysis and antibiotic resistance in patients with diabetic foot ulcers in Dhaka.</ArticleTitle><Pagination><StartPage>e0301767</StartPage><MedlinePgn>e0301767</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1371/journal.pone.0301767</ELocationID><Abstract><AbstractText>The primary objective of this study was to isolate bacteria from diabetic foot ulcers and subsequently assess their antibiotic resistance capabilities. Seventy-five patients diagnosed with diabetic foot ulcers were investigated. A number of these patients (97.33%) had type 2 diabetes, with a significant proportion of them having been diagnosed for 1-5 years (29.33%). Notably, a substantial number of these individuals were on insulin usage (78.66%). Among the patients under examination, 49.33% reported having no use of tobacco products, alcohol, or betel leaf. The ulcers analyzed in this study were classified into grades 1-5 according to the Wagner scale. Wagner grade 2 diabetic foot ulcers had the highest number of culture-positive patients, at 33.33%. Pus samples collected from patients were cultured on selective media, and bacterial identity was confirmed by biochemical tests and polymerase chain reaction. A total of 141 isolates were isolated. Among the isolates, 82.97% gram-negative bacteria and 17.02% gram-positive bacteria were detected. Klebsiella pneumoniae was the most common isolate. Proteus spp., Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus were also detected. Approximately 61.33% of the ulcers exhibited were polybacterial. In this study, it was observed that all bacterial isolates, except for Proteus spp., were primarily detected in patients classified under Wagner's grade 2. Moreover, antibiotic susceptibility was also tested on these 141 isolates. Among them, Escherichia coli showed the highest multidrug resistance, 81.81%. Most of the gram-negative bacteria were resistant to ampicillin. All of the gram-negative isolates exhibited high levels of susceptibility to piperacillin-tazobactam, and these levels were Klebsiella pneumoniae (97.56%), Pseudomonas aeruginosa (95.24%), Escherichia coli (81.82%), and Proteus spp. (80%). On the other hand, gram-positive Staphylococcus aureus mostly showed sensitivity towards vancomycin and norfloxacin (79.17%).</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Baral et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Baral</LastName><ForeName>Poulomi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Microbiology Program, Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Afnan</LastName><ForeName>Nafisa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Microbiology Program, Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ahmad Zahra</LastName><ForeName>Maftuha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microbiology Program, Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Akter</LastName><ForeName>Baby</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biotechnology Program, Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rabia Prapti</LastName><ForeName>Shek</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biotechnology Program, Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Muazzam Hossan</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Shaheed Suhrawardy Medical College, Sher-E-Bangla Nagar, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Haque</LastName><ForeName>Fahim Kabir Monjurul</ForeName><Initials>FKM</Initials><Identifier Source=\"ORCID\">0000-0001-6347-1836</Identifier><AffiliationInfo><Affiliation>Microbiology Program, Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D017719\" MajorTopicYN=\"Y\">Diabetic Foot</DescriptorName><QualifierName UI=\"Q000382\" MajorTopicYN=\"N\">microbiology</QualifierName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000900\" MajorTopicYN=\"Y\">Anti-Bacterial Agents</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName><QualifierName UI=\"Q000494\" MajorTopicYN=\"N\">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008826\" MajorTopicYN=\"Y\">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D001459\" MajorTopicYN=\"N\" Type=\"Geographic\">Bangladesh</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D024881\" MajorTopicYN=\"N\">Drug Resistance, Bacterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006090\" MajorTopicYN=\"N\">Gram-Negative Bacteria</DescriptorName><QualifierName UI=\"Q000187\" MajorTopicYN=\"N\">drug effects</QualifierName><QualifierName UI=\"Q000302\" MajorTopicYN=\"N\">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D006094\" MajorTopicYN=\"N\">Gram-Positive Bacteria</DescriptorName><QualifierName UI=\"Q000187\" MajorTopicYN=\"N\">drug effects</QualifierName><QualifierName UI=\"Q000302\" MajorTopicYN=\"N\">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D004926\" MajorTopicYN=\"N\">Escherichia coli</DescriptorName><QualifierName UI=\"Q000187\" MajorTopicYN=\"N\">drug effects</QualifierName><QualifierName UI=\"Q000302\" MajorTopicYN=\"N\">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D003924\" MajorTopicYN=\"N\">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI=\"Q000382\" MajorTopicYN=\"N\">microbiology</QualifierName><QualifierName UI=\"Q000150\" MajorTopicYN=\"N\">complications</QualifierName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D013211\" MajorTopicYN=\"N\">Staphylococcus aureus</DescriptorName><QualifierName UI=\"Q000187\" MajorTopicYN=\"N\">drug effects</QualifierName><QualifierName UI=\"Q000302\" MajorTopicYN=\"N\">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>14</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758936</ArticleId><ArticleId IdType=\"doi\">10.1371/journal.pone.0301767</ArticleId><ArticleId IdType=\"pii\">PONE-D-24-01408</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758907</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1536-5964</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>103</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Electrolyte disturbances in patients hospitalized for COVID-19 infection: An observational study.</ArticleTitle><Pagination><StartPage>e37749</StartPage><MedlinePgn>e37749</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1097/MD.0000000000037749</ELocationID><Abstract><AbstractText>There are multiple mechanisms by which The Coronavirus-19 (COVID-19) infection can cause electrolyte abnormalities, which may not be the case for bacterial causes of pneumonia. This study aimed to assess the differences in electrolyte levels between patients suffering from COVID-19 and bacterial pneumonia. This is an original, retrospective study. Two cohorts of hospitalized patients were included, 1 suffering from COVID-19 and the other from bacterial pneumonia. Their day 1 and day 3 levels of sodium, potassium, magnesium, and phosphorus, as well as their outcomes, were extracted from the charts. Statistical analysis was subsequently performed. Mean admission levels of sodium, potassium, phosphorus, and magnesium were 135.64&#x2005;&#xb1;&#x2005;6.13, 4.38&#x2005;&#xb1;&#x2005;0.69, 3.53&#x2005;&#xb1;&#x2005;0.69, and 2.03&#x2005;&#xb1;&#x2005;0.51, respectively. The mean day 3 levels of these electrolytes were 138.3&#x2005;&#xb1;&#x2005;5.06, 4.18&#x2005;&#xb1;&#x2005;0.59, 3.578&#x2005;&#xb1;&#x2005;0.59, and 2.11&#x2005;&#xb1;&#x2005;0.64, respectively. Patients suffering from bacterial pneumonia were significantly older (N&#x2005;=&#x2005;219, mean&#x2005;=&#x2005;64.88&#x2005;&#xb1;&#x2005;15.99) than patients with COVID-19 pneumonia (N&#x2005;=&#x2005;240, mean&#x2005;=&#x2005;57.63&#x2005;&#xb1;&#x2005;17.87). Bacterial pneumonia group had significantly higher serum potassium (N&#x2005;=&#x2005;211, mean&#x2005;=&#x2005;4.51&#x2005;&#xb1;&#x2005;0.76), and magnesium (N&#x2005;=&#x2005;115, mean&#x2005;=&#x2005;2.12&#x2005;&#xb1;&#x2005;0.60) levels compared to COVID-19 group (N&#x2005;=&#x2005;227, mean&#x2005;=&#x2005;4.254&#x2005;&#xb1;&#x2005;0.60 for potassium and N&#x2005;=&#x2005;118, mean&#x2005;=&#x2005;1.933&#x2005;&#xb1;&#x2005;0.38 for magnesium). Only magnesium was significantly higher among day 3 electrolytes in the bacterial pneumonia group. No significant association between electrolyte levels and outcomes was seen. We found that COVID-19 patients had lower potassium and magnesium levels on admission, possibly due to the effect of COVID-19 on the renin-angiotensin-aldosterone system as well as patient characteristics and management. We did not find enough evidence to recommend using electrolyte levels as a determinator of prognosis, but more research is needed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Cancarevic</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><Identifier Source=\"ORCID\">0000-0002-7455-6381</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nassar</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0002-5401-9562</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Foster</LastName><ForeName>Allison</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0001-5900-7969</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Umar</LastName><ForeName>Zaryab</ForeName><Initials>Z</Initials><Identifier Source=\"ORCID\">0000-0003-4431-635</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Parikh</LastName><ForeName>Avish</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0002-2008-9861</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ahammed</LastName><ForeName>Md Ripon</ForeName><Initials>MR</Initials><Identifier Source=\"ORCID\">0000-0001-6209-9809</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shaban</LastName><ForeName>Lilia</ForeName><Initials>L</Initials><Identifier Source=\"ORCID\">0009-0000-7949-926</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Abosheaishaa</LastName><ForeName>Hazem</ForeName><Initials>H</Initials><Identifier Source=\"ORCID\">0000-0002-5581-8702</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mergen</LastName><ForeName>Damla</ForeName><Initials>D</Initials><Identifier Source=\"ORCID\">0000-0002-1845-3353</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Amin</LastName><ForeName>Toka</ForeName><Initials>T</Initials><Identifier Source=\"ORCID\">0000-0002-0950-4411</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ozkan</LastName><ForeName>Bike Ilayda</ForeName><Initials>BI</Initials><Identifier Source=\"ORCID\">0009-0000-1040-1260</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>S&#xe1;nchez Ruiz</LastName><ForeName>Ang&#xe9;lica M</ForeName><Initials>AM</Initials><Identifier Source=\"ORCID\">0000-0002-7335-2002</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hosna</LastName><ForeName>Asma</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0002-4780-2858</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ul Rasool</LastName><ForeName>Muhammad Haseeb</ForeName><Initials>MH</Initials><Identifier Source=\"ORCID\">0000-0002-0304-3378</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ahmed</LastName><ForeName>Nazaakat</ForeName><Initials>N</Initials><Identifier Source=\"ORCID\">0000-0002-6892-0319</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ayotunde</LastName><ForeName>Fatima</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0000-0002-4709-3350</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ashfaq</LastName><ForeName>Salman</ForeName><Initials>S</Initials><Identifier Source=\"ORCID\">0000-0002-9602-8205</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lopez</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><Identifier Source=\"ORCID\">0009-0002-2485-7810</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rizzo</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source=\"ORCID\">0000-0002-5530-447</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, NYC Health and Hospitals, Queens, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D064888\">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000086382\" MajorTopicYN=\"Y\">COVID-19</DescriptorName><QualifierName UI=\"Q000150\" MajorTopicYN=\"N\">complications</QualifierName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006760\" MajorTopicYN=\"Y\">Hospitalization</DescriptorName><QualifierName UI=\"Q000706\" MajorTopicYN=\"N\">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D014883\" MajorTopicYN=\"Y\">Water-Electrolyte Imbalance</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D018410\" MajorTopicYN=\"Y\">Pneumonia, Bacterial</DescriptorName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName><QualifierName UI=\"Q000150\" MajorTopicYN=\"N\">complications</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011188\" MajorTopicYN=\"Y\">Potassium</DescriptorName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008274\" MajorTopicYN=\"Y\">Magnesium</DescriptorName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000086402\" MajorTopicYN=\"N\">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D004573\" MajorTopicYN=\"N\">Electrolytes</DescriptorName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012964\" MajorTopicYN=\"N\">Sodium</DescriptorName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D010758\" MajorTopicYN=\"N\">Phosphorus</DescriptorName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>14</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758907</ArticleId><ArticleId IdType=\"doi\">10.1097/MD.0000000000037749</ArticleId><ArticleId IdType=\"pii\">00005792-202405170-00070</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hirsch JS, Ng JH, Ross DW, et al.; Northwell COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98:209&#x2013;18.</Citation></Reference><Reference><Citation>Faour WH, Choaib A, Issa E, et al. Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. Inflamm Res. 2022;71:39&#x2013;56.</Citation></Reference><Reference><Citation>Cantuti-Castelvetri L, Ojha R, Pedro LD, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370:856&#x2013;60.</Citation></Reference><Reference><Citation>Hilton J, Boyer N, Nadim MK, Forni LG, Kellum JA. COVID-19 and acute kidney injury. Crit Care Clin. 2022;38:473&#x2013;89.</Citation></Reference><Reference><Citation>Pourfridoni M, Abbasnia SM, Shafaei F, Razaviyan J, Heidari-Soureshjani R. Fluid and electrolyte disturbances in COVID-19 and their complications. Biomed Res Int. 2021;2021:6667047.</Citation></Reference><Reference><Citation>Sharmin Moutushi S, Akter T, Haq MA, et al. Electrolyte imbalance among bangladeshi patients with COVID-19. Cureus. 2023;15:e35352.</Citation></Reference><Reference><Citation>Song H, Chia AZQ, Tan BKJ, et al. Electrolyte imbalances as poor prognostic markers in COVID-19: a systemic review and meta-analysis. J Endocrinol Invest. 2023;46:235&#x2013;59.</Citation></Reference><Reference><Citation>Moreno PO, Leon-Ramirez JM, Fuertes-Kenneally L, et al. Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: a case series of 306 Mediterranean patients. Int J Infect Dis. 2020;100:449&#x2013;54.</Citation></Reference><Reference><Citation>Chevinsky JR, Tao G, Lavery AM, et al. Late conditions diagnosed 1-4 months following an initial coronavirus disease 2019 (COVID-19) encounter: a matched-cohort study using inpatient and outpatient administrative data-United States, 1 March-30 June 2020. Clin Infect Dis. 2021;73(Suppl 1):S5&#x2013;S16.</Citation></Reference><Reference><Citation>Sakellaropoulou A, Hatzistilianou M, Eboriadou M, Athanasiadou-Piperopoulou F. Hyponatraemia in cases of children with pneumonia. Arch Med Sci. 2010;6:578&#x2013;83.</Citation></Reference><Reference><Citation>Balci AK, Koksal O, Kose A, et al. General characteristics of patients with electrolyte imbalance admitted to emergency department. World J Emerg Med. 2013;4:113&#x2013;6.</Citation></Reference><Reference><Citation>The COVID-19 sex-disaggregated data tracker. 15 September 2022; 2022.</Citation></Reference><Reference><Citation>Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507&#x2013;13.</Citation></Reference><Reference><Citation>Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11:29.</Citation></Reference><Reference><Citation>Corica B, Tartaglia F, D&#x2019;Amico T, Romiti GF, Cangemi R. Sex and gender differences in community-acquired pneumonia. Intern Emerg Med. 2022;17:1575&#x2013;88.</Citation></Reference><Reference><Citation>Saliaj M, Li M, Rizzo V, et al. Tocilizumab treatment reduces mortality in hospitalized patients with COVID-19: a retrospective cohort study at a New York City Hospital. Infect Dis Clin Pract. 2022;30:e1146.</Citation></Reference><Reference><Citation>de Miguel-Yanes JM, Lopez-de-Andres A, Jimenez-Garcia R, et al. Incidence, outcomes and sex-related disparities in pneumonia: a matched-pair analysis with data from Spanish Hospitals (2016-2019). J Clin Med. 2021;10:4339.</Citation></Reference><Reference><Citation>Quero BG, Fernandez LS, Moyano MG, et al. Differences in community acquired pneumonia according to gender. Eur Respir Soc. 2017;50. https://doi.org/10.1183/1393003.congress-2017.PA4101 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/1393003.congress-2017.PA4101</ArticleId></ArticleIdList></Reference><Reference><Citation>Provisional COVID-19 deaths by sex and age. 2024. https://data.cdc.gov/widgets/9bhg-hcku?mobile_redirect . Accessed April 29, 2024.</Citation></Reference><Reference><Citation>Sjostrom A, Rysz S, Sjostrom H, Hoybye C. Electrolyte and acid-base imbalance in severe COVID-19. Endocr Connect. 2021;10:805&#x2013;14.</Citation></Reference><Reference><Citation>Yasari F, Akbarian M, Abedini A, Vasheghani M. The role of electrolyte imbalances in predicting the severity of COVID-19 in the hospitalized patients: a cross-sectional study. Sci Rep. 2022;12:14732.</Citation></Reference><Reference><Citation>Lippi G, South AM, Henry BM. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Ann Clin Biochem. 2020;57:262&#x2013;5.</Citation></Reference><Reference><Citation>Sarvazad H, Cahngaripour SH, Eskandari Roozbahani N, Izadi B. Evaluation of electrolyte status of sodium, potassium and magnesium, and fasting blood sugar at the initial admission of individuals with COVID-19 without underlying disease in Golestan Hospital, Kermanshah. New Microbes New Infect. 2020;38:100807.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758866</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1536-5964</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>103</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Influence of continuous 4C nursing on quality of life and self-care ability of patients with diabetes retinopathy: An observational study.</ArticleTitle><Pagination><StartPage>e37920</StartPage><MedlinePgn>e37920</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1097/MD.0000000000037920</ELocationID><Abstract><AbstractText>This study aims to investigate the impact of continuous 4C nursing on patients with diabetes retinopathy (DR) and its influence on self-care ability. A total of 100 DR patients admitted to our hospital from October 2020 to October 2022 were randomly divided into a control group and an observation group, with 50 cases in each group. The control group received routine care, while the observation group received continuous 4C care. The nursing effects of both groups were compared. After nursing, the observation group showed a lower self-rating anxiety scale score and a higher self-care ability scale score compared to the control group (P&#x2005;&lt;&#x2005;.05). The SQQL-VI scores for all social activities were also higher in the observation group (P&#x2005;&lt;&#x2005;.05). Additionally, the observation group had lower levels of fasting blood glucose, 2-hour postprandial blood glucose, and glycated hemoglobin than the control group (P&#x2005;&lt;&#x2005;.05). Moreover, the observation group had higher visual acuity and lower intraocular pressure than the control group (P&#x2005;&lt;&#x2005;.05). The visual impairment rate was lower and the overall compliance rate was higher in the observation group compared to the control group (P&#x2005;&lt;&#x2005;.05). After nursing, both groups showed improvements in symptoms, visual function, physical function, psychological and social activity scores, visual acuity, and patient satisfaction scores. The observation group showed greater improvements compared to the control group (P&#x2005;&lt;&#x2005;.05). The application of continuous 4C nursing in DR patients has shown positive effects, including improved patient compliance and satisfaction, enhanced patient quality of life and visual acuity. These findings suggest that continuous 4C nursing should be widely promoted and applied in clinical practice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Wufuer</LastName><ForeName>Ayixianmuguli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ophthalmology Department of Xinjiang Uygur Autonomous Region People's Hospital Urumqi, Xinjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ma</LastName><ForeName>Jiamei</ForeName><Initials>J</Initials></Author><Author ValidYN=\"Y\"><LastName>Ainiwa</LastName><ForeName>Pazilaiti</ForeName><Initials>P</Initials></Author><Author ValidYN=\"Y\"><LastName>Zhou</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><Identifier Source=\"ORCID\">0009-0002-9514-5458</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D064888\">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011788\" MajorTopicYN=\"Y\">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D003930\" MajorTopicYN=\"Y\">Diabetic Retinopathy</DescriptorName><QualifierName UI=\"Q000451\" MajorTopicYN=\"N\">nursing</QualifierName><QualifierName UI=\"Q000523\" MajorTopicYN=\"N\">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012648\" MajorTopicYN=\"Y\">Self Care</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D014792\" MajorTopicYN=\"N\">Visual Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D001786\" MajorTopicYN=\"N\">Blood Glucose</DescriptorName><QualifierName UI=\"Q000032\" MajorTopicYN=\"N\">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D006442\" MajorTopicYN=\"N\">Glycated Hemoglobin</DescriptorName><QualifierName UI=\"Q000032\" MajorTopicYN=\"N\">analysis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>14</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758866</ArticleId><ArticleId IdType=\"doi\">10.1097/MD.0000000000037920</ArticleId><ArticleId IdType=\"pii\">00005792-202405170-00029</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124&#x2013;36.</Citation></Reference><Reference><Citation>Hammes H-P, Lemmen KD, Bertram B. Diabetic retinopathy and maculopathy. Exp Clin Endocrinol Diabetes. 2023;131:66&#x2013;71.</Citation></Reference><Reference><Citation>Widyaputri F, Lim LL. Diabetic retinopathy in pregnancy: a growing problem. Clin Exp Ophthalmol. 2023;51:192&#x2013;4.</Citation></Reference><Reference><Citation>Li H, Chang GY, Jiang YH, et al. System dynamic model simulates the growth trend of diabetes mellitus in Chinese Population: implications for future Urban Public Health Governance. Int J Public Health. 2022;67:1605064.</Citation></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2024. Diabetes Care. 2024;47:S231&#x2013;43.</Citation></Reference><Reference><Citation>Sun Y, Kong L, Zhang AH, et al. A hypothesis from metabolomics analysis of diabetic retinopathy: arginine&#x2013;creatine metabolic pathway may be a new treatment strategy for diabetic retinopathy. Front Endocrinol (Lausanne). 2022;13:858012.</Citation></Reference><Reference><Citation>Chen SN, Chen SJ, Wu TT, Wu W-C, Yang C-H, Yang C-M. Refining vitrectomy for proliferative diabetic retinopathy. Graefe's Arch Clin Exp Ophthalmol 2023;261:3659&#x2013;70.</Citation></Reference><Reference><Citation>Zang B, Rong S, Li D, et al. Undiagnosed diabetic retinopathy in Northeast China: prevalence and determinants. Front Endocrinol (Lausanne). 2023;14:1263508.</Citation></Reference><Reference><Citation>B&#x142;aszkiewicz M, Walulik A, Florek K, G&#xf3;recki I, S&#x142;awatyniec O, Gomu&#x142;ka K. Advances and perspectives in relation to the molecular basis of diabetic retinopathy: a review. Biomedicines. 2023;11 [undefined 2951].</Citation></Reference><Reference><Citation>Zhang J, Gu LL, Xu Y, Zhao BB, Li D, Xiao CL. Integrated medical care and the continuous 4C nursing model to improve nursing quality and clinical treatment of patients with acute stroke: based on a retrospective case&#x2013;control study. Contrast Media Mol Imaging. 2022;2022:4810280.</Citation></Reference><Reference><Citation>Zhang M, Hu Y, Zhang J, Zhang J. FTY720 prevents spatial memory impairment in a rat model of chronic cerebral hypoperfusion via a SIRT3-independent pathway. Front Aging Neurosci. 2021;12:156&#x2013;9.</Citation></Reference><Reference><Citation>Zhang R, Li Y, Zhang S, Cai X, Zhou X, Ji L. The association of retinopathy and plasma glucose and HbA1c: a validation of diabetes diagnostic criteria in a Chinese population. J Diabetes Res. 2016;2016:4034129.</Citation></Reference><Reference><Citation>Trento M, Trevisan M, Raballo M, et al. Depression, anxiety, cognitive impairment and their association with clinical and demographic variables in people with type 2 diabetes: a 4-year prospective study. J Endocrinol Invest. 2014;37:79&#x2013;85.</Citation></Reference><Reference><Citation>Trento M, Raballo M, Trevisan M, et al. A cross-sectional survey of depression, anxiety, and cognitive function in patients with type 2 diabetes. Acta Diabetol. 2012;49:199&#x2013;203.</Citation></Reference><Reference><Citation>Zhang B, Wang Q, Zhang X, Jiang L, Li L, Liu B. Association between self-care agency and depression and anxiety in patients with diabetic retinopathy. BMC Ophthalmol. 2021;21:123.</Citation></Reference><Reference><Citation>Rosenstock J, Wysham C, Fr&#xed;as Juan P, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398:143&#x2013;55.</Citation></Reference><Reference><Citation>Ferris FL, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med. 1999;341:667&#x2013;78.</Citation></Reference><Reference><Citation>Walker R. Diabetic retinopathy: protecting the vision of people with diabetes. Br J Community Nurs. 2004;9:545&#x2013;7.</Citation></Reference><Reference><Citation>Li Y, Zhang J, Wang Y. Evaluation of the effect of multidisciplinary collaborative nutrition management model in acute stroke patients with dysphagia. Chin J Clin Nutrit. 2021;29:14&#x2013;21.</Citation></Reference><Reference><Citation>Nicol&#xf2; M, Lorenzo FD, Vagge A, et al. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021;30:193&#x2013;200.</Citation></Reference><Reference><Citation>Moinul P, Barbosa J, Qian J, et al. Does patient education improve compliance to routine diabetic retinopathy screening? J Telemed Telecare. 2020;26:161&#x2013;73.</Citation></Reference><Reference><Citation>Allen Rachael S, Hanif Adam M, Gogniat Marissa A, et al. TrkB signalling pathway mediates the protective effects of exercise in the diabetic rat retina. Eur J Neurosci. 2018;47:1254&#x2013;65.</Citation></Reference><Reference><Citation>Boucher MC, Ouazani Chahdi H, El Yamani MEM. Compliance to follow-up care after urban diabetic retinopathy tele-screening. Can J Ophthalmol. 2020;55:2&#x2013;7.</Citation></Reference><Reference><Citation>Hudson Sharon M, Modjtahedi Bobeck S, Altman D, et al. Factors affecting compliance with diabetic retinopathy screening: a qualitative study comparing English and Spanish speakers. Clin Ophthalmol. 2022;16:1009&#x2013;18.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758863</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1536-5964</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>103</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Regulatory patterns of Chinese patent medicine for lipid metabolism disorders in patients with type 2 diabetes mellitus complicated by ischemic stroke: A systematic review and network meta-analysis.</ArticleTitle><Pagination><StartPage>e35050</StartPage><MedlinePgn>e35050</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1097/MD.0000000000035050</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">To investigate the regulatory patterns of Chinese patent medicine (CPM) interventions on lipid metabolism disorders in patients with type 2 diabetes mellitus (T2DM) complicated by ischemic stroke.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">Two researchers independently searched 8 major databases and created a comprehensive database containing all randomized controlled trials (RCTs) that investigated the application of \"blood-activating and stasis-removing\" CPM in the treatment of stroke combined with T2DM until October 1, 2022. The collected data were compiled and organized in Excel. Quality assessment was performed using the Cochrane 5.3 bias risk assessment tool, and the network meta-analysis was conducted using R software.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">A total of 12 articles were included in the final analysis, covering 4 types of CPM: Naoxintong Capsules (NXT), Tongmai Jiangtang Capsules, Tongxinluo Capsules (TXL), and Yindan Xinnaotong Soft Capsules. Among these, CPM formulations containing herbs with blood-activating and stasis-removing properties were the most commonly used. The results of the network meta-analysis are as follows: (1) the combination of 3 CPM formulations showed superior efficacy in improving total cholesterol levels compared to conventional Western medicine treatment (CT). In particular, Yindan Xinnaotong Soft Capsules&#x2005;+&#x2005;CT (surface under the cumulative ranking curve [SUCRA]&#x2005;=&#x2005;97.24%) demonstrated the highest efficacy, followed by NXT&#x2005;+&#x2005;CT (SUCRA&#x2005;=&#x2005;66.23%), and then TXL&#x2005;+&#x2005;CT (SUCRA&#x2005;=&#x2005;55.16%). (2) TXL&#x2005;+&#x2005;CT treatment exhibited the most promising efficacy in improving triglyceride levels (P&#x2005;&lt;&#x2005;.05), while the effects of the other 3 CPM formulations were not statistically significant. (3) In terms of improving low-density lipoprotein levels, NXT&#x2005;+&#x2005;CT (SUCRA&#x2005;=&#x2005;82.27%) showed better efficacy than TXL&#x2005;+&#x2005;CT (SUCRA&#x2005;=&#x2005;73.99%), while the effects of the other 2 CPM formulations were not statistically significant. (4) The combination of CPM formulations and CT resulted in a lower incidence of adverse reactions compared to CT (P&#x2005;&lt;&#x2005;.05).</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">The treatment of patients with T2DM complicated by ischemic stroke commonly involved the use of \"blood-activating and stasis-removing\" herbal medicines. These herbal medicines have shown effectiveness in regulating patients' blood lipid levels. However, it is crucial to acknowledge that the analysis was influenced by variations in the number and quality of RCTs involving different CPM formulations. Therefore, additional validation through large-scale, high-quality RCT studies is required.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Lu</LastName><ForeName>Zhenkai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhang</LastName><ForeName>Xuming</ForeName><Initials>X</Initials></Author><Author ValidYN=\"Y\"><LastName>Xie</LastName><ForeName>Yanming</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D000078182\">Systematic Review</PublicationType><PublicationType UI=\"D017418\">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"C571443\">naoxintong</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D003924\" MajorTopicYN=\"Y\">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI=\"Q000150\" MajorTopicYN=\"N\">complications</QualifierName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D004365\" MajorTopicYN=\"Y\">Drugs, Chinese Herbal</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000083242\" MajorTopicYN=\"Y\">Ischemic Stroke</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000071076\" MajorTopicYN=\"Y\">Network Meta-Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D052439\" MajorTopicYN=\"N\">Lipid Metabolism Disorders</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000209\" MajorTopicYN=\"N\">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D016032\" MajorTopicYN=\"N\">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008516\" MajorTopicYN=\"N\">Medicine, Chinese Traditional</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>14</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758863</ArticleId><ArticleId IdType=\"doi\">10.1097/MD.0000000000035050</ArticleId><ArticleId IdType=\"pii\">00005792-202405170-00026</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yan W, Lu Y, Zhang R, et al. Multimorbidity status of the elderly in China-research based on CHARLS datta. Chin J Dis Control Prevention. 2019;23:426&#x2013;30.</Citation></Reference><Reference><Citation>Zhang Y, Huang X, Qi B, et al. Multimorbidity in elderly population: challenges and coping strategies. Chin Gen Pract. 2022;25:4363&#x2013;8.</Citation></Reference><Reference><Citation>Chinese Society of Endocrinology, Lipid Metabolism Group. Expert consensus on the prevention and treatment of dyslipidemia in type 2 diabetes mellitus in China (Revised edition 2017). Chin J Endocrinol Metab. 2017;33:936.</Citation></Reference><Reference><Citation>Fu Y, Liu Q, Anrather J, et al. Immune interventions in stroke. Nat Rev Neurol. 2015;11:524&#x2013;35.</Citation></Reference><Reference><Citation>Vekic J, Zeljkovic A, Stefanovic A, et al. Obesity and dyslipidemia. Metabolism. 2018;92:71&#x2013;81.</Citation></Reference><Reference><Citation>Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685&#x2013;96.</Citation></Reference><Reference><Citation>Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539&#x2013;53.</Citation></Reference><Reference><Citation>Chinese Society of Neurology. Various diagnostic criteria for cerebrovascular diseases (1995). J Clin Exp Med. 2013;12:559.</Citation></Reference><Reference><Citation>Yuan M. Analysis of the clinical efficacy of Tongxinluo Capsule combined with Rosuvastatin on patients with cerebral infarction and diabetes mellitus. Jiangxi Med J. 2022;57:592&#x2013;5.</Citation></Reference><Reference><Citation>Lu Y. Observation of curative effect for type 2 diabetes with acute cerebral infarction treated by Tongxinluo capsule. J Vasc Dis Transl Res. 2014;10:520&#x2013;1.</Citation></Reference><Reference><Citation>Dong R. Observation on the efficacy of Tongxinluo Capsule in the treatment of acute cerebral infarction with type 2 diabetes mellitus. Med J Chin People&#x2019;s Health. 2015;27:74&#x2013;5.</Citation></Reference><Reference><Citation>Sun B. Experience on the efficacy of Tongxinluo Capsule in the treatment of acute cerebral infarction with type 2 diabetes mellitus. Our Health. 2019;13:140&#x2013;1.</Citation></Reference><Reference><Citation>Zhao J, Geng W, Zhai B, et al. Effects of combination of Yindan Xinnao Tong Soft Capsule and atorvastatin, Clopidogre Tablets on blood lipids, carotid artery plaque, and neurological function recovery in patients of acute cerebral infarction with type 2 diabetes. Chin Tradit Herb Drugs. 2016;47:2707&#x2013;12.</Citation></Reference><Reference><Citation>Xiao D, Hong Y. Observation on the efficacy of Yindan Xinnaotong Capsule in the treatment of brainstem infarction with type 2 diabetes mellitus. Chin J Integr Med Cardio Cerebrovasc Dis. 2012;10:1139&#x2013;40.</Citation></Reference><Reference><Citation>Wang L. Observation on the efficacy of Naoxintong in the treatment of type 2 diabetes mellitus complicated with cerebral infarction. People&#x2019;s Mil Surgeon 2010;53:845&#x2013;6.</Citation></Reference><Reference><Citation>An X, Xiao B. Effect of Tongmai Jiangtang Capsule on prognosis of convalescent patients with cerebral infarction complicated with type 2 diabetes mellitus. Med Pharm J Chin People&#x2019;s Liberation Army. 2018;30:83&#x2013;7.</Citation></Reference><Reference><Citation>Chen X. Clinical observation on the treatment of type 2 diabetes mellitus combined with cerebral infarction in the recovery period with Tongmai Jiangtang Capsule[D]. Fujian University of Traditional Chinese Medicine, 2016.</Citation></Reference><Reference><Citation>Wu M, Li F. Effects of Tongxinluo Capsule on blood lipids and inflammatory factors in Acute Cerebral Infarction Patients with type 2 diabetes mellitus Mellitus. Guiding J Tradit Chin Med Pharm. 2015;21:90&#x2013;2.</Citation></Reference><Reference><Citation>Zhong J, Liu H, Qing Y, et al. The influence of Naoxintong on hypercoagulable state in patients with type 2 diabetes mellitus and cerebral infarction. Chin Community Doctors. 2011;13:17&#x2009;+&#x2009;19.</Citation></Reference><Reference><Citation>Fu Q. Clinical effects of Naoxintong Capsule combined with Clopidogrel in the treatment of diabetes mellitus combined with cerebral infarction. Med Forum. 2017;21:3883&#x2013;4.</Citation></Reference><Reference><Citation>Chinese Cardiovascular Health and Disease report writing group. Summary of the 2021 report on cardiovascular health and diseases in China. Prev Treat Cardio Cerebralvasc Dis. 2022;22:20&#x2013;36&#x2009;+&#x2009;40.</Citation></Reference><Reference><Citation>Guasch-Ferr&#xe9; M, Satija A, Blondin SA, et al. Meta-analysis of randomized controlled trials of red meat consumption in comparison with various comparison diets on cardiovascular risk factors. J Clin Intern Med. 2019;139:1828&#x2013;45.</Citation></Reference><Reference><Citation>Kim SY, Woo HW, Lee YH, et al. Association of dietary glycaemic index, glycaemic load, and total carbohydrates with incidence of type-2 diabetes in adults aged&#x2265;40 years: the multi-rural communities cohort (MRCohort). Diabetes Res Clin Pract. 2020;160:108007.</Citation></Reference><Reference><Citation>Cheng Z, Zhou G, Gao Z. Cross-sectional survey of secondary prevention of stroke in Jiangyin area of Jiangsu Province and analysis of ischemic stroke recurrence factors. J Clin Intern Med. 2020;37:639&#x2013;41.</Citation></Reference><Reference><Citation>Li S. Treatment of elderly hyperlipidemia from the perspective of liver, spleen, and kidney. Chin J Gerontol. 2013;33:5220&#x2013;1.</Citation></Reference><Reference><Citation>Bai Y, Bai Y, Lian F, et al. Research on experience of TONG Xiao-lin in the treatment of lipid metabolism disorder in obesity induced type 2 diabetes melitus. China J Tradit Chin Med Pharm. 2017;32:1114&#x2013;6.</Citation></Reference><Reference><Citation>Zhu S, Gui J, Cao Y. Efficacy of Ginkgo Biloba Leaf Capsules combined with insulin pump in the treatment of diabetic nephropathy proteinuria and analysis of changes in inflammatory stress markers. Chin J Integr Tradit West Nephrol. 2019;20:986&#x2013;8.</Citation></Reference><Reference><Citation>Wang Y, Xun X, Guo J. Network pharmacology research of ginkgo folium intervening thromboangiitis obliterans disease by regulating TNF/NF-&#x3ba;B signaling pathway. Tradit Chin Drug Res Clin Pharm. 2022;33:1665&#x2013;72.</Citation></Reference><Reference><Citation>Wang XY, Yang Y, Liu X, et al. Pharmacological properties of tanshinones, the natural products from Salvia miltiorrhiza . Adv Pharmacol. 2020;87:43&#x2013;70.</Citation></Reference><Reference><Citation>Wu Z, Cao X, Cao D. Effects of Sanqi Danshen tablet on blood lipid levels of hyperlipidemia mice. J Sichuan Agric Univ. 2021;39:660&#x2013;5.</Citation></Reference><Reference><Citation>Li X. Clinical efficacy of Ligusticum Chuanxiong Injection in patients with ischemic stroke. Chin J Gerontol. 2018;38:3850&#x2013;1.</Citation></Reference><Reference><Citation>Su Q, Liang F, Li Y, et al. Comparison of the efficacy of 2 different regimens for patients with HAART-associated dyslipidemia. Chin Pharm. 2013;24:332&#x2013;4.</Citation></Reference><Reference><Citation>Yan Y, Guo J, Yang F, et al. Anti-oxidative effect of gynostemma and hawthorn extracts on the aging mouse model induced by D-galactose. Lab Anim Sci. 2009;26:24&#x2013;6.</Citation></Reference><Reference><Citation>Ji M, Zhu B, Wei Y, et al. Mechanism Buyang Huanwu decoction for hyperlipidemia based on network pharmacology. Mod Trad Chin Med Mater Med World Sci Technol. 2020;22:2318&#x2013;25.</Citation></Reference><Reference><Citation>Liang Z, Hong Y, Wu L. Overview of the research on centipede in Zhuang medicine. J Zhuang Yao Ethnic Med. 2018;2:13&#x2013;7.</Citation></Reference><Reference><Citation>Sun W, Xu G, Tang X, et al. Lipid-lowering effects of total ginsenosides in hyperlipidemia mice. Chin Tradit Pat Med. 2020;42:1726&#x2013;31.</Citation></Reference><Reference><Citation>Xue J, Zhang XJ, Zhang C, et al. Protectiv effect of Naoxintong against cerebral ischemia reperfusion injury in mice. J Ethnopharmacol. 2016;182:181&#x2013;9.</Citation></Reference><Reference><Citation>Liu X, Yang M, Song J. Protective effects of Naoxintong capsule on brain cell injury in rats with ketamine addiction. Lab Anim Comp Med. 2019;39:437&#x2013;42.</Citation></Reference><Reference><Citation>Li J, Xu X, Zhang Q, et al. Compatibility of Salviae Miltiorrhizae Radix et Rhizoma and Carthami Flos regulate insulin signaling pathway and alleviate insulin resistance in mice. Acta Pharm Sinica. 2021;56:1049&#x2013;56.</Citation></Reference><Reference><Citation>Ma Y, Duan Y, Hu J, et al. Research progress of Astragalus membrancaceus in treating DM and its complications. Acta Chin Med Pharm. 2022;50:103&#x2013;7.</Citation></Reference><Reference><Citation>Gao Z, Wang L. Protective effects of Tongxinluo capsule on cerebral ischemia-reperfusion injury and its mechanism of action. Chin J Exp Tradit Med Formulae. 2020;26:93&#x2013;9.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758855</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1536-5964</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>103</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.</ArticleTitle><Pagination><StartPage>e38018</StartPage><MedlinePgn>e38018</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1097/MD.0000000000038018</ELocationID><Abstract><AbstractText>Incretin-based drugs, a class of Antidiabetic medications (ADMs) used in the treatment of type 2 diabetes, may affect the incidence of prostate cancer (PCa). But real-world evidence for this possible effect is lacking. Therefore, the aim of this study is to assess the effect of incretin-based drugs on the incidence of PCa, including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. We searched PubMed, Embase, and Cochrane Library databases for eligible studies through September 2023. Two independent reviewers performed screening and data extraction. We used the Cochrane Handbook for Systematic Reviews and the Newcastle-Ottawa Scale (NOS) to assess the quality of included randomized controlled trials (RCTs) and cohort studies. We did a meta-analysis of available trial data to calculate overall risk ratios (RRs) for PCa. A total of 1238 articles were identified in our search. After screening for eligibility, 7 high-quality studies met the criteria for meta-analysis, including 2 RCTs and 5 cohort studies, with a total of 1165,738 patients. Compared with the control group, we found that incretin-based drugs reduced the relative risk of PCa by 35% (95% confidence interval (CI), 0.17-0.49; P&#x2005;=&#x2005;.0006). In subgroup analysis, the RR values for GLP-1 receptor agonists and DPP-4 inhibitors were 62% (95% CI, 0.45-0.85; P&#x2005;=&#x2005;.003) and 72% (95% CI, 0.46-1.12; P&#x2005;=&#x2005;.14), respectively. Incretin-based drugs are associated with lower incidence of prostate cancer and may have a preventive effect on prostate cancer in patients with type 2 diabetes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Lin</LastName><ForeName>Yuxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xu</LastName><ForeName>Guangyong</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Li</LastName><ForeName>Liangyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xiang</LastName><ForeName>Jingyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhai</LastName><ForeName>Lingyun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D017418\">Meta-Analysis</PublicationType><PublicationType UI=\"D000078182\">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011471\" MajorTopicYN=\"Y\">Prostatic Neoplasms</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D003924\" MajorTopicYN=\"Y\">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000150\" MajorTopicYN=\"N\">complications</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D015994\" MajorTopicYN=\"N\">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D054795\" MajorTopicYN=\"Y\">Incretins</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D007004\" MajorTopicYN=\"Y\">Hypoglycemic Agents</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D054873\" MajorTopicYN=\"N\">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>14</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758855</ArticleId><ArticleId IdType=\"doi\">10.1097/MD.0000000000038018</ArticleId><ArticleId IdType=\"pii\">00005792-202405170-00018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen Y, Mushashi F, Son S, et al. Diabetes medications and cancer risk associations: a systematic review and meta-analysis of evidence over the past 10 years. Sci Rep. 2023;13:11844.</Citation></Reference><Reference><Citation>Arvind A, Memel ZN, Philpotts LL, et al. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: a meta-analysis. Metabolism. 2021;120:154780.</Citation></Reference><Reference><Citation>Liu Y, Jin PP, Sun XC, et al. Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis. Saudi J Gastroenterol. 2018;24:75&#x2013;81.</Citation></Reference><Reference><Citation>Orchard SG, Lockery JE, Broder JC, et al. Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes. JNCI Cancer Spectr. 2023;7:pkad017.</Citation></Reference><Reference><Citation>Hu J, Fan HD, Gong JP, et al. The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis. BMC Gastroenterol. 2023;23:50.</Citation></Reference><Reference><Citation>Wang Z, Luo J, Zhang Y, et al. Metformin and thyroid carcinoma incidence and prognosis: a systematic review and meta-analysis. PLoS One. 2022;17:e0271038.</Citation></Reference><Reference><Citation>Tian J, Liang Y, Qu P. Antidiabetic medications and the risk of endometrial cancer in patients. Gynecol Obstet Invest. 2019;84:455&#x2013;62.</Citation></Reference><Reference><Citation>Tsch&#xf6;p M, Nogueiras R, Ahr&#xe9;n B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023;66:1796&#x2013;808.</Citation></Reference><Reference><Citation>Saini K, Sharma S, Khan Y. DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Front Mol Biosci. 2023;10:1130625.</Citation></Reference><Reference><Citation>Cui H, Wang Y, Yang S, et al. Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Pharmacol Res. 2022;177:106094.</Citation></Reference><Reference><Citation>Nomiyama T, Kawanami T, Irie S, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014;63:3891&#x2013;905.</Citation></Reference><Reference><Citation>Deacon CF. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes Obes Metab. 2018;20:34&#x2013;46.</Citation></Reference><Reference><Citation>Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res. 2005;65:1325&#x2013;34.</Citation></Reference><Reference><Citation>Nauck MA, Jensen TJ, Rosenkilde C, et al. Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial. Diabetes Care. 2018;41:1663&#x2013;71.</Citation></Reference><Reference><Citation>Leiter LA, Teoh H, Mosenzon O, et al. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Diabetes Obes Metab. 2016;18:186&#x2013;90.</Citation></Reference><Reference><Citation>Tseng CH. Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes. Oncotarget. 2017;8:19057&#x2013;64.</Citation></Reference><Reference><Citation>Rokszin G, Kiss Z, S&#xfc;t&#x151; G, et al. Sodium-glucose co-transporter 2 inhibitors may change the development of urinary tract and hematological malignancies as compared with dipeptidyl peptidase-4 inhibitors: data of the post-hoc analysis of a nationwide study. Front Oncol. 2021;11:725465.</Citation></Reference><Reference><Citation>Lu S, Yin H, Yu OHY, et al. Incretin-based drugs and the incidence of prostate cancer among patients with type 2 diabetes. Epidemiology. 2022;33:563&#x2013;71.</Citation></Reference><Reference><Citation>Wang J, Kim CH. Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases. Endocr Res. 2022;47:18&#x2013;25.</Citation></Reference><Reference><Citation>Skriver C, Friis S, Knudsen LB, et al. Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study. Diabetologia. 2023;66:2007&#x2013;16.</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603&#x2013;5.</Citation></Reference><Reference><Citation>Wells GA, Wells G, Shea B, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014.</Citation></Reference><Reference><Citation>Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.</Citation></Reference><Reference><Citation>Cumpston MS, McKenzie JE, Welch VA, et al. Strengthening systematic reviews in public health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions, 2nd edition. J Public Health (Oxf). 2022;44:e588&#x2013;92.</Citation></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539&#x2013;58.</Citation></Reference><Reference><Citation>Bowden J, Tierney JF, Copas AJ, et al. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.</Citation></Reference><Reference><Citation>Chen B, Benedetti A. Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Syst Rev. 2017;6:243.</Citation></Reference><Reference><Citation>Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14:951&#x2013;7.</Citation></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629&#x2013;34.</Citation></Reference><Reference><Citation>Li XN, Bu HM, Ma XH, et al. Glucagon-like peptide-1 analogues inhibit proliferation and increase apoptosis of human prostate cancer cells in vitro. Exp Clin Endocrinol Diabetes. 2017;125:91&#x2013;7.</Citation></Reference><Reference><Citation>Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473&#x2013;86.</Citation></Reference><Reference><Citation>Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61:1250&#x2013;62.</Citation></Reference><Reference><Citation>Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. Endocrine. 2020;68:518&#x2013;25.</Citation></Reference><Reference><Citation>Hu W, Song R, Cheng R, et al. Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:927859.</Citation></Reference><Reference><Citation>Liu Y, Zhang X, Chai S, et al. Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: a meta-analysis. J Diabetes Res. 2019;2019:1534365.</Citation></Reference><Reference><Citation>Piccoli GF, Mesquita LA, Stein C, et al. Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis. J Clin Endocrinol Metab. 2021;106:912&#x2013;21.</Citation></Reference><Reference><Citation>Zhang X, Wang M, Wang X, et al. Comparison of new glucose-lowering drugs on the risk of pancreatitis in type 2 diabetes: a network meta-analysis. Endocr Pract. 2022;28:333&#x2013;41.</Citation></Reference><Reference><Citation>Yang D, Yang B, Zhu Y, et al. Circular RNA-DPP4 serves an oncogenic role in prostate cancer progression through regulating miR-195/cyclin D1 axis. Cancer Cell Int. 2021;21:379.</Citation></Reference><Reference><Citation>Dicembrini I, Nreu B, Montereggi C, et al. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta Diabetol. 2020;57:689&#x2013;96.</Citation></Reference><Reference><Citation>Overbeek JA, Bakker M, van der Heijden A, et al. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2018;34:e3004.</Citation></Reference><Reference><Citation>Pinto LC, Rados DV, Barkan SS, et al. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep. 2018;8:782.</Citation></Reference><Reference><Citation>Benedetti R, Benincasa G, Glass K, et al. Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res. 2022;175:106039.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758848</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1536-5964</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>103</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Limb salvage and systemic management of gouty tophi: Case series.</ArticleTitle><Pagination><StartPage>e38137</StartPage><MedlinePgn>e38137</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1097/MD.0000000000038137</ELocationID><Abstract><AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Gout is a chronic disease characterized by deposition of monosodium urate crystals. Tophi develop in some individuals with untreated or uncontrolled gout, which leads to ulcerations, cosmetic problems, mechanical obstruction of joint movement, joint damage and musculoskeletal disability. Currently, the treatment of gouty tophi is controversial and challenging. Both surgical and internal medical treatments have limitations and require further exploration in clinical practice.</AbstractText><AbstractText Label=\"PATIENT CONCERNS\" NlmCategory=\"METHODS\">In Case 1, we treated a patient with severe infection of diabetic foot ulcers with concomitant multiple gouty tophi in the same limb. A systematic management strategy was formulated to close the wound and save the limb. The ulcers healed successfully after half a year. In Case 2, a giant gouty tophi located in the first metatarsophalangeal joint of the left foot was removed by surgical treatment and vancomycin-loaded bone cement implantation. In Case 3, we present a case of gouty tophi that was resolved by standardized systemic medical management.</AbstractText><AbstractText Label=\"DIAGNOSIS\" NlmCategory=\"METHODS\">Three patients were all diagnosed with gout accompanied by gouty deposition, although there were other different comorbidities.</AbstractText><AbstractText Label=\"INTERVENTIONS\" NlmCategory=\"METHODS\">In case 1, we used debridement to gradually remove gouty tophi. In case 2, the giant gouty tophi was removed by surgical operation. In case 3, the gouty tophi disappeared after standardized treatment with medicine, diet and lifestyle management.</AbstractText><AbstractText Label=\"OUTCOMES\" NlmCategory=\"RESULTS\">Three patients underwent different treatment therapies to remove gouty tophi based on their specific conditions.</AbstractText><AbstractText Label=\"LESSONS\" NlmCategory=\"CONCLUSIONS\">We explored effective interventions for tophi in gout by surgical or other interventions in combination with pharmacotherapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Jiang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><Identifier Source=\"ORCID\">0000-0002-1968-6810</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Diabetic Foot Center, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Li</LastName><ForeName>Anxin</ForeName><Initials>A</Initials></Author><Author ValidYN=\"Y\"><LastName>Hao</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Cheng</ForeName><Initials>C</Initials></Author><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Hongyan</ForeName><Initials>H</Initials></Author><Author ValidYN=\"Y\"><LastName>Deng</LastName><ForeName>Wuquan</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D002363\">Case Reports</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006073\" MajorTopicYN=\"Y\">Gout</DescriptorName><QualifierName UI=\"Q000150\" MajorTopicYN=\"N\">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D023821\" MajorTopicYN=\"Y\">Limb Salvage</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D003646\" MajorTopicYN=\"N\">Debridement</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008683\" MajorTopicYN=\"N\">Metatarsophalangeal Joint</DescriptorName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000900\" MajorTopicYN=\"N\">Anti-Bacterial Agents</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D014640\" MajorTopicYN=\"N\">Vancomycin</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName><QualifierName UI=\"Q000008\" MajorTopicYN=\"N\">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D017719\" MajorTopicYN=\"N\">Diabetic Foot</DescriptorName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>14</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758848</ArticleId><ArticleId IdType=\"doi\">10.1097/MD.0000000000038137</ArticleId><ArticleId IdType=\"pii\">00005792-202405170-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3:443&#x2013;9.</Citation></Reference><Reference><Citation>Wu Z, Liu C, Dai K, et al. Intraspinal extradural gout tophus in the lumbar vertebral canal: case reports. Medicine (Baltimore). 2022;101:e28418.</Citation></Reference><Reference><Citation>Sriranganathan MK, Vinik O, Falzon L, et al. Interventions for tophi in gout: a Cochrane systematic literature review. J Rheumatol Suppl. 2014;92:63&#x2013;9.</Citation></Reference><Reference><Citation>Everett E, Mathioudakis N. Update on management of diabetic foot ulcers. Ann N Y Acad Sci. 2018;1411:153&#x2013;65.</Citation></Reference><Reference><Citation>Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29&#x2013;42.</Citation></Reference><Reference><Citation>Dalbeth N, Petrie K, House M, et al. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res. 2011;63:1605&#x2013;12.</Citation></Reference><Reference><Citation>Kasper IR, Juriga MD, Giurini JM, et al. Treatment of tophaceous gout: when medication is not enough. Semin Arthritis Rheum. 2016;45:669&#x2013;74.</Citation></Reference><Reference><Citation>Carcione J, Bodofsky S, LaMoreaux B, et al. Beyond medical treatment: surgical treatment of gout. Curr Rheumatol Rep. 2020;23:1.</Citation></Reference><Reference><Citation>Khanna PP, Nuki G, Bardin T, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from across&#x2013;sectional survey. Health Qual Life Outcomes. 2012;10:117.</Citation></Reference><Reference><Citation>Zhengping H, Xiuqi L, Yuqi L, et al. Clinical characteristics and risk factors of ulceration over tophi in patients with gout. Int J Rheum Dis. 2019;22:1052&#x2013;7.</Citation></Reference><Reference><Citation>Fang ZH, Waizy H. Current concepts in the treatment of gouty arthritis. Orthop Surg. 2013;5:6&#x2013;12.</Citation></Reference><Reference><Citation>Jiang X, Li N, Yuan Y, et al. Limb salavge and prevention of ulcer recurrence in a chronic refractory diabetic foot osteomuelitis. Diabetes Metab Syndr Obes. 2020;13:2289&#x2013;96.</Citation></Reference><Reference><Citation>British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for rheumatology guideline for the management of gout. Rheumatology (Oxford). 2017;56:1056&#x2013;9.</Citation></Reference><Reference><Citation>Kiltz U, Smolen J, Bardin T, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76:632&#x2013;8.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758847</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1536-5964</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>103</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Evaluation of adverse reactions induced by anti-tuberculosis drugs among hospitalized patients in Wuhan, China: A retrospective study.</ArticleTitle><Pagination><StartPage>e38273</StartPage><MedlinePgn>e38273</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1097/MD.0000000000038273</ELocationID><Abstract><AbstractText>The study aims to estimate the incidence and risk factors of adverse drug reactions (ADRs) induced by anti-tuberculosis (TB) drugs. A single center retrospective analysis of patients taking anti-TB therapy from January 2016 to December 2018 in the hospital was conducted. Univariate and multivariate logistic regression analysis were used to identify these risk factors of ADRs induced by anti-TB drugs. Among 1430 patients receiving anti-TB therapy, 440 (30.77%) patients showed at least 1 ADR induced by anti-TB drugs. Hyperuricemia was the most common ADR, followed by hepatic function test abnormality, liver damage and gastrointestinal reactions. Significant differences (P&#x2005;&lt;&#x2005;.05) were also seen in diabetes, age, treatment duration, type of TB (extrapulmonary) and some therapeutic regimens between ADR group and non-ADR group, respectively. Multivariate logistic regression analysis showed that treatment duration (OR&#x2005;=&#x2005;1.029, 95%CI[1.018-1.040], P&#x2005;=&#x2005;.000), type of TB (extrapulmonary, OR&#x2005;=&#x2005;1.487, 95%CI[1.134-1.952], P&#x2005;=&#x2005;.004) and some therapeutic regimens (HREZ, OR&#x2005;=&#x2005;1.425, 95%CI[0.922-2.903], P&#x2005;=&#x2005;.001; HRZS, OR&#x2005;=&#x2005;2.063, 95% CI[1.234-3.449], P&#x2005;=&#x2005;.006; HRZ, OR&#x2005;=&#x2005;3.623, 95%CI[2.289-5.736], P&#x2005;=&#x2005;.000) were risk factors for ADRs induced by anti-TB drugs. Anti-TB drugs usually induced the occurrence of severe and frequent adverse effects, such as hyperuricemia. Treatment duration, HREZ, HRZS and HRZ regimens, and type of TB (extrapulmonary) should be considered as high-risk factors. Thus, it should be recommended to consider optimum management during anti-TB therapy, particularly hyperuricemia monitoring and hepatic function test.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Shi</LastName><ForeName>Cai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Boning</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Jingxiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Song</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chen</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhang</LastName><ForeName>Shuxiao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhan</LastName><ForeName>Hanyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xiong</LastName><ForeName>Yuanguo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rong</LastName><ForeName>Peipei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Luo</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0001-9734-8588</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D064888\">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000995\" MajorTopicYN=\"Y\">Antitubercular Agents</DescriptorName><QualifierName UI=\"Q000009\" MajorTopicYN=\"N\">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002681\" MajorTopicYN=\"N\" Type=\"Geographic\">China</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012307\" MajorTopicYN=\"N\">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D015994\" MajorTopicYN=\"N\">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D033461\" MajorTopicYN=\"N\">Hyperuricemia</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D014376\" MajorTopicYN=\"N\">Tuberculosis</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D006760\" MajorTopicYN=\"N\">Hospitalization</DescriptorName><QualifierName UI=\"Q000706\" MajorTopicYN=\"N\">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D064420\" MajorTopicYN=\"N\">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName><QualifierName UI=\"Q000209\" MajorTopicYN=\"N\">etiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>14</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758847</ArticleId><ArticleId IdType=\"doi\">10.1097/MD.0000000000038273</ArticleId><ArticleId IdType=\"pii\">00005792-202405170-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Global Tuberculosis Report, 2018; 2018.</Citation></Reference><Reference><Citation>World Health Organization. Global Tuberculosis Report, 2020; 2020.</Citation></Reference><Reference><Citation>Choi H. Nosocomial exposure to tuberculosis: a snapshot of South Korea. Korean J Intern Med. 2021;36:1061&#x2013;2.</Citation></Reference><Reference><Citation>Xia YY, Hu DY, Liu FY, et al. Design of the antituberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). BMC Public Health. 2010;10:267.</Citation></Reference><Reference><Citation>China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet. 2004;364:417&#x2013;22.</Citation></Reference><Reference><Citation>World Health Organization. An expanded DOTS framework for effective tuberculosis control. Stop TB Communicable Diseases. Geneva: WHO Press. 2002:1&#x2013;20p.</Citation></Reference><Reference><Citation>Burman WJ, Reves RR. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers. Am J Respir Crit Care Med. 2001;164:1112&#x2013;3.</Citation></Reference><Reference><Citation>Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472&#x2013;7.</Citation></Reference><Reference><Citation>Lv X, Tang S, Xia Y, et al. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study. PLoS One. 2013;8:e65037.</Citation></Reference><Reference><Citation>Singh A, Prasad R, Balasubramanian V, et al. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. Clin Epidemiol Global Health. 2015;3:S80&#x2013;90.</Citation></Reference><Reference><Citation>Chen Y, Shi C, Zhan H, et al. Drug-induced liver injury in COVID-19 patients during hospitalization. Medicine (Baltim). 2023;102:e33294.</Citation></Reference><Reference><Citation>Xia YY, Zhan SY. Systematic review of anti-tuberculosis drug induced adverse reactions in China. Chin J Tuberc Respir Dis. 2007;30:419&#x2013;23.</Citation></Reference><Reference><Citation>Zhang T, Du J, Yin X, et al. Adverse events in treating smear-positive tuberculosis patients in China. Int J Environ Res Public Health. 2015;13:86.</Citation></Reference><Reference><Citation>Sankar KNH, Roch K, Jom D, et al. Adverse drug reaction profile of daily regimen antituberculosis treatment. Perspect Clin Res. 2022;13:194&#x2013;8.</Citation></Reference><Reference><Citation>Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc. 2019;66:520&#x2013;32.</Citation></Reference><Reference><Citation>Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5:231&#x2013;49.</Citation></Reference><Reference><Citation>BRASIL. Manual de Recomendac&#xf5;es parao Controle da Tuberculose no Brasil. 2019;366.</Citation></Reference><Reference><Citation>Horsburgh CR, Barry CE, Lange C. Treatment of tuberculosis. N Engl J Med. 2015;373:2149&#x2013;60.</Citation></Reference><Reference><Citation>Choi H, Park HA, Hyun IG, et al. Incidence and outcomes of adverse drug reactions to first-line anti-tuberculosis drugs and their effects on the quality of life: a multicenter prospective cohort study. Pharmacoepidemiol Drug Saf. 2022;31:1153&#x2013;63.</Citation></Reference><Reference><Citation>Angamo MT, Curtain CM, Chalmers L, et al. Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: a prospective cross-sectional study. PLoS One. 2017;12:e0186631.</Citation></Reference><Reference><Citation>Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026&#x2013;30.</Citation></Reference><Reference><Citation>Marra F, Marra CA, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis. 2007;11:868&#x2013;75.</Citation></Reference><Reference><Citation>Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, et al. Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru. PLoS One. 2011;6:e27610.</Citation></Reference><Reference><Citation>Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006;11:699&#x2013;707.</Citation></Reference><Reference><Citation>Fei CM, Zainal H, Ali IAH. Evaluation of adverse reactions induced by anti-tuberculosis drugs in Hospital Pulau Pinang. Malays J Med Sci. 2018;25:103&#x2013;14.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758689</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1930-8264</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>114</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Journal of the American Podiatric Medical Association</Title><ISOAbbreviation>J Am Podiatr Med Assoc</ISOAbbreviation></Journal><ArticleTitle>A Comparison of Adverse Short-Term Outcomes After Forefoot Amputation Based on Patient Height.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">21-257</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.7547/21-257</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">The objective of this investigation was to evaluate adverse short-term outcomes after partial forefoot amputation with a specific comparison performed based on patient height.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">The American College of Surgeons National Surgical Quality Improvement Program database was analyzed to select patients with a 28805 Current Procedural Terminology code (amputation, foot; transmetatarsal) who underwent the procedure with \"all layers of incision (deep and superficial) fully closed.\" This resulted in 11 patients with a height of 60 inches or less, 202 with a height greater than 60 inches and less than 72 inches, and 55 with a height of 72 inches or greater.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Results of the primary outcome measures found no significant differences among groups with respect to the development of a superficial surgical site infection (0% versus 6.4% versus 5.5%; P = .669), deep incisional infection (9.1% versus 3.5% versus 10.9%; P = .076), or wound disruption (0% versus 5.4% versus 5.5%; P = .730). In addition, no significant differences were observed among groups with respect to unplanned reoperations (9.1% versus 16.8% versus 12.7%; P = .630) or unplanned hospital readmissions (45.5% versus 23.3% versus 20.0%; P = .190).</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">The results of this investigation demonstrate no differences in short-term adverse outcomes after partial forefoot amputation with primary closure based on patient height. Although height has previously been described as a potential risk factor in the development of lower-extremity pathogenesis, this finding was not observed in this study from a large US database.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Kaur</LastName><ForeName>Kushkaran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>*Department of Podiatric Surgery, Temple University School of Podiatric Medicine, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cornell</LastName><ForeName>Rhonda S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>&#x2020;Delaware County Memorial Hospital Center for Wound Healing, Havertown, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Meyr</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>*Department of Podiatric Surgery, Temple University School of Podiatric Medicine, Philadelphia, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D003160\">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Podiatr Med Assoc</MedlineTA><NlmUniqueID>8501423</NlmUniqueID><ISSNLinking>1930-8264</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000671\" MajorTopicYN=\"Y\">Amputation, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005545\" MajorTopicYN=\"Y\">Forefoot, Human</DescriptorName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D001827\" MajorTopicYN=\"Y\">Body Height</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011183\" MajorTopicYN=\"N\">Postoperative Complications</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D017719\" MajorTopicYN=\"N\">Diabetic Foot</DescriptorName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012086\" MajorTopicYN=\"N\">Reoperation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758689</ArticleId><ArticleId IdType=\"doi\">10.7547/21-257</ArticleId><ArticleId IdType=\"pii\">21-257</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758687</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1930-8264</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>114</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Journal of the American Podiatric Medical Association</Title><ISOAbbreviation>J Am Podiatr Med Assoc</ISOAbbreviation></Journal><ArticleTitle>Association of Preulcerative Foot Care and Outcomes of Diabetic Foot Ulceration.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">22-071</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.7547/22-071</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">The purpose of this study was to determine the association of preulcerative foot care and outcomes of diabetic foot ulcerations (DFUs).</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">This retrospective cohort study using the Mariner all-payers claims data set included participants with a new DFU from 2010 to 2019. Patients were stratified into two cohorts (foot care and control) based on whether they had received any outpatient foot care within 12 months before DFU. Adjusted comparison was performed by propensity matching for age, sex, and the Charlson Comorbidity Index (1:2 ratio). Kaplan-Meier estimates and logistic regression examined the association between foot care and outcomes of DFUs.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Of the 307,131 patients in the study cohort, 4.7% (n = 14,477) received outpatient preulcerative foot care within the 12-month period before DFU. The rate of major amputation was 1.8% (foot care, 1.2%), and 9.0% of patients had hospitalizations for foot infection within 12 months after DFU (foot care, 7.8%). In the study cohort, patients who received pre-DFU foot care had greater major amputation-free survival (P &lt; .001) on Kaplan-Meier estimate. In both the study and matched cohorts, multivariable analysis demonstrated that foot care was associated with lower odds of major amputation for both study (odds ratio [OR], 0.56; 95% confidence interval [CI], 0.48-0.66) and matched (OR, 0.61; 95% CI, 0.51-0.72) cohorts, and lower odds of hospitalizations for a foot infection in both study (OR, 0.91; 95% CI, 0.86-0.96) and matched (OR, 0.88, 95% CI, 0.82-0.94) cohorts.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Among patients with a new DFU, those who received outpatient preulcerative foot care within 12 months of diagnosis had lower risks of major amputation and hospitalizations for foot infection.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Tan</LastName><ForeName>Tze-Woei</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>*University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tolson</LastName><ForeName>Jeffrey P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>&#x2020;University of Arizona, Tucson, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Aristizabal</LastName><ForeName>Juan C Arias</ForeName><Initials>JCA</Initials><AffiliationInfo><Affiliation>&#x2020;University of Arizona, Tucson, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Urbina</LastName><ForeName>Diego J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>&#x2020;University of Arizona, Tucson, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fermawi</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>&#x2020;University of Arizona, Tucson, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Weinkauf</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>&#x2020;University of Arizona, Tucson, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Marrero</LastName><ForeName>David G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>&#x2020;University of Arizona, Tucson, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Armstrong</LastName><ForeName>David G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>&#x2020;University of Arizona, Tucson, AZ.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Podiatr Med Assoc</MedlineTA><NlmUniqueID>8501423</NlmUniqueID><ISSNLinking>1930-8264</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D017719\" MajorTopicYN=\"Y\">Diabetic Foot</DescriptorName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000671\" MajorTopicYN=\"Y\">Amputation, Surgical</DescriptorName><QualifierName UI=\"Q000706\" MajorTopicYN=\"N\">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000553\" MajorTopicYN=\"N\">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D053208\" MajorTopicYN=\"N\">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D016896\" MajorTopicYN=\"N\">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006760\" MajorTopicYN=\"N\">Hospitalization</DescriptorName><QualifierName UI=\"Q000706\" MajorTopicYN=\"N\">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758687</ArticleId><ArticleId IdType=\"doi\">10.7547/22-071</ArticleId><ArticleId IdType=\"pii\">22-071</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758679</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1930-8264</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>114</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Journal of the American Podiatric Medical Association</Title><ISOAbbreviation>J Am Podiatr Med Assoc</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of Peripheral Nerve Block in Terms of Search for a Standardized Treatment Protocol in Diabetic Foot Patients Using Anticoagulants: A Double-Center Study.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">21-115</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.7547/21-115</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Lower-extremity amputation for a diabetic foot is mainly performed under general or central neuraxial anesthesia. Ultrasound-guided peripheral nerve block (PNB) can be a good alternative, especially for patients who require continuous anticoagulation treatment and patients with additional comorbidities. We evaluated bleeding due to PNB application in patients with diabetic foot receiving antiplatelet or anticoagulant therapy. Perioperative morbidity and mortality and the need for intensive care hospitalization were analyzed.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">This study included 105 patients with diabetic foot or debridement who underwent distal foot amputation or debridement between February and October 2020. Popliteal nerve block (17 mL of 5% bupivacaine and 3 mL of saline) and saphenous nerve block (5 mL of 2% lidocaine) were applied to the patients. Postoperative pain scores (at 4, 8, 12, and 24 hours) and complications due to PNB were evaluated. Intensive care admission and 1-month mortality were recorded.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The most common diseases accompanying diabetes were hypertension and peripheral artery disease. No complications due to PNB were observed. Mean &#xb1; SD postoperative first analgesic need was determined to be 14.1 &#xb1; 4.1 hours. Except for one patient, this group was followed up without the need for postoperative intensive care. In 16 patients, bleeding occurred as leakage from the surgical area, and it was stopped with repeated pressure dressing. Mean &#xb1; SD patient satisfaction score was 8.36 &#xb1; 1.59. Perioperative mortality was not observed.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Ultrasound-guided PNB can be an effective and safe anesthetic technique for diabetic patients undergoing distal foot amputation, especially those receiving antiplatelet or anticoagulant therapy and considered high risk.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Ozkan</LastName><ForeName>Derya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>*Department of Anaesthesiology and Reanimation, Diskapi Research and Training Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Arslan</LastName><ForeName>M Tugba</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>*Department of Anaesthesiology and Reanimation, Diskapi Research and Training Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Eskin</LastName><ForeName>Mehmet Burak</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>&#x2020;Department of Anaesthesiology and Reanimation, Gulhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sipahioglu</LastName><ForeName>Fatma Ozkan</ForeName><Initials>FO</Initials><AffiliationInfo><Affiliation>*Department of Anaesthesiology and Reanimation, Diskapi Research and Training Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ermis</LastName><ForeName>Yasemin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>*Department of Anaesthesiology and Reanimation, Diskapi Research and Training Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ozkan</LastName><ForeName>Gokhan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>&#x2020;Department of Anaesthesiology and Reanimation, Gulhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yilmaz</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>&#x2021;Department of General Surgery, Diskapi Research and Training Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nalbant</LastName><ForeName>Burak</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>*Department of Anaesthesiology and Reanimation, Diskapi Research and Training Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yuksel</LastName><ForeName>Sinan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>&#xa7;Department of Orthopedics and Traumatology, Diskapi Research and Training Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yilmaz</LastName><ForeName>Kerim Bora</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>&#x2016;Department of General Surgery, Diabetic Foot Clinic, Gulhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016448\">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Podiatr Med Assoc</MedlineTA><NlmUniqueID>8501423</NlmUniqueID><ISSNLinking>1930-8264</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D009407\" MajorTopicYN=\"Y\">Nerve Block</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000925\" MajorTopicYN=\"Y\">Anticoagulants</DescriptorName><QualifierName UI=\"Q000008\" MajorTopicYN=\"N\">administration &amp; dosage</QualifierName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D017719\" MajorTopicYN=\"Y\">Diabetic Foot</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000671\" MajorTopicYN=\"Y\">Amputation, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D010149\" MajorTopicYN=\"N\">Pain, Postoperative</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D018084\" MajorTopicYN=\"N\">Ultrasonography, Interventional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D003646\" MajorTopicYN=\"N\">Debridement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D016896\" MajorTopicYN=\"N\">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758679</ArticleId><ArticleId IdType=\"doi\">10.7547/21-115</ArticleId><ArticleId IdType=\"pii\">21-115</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758678</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1930-8264</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>114</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Journal of the American Podiatric Medical Association</Title><ISOAbbreviation>J Am Podiatr Med Assoc</ISOAbbreviation></Journal><ArticleTitle>Postoperative Opioid-Prescribing Practice in Limb Preservation Surgery.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">21-256</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.7547/21-256</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Limb preservation surgery affects more than 100,000 Americans annually. Current postoperative pain management prescribing practices of podiatric physicians in the United States are understudied. We examined prescribing practices for limb preservation surgery to identify prescriber characteristics' that may be associated with postoperative opioid-prescribing practices.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">We administered an anonymous online questionnaire consisting of five patient scenarios with limb preservation surgery commonly performed by podiatric physicians. Respondents provided information about their prescription choice for each surgery. Basic provider demographics were collected. We developed linear regression models to identify the strength and direction of association between prescriber characteristics and quantity of postoperative opioid \"pills\" (dosage units) prescribed at surgery. Logistic regression models were used to identify the odds of prescribing opioids for each scenario.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">One hundred fifteen podiatric physicians completed the survey. Podiatric physicians reported using regional nerve blocks 70% to 88% of the time and prescribing opioids 43% to 67% of the time across all scenarios. Opioids were more commonly prescribed than nonsteroidal anti-inflammatory drugs and anticonvulsants. Practicing in the Northeast United States was a significant variable in linear regression (P = .009, a decrease of 9-10 dosage units) and logistic regression (odds ratio, 0.23; 95% confidence interval, 0.07-0.68; P = .008) models for the transmetatarsal amputation scenario.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Prescribing practice variation exists in limb preservation surgery by region. Podiatric physicians reported using preoperative regional nerve blocks more than prescribing postoperative opioids for limb preservation surgeries. Through excess opioid prescribing, the diabetes pandemic has likely contributed to the US opioid epidemic. Podiatric physicians stand at the intersection of these two public health crises and are equipped to reduce their impact via preventive foot care and prescribing nonopioid analgesics when warranted.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Brooks</LastName><ForeName>Brandon M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>*The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>&#x2020;Columbia VA Health Care System, Columbia, SC.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shih</LastName><ForeName>Chia-Ding</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>&#x2021;California School of Podiatric Medicine at Samuel Merritt University, Oakland, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bratches</LastName><ForeName>Reed W R</ForeName><Initials>RWR</Initials><AffiliationInfo><Affiliation>*The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pham</LastName><ForeName>Kevin T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>&#xa7;Community Health Alliance of Pasadena, Pasadena, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Brooks</LastName><ForeName>Bradley M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>&#xb6;USA Health, Mobile, AL.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hooshivar</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>&#x2021;California School of Podiatric Medicine at Samuel Merritt University, Oakland, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wolff</LastName><ForeName>Kristina B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>*The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Podiatr Med Assoc</MedlineTA><NlmUniqueID>8501423</NlmUniqueID><ISSNLinking>1930-8264</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000701\" MajorTopicYN=\"Y\">Analgesics, Opioid</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D010149\" MajorTopicYN=\"Y\">Pain, Postoperative</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D010818\" MajorTopicYN=\"Y\">Practice Patterns, Physicians'</DescriptorName><QualifierName UI=\"Q000706\" MajorTopicYN=\"N\">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011795\" MajorTopicYN=\"N\">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D014481\" MajorTopicYN=\"N\" Type=\"Geographic\">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011032\" MajorTopicYN=\"N\">Podiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D059408\" MajorTopicYN=\"N\">Pain Management</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011307\" MajorTopicYN=\"N\">Drug Prescriptions</DescriptorName><QualifierName UI=\"Q000706\" MajorTopicYN=\"N\">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D059351\" MajorTopicYN=\"N\">Organ Sparing Treatments</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758678</ArticleId><ArticleId IdType=\"doi\">10.7547/21-256</ArticleId><ArticleId IdType=\"pii\">21-256</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758675</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1930-8264</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>114</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Journal of the American Podiatric Medical Association</Title><ISOAbbreviation>J Am Podiatr Med Assoc</ISOAbbreviation></Journal><ArticleTitle>Rate and Location of Reulceration and Reamputation After Partial First-Ray Amputation versus Hallux Amputation in Diabetic and Nondiabetic Populations.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">22-029</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.7547/22-029</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">We sought to determine the rates of reulceration and reamputation in individuals who underwent partial first-ray amputations versus hallux amputations in diabetic and nondiabetic populations.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">Eighty-four amputations were reviewed in a retrospective fashion. A retrospective medical record review was performed to determine patients who underwent a hallux amputation, both partial and complete, and patients who underwent a partial first-ray amputation. Only patients from 2007 to 2019 were reviewed. The reulceration rate of hallux amputations was 61% compared with a partial first-ray amputation reulceration rate of 74%.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The reamputation rate of hallux amputation versus partial first-ray amputation was 43% versus 51%. At final follow-up, it was statistically significant that patients who underwent hallux amputation were more likely to be healed than those who underwent partial first-ray amputation, regardless of reulceration or reamputation. In addition, patients who underwent hallux amputation went on to digital amputation, and those who underwent partial first-ray amputation went on to transmetatarsal amputation.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Comparing partial first-ray amputation to hallux amputation, hallux amputation patients are more prone to subsequent digital ulceration. Patients who initially undergo hallux amputation have variable subsequent amputations, often digital. Reulceration primarily occurs at the incision site for partial first-ray amputations, with a higher likelihood of subsequent transmetatarsal amputation. Patients with a medical history of diabetes and staged procedures are more likely to receive partial first-ray amputations. However, hallux amputation patients have a lower risk of reulceration and reamputation, regardless of subsequent events. These findings underscore the importance of discussing risks and preventive measures with patients undergoing such amputations, emphasizing postoperative examinations for specific areas of concern. Hallux amputation appears to offer greater protection against reulceration and reamputation for both diabetic and nondiabetic populations.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Hughes</LastName><ForeName>Hannah J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>*Podiatric Medicine and Surgery Residency Program, University of Pittsburgh Medical Center Mercy, Pittsburgh, PA. Drs Hughes and Hurst are now with Foot and Ankle Surgery Department, Davis Medical Center, Elkins, WV.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hurst</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>*Podiatric Medicine and Surgery Residency Program, University of Pittsburgh Medical Center Mercy, Pittsburgh, PA. Drs Hughes and Hurst are now with Foot and Ankle Surgery Department, Davis Medical Center, Elkins, WV.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Burns</LastName><ForeName>Patrick R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>&#x2020;Department of Orthopedics, University of Pittsburgh Medical Center, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D003160\">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Podiatr Med Assoc</MedlineTA><NlmUniqueID>8501423</NlmUniqueID><ISSNLinking>1930-8264</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000671\" MajorTopicYN=\"Y\">Amputation, Surgical</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006214\" MajorTopicYN=\"Y\">Hallux</DescriptorName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D017719\" MajorTopicYN=\"Y\">Diabetic Foot</DescriptorName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012086\" MajorTopicYN=\"Y\">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758675</ArticleId><ArticleId IdType=\"doi\">10.7547/22-029</ArticleId><ArticleId IdType=\"pii\">22-029</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758674</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1930-8264</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>114</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Journal of the American Podiatric Medical Association</Title><ISOAbbreviation>J Am Podiatr Med Assoc</ISOAbbreviation></Journal><ArticleTitle>The Utility of Advanced Lower-Extremity Duplex Using Pedal Acceleration Time in the Management of the Threatened Diabetic Foot.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">22-221</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.7547/22-221</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Patients with diabetes and diffuse infrageniculate arterial disease who present with chronic limb-threatening ischemia require an exact anatomical plan for revascularization. Advanced pedal duplex can be used to define possible routes for revascularization. In addition, pedal acceleration time (PAT) can predict the success or failure of both medical and surgical interventions.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">A retrospective review of patients who were referred to our group for unilateral limb-threatening ischemia with isolated infrageniculate disease was conducted. Pedal duplex and PAT at the base of the wound was performed before and 1 week after intervention. The primary endpoint was limb salvage at 1 year. Revascularization was defined as direct or indirect based on the angiosome concept.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Fifty-four patients meeting inclusion criteria presented over a 5-year period (toe wound, n = 42; heel wound, n = 8; both, n = 4). At 1 year, 10 (18.5%) had required below-knee amputation, whereas the remainder had healed/improved. Limb salvage was predicted by absence of ongoing smoking, absence of dialysis, and postprocedural PAT (class I/II). Limb salvage did not correlate with direct versus indirect revascularization.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Advanced lower-extremity duplex in conjunction with determining PAT at the area of concern is a useful technique for mapping the vasculature and identifying targets for revascularization in patients with diffuse infrageniculate disease. Target artery revascularization to the wound bed resulting in a PAT less than 180 msec is predictive of limb salvage, regardless of whether perfusion is direct or indirect.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Karmy-Jones</LastName><ForeName>Riyad</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>*PeaceHealth Southwest Washington Medical Center, Vancouver, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Feliciano</LastName><ForeName>BeeJay</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>*PeaceHealth Southwest Washington Medical Center, Vancouver, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Teso</LastName><ForeName>Desarom</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>*PeaceHealth Southwest Washington Medical Center, Vancouver, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sommerset</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>*PeaceHealth Southwest Washington Medical Center, Vancouver, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Vea</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>*PeaceHealth Southwest Washington Medical Center, Vancouver, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Dally</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>*PeaceHealth Southwest Washington Medical Center, Vancouver, WA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Podiatr Med Assoc</MedlineTA><NlmUniqueID>8501423</NlmUniqueID><ISSNLinking>1930-8264</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D017719\" MajorTopicYN=\"Y\">Diabetic Foot</DescriptorName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D023821\" MajorTopicYN=\"Y\">Limb Salvage</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D018616\" MajorTopicYN=\"Y\">Ultrasonography, Doppler, Duplex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D035002\" MajorTopicYN=\"N\">Lower Extremity</DescriptorName><QualifierName UI=\"Q000098\" MajorTopicYN=\"N\">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000671\" MajorTopicYN=\"N\">Amputation, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000369\" MajorTopicYN=\"N\">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D013997\" MajorTopicYN=\"N\">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758674</ArticleId><ArticleId IdType=\"doi\">10.7547/22-221</ArticleId><ArticleId IdType=\"pii\">22-221</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758639</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1552-5783</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>65</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Investigative ophthalmology &amp; visual science</Title><ISOAbbreviation>Invest Ophthalmol Vis Sci</ISOAbbreviation></Journal><ArticleTitle>Intraretinal Hyper-Reflective Foci Are Almost Universally Present and Co-Localize With Intraretinal Fluid in Diabetic Macular Edema.</ArticleTitle><Pagination><StartPage>26</StartPage><MedlinePgn>26</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1167/iovs.65.5.26</ELocationID><Abstract><AbstractText Label=\"PURPOSE\" NlmCategory=\"UNASSIGNED\">In diabetic macular edema (DME), hyper-reflective foci (HRF) has been linked to disease severity and progression. Using an automated approach, we aimed to investigate the baseline distribution of HRF in DME and their co-localization with cystoid intraretinal fluid (IRF).</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">Baseline spectral-domain optical coherence tomography (SD-OCT) volume scans (N = 1527) from phase III clinical trials YOSEMITE (NCT03622580) and RHINE (NCT03622593) were segmented using a deep-learning-based algorithm (developed using B-scans from BOULEVARD NCT02699450) to detect HRF. The HRF count and volume were assessed. HRF distributions were analyzed in relation to best-corrected visual acuity (BCVA), central subfield thickness (CST), and IRF volume in quartiles, and Diabetic Retinopathy Severity Scores (DRSS) in groups. Co-localization of HRF with IRF was calculated in the central 3-mm diameter using the en face projection.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">HRF were present in most patients (up to 99.7%). Median (interquartile range [IQR]) HRF volume within the 3-mm diameter Early Treatment Diabetic Retinopathy Study ring was 1964.3 (3325.2) pL, and median count was 64.0 (IQR = 96.0). Median HRF volumes were greater with decreasing BCVA (nominal P = 0.0109), and increasing CST (nominal P &lt; 0.0001), IRF (nominal P &lt; 0.0001), and DRSS up to very severe nonproliferative diabetic retinopathy (nominal P &lt; 0.0001). HRF co-localized with IRF in the en face projection.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">Using automated HRF segmentation of full SD-OCT volumes, we observed that HRF are a ubiquitous feature in DME and exhibit relationships with BCVA, CST, IRF, and DRSS, supporting a potential link to disease severity. The spatial distribution of HRF closely followed that of IRF.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>von Schulthess</LastName><ForeName>Esther L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>https://orcid.org/0000-0003-4497-8185.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Maunz</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chakravarthy</LastName><ForeName>Usha</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Queen's University of Belfast, Royal Victoria Hospital, Belfast, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Holekamp</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pepose Vision Institute, Chesterfield, Missouri, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pauleikhoff</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Augenzentrum am St. Franziskus Hospital, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Patel</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Roche Products Ltd., Welwyn Garden City, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bachmeier</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yu</LastName><ForeName>Siqing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cohen</LastName><ForeName>Yaniv</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Scherb</LastName><ForeName>Mahnaz Parian</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jones</LastName><ForeName>Ian L</ForeName><Initials>IL</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gibson</LastName><ForeName>Kara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Roche Products Ltd., Welwyn Garden City, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Willis</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Glittenberg</LastName><ForeName>Carl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Singh</LastName><ForeName>Rishi P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fauser</LastName><ForeName>Sascha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D017428\">Clinical Trial, Phase III</PublicationType><PublicationType UI=\"D016449\">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA><NlmUniqueID>7703701</NlmUniqueID><ISSNLinking>0146-0404</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008269\" MajorTopicYN=\"Y\">Macular Edema</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName><QualifierName UI=\"Q000000981\" MajorTopicYN=\"N\">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D003930\" MajorTopicYN=\"Y\">Diabetic Retinopathy</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D041623\" MajorTopicYN=\"Y\">Tomography, Optical Coherence</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D014792\" MajorTopicYN=\"Y\">Visual Acuity</DescriptorName><QualifierName UI=\"Q000502\" MajorTopicYN=\"N\">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D058471\" MajorTopicYN=\"Y\">Subretinal Fluid</DescriptorName><QualifierName UI=\"Q000378\" MajorTopicYN=\"N\">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D020533\" MajorTopicYN=\"N\">Angiogenesis Inhibitors</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000465\" MajorTopicYN=\"N\">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D058449\" MajorTopicYN=\"N\">Intravitreal Injections</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758639</ArticleId><ArticleId IdType=\"doi\">10.1167/iovs.65.5.26</ArticleId><ArticleId IdType=\"pii\">2793666</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758517</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Print\">2193-8245</ISSN><JournalIssue CitedMedium=\"Print\"><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Ophthalmology and therapy</Title><ISOAbbreviation>Ophthalmol Ther</ISOAbbreviation></Journal><ArticleTitle>Improvement in Central Serous Chorioretinopathy Following Multiwavelength Photobiomodulation Treatment - Case Report.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s40123-024-00963-6</ELocationID><Abstract><AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Central serous chorioretinopathy (CSCR) is a condition where fluid build-up accumulates underneath the retina, resulting in retinal pigment epithelium (RPE) detachment and vision loss. Irreversible retinal functional and anatomical changes are possible consequences. Research into novel strategies to aid in recovery are of interest. Photobiomodulation (PBM) uses light wavelengths to improve cellular function and shows positive effects in several conditions including those with edema.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">This prospective case report details a 39-year-old woman with CSCR. Multiwavelength PBM treatment was initiated with the Valeda&#xae; Light Delivery System. A series of treatment included nine sessions delivered over 3-5&#xa0;weeks. Follow-up treatments were conducted. Optical coherence tomography (OCT) imaging and best-corrected visual acuity (BCVA) measures were taken. The patient has been followed for approximately 1&#xa0;year.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The patient presented with blurred vision and a BCVA score of 65 letters in the left eye. After 3&#xa0;weeks of observation, the patient's vision had further declined two lines on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart to 55 letters. Fluorescein angiography was performed, confirming CSCR diagnosis, and PBM was initiated. PBM treatment improved BCVA and fluid build-up in the RPE within 1&#xa0;week of treatment (three treatment sessions). Following the full series of treatment (nine PBM treatment sessions), fluid was completely resolved and BCVA scored at 80 letters. The patient had a repeat PBM treatment&#xa0;series&#x2009;~&#x2009;6&#xa0;months later and has shown stable vision and no fluid present on OCT scan. The patient was seen again&#x2009;~&#x2009;1&#xa0;year later with continued stable vision and no fluid detection.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">PBM is a non-invasive treatment option that may provide benefit in CSCR to resolve fluid build-up, macular change, and vision loss. Research into PBM as an immediate treatment option for CSCR, especially those with chronic presentations or those posed to have irreversible damage, is warranted to confirm effectiveness.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Sachdev</LastName><ForeName>Arun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Macclesfield District General Hospital, Macclesfield, England. arun.sachdev@nhs.net.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ophthalmol Ther</MedlineTA><NlmUniqueID>101634502</NlmUniqueID></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Case report</Keyword><Keyword MajorTopicYN=\"N\">Central serous chorioretinopathy</Keyword><Keyword MajorTopicYN=\"N\">Photobiomodulation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758517</ArticleId><ArticleId IdType=\"doi\">10.1007/s40123-024-00963-6</ArticleId><ArticleId IdType=\"pii\">10.1007/s40123-024-00963-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liegl R, Ulbig MW. Central serous chorioretinopathy. Ophthalmologica. 2014;232(2):65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000360014</ArticleId><ArticleId IdType=\"pubmed\">24776999</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung AT, Yang Y, Kam AW. Central serous chorioretinopathy: a review. Clin Exp Ophthalmol. 2023;51(3):243&#x2013;70.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/ceo.14201</ArticleId><ArticleId IdType=\"pubmed\">36597282</ArticleId></ArticleIdList></Reference><Reference><Citation>Dompe C, et al. Photobiomodulation-underlying mechanism and clinical applications. J Clin Med. 2020;9(6):1724.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/jcm9061724</ArticleId><ArticleId IdType=\"pubmed\">32503238</ArticleId><ArticleId IdType=\"pmc\">7356229</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurya PK, et al. The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2016;65:134&#x2013;44.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.pnpbp.2015.08.016</ArticleId><ArticleId IdType=\"pubmed\">26348786</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337&#x2013;61.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3934/biophy.2017.3.337</ArticleId><ArticleId IdType=\"pubmed\">28748217</ArticleId><ArticleId IdType=\"pmc\">5523874</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong-Riley MT, et al. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J Biol Chem. 2005;280(6):4761&#x2013;71.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1074/jbc.M409650200</ArticleId><ArticleId IdType=\"pubmed\">15557336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahadi M, Ebrahimi A, Ramin S. Long-term outcome of photobiomodulation for diabetic macular edema: a case report. Photobiomodul Photomed Laser Surg. 2022;40(11):742&#x2013;6.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36395083</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaymak H, et al. Non-invasive treatment of early diabetic macular edema by multiwavelength photobiomodulation with the Valeda Light Delivery System. Clin Ophthalmol. 2023;17:3549&#x2013;59.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/OPTH.S415883</ArticleId><ArticleId IdType=\"pubmed\">38026594</ArticleId><ArticleId IdType=\"pmc\">10676639</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, T.K., Central serous chorioretinopathy, ed. T. Island. 2023, Florida: StatPearls Publishing.</Citation></Reference><Reference><Citation>Kent AL, et al. A pilot randomised clinical trial of 670 nm red light for reducing retinopathy of prematurity. Pediatr Res. 2020;87(1):131&#x2013;6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41390-019-0520-7</ArticleId><ArticleId IdType=\"pubmed\">31430763</ArticleId></ArticleIdList></Reference><Reference><Citation>Luque-Mialdea F, Molina-Seoane V. Retinitis pigmentosa: significant improvement with photobiomodulation. Arch Soc Esp Oftalmol (Engl Ed). 2023. https://doi.org/10.1016/j.oftale.2023.10.001 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.oftale.2023.10.001</ArticleId><ArticleId IdType=\"pubmed\">37813185</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenbarth W. What can we expect from photobiomodulation therapy in patients with AMD. Invest Ophthalmol Vis Sci. 2023;64:3504.</Citation></Reference><Reference><Citation>Benlahbib M, et al. Photobiomodulation therapy for large soft drusen and drusenoid pigment epithelial detachment in age-related macular degeneration: a single-center prospective pilot study. Retina. 2023;43(8):1246&#x2013;54.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/IAE.0000000000003805</ArticleId><ArticleId IdType=\"pubmed\">37027819</ArticleId></ArticleIdList></Reference><Reference><Citation>Le HM, et al. Effects of photobiomodulation in patients presenting with reticular pseudodrusen: a retrospective observational case series study. Medicina (Kaunas). 2022;58(11):1662.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/medicina58111662</ArticleId><ArticleId IdType=\"pubmed\">36422201</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker I, et al. Non-invasive treatment of early diabetic macular edema by multi-wavelength photobiomodulation with the Valeda Light Delivery System. Investig Ophthalmol Vis Sci. 2021;62:1066.</Citation></Reference><Reference><Citation>Kaymak H, Schwahn H. Photobiomodulation as a treatment in dry AMD. Retina Today, 2020(May/June): p. 23&#x2013;25.</Citation></Reference><Reference><Citation>Merry GF, et al. Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration. Acta Ophthalmol. 2017;95(4):e270&#x2013;7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/aos.13354</ArticleId><ArticleId IdType=\"pubmed\">27989012</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz SN, et al. A double-masked, randomized, sham-controlled, single-center study with photobiomodulation for the treatment of dry age-related macular degeneration. Retina. 2020;40(8):1471&#x2013;82.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/IAE.0000000000002632</ArticleId><ArticleId IdType=\"pubmed\">31404033</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton B, et al. LIGHTSITE II randomized multicenter trial: evaluation of multiwavelength photobiomodulation in non-exudative age-related macular degeneration. Ophthalmol Therapy. 2023. https://doi.org/10.1007/s40123-022-00640-6 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s40123-022-00640-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer D, et al. LIGHTSITE III: 13-month efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (dry) age-related macular degeneration using the LumiThera Valeda Light Delivery System. Retina. 2023. https://doi.org/10.1097/IAE.0000000000003980 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/IAE.0000000000003980</ArticleId><ArticleId IdType=\"pubmed\">36542081</ArticleId><ArticleId IdType=\"pmc\">10885856</ArticleId></ArticleIdList></Reference><Reference><Citation>Koev K, et al. Five-year follow-up of low-level laser therapy (LLLT) in patients with age-related macular degeneration (AMD). J Phys: Conf Ser. 2018;2018(992):012061.</Citation></Reference><Reference><Citation>Ivandic BT, Ivandic T. Low-level laser therapy improves vision in patients with age-related macular degeneration. Photomed Laser Surg. 2008;26(3):241&#x2013;5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1089/pho.2007.2132</ArticleId><ArticleId IdType=\"pubmed\">18588438</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen W, et al. Preclinical and clinical studies of photobiomodulation therapy for macular oedema. Diabetologia. 2020;63(9):1900&#x2013;15.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00125-020-05189-2</ArticleId><ArticleId IdType=\"pubmed\">32661752</ArticleId></ArticleIdList></Reference><Reference><Citation>Eells J, G.S, Connor T, 670 nm photobiomodulation as a therapy for diabetic macular edema: a pilot study. Poster presented at: 2017 ARVO Annual Meeting, 2017.</Citation></Reference><Reference><Citation>Tang J, Herda AA, Kern TS. Photobiomodulation in the treatment of patients with non-center-involving diabetic macular oedema. Br J Ophthalmol. 2014;98(8):1013&#x2013;5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bjophthalmol-2013-304477</ArticleId><ArticleId IdType=\"pubmed\">24682183</ArticleId></ArticleIdList></Reference><Reference><Citation>Geneva II. Photobiomodulation for the treatment of retinal diseases: a review. Int J Ophthalmol. 2016;9(1):145&#x2013;52.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26949625</ArticleId><ArticleId IdType=\"pmc\">4768515</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758435</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1432-1440</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of molecular medicine (Berlin, Germany)</Title><ISOAbbreviation>J Mol Med (Berl)</ISOAbbreviation></Journal><ArticleTitle>Mitochondria targeted esculetin administration improves insulin resistance and hyperglycemia-induced atherosclerosis in db/db mice.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s00109-024-02449-1</ELocationID><Abstract><AbstractText>The development and progression of hyperglycemia (HG) and HG-associated atherosclerosis are exacerbated by mitochondrial dysfunction due to dysregulated mitochondria-derived ROS generation. We recently synthesized a novel mitochondria-targeted esculetin (Mito-Esc) and tested its dose-response therapeutic efficacy in mitigating HG-induced atherosclerosis in db/db mice. In comparison to simvastatin and pioglitazone, Mito-Esc administration resulted in a considerable reduction in body weights and improved glucose homeostasis, possibly by reducing hepatic gluconeogenesis, as indicated by a reduction in glycogen content, non-esterified free fatty acids (NEFA) levels, and fructose 1,6-bisphosphatase (FBPase) activity. Interestingly, Mito-Esc treatment, by regulating phospho-IRS and phospho-AKT levels, greatly improved palmitate-induced insulin resistance, resulting in enhanced glucose uptake in adipocytes and HepG2 cells. Also, and importantly, Mito-Esc administration prevented HG-induced atheromatous plaque formation and lipid accumulation in the descending aorta. In addition, Mito-Esc administration inhibited the HG-mediated increase in VACM, ICAM, and MAC3 levels in the aortic tissue, as well as reduced the serum pro-inflammatory cytokines and markers of senescence. In line with this, Mito-Esc significantly inhibited monocyte adherence to human aortic endothelial cells (HAECs) treated with high glucose and reduced high glucose-induced premature senescence in HAECs by activating the AMPK-SIRT1 pathway. In contrast, Mito-Esc failed to regulate high glucose-induced endothelial cell senescence under AMPK/SIRT1-depleted conditions. Together, the therapeutic efficacy of Mito-Esc in the mitigation of hyperglycemia-induced insulin resistance and the associated atherosclerosis is in part mediated by potentiating the AMPK-SIRT1 axis. KEY MESSAGES: Mito-Esc administration significantly mitigates diabetes-induced atherosclerosis. Mito-Esc improves hyperglycemia (HG)-associated insulin resistance. Mito-Esc inhibits HG-induced vascular senescence and inflammation in the aorta. Mito-Esc-mediated activation of the AMPK-SIRT1 axis regulates HG-induced endothelial cell senescence.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Singuru</LastName><ForeName>Gajalakshmi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research, Ghaziabad, 201002, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pulipaka</LastName><ForeName>Sriravali</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research, Ghaziabad, 201002, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shaikh</LastName><ForeName>Altab</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research, Ghaziabad, 201002, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Organic Synthesis and Process Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sahoo</LastName><ForeName>Shashikanta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research, Ghaziabad, 201002, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jangam</LastName><ForeName>Aruna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research, Ghaziabad, 201002, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Thennati</LastName><ForeName>Rajamannar</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>High Impact Innovations-Sustainable Health Solutions (HISHS), Sun Pharmaceutical Industries Ltd., Vadodara, 390012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kotamraju</LastName><ForeName>Srigiridhar</ForeName><Initials>S</Initials><Identifier Source=\"ORCID\">0000-0003-0525-7553</Identifier><AffiliationInfo><Affiliation>Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India. giridhar@iict.res.in.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovative Research, Ghaziabad, 201002, India. giridhar@iict.res.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><GrantID>internal funding</GrantID><Agency>cSIR-IICT</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Mol Med (Berl)</MedlineTA><NlmUniqueID>9504370</NlmUniqueID><ISSNLinking>0946-2716</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">AMPK</Keyword><Keyword MajorTopicYN=\"N\">Atherosclerosis</Keyword><Keyword MajorTopicYN=\"N\">Diabetes</Keyword><Keyword MajorTopicYN=\"N\">Insulin resistance</Keyword><Keyword MajorTopicYN=\"N\">SIRT-1</Keyword><Keyword MajorTopicYN=\"N\">Senescence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2024</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758435</ArticleId><ArticleId IdType=\"doi\">10.1007/s00109-024-02449-1</ArticleId><ArticleId IdType=\"pii\">10.1007/s00109-024-02449-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Di Pietrantonio N, Di Tomo P, Mandatori D, Formoso G, Pandolfi A (2023) Diabetes and its cardiovascular complications: potential role of the acetyltransferase p300. Cells 12(3):1&#x2013;16</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cells12030431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23(2):168&#x2013;175</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/01.ATV.0000051384.43104.FC</ArticleId><ArticleId IdType=\"pubmed\">12588755</ArticleId></ArticleIdList></Reference><Reference><Citation>Badimon L, Vilahur G (2014) Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med 276(6):618&#x2013;632</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/joim.12296</ArticleId><ArticleId IdType=\"pubmed\">25156650</ArticleId></ArticleIdList></Reference><Reference><Citation>Beverly JK, Budoff MJ (2020) Atherosclerosis: pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation. J Diabetes 12(2):102&#x2013;104</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/1753-0407.12970</ArticleId><ArticleId IdType=\"pubmed\">31411812</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MC, Shulman GI (2018) Mechanisms of insulin action and insulin resistance. Physiol Rev 98(4):2133&#x2013;2223</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/physrev.00063.2017</ArticleId><ArticleId IdType=\"pubmed\">30067154</ArticleId><ArticleId IdType=\"pmc\">6170977</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H (2022) Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther 7(1):1&#x2013;25</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34980881</ArticleId><ArticleId IdType=\"pmc\">8724278</ArticleId></ArticleIdList></Reference><Reference><Citation>Popov D (2010) Endothelial cell dysfunction in hyperglycemia: phenotypic change, intracellular signaling modification, ultrastructural alteration, and potential clinical outcomes. Int J Diabetes Mellit [Internet] 2(3):189&#x2013;95. https://doi.org/10.1016/j.ijdm.2010.09.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijdm.2010.09.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur R, Kaur M, Singh J (2018) Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol [Internet] 17(1):1&#x2013;17. https://doi.org/10.1186/s12933-018-0763-3</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12933-018-0763-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY et al (2003) The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 111(9):1373&#x2013;1380</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1172/JCI15211</ArticleId><ArticleId IdType=\"pubmed\">12727929</ArticleId><ArticleId IdType=\"pmc\">154437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamed S, Brenner B, Roguin A (2011) Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2. Cardiovasc Res 91(1):9&#x2013;15</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/cvr/cvq412</ArticleId><ArticleId IdType=\"pubmed\">21186243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Y, Liu Z, Wu A, Khan AH, Zhu Y, Ding S et al (2022) Hyperglycemia promotes endothelial cell senescence through AQR/PLAU signaling axis. Int J Mol Sci 23(5):5&#x2013;9</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijms23052879</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun HJ, Wu ZY, Nie XW, Bian JS (2020) Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide. Front Pharmacol 10(January):1&#x2013;15</Citation></Reference><Reference><Citation>Ye X, Li M, Hou T, Gao T, Zhu WG, Yang Y (2017) Sirtuins in glucose and lipid metabolism. Oncotarget 8(1):1845&#x2013;1859</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18632/oncotarget.12157</ArticleId><ArticleId IdType=\"pubmed\">27659520</ArticleId></ArticleIdList></Reference><Reference><Citation>Winnik S, Auwerx J, Sinclair DA, Matter CM (2015) Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J 36(48):3404&#x2013;3412</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/eurheartj/ehv290</ArticleId><ArticleId IdType=\"pubmed\">26112889</ArticleId><ArticleId IdType=\"pmc\">4685177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivanand (2019) Sirtuins, cell senescence, and vascular aging HHS Public Access. Physiol Behav 176(3):139&#x2013;148</Citation></Reference><Reference><Citation>Yan P, Li Z, Xiong J, Geng Z, Wei W, Zhang Y et al (2021) LARP7 ameliorates cellular senescence and aging by allosterically enhancing SIRT1 deacetylase activity. Cell Rep 37(8):110038</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.celrep.2021.110038</ArticleId><ArticleId IdType=\"pubmed\">34818543</ArticleId></ArticleIdList></Reference><Reference><Citation>Budbazar E, Rodriguez F, Sanchez JM, Seta F (2020) The role of sirtuin-1 in the vasculature: focus on aortic aneurysm. Front Physiol 11(August):1&#x2013;10</Citation></Reference><Reference><Citation>Winnik S, Stein S, M Matter C (2012) SIRT1 &#x2013; an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr Vasc Pharmacol 10(6):693&#x2013;696</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2174/157016112803520756</ArticleId><ArticleId IdType=\"pubmed\">23259556</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Li J, Zhang X (2019) Salidroside protects against ox-LDL-induced endothelial injury by enhancing autophagy mediated by SIRT1-FoxO1 pathway. BMC Complement Altern Med 19(1):1&#x2013;10</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12906-019-2526-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Tan Y, Xu B, Wang Y, Cheang WS (2022) 3,4&#x2032;,5-Trimethoxy-trans-stilbene alleviates endothelial dysfunction in diabetic and obese mice via activation of the AMPK/SIRT1/eNOS pathway. Antioxidants 11(7):1&#x2013;15</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/antiox11071286</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa T, Kukidome D, Sonoda K, Fujisawa K, Matsuhisa T, Motoshima H et al (2007) Impact of mitochondrial ROS production in the pathogenesis of insulin resistance. Diabetes Res Clin Pract 77(3 SUPPL.):161&#x2013;164</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.diabres.2007.01.071</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa T, Edelstein D, Du XL, Yamagishi SI, Matsumura T, Kaneda Y et al (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404(6779):787&#x2013;790</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/35008121</ArticleId><ArticleId IdType=\"pubmed\">10783895</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyewole AO, Birch-Machin MA (2015) Mitochondria-targeted antioxidants. FASEB J 29(12):4766&#x2013;4771</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1096/fj.15-275404</ArticleId><ArticleId IdType=\"pubmed\">26253366</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaikh A, Neeli PK, Singuru G, Panangipalli S, Banerjee R, Maddi SR et al (2021) A functional and self-assembling octyl-phosphonium-tagged esculetin as an effective siRNA delivery agent. Chem Commun 57(92):12329&#x2013;12332</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1039/D1CC03497A</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnewar S, Vasamsetti SB, Gopoju R, Kanugula AK, Ganji SK, Prabhakar S et al (2016) Mitochondria-targeted esculetin alleviates mitochondrial dysfunction by AMPK-mediated nitric oxide and SIRT3 regulation in endothelial cells: potential implications in atherosclerosis. Sci Rep [Internet] 6(December 2015):1&#x2013;18. https://doi.org/10.1038/srep24108</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/srep24108</ArticleId></ArticleIdList></Reference><Reference><Citation>Katta S, Karnewar S, Panuganti D, Jerald MK, Sastry BKS, Kotamraju S (2018) Mitochondria-targeted esculetin inhibits PAI-1 levels by modulating STAT3 activation and miR-19b via SIRT3: role in acute coronary artery syndrome. J Cell Physiol 233(1):214&#x2013;225</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/jcp.25865</ArticleId><ArticleId IdType=\"pubmed\">28213977</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnewar S, Pulipaka S, Katta S, Panuganti D, Neeli PK, Thennati R, Jerald MK, Kotamraju S (2022) Mitochondria-targeted esculetin mitigates atherosclerosis in the setting of aging via the modulation of SIRT1-mediated vascular cell senescence and mitochondrial function in Apoe<sup>&#x2212;/&#x2212;</sup> mice. Atherosclerosis 356:28&#x2013;40</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.atherosclerosis.2022.07.012</ArticleId><ArticleId IdType=\"pubmed\">35961209</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnewar S, Neeli PK, Panuganti D, Kotagiri S, Mallappa S, Jain N et al (2018) Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: Relevance in age-associated vascular dysfunction. Biochim Biophys Acta Mol Basis Dis [Internet] 1864(4):1115&#x2013;1128. https://doi.org/10.1016/j.bbadis.2018.01.018</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.bbadis.2018.01.018</ArticleId><ArticleId IdType=\"pubmed\">29366775</ArticleId></ArticleIdList></Reference><Reference><Citation>Cant&#xf3; C, Auwerx J (2009) PGC-1&#x3b1;, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20(2):98&#x2013;105</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MOL.0b013e328328d0a4</ArticleId><ArticleId IdType=\"pubmed\">19276888</ArticleId><ArticleId IdType=\"pmc\">3627054</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegarty BD, Turner N, Cooney GJ, Kraegen EW (2009) Insulin resistance and fuel homeostasis: the role of AMP-activated protein kinase. Acta Physiol 196(1):129&#x2013;145</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1748-1716.2009.01968.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono-Moore KD, Blackburn ML, Adams SH (2018) Is palmitate truly proinflammatory? Experimental confounders and context-specificity. Am J Physiol Endocrinol Metab 315(5):E780&#x2013;E794</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/ajpendo.00187.2018</ArticleId><ArticleId IdType=\"pubmed\">30016150</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinsella GK, Cannito S, Bordano V, Stephens JC, Rosa AC, Miglio G et al (2021) GPR21 inhibition increases glucose-uptake in HepG2 cells. Int J Mol Sci 22(19):1&#x2013;14</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijms221910784</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho RP, Feksa DL, Oliveira PM, da Costa G&#xfc;llich AA, Pilar BC, da Costa Escobar Piccoli J et al (2018) Protective effect of the hydroalcoholic extract of Tripodanthus acutifolius in hypercholesterolemic Wistar rats. Biomed Pharmacother [Internet] 97(July 2017):300&#x2013;309. https://doi.org/10.1016/j.biopha.2017.10.003</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.biopha.2017.10.003</ArticleId><ArticleId IdType=\"pubmed\">29091879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H et al (2006) Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem [Internet] 281(13):8748&#x2013;8755. https://doi.org/10.1074/jbc.M505649200</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1074/jbc.M505649200</ArticleId><ArticleId IdType=\"pubmed\">16431926</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanishi M, Kobayashi M (1993) Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. Metabolism 42(8):1017&#x2013;1021</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/0026-0495(93)90016-H</ArticleId><ArticleId IdType=\"pubmed\">8345805</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscar&#xe0; C, Molonia MS, Speciale A, Bashllari R, Cimino F, Occhiuto C et al (2019) Anthocyanins ameliorate palmitate-induced inflammation and insulin resistance in 3T3-L1 adipocytes. Phyther Res 33(7):1888&#x2013;1897</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ptr.6379</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik SA, Acharya JD, Mehendale NK, Kamat SS, Ghaskadbi SS (2019) Pterostilbene reverses palmitic acid mediated insulin resistance in HepG2 cells by reducing oxidative stress and triglyceride accumulation. Free Radic Res 53(7):815&#x2013;827</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/10715762.2019.1635252</ArticleId><ArticleId IdType=\"pubmed\">31223033</ArticleId><ArticleId IdType=\"pmc\">6675602</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhupathiraju SN, Hu FB (2016) Epidemiolog&#xed;a de la Obesidad y la Diabetes y sus Complicaciones Cardiovasculares. Circ Res [Internet] 118(11):1723&#x2013;1735.&#xa0; http://www.ncbi.nlm.nih.gov/pubmed/27230638</Citation></Reference><Reference><Citation>Reusch JEB, Draznin BB (2007) Atherosclerosis in diabetes and insulin resistance. Diabetes Obes Metab 9(4):455&#x2013;463</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1463-1326.2006.00620.x</ArticleId><ArticleId IdType=\"pubmed\">17587387</ArticleId></ArticleIdList></Reference><Reference><Citation>Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN (2020) The diabetes mellitus&#x2013;atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci 21(5):1&#x2013;13</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijms21051835</ArticleId></ArticleIdList></Reference><Reference><Citation>Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440(7086):944&#x2013;948</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/nature04634</ArticleId><ArticleId IdType=\"pubmed\">16612386</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-&#x3b1;- and obesity-induced insulin resistance. Science&#xa0;(80-) 271(5249):665&#x2013;668</Citation></Reference><Reference><Citation>Schwanstecher M (2011) Diabetes - perspectives in drug therapy. Handbook of experimental pharmacology: preface, vol 203. Springer</Citation></Reference><Reference><Citation>McGuinness OP, Ejiofor J, Audoly LP, Schrom N (1998) Regulation of glucose production by NEFA and gluconeogenic precursors during chronic glucagon infusion. Am J Physiol Endocrinol Metab 275(3):432&#x2013;439</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/ajpendo.1998.275.3.E432</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Soodvilai S (2008) Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res 2008:943614</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1155/2008/943614</ArticleId><ArticleId IdType=\"pubmed\">18784848</ArticleId><ArticleId IdType=\"pmc\">2531205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupasinghe HPV, Sekhon-Loodu S, Mantso T, Panayiotidis MI (2016) Phytochemicals in regulating fatty acid &#x3b2;-oxidation: potential underlying mechanisms and their involvement in obesity and weight loss. Pharmacol Ther [Internet] 165:153&#x2013;163. https://doi.org/10.1016/j.pharmthera.2016.06.005</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.pharmthera.2016.06.005</ArticleId><ArticleId IdType=\"pubmed\">27288729</ArticleId></ArticleIdList></Reference><Reference><Citation>Singuru G, Pulipaka S, Shaikh A, Andugulapati SB, Thennati R, Kotamraju S (2023) Therapeutic efficacy of mitochondria-targeted esculetin in the improvement of NAFLD-NASH via modulating AMPK-SIRT1 axis. Int Immunopharmacol 124:111070. ISSN 1567-5769</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.intimp.2023.111070</ArticleId><ArticleId IdType=\"pubmed\">37862737</ArticleId></ArticleIdList></Reference><Reference><Citation>Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC et al (2018) Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes [Internet]. J Am Coll Cardiol 71:2392&#x2013;2401. https://doi.org/10.1016/j.jacc.2018.03.002 . American College of Cardiology Foundation</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jacc.2018.03.002</ArticleId><ArticleId IdType=\"pubmed\">29544870</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D et al (2013) A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 56(4):714&#x2013;723</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00125-012-2819-3</ArticleId><ArticleId IdType=\"pubmed\">23370525</ArticleId><ArticleId IdType=\"pmc\">4948114</ArticleId></ArticleIdList></Reference><Reference><Citation>Soehnlein O, Libby P (2021) Targeting inflammation in atherosclerosis &#x2014; from experimental insights to the clinic. Nat Rev Drug Discov [Internet] 20(8):589&#x2013;610. https://doi.org/10.1038/s41573-021-00198-1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41573-021-00198-1</ArticleId><ArticleId IdType=\"pubmed\">33976384</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi C, Li DJ, Jiang YJ, Tong J, Fu H, Wu YH et al (2019) Vascular smooth muscle cell senescence and age-related diseases: state of the art. Biochim Biophys Acta Mol Basis Dis [Internet] 1865(7):1810&#x2013;1821. https://doi.org/10.1016/j.bbadis.2018.08.015</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.bbadis.2018.08.015</ArticleId><ArticleId IdType=\"pubmed\">31109451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting KK, Coleman P, Zhao Y, Vadas MA, Gamble JR (2021) The aging endothelium. Vasc Biol 3(1):R35&#x2013;R47</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1530/VB-20-0013</ArticleId><ArticleId IdType=\"pubmed\">33880430</ArticleId><ArticleId IdType=\"pmc\">8052565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758423</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Print\">2193-8210</ISSN><JournalIssue CitedMedium=\"Print\"><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Dermatology and therapy</Title><ISOAbbreviation>Dermatol Ther (Heidelb)</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the Factors Influencing Mortality in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Study of 166 Patients.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s13555-024-01180-6</ELocationID><Abstract><AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening acute mucocutaneous disorders usually triggered by drugs. In this study, we aimed to evaluate the factors affecting mortality in patients with SJS-TEN.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">Our study is a retrospective cohort study, analyzing data collected from a total of 12 tertiary care centers between April 2012 and April 2022.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The study included 59 males and 107 females, a total of 166 patients, with an average age of 50.91&#x2009;&#xb1;&#x2009;21.25&#xa0;years. Disease classification was TEN in 50% of cases, SJS in 33.1%, and SJS-TEN overlap in 16.9%. The average SCORTEN within the first 24&#xa0;h was 2.44&#x2009;&#xb1;&#x2009;1.42. Supportive care was provided to 99.4% of patients. The most commonly used systemic immunomodulatory treatments were systemic steroids (84.3%), IVIG (intravenous immunoglobulin) (49.3%), and cyclosporine (38.6%). Plasmapheresis was administered to five patients. While 66.3% of patients were discharged, 24.1% resulted in exitus. Our comparative analysis of survivors and deceased patients found no effect of systemic steroids, IVIG, and cyclosporine treatments on mortality. Univariate analysis revealed that the SCORTEN scores on days 1 and 3 as well as the rates of detachment at the onset and during follow-up were significantly higher in deceased patients compared to survivors. The rates of fever, positive blood cultures, and systemic antibiotic use were higher in deceased patients compared to survivors. The presence of comorbidities, diabetes, and malignancy were significantly more common in deceased patients. Multivariate regression analysis indicated that over SCORTEN 2, the mortality risk exponentially rose with each SCORTEN increment, culminating in an 84-fold increase in mortality at SCORTEN 5-6 (odds ratio [95% confidence interval]: 13.902-507.537, p&#x2009;&lt;&#x2009;0.001) compared to SCORTEN 0-1. Additionally, the utilization of plasmapheresis was associated with a 22-fold increase in mortality (odds ratio [95% confidence interval]: 1.96-247.2, p&#x2009;=&#x2009;0.012).</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Our study found that a high SCORTEN score within the first 24&#xa0;h and the use of plasmapheresis were related to increased mortality, while systemic steroids, IVIG, and cyclosporine treatments had no impact on mortality. We believe that data gathered from one of the most comprehensive studies which we conducted on SJS-TEN will enrich the literature, although additional research is warranted.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Erduran</LastName><ForeName>Funda</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0000-0002-3318-2248</Identifier><AffiliationInfo><Affiliation>Ankara Bilkent City Hospital, Department of Dermatology, Ankara, Turkey. fnderdrn@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ad&#x131;&#x15f;en</LastName><ForeName>Esra</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Gazi University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Emre</LastName><ForeName>Selma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Ankara Y&#x131;ld&#x131;r&#x131;m Beyaz&#x131;t University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hayran</LastName><ForeName>Y&#x131;ld&#x131;z</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ankara Bilkent City Hospital, Department of Dermatology, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ba&#x15f;kan</LastName><ForeName>Emel B&#xfc;lb&#xfc;l</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Bursa Uluda&#x11f; University, Bursa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yaz&#x131;c&#x131;</LastName><ForeName>Serkan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Bursa Uluda&#x11f; University, Bursa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bilgi&#xe7;</LastName><ForeName>Asl&#x131;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Akdeniz University, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Alpsoy</LastName><ForeName>Erkan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Akdeniz University, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>G&#xfc;nayd&#x131;n</LastName><ForeName>Sibel Do&#x11f;an</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Elmas</LastName><ForeName>Leyla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Akyol</LastName><ForeName>Melih</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Sivas Cumhuriyet University, Sivas, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>G&#xfc;ner</LastName><ForeName>RukiyeYasak</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Sivas Cumhuriyet University, Sivas, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ar&#x131;ca</LastName><ForeName>Deniz Aksu</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Karadeniz Technical University, Trabzon, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Aypek</LastName><ForeName>Ya&#x11f;mur</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Gazi University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ergun</LastName><ForeName>T&#xfc;lin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Marmara University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Karavelio&#x11f;lu</LastName><ForeName>Dilan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Marmara University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yaz&#x131;c&#x131;</LastName><ForeName>Ay&#xe7;a Cordan</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Mersin University, Mersin, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Aydo&#x11f;an</LastName><ForeName>K&#xfc;bra</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Mersin University, Mersin, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bayramg&#xfc;rler</LastName><ForeName>Dilek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Kocaeli University, Kocaeli, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>K&#x131;ran</LastName><ForeName>Rebiay</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Kocaeli University, Kocaeli, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Erdo&#x11f;an</LastName><ForeName>Hilal Kaya</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Eski&#x15f;ehir Osmangazi University, Eski&#x15f;ehir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Acer</LastName><ForeName>Ersoy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Eski&#x15f;ehir Osmangazi University, Eski&#x15f;ehir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Akta&#x15f;</LastName><ForeName>Ak&#x131;n</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Ankara Y&#x131;ld&#x131;r&#x131;m Beyaz&#x131;t University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dermatol Ther (Heidelb)</MedlineTA><NlmUniqueID>101590450</NlmUniqueID></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Mortality</Keyword><Keyword MajorTopicYN=\"N\">Plasmapheresis</Keyword><Keyword MajorTopicYN=\"N\">SCORTEN</Keyword><Keyword MajorTopicYN=\"N\">Stevens-Johnson syndrome</Keyword><Keyword MajorTopicYN=\"N\">Survival</Keyword><Keyword MajorTopicYN=\"N\">Toxic epidermal necrolysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758423</ArticleId><ArticleId IdType=\"doi\">10.1007/s13555-024-01180-6</ArticleId><ArticleId IdType=\"pii\">10.1007/s13555-024-01180-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012;66:995&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jaad.2011.09.029</ArticleId><ArticleId IdType=\"pubmed\">22169256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149&#x2013;53.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1046/j.1523-1747.2000.00061.x</ArticleId><ArticleId IdType=\"pubmed\">10951229</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Navarro I, Briz-Red&#xf3;n &#xc1;, Botella-Estrada R. Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34:2066&#x2013;77.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/jdv.16137</ArticleId><ArticleId IdType=\"pubmed\">31912590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanagarajan A, Murthy AB, Moni PK, Palanivel N. Clinicoetiological Study of Stevens-Johnson syndrome and toxic epidermal necrolysis spectrum and the correlation of SCORTEN with prognosis. Indian J Dermatol. 2023;68:25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.4103/ijd.ijd_783_22</ArticleId><ArticleId IdType=\"pubmed\">37151260</ArticleId><ArticleId IdType=\"pmc\">10162746</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang MS, Lee JY, Kim J, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea. PLoS ONE. 2016;11: e0165933.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1371/journal.pone.0165933</ArticleId><ArticleId IdType=\"pubmed\">27835661</ArticleId><ArticleId IdType=\"pmc\">5106005</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhat S, Banday M, Hassan I. Antecedent drug exposure aetiology and management protocols in Steven-Johnson syndrome and toxic epidermal necrolysis, a hospital based prospective study. J Clin Diagn Res. 2016;10:FC01-4.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26894082</ArticleId><ArticleId IdType=\"pmc\">4740610</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.e1-13.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jaad.2013.05.003</ArticleId><ArticleId IdType=\"pubmed\">23866878</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina (Kaunas). 2021;57:895.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/medicina57090895</ArticleId><ArticleId IdType=\"pubmed\">34577817</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;9:612.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.12688/f1000research.24748.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CB, Wang CW, Chung WH. Stevens-johnson syndrome and toxic epidermal necrolysis in the era of systems medicine. Methods Mol Biol. 2022;2486:37&#x2013;54.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/978-1-0716-2265-0_3</ArticleId><ArticleId IdType=\"pubmed\">35437717</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert M, Scherrer LA. Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis. Dermatol Ther. 2019;32: e12758.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/dth.12758</ArticleId><ArticleId IdType=\"pubmed\">30285308</ArticleId></ArticleIdList></Reference><Reference><Citation>Abulatan IT, Ben-David SG, Morales-Colon LA, Beason E, Fakoya AO. A compilation of drug etiologies of stevens-johnson syndrome and toxic epidermal necrolysis. Cureus. 2023;15: e48728.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">38094551</ArticleId><ArticleId IdType=\"pmc\">10718167</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States. J Invest Dermatol. 2018;138:2315&#x2013;21.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jid.2018.04.027</ArticleId><ArticleId IdType=\"pubmed\">29758282</ArticleId></ArticleIdList></Reference><Reference><Citation>Manvi S, Mahajan VK, Mehta KS, et al. The clinical characteristics, putative drugs, and optimal management of 62 patients with Stevens-Johnson syndrome and/or toxic epidermal necrolysis: a retrospective observational study. Indian Dermatol Online J. 2022;13:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.4103/idoj.idoj_530_21</ArticleId><ArticleId IdType=\"pubmed\">35198464</ArticleId><ArticleId IdType=\"pmc\">8809144</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder JW, Caputo V, Guida S, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: 11-year retrospective experience in a high-complexity tertiary hospital in Milan, Italy. Clin Dermatol. 2023;41:712&#x2013;20.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.clindermatol.2023.09.014</ArticleId><ArticleId IdType=\"pubmed\">37716583</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu TJ, Yeh HH, Lee CH, Liu KL. Stevens-Johnson syndrome and toxic epidermal necrolysis in a referral center in Taiwan. Int J Dermatol. 2021;60:964&#x2013;72.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/ijd.15586</ArticleId><ArticleId IdType=\"pubmed\">33848012</ArticleId></ArticleIdList></Reference><Reference><Citation>Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163:847&#x2013;53.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1365-2133.2010.09863.x</ArticleId><ArticleId IdType=\"pubmed\">20500799</ArticleId></ArticleIdList></Reference><Reference><Citation>Chafranska L, Saunte DM, Behrendt N, et al. Pediatric toxic epidermal necrolysis treated successfully with infliximab. Pediatr Dermatol. 2019;36:342&#x2013;5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/pde.13778</ArticleId><ArticleId IdType=\"pubmed\">30834560</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulombe J, Belzile E, Duhamel A, et al. Pediatric SJS/TEN subdued by a combination of dexamethasone, cyclosporine, and etanercept. J Cutan Med Surg. 2019;23:547&#x2013;50.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/1203475419861078</ArticleId><ArticleId IdType=\"pubmed\">31478770</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng YT, Xiong JX, Wei B, et al. Tumor necrosis factor-&#x3b1; inhibitor for successful treatment of toxic epidermal necrolysis with severe infection: a case series. J Int Med Res. 2024;52:3000605231223059.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/03000605231223059</ArticleId><ArticleId IdType=\"pubmed\">38296223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, Xiao Y, Gao T, Zhang J, Wang T. Etanercept combined with glucocorticoid and gamma globulin for treating children with toxic epidermal necrolysis: a case report. Clin Cosmet Investig Dermatol. 2024;17:167&#x2013;71.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/CCID.S440476</ArticleId><ArticleId IdType=\"pubmed\">38283797</ArticleId><ArticleId IdType=\"pmc\">10821656</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153:514&#x2013;22.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamadermatol.2016.5668</ArticleId><ArticleId IdType=\"pubmed\">28329382</ArticleId><ArticleId IdType=\"pmc\">5817620</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis. J Am Acad Dermatol. 2021;84:390&#x2013;7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jaad.2020.08.122</ArticleId><ArticleId IdType=\"pubmed\">32898587</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisano C, Brown M, Jambusaria A. A comparison of international treatment guidelines for Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Dermatol. 2023;62:397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/ijd.16561</ArticleId><ArticleId IdType=\"pubmed\">36562634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71:941&#x2013;7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jaad.2014.07.016</ArticleId><ArticleId IdType=\"pubmed\">25087214</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA. 1980;244:2423&#x2013;6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.1980.03310210025020</ArticleId><ArticleId IdType=\"pubmed\">7431570</ArticleId></ArticleIdList></Reference><Reference><Citation>Senda A, Fushimi K. Effectiveness of early treatment with plasma exchange in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Sci Rep. 2024;14:2893.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-024-53653-5</ArticleId><ArticleId IdType=\"pubmed\">38316978</ArticleId><ArticleId IdType=\"pmc\">10844598</ArticleId></ArticleIdList></Reference><Reference><Citation>Krajewski A, Mazurek MJ, Mlynska-Krajewska E, Piorun K, Knakiewicz M, Markowska M. Toxic epidermal necrolysis therapy with TPE and IVIG-10 years of experience of the burns treatment center. J Burn Care Res. 2019;40:652&#x2013;7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jbcr/irz073</ArticleId><ArticleId IdType=\"pubmed\">31032516</ArticleId></ArticleIdList></Reference><Reference><Citation>Han F, Zhang J, Guo Q, et al. Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. J Crit Care. 2017;42:65&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jcrc.2017.07.002</ArticleId><ArticleId IdType=\"pubmed\">28688239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasuwanich P, So JM, Chakrala TS, Chen J, Motaparthi K. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome. JAAD Int. 2023;13:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jdin.2023.06.014</ArticleId><ArticleId IdType=\"pubmed\">37575514</ArticleId><ArticleId IdType=\"pmc\">10413346</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunaga Y, Hama N, Ochiai H, et al. Risk factors for sepsis and effects of pretreatment with systemic steroid therapy for underlying condition in SJS/TEN patients: results of a nationwide cross-sectional survey in 489 Japanese patients. J Dermatol Sci. 2022;107:75&#x2013;81.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jdermsci.2022.07.004</ArticleId><ArticleId IdType=\"pubmed\">35882616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133:1197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/jid.2012.510</ArticleId><ArticleId IdType=\"pubmed\">23389396</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758248</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1591-9528</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Clinical and experimental medicine</Title><ISOAbbreviation>Clin Exp Med</ISOAbbreviation></Journal><ArticleTitle>Cardioprotective effects of vaccination in hospitalized patients with COVID-19.</ArticleTitle><Pagination><StartPage>103</StartPage><MedlinePgn>103</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s10238-024-01367-3</ELocationID><Abstract><AbstractText>COVID-19 vaccination has been shown to prevent and reduce the severity of COVID-19 disease. The aim of this study was to explore the cardioprotective effect of COVID-19 vaccination in hospitalized COVID-19 patients. In this retrospective, single-center cohort study, we included hospitalized COVID-19 patients with confirmed vaccination status from July 2021 to February 2022. We assessed outcomes such as acute cardiac events and cardiac biomarker levels through clinical and laboratory data. Our analysis covered 167 patients (69% male, mean age 58&#xa0;years, 42% being fully vaccinated). After adjustment for confounders, vaccinated hospitalized COVID-19 patients displayed a reduced relative risk for acute cardiac events (RR: 0.33, 95% CI [0.07; 0.75]) and showed diminished troponin T levels (Cohen's d:&#x2009;-&#x2009;0.52, 95% CI [-&#x2009;1.01;&#x2009;-&#x2009;0.14]), compared to their non-vaccinated peers. Type 2 diabetes (OR: 2.99, 95% CI [1.22; 7.35]) and existing cardiac diseases (OR: 4.31, 95% CI [1.83; 10.74]) were identified as significant risk factors for the emergence of acute cardiac events. Our findings suggest that COVID-19 vaccination may confer both direct and indirect cardioprotective effects in hospitalized COVID-19 patients.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Madrid</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0001-5135-6873</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Pneumology, Angiology, Acute Geriatrics and Intensive Care, Ortenau Klinikum, Klostenstra&#xdf;e 19, 77933, Lahr/Schwarzwald, Germany. julian.madrid@ortenau-klinikum.de.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Agarwal</LastName><ForeName>Prerana</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>M&#xfc;ller-Peltzer</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Benning</LastName><ForeName>Leo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University Emergency Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Selig</LastName><ForeName>Mischa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>G.E.R.N. Research Center for Tissue Replacement, Regeneration &amp; Neogenesis, Department of Orthopedics and Trauma Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rolauffs</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>G.E.R.N. Research Center for Tissue Replacement, Regeneration &amp; Neogenesis, Department of Orthopedics and Trauma Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Diehl</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Pneumology, Angiology, Acute Geriatrics and Intensive Care, Ortenau Klinikum, Klostenstra&#xdf;e 19, 77933, Lahr/Schwarzwald, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kalbhenn</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Trummer</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Utzolino</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General and Visceral Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wengenmayer</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Interdisciplinary Medical Intensive Care, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Busch</LastName><ForeName>Hans-J&#xf6;rg</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>University Emergency Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Stolz</LastName><ForeName>Daiana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinic of Respiratory Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rieg</LastName><ForeName>Siegbert</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine II, Medical Center -University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Panning</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Virology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bamberg</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Schlett</LastName><ForeName>Christopher L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Askani</LastName><ForeName>Esther</ForeName><Initials>E</Initials><Identifier Source=\"ORCID\">0000-0001-6553-7763</Identifier><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. esther.askani@uniklinik-freiburg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Med</MedlineTA><NlmUniqueID>100973405</NlmUniqueID><ISSNLinking>1591-8890</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000086382\" MajorTopicYN=\"Y\">COVID-19</DescriptorName><QualifierName UI=\"Q000517\" MajorTopicYN=\"N\">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000086663\" MajorTopicYN=\"Y\">COVID-19 Vaccines</DescriptorName><QualifierName UI=\"Q000008\" MajorTopicYN=\"N\">administration &amp; dosage</QualifierName><QualifierName UI=\"Q000276\" MajorTopicYN=\"N\">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006760\" MajorTopicYN=\"Y\">Hospitalization</DescriptorName><QualifierName UI=\"Q000706\" MajorTopicYN=\"N\">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000086402\" MajorTopicYN=\"Y\">SARS-CoV-2</DescriptorName><QualifierName UI=\"Q000276\" MajorTopicYN=\"N\">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D014611\" MajorTopicYN=\"N\">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006331\" MajorTopicYN=\"N\">Heart Diseases</DescriptorName><QualifierName UI=\"Q000517\" MajorTopicYN=\"N\">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012307\" MajorTopicYN=\"N\">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D020107\" MajorTopicYN=\"N\">Troponin T</DescriptorName><QualifierName UI=\"Q000097\" MajorTopicYN=\"N\">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Acute cardiac events</Keyword><Keyword MajorTopicYN=\"N\">Biomarker</Keyword><Keyword MajorTopicYN=\"N\">COVID-19 disease</Keyword><Keyword MajorTopicYN=\"N\">Cardiotropism</Keyword><Keyword MajorTopicYN=\"N\">Troponin</Keyword><Keyword MajorTopicYN=\"N\">Vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2024</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758248</ArticleId><ArticleId IdType=\"doi\">10.1007/s10238-024-01367-3</ArticleId><ArticleId IdType=\"pii\">10.1007/s10238-024-01367-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398:2126&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(21)02758-6</ArticleId><ArticleId IdType=\"pubmed\">34871545</ArticleId><ArticleId IdType=\"pmc\">8640673</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet. 2021;397:952&#x2013;4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(21)00370-6</ArticleId><ArticleId IdType=\"pubmed\">33581803</ArticleId><ArticleId IdType=\"pmc\">7906631</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5:1&#x2013;22.</Citation></Reference><Reference><Citation>Sarkesh A, Sorkhabi AD, Sheykhsaran E, Alinezhad F, Mohammadzadeh N, Hemmat N, et al. Extrapulmonary clinical manifestations in COVID-19 patients. Am J Trop Med Hyg. 2020;103:1783.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.4269/ajtmh.20-0986</ArticleId><ArticleId IdType=\"pubmed\">32940201</ArticleId><ArticleId IdType=\"pmc\">7646754</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: implications for long-term surveillance and outcomes in survivors. Heart Rhythm. 2020;17:1984&#x2013;90.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.hrthm.2020.06.026</ArticleId><ArticleId IdType=\"pubmed\">32599178</ArticleId><ArticleId IdType=\"pmc\">7319645</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CX, Noreen S, Zhang LX, Saeed M, Wu PF, Ijaz M, et al. A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies. Biomed Pharmacother. 2022;146: 112550.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.biopha.2021.112550</ArticleId><ArticleId IdType=\"pubmed\">34959116</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonigk D, Werlein C, Acker T, Aepfelbacher M, Amann KU, Baretton G, et al. Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies? Virchows Archiv. 2022;481:139&#x2013;59.</Citation></Reference><Reference><Citation>Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142:786&#x2013;91.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.7326/0003-4819-142-9-200505030-00015</ArticleId><ArticleId IdType=\"pubmed\">15867411</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Wang J, Yan Y, Zhang Z, Gong W, Nie S. Clinical characterization and possible pathological mechanism of acute myocardial injury in COVID-19. Front Cardiovascular Med. 2022;9: 862571.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fcvm.2022.862571</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39:618&#x2013;25.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1365-2362.2009.02153.x</ArticleId><ArticleId IdType=\"pubmed\">19453650</ArticleId><ArticleId IdType=\"pmc\">7163766</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097&#x2013;100.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/cvr/cvaa078</ArticleId><ArticleId IdType=\"pubmed\">32227090</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603&#x2013;15.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType=\"pubmed\">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl A, Johnson S, Maine G, Garcia MH, Nimmagadda S, Qu L, et al. Vaccination reduces need for emergency care in breakthrough COVID-19 infections: a multicenter cohort study. Lancet Regional Health Am. 2021;4: 100065.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lana.2021.100065</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieminen MS, Dickstein K, Fonseca C, Serrano JM, Parissis J, Fedele F, et al. The patient perspective: quality of life in advanced heart failure with frequent hospitalisations. Int J Cardiol. 2015;191:256&#x2013;64.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijcard.2015.04.235</ArticleId><ArticleId IdType=\"pubmed\">25981363</ArticleId></ArticleIdList></Reference><Reference><Citation>von Spee-Mayer C, Echternach C, Agarwal P, Gutenberger S, Soetedjo V, Goldacker S, et al. Abatacept use Is associated with steroid dose reduction and improvement in fatigue and CD4-dysregulation in COVID patients with interstitial lung disease. J Allergy Clin Immunol Pract. 2021;9:760&#x2013;770.e10.</Citation></Reference><Reference><Citation>De Jong PA, Vos R, Verleden GM, Vanaudenaerde BM, Verschakelen JA. Thin-section computed tomography findings before and after azithromycin treatment of neutrophilic reversible lung allograft dysfunction. Eur Radiol. 2011;21:2466&#x2013;74.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00330-011-2224-1</ArticleId><ArticleId IdType=\"pubmed\">21792614</ArticleId><ArticleId IdType=\"pmc\">3217146</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoltzfus JC. Logistic regression: a brief primer. Acad Emerg Med. 2011;18:1099&#x2013;104.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1553-2712.2011.01185.x</ArticleId><ArticleId IdType=\"pubmed\">21996075</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18637/jss.v033.i01</ArticleId><ArticleId IdType=\"pubmed\">20808728</ArticleId><ArticleId IdType=\"pmc\">2929880</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev. 2007;82:591&#x2013;605.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1469-185X.2007.00027.x</ArticleId><ArticleId IdType=\"pubmed\">17944619</ArticleId></ArticleIdList></Reference><Reference><Citation>Madrid J, Agarwal P, M&#xfc;ller-Peltzer K, et al. Vaccination protects against acute respiratory distress syndrome (ARDS) in hospitalized patients with COVID-19. Clin Exp Med 2024;24:21. https://doi.org/10.1007/s10238-023-01293-w</Citation></Reference><Reference><Citation>Madrid J, Agarwal P, M&#xfc;ller-Peltzer K, et al. Vaccination protects against mortality and intensive care unit (ICU) admission in hospitalized patients with COVID-19, 17 November 2023, PREPRINT (Version 1) available at Research Square. https://doi.org/10.21203/rs.3.rs-3586640/v1</Citation></Reference><Reference><Citation>Askani E, Mueller-Peltzer K, Madrid J, Knoke M, Hasic D, Schlett CL, et al. Pulmonary computed tomographic manifestations of COVID-19 in vaccinated and non-vaccinated patients. Scientific Reports. 2023;13:1&#x2013;13.</Citation></Reference><Reference><Citation>Askani E, Mueller-Peltzer K, Madrid J, Knoke M, Hasic D, Bamberg F, et al. Computed tomographic imaging fof COVID-19 pneumonia caused by the elta (B.1.617.2) and Omicron (B.1.1.529) variant in a German nested cohort Pilot Study Group. Tomography 2022;8:2435&#x2013;49.</Citation></Reference><Reference><Citation>Pizzini A, Burkert F, Theurl I, Weiss G, Bellmann-Weiler R. Prognostic impact of high sensitive Troponin T in patients with influenza virus infection: a retrospective analysis. Heart Lung. 2020;49:105&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.hrtlng.2019.05.009</ArticleId><ArticleId IdType=\"pubmed\">31146968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindner D, Fitzek A, Br&#xe4;uninger H, Aleshcheva G, Edler C, Meissner K, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5:1281&#x2013;5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamacardio.2020.3551</ArticleId><ArticleId IdType=\"pubmed\">32730555</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M. Cellular tropism of SARS-CoV-2 across human tissues and age-related expression of ACE2 and TMPRSS2 in immune-inflammatory stromal cells. Aging Dis. 2021;12:718.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.14336/AD.2021.0429</ArticleId><ArticleId IdType=\"pubmed\">34094637</ArticleId><ArticleId IdType=\"pmc\">8139212</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Yang X, Li Y, Huang J an, Jiang J, Su N. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction. Virol J. 2021;18:1&#x2013;12.</Citation></Reference><Reference><Citation>Peric S, Stulnig TM. Diabetes and COVID-19: disease&#x2014;management&#x2014;people. Wien Klin Wochenschr. 2020;132:356&#x2013;61.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00508-020-01672-3</ArticleId><ArticleId IdType=\"pubmed\">32435867</ArticleId><ArticleId IdType=\"pmc\">7238399</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio R, Marcus NJ, Inestrosa NC. Potential role of autonomic dysfunction in Covid-19 morbidity and mortality. Front Physiol. 2020;11: 561749.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fphys.2020.561749</ArticleId><ArticleId IdType=\"pubmed\">33178034</ArticleId><ArticleId IdType=\"pmc\">7597395</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14:303&#x2013;10.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.dsx.2020.04.004</ArticleId><ArticleId IdType=\"pubmed\">32298981</ArticleId><ArticleId IdType=\"pmc\">7195120</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Sailani MR, Contrepois K, Zhou Y, Ahadi S, Leopold SR, et al. Longitudinal multi-omics of host&#x2013;microbe dynamics in prediabetes. Nature. 2019;569:663&#x2013;71.</Citation></Reference><Reference><Citation>Salesi M, Shojaie B, Farajzadegan Z, Salesi N, Mohammadi E. TNF-&#x3b1; blockers showed prophylactic effects in preventing COVID-19 in patients with rheumatoid arthritis and seronegative spondyloarthropathies: a case-control study. Rheumatol Therapy. 2021;8:1355&#x2013;70.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s40744-021-00342-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela-Almada MO, Putman MS, Duarte-Garc&#xed;a A. The protective effect of rheumatic disease agents in COVID-19. Best Pract Res Clin Rheumatol. 2021;35: 101659.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.berh.2021.101659</ArticleId><ArticleId IdType=\"pubmed\">33526326</ArticleId><ArticleId IdType=\"pmc\">7833968</ArticleId></ArticleIdList></Reference><Reference><Citation>Karami H, Derakhshani A, Ghasemigol M, Fereidouni M, Miri&#x2010;moghaddam E, Baradaran B, et al. Weighted gene co-expression network analysis combined with machine learning validation to identify key modules and hub genes associated with SARS-CoV-2 infection. J Clin Med [Internet]. 2021 [cited 2023 Dec 24];10. Available from: https://pubmed.ncbi.nlm.nih.gov/34441862/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758212</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1557-8593</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Diabetes technology &amp; therapeutics</Title><ISOAbbreviation>Diabetes Technol Ther</ISOAbbreviation></Journal><ArticleTitle>Psychometric Properties of the Automated Insulin Delivery - Benefits and Burdens Scale (AID-BBS) for Adults with Type 1 Diabetes.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1089/dia.2024.0117</ELocationID><Abstract><AbstractText Label=\"OBJECTIVE\" NlmCategory=\"OBJECTIVE\">To evaluate the psychometric properties of a patient-reported outcome measure, The Automated Insulin Delivery - Benefits and Burdens Scale (AID-BBS), which was designed to assess benefits and burdens of AID use in adults with type 1 diabetes (T1D). The measure was hypothesized to have validity, reliability, and clinical utility for predicting likelihood of continued use of an AID system.</AbstractText><AbstractText Label=\"RESEARCH DESIGN AND METHODS\" NlmCategory=\"METHODS\">217 adults with T1D (ages 18 to 82 years) who were enrolled in an AID system research trial completed AID-BBS items at study midpoint (6 weeks) and at the end of the trial (13 weeks). Data were collected on pre-post glycemic outcomes. Participants completed other patient-reported psychosocial outcome measures (e.g., emotional well-being, diabetes distress, attitudes toward diabetes technology, diabetes treatment satisfaction) at Week 13. Likelihood of continued device use was assessed with three items at 13 weeks.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Exploratory factor analysis supported a one-factor structure for each subscale (15-item benefit and 9-item burden subscale) when evaluated separately. Convergent, discriminant, and predictive validity, internal consistency, and test-retest reliability were supported. Benefit and burden subscales at week 6 predicted usage intention above and beyond device impact on glycemic outcomes, also controlling for baseline glycemic outcomes.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Findings support the AID-BBS as a psychometrically valid, reliable, and useful instrument for assessing burdens and benefits associated with AID system use in adults with T1D. The measure can be used to help health care providers set realistic expectations and proactively address modifiable burdens.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Shapiro</LastName><ForeName>Jenna B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Ann and Robert H Lurie Children's Hospital of Chicago, Pritzker Department of Psychiatry and Behavioral Health, Chicago, Illinois, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Department of Psychiatry &amp; Behavioral Sciences, Chicago, Illinois, United States; jeshapiro@luriechildrens.org.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Vesco</LastName><ForeName>Anthony T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Ann and Robert H Lurie Children's Hospital of Chicago, Pritzker Department of Psychiatry and Behavioral Health, Chicago, Illinois, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Department of Psychiatry &amp; Behavioral Sciences, Chicago, Illinois, United States; AVesco@luriechildrens.org.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Carroll</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago, Mary Ann &amp; J. Milburn Smith Outcomes Research and Evaluation Center, Stanley Manne Children's Research Institute, Chicago, Illinois, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Department of Pediatrics, Chicago, Illinois, United States; mscarroll@luriechildrens.org.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Weissberg-Benchell</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago, Pritzker Department of Psychiatry and Behavioral Health, Chicago, Illinois, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences, Chicago, Illinois, United States; JWBenchell@luriechildrens.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes Technol Ther</MedlineTA><NlmUniqueID>100889084</NlmUniqueID><ISSNLinking>1520-9156</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758212</ArticleId><ArticleId IdType=\"doi\">10.1089/dia.2024.0117</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38758211</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1557-8593</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Diabetes technology &amp; therapeutics</Title><ISOAbbreviation>Diabetes Technol Ther</ISOAbbreviation></Journal><ArticleTitle>Performance of subcutaneous continuous glucose monitoring in adult critically ill patients receiving vasopressor therapy.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1089/dia.2024.0035</ELocationID><Abstract><AbstractText>Background Subcutaneous continuous glucose monitoring (CGM) may facilitate glucose control in the ICU. We aimed to assess the accuracy of CGM (Dexcom G6) against arterial blood glucose (ABG) in adult critically ill patients receiving intravenous insulin infusion and vasopressor therapy. We also aimed to assess feasibility and tolerability of CGM in this setting. Methods We included ICU patients receiving mechanical ventilation, insulin, and vasopressor therapy. Numerical accuracy was assessed by the mean absolute relative difference (MARD), overall, across arterial glucose strata, over different noradrenaline equivalent infusion rates, and over time since CGM start. MARD below 14% was considered acceptable. Clinical accuracy was assessed using Clarke Error Grid (CEG) analysis. Feasibility outcome included number and duration of interrupted sensor readings due to signal loss. Tolerability outcome included skin reactions related to sensor insertion or sensor adhesives. Results We obtained 2946 paired samples from 40 patients (18 with type 2 diabetes) receiving a median (IQR) maximum noradrenaline equivalent infusion rate of 0.18 (0.08-0.33) &#xb5;g/kg/min during CGM. Overall, MARD was 12.7 (95% CI 10.7-15.3) % and 99.8% of CGM readings were within CEG zones A and B. MARD values &#x2265;14% were observed when ABG was outside target range (6-10 mmol/l [108-180 mg/dl]) and with noradrenaline equivalent infusion rates above 0.10 &#xb5;g/kg/min. Accuracy improved with time after CGM start, reaching MARD values below 14% after 36 hours. We observed four episodes of interrupted sensor readings due to signal loss ranging from 5 to 20 minutes. We observed no skin reactions related to sensor insertion or sensor adhesives. Conclusions In our ICU cohort of patients receiving vasopressor infusion, subcutaneous CGM demonstrated acceptable overall numerical and clinical accuracy. However, suboptimal accuracy may occur outside glucose ranges of 6-10 mmol/l (108-180 mg/dl), during higher dose vasopressor infusion, and during the first 36 hours after CGM start.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Friman</LastName><ForeName>Ola</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Karolinska Universitetssjukhuset, PMI, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karolinska Institutet, Stockholm, Stockholm, Sweden; ola.friman@regionstockholm.se.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Soltani</LastName><ForeName>Navid</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Karolinska Universitetssjukhuset, PMI, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karolinska Institutet, Stockholm, Stockholm, Sweden; navid.soltani@regionstockholm.se.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lind</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Gothenburg Institute of Clinical Sciences, Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Bl&#xe5; str&#xe5;ket 5, staircase H, Sahlgrenska University Hospital, Goteborg, V&#xe4;stra G&#xf6;taland, Sweden, 413 45.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NU-hospital group, Department of medicine, Uddevalla sjukhus, Uddevalla, Sweden, 45180; Marcus.lind@gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zetterqvist</LastName><ForeName>Pia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Karolinska Universitetssjukhuset, Stockholm, Sweden; pia.zetterqvist@regionstockholm.se.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Balintescu</LastName><ForeName>Anca</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Karolinska Institutet, Stockholm, Stockholm, Sweden; anca.balintescu@regionstockholm.se.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Perner</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Copenhagen University Hospital, Kobenhavn, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rigshospitalet, Kobenhavn, Denmark; anders.perner@regionh.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Oldner</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Karolinska Universitetssjukhuset, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karolinska Institutet, Stockholm, Stockholm, Sweden; anders.oldner@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rooyackers</LastName><ForeName>Olav</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Karolinska Institutet, Stockholm, Stockholm, Sweden; olav.rooyackers@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>M&#xe5;rtensson</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Karolinska Institutet, Physiology and Pharmacology, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karolinska Universitetssjukhuset, Stockholm, Sweden; johan.martensson@regionstockholm.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes Technol Ther</MedlineTA><NlmUniqueID>100889084</NlmUniqueID><ISSNLinking>1520-9156</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38758211</ArticleId><ArticleId IdType=\"doi\">10.1089/dia.2024.0035</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from bs4 import BeautifulSoup\n",
        "\n",
        "def parse_article_details(article_xml):\n",
        "    soup = BeautifulSoup(article_xml, 'xml')\n",
        "    articles = soup.find_all('PubmedArticle')\n",
        "    parsed_data = []\n",
        "    for article in articles:\n",
        "        title = article.find('ArticleTitle').text if article.find('ArticleTitle') else \"\"\n",
        "        abstract = article.find('AbstractText').text if article.find('AbstractText') else \"\"\n",
        "        parsed_data.append((title, abstract))\n",
        "    return parsed_data\n",
        "\n",
        "parsed_articles = parse_article_details(article_details_xml)\n",
        "for title, abstract in parsed_articles:\n",
        "    print(f\"Title: {title}\\nAbstract: {abstract}\\n\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "iAriAqWgojrI",
        "outputId": "c2bb1237-c052-4a50-e385-8ffa9d3a8209"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Title: Response to semaglutide of non-drinker subjects with type 2 diabetes.\n",
            "Abstract: Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) displays a worse prognosis in subjects with type 2 diabetes (T2D); effective treatments are, so far, scanty. Semaglutide showed efficacy in improving steatohepatitis. We longitudinally observed a MASLD cohort of T2D subjects starting semaglutide, to detect an improvement of non-invasive surrogates of steatosis and fibro-inflammatory liver involvement, evaluating the role of mild alcohol consumption.\n",
            "\n",
            "Title: Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia.\n",
            "Abstract: Polycystic ovary syndrome (PCOS) is an endocrinopathy in childbearing-age females which can cause many complications, such as diabetes, obesity, and dyslipidemia. The metabolic disorders in patients with PCOS were linked to gut microbial dysbiosis. However, the correlation between the gut microbial community and dyslipidemia in PCOS remains unillustrated. Our study elucidated the different gut microbiota in patients with PCOS and dyslipidemia (PCOS.D) compared to those with only PCOS and healthy women.\n",
            "\n",
            "Title: AMPK activation eliminates senescent cells in diabetic wound by inducing NCOA4 mediated ferritinophagy.\n",
            "Abstract: Diabetic wounds are one of the long-term complications of diabetes, with a disordered microenvironment, diabetic wounds can easily develop into chronic non-healing wounds, which can impose a significant burden on healthcare. In diabetic condition, senescent cells accumulate in the wound area and suppress the wound healing process. AMPK, as a molecule related to metabolism, has a close relationship with aging and diabetes. The purpose of this study was to investigate the effects of AMPK activation on wound healing and explore the underlying mechanisms.\n",
            "\n",
            "Title: Association between lipid accumulation product and psoriasis among adults: a nationally representative cross-sectional study.\n",
            "Abstract: Lipid accumulation product (LAP) is an accessible and relatively comprehensive assessment of obesity that represents both anatomical and physiological lipid accumulation. Obesity and psoriasis are potentially related, according to previous research. Investigating the relationship between adult psoriasis and the LAP index was the goal of this study.\n",
            "\n",
            "Title: Medical treatment of functional pituitary adenomas, trials and tribulations.\n",
            "Abstract: Functioning pituitary adenomas (FPAs) include most frequently prolactinomas, somatotroph or corticotroph adenomas, while thyrotroph and gonadotroph adenomas are very rare. Despite their benign histological nature (aggressive tumors are rare and malignant ones exceptional), FPAs could cause significant morbidity and increased mortality due to complications associated with hormonal excess syndromes and/or mass effect leading to compression of adjacent structures. This mini review will focus on the increasing role of medical therapy in the multimodal treatment, which also includes transsphenoidal surgery (TSS) and radiotherapy.\n",
            "\n",
            "Title: Therapy-Related Satisfaction and Quality of Life for Japanese People with Diabetes Using Rapid-Acting Insulin Analogs: A Web-Based Survey.\n",
            "Abstract: People with diabetes require insulin to regulate blood glucose (BG); rapid-acting insulin analogs (RAIA) represent one approach for BG management. New fast-acting RAIA administered at the start of a meal suppress postprandial BG better than conventional RAIA. New RAIA are expected to confer higher treatment satisfaction and improved quality of life (QOL) than conventional RAIA.\n",
            "\n",
            "Title: Association of OPRM1 rs1799971, HTR1B rs6296 and COMT rs4680 polymorphisms with clinical phenotype among women with fibromyalgia.\n",
            "Abstract: To investigate the association between three selected pain polymorphisms and clinical, functional, sensory-related, psychophysical, psychological or cognitive variables in a sample of women with fibromyalgia (FMS). One hundred twenty-three (n = 123) women with FMS completed demographic (age, height, weight), clinical (years with pain, intensity of pain at rest and during daily living activities), functional (quality of life, physical function), sensory-related (sensitization-associated and neuropathic-associated symptoms), psychophysical (pressure pain thresholds), psychological (sleep quality, depressive and anxiety level) and cognitive (pain catastrophizing, kinesiophobia) variables. Those three genotypes of the OPRM1 rs1799971, HTR1B rs6296 and COMT rs4680 single nucleotide polymorphisms were obtained by polymerase chain reactions from no-stimulated whole saliva collection. No significant differences in demographic, clinical, functional, sensory-related, psychophysical, psychological and cognitive variables according to OPRM1 rs1799971, HTR1B rs6296 or COMT rs4680 genotype were identified in our sample of women with FMS. A multilevel analysis did not either reveal any significant gene-to-gene interaction between OPRM1 rs1799971 x HTR1B rs6296, OPRM1 rs1799971 x COMT rs4680 and HTR1B rs6296 x COMT rs4680 for any of the investigated outcomes. This study revealed that three single nucleotide polymorphisms, OPRM1 rs1799971, HTR1B rs6296 or COMT rs4680, mostly associated with chronic pain were not involved in phenotyping features of FMS. Potential gene-to-gene interaction and their association with clinical phenotype in women with FMS should be further investigated in future studies including large sample sizes.\n",
            "\n",
            "Title: Comparison of HIIT and MICT and further detraining on metabolic syndrome and asprosin signaling pathway in metabolic syndrome model of rats.\n",
            "Abstract: Physical activity promotes various metabolic benefits by balancing pro and anti-inflammatory adipokines. Recent studies suggest that asprosin might be involved in progression of metabolic syndrome (MetS), however, the underlying mechanisms have not been understood yet. This study aimed to evaluate the effects of high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), and further detraining on MetS indices, insulin resistance, serum and the liver levels of asprosin, and AMP-activated protein kinase (AMPK) pathway in menopause-induced MetS model of rats. A total of 64 Wistar rats were used in this study and divided into eight groups: Sham1, OVX1 (ovariectomized), Sham2, OVX2, OVX + HIIT, OVX + MICT, OVX + HIIT + Det (detraining), and OVX + MICT + Det. Animals performed the protocols, and then serum concentrations of asprosin, TNF-α, insulin, fasting blood glucose, and lipid profiles (TC, LDL, TG, and HDL) were assessed. Additionally, the liver expression of asprosin, AMPK, and P-AMPK was measured by western blotting. Both HIIT and MICT caused a significant decrease in weight, waist circumference, BMI (P = 0.001), and serum levels of glucose, insulin, asprosin (P = 0.001), triglyceride, total cholesterol, low-density lipoprotein (LDL), and TNF-α (P = 0.001), but an increase in the liver AMPK, P-AMPK, and P-AMPK/AMPK (P = 0.001), compared with OVX2 noexercised group. MICT was superior to HIIT in reducing serum asprosin, TNF-a, TG, LDL (P = 0.001), insulin, fasting blood glucose, HOMA-IR, and QUEKI index (P = 0.001), but an increase in the liver AMPK, and p-AMPK (P = 0.001). Although after two months of de-training almost all indices returned to the pre exercise values (P < 0.05). The findings suggest that MICT effectively alleviates MetS induced by menopause, at least partly through the activation of liver signaling of P-AMPK and the reduction of asprosin and TNF-α. These results have practical implications for the development of exercise interventions targeting MetS in menopausal individuals, emphasizing the potential benefits of MICT in mitigating MetS-related complications.\n",
            "\n",
            "Title: Extracellular vesicles in glioblastoma: a challenge and an opportunity.\n",
            "Abstract: Glioblastoma is a highly heterogeneous tumor whose pathophysiological complexities dictate both the diagnosis of disease severity as well as response to therapy. Conventional diagnostic tools and standard treatment regimens have only managed to achieve limited success in the management of patients suspected of glioblastoma. Extracellular vesicles are an emerging liquid biopsy tool that has shown great promise in resolving the limitations presented by the heterogeneous nature of glioblastoma. Here we discuss the contrasting yet interdependent dual role of extracellular vesicles as communication agents that contribute to the progression of glioblastoma by creating a heterogeneous microenvironment and as a liquid biopsy tool providing an opportunity to accurately identify the disease severity and progression.\n",
            "\n",
            "Title: Development of a nomogram for identifying periodontitis cases in Denmark.\n",
            "Abstract: Although self-reported health outcomes are of importance, attempts to validate a clinical applicable instrument (e.g., nomogram) combining sociodemographic and self-reported information on periodontitis have yet to be performed to identify periodontitis cases. Clinical and self-reported periodontitis, along with sociodemographic data, were collected from 197 adults. Akaike information criterion models were developed to identify periodontitis, and nomograms developed based on its regression coefficients. The discriminatory capability was evaluated by receiver-operating characteristic curves. Decision curve analysis was performed. Smoking [OR 3.69 (95%CI 1.89, 7.21)], poor/fair self-rated oral health [OR 6.62 (95%CI 3.23, 13.56)], previous periodontal treatment [OR 9.47 (95%CI 4.02, 22.25)], and tooth loss [OR 4.96 (95%CI 2.47, 9.97)], determined higher probability of having \"Moderate/Severe Periodontitis\". Age [OR 1.08 (95%CI 1.05, 1.12)], low educational level [OR 1.65 (95%CI 1.34, 2.23)], poor/fair self-rated oral health [OR 3.57 (95%CI 1.82, 6.99)], and previous periodontal treatment [OR 6.66 (95%CI 2.83, 15.68)] determined higher probability for \"Any Periodontitis\". Both nomograms showed excellent discriminatory capability (AUC of 0.83 (95%CI 0.75, 0.91) and 0.81 (95% CI 0.74, 0.88), good calibration, and slight overestimation of high risk and underestimation of low risk. Hence, our nomograms could help identify periodontitis among adults in Denmark.\n",
            "\n",
            "Title: Are novel plant-based meat alternatives the healthier choice?\n",
            "Abstract: The global market for plant-based meat alternatives (PBMAs) is expanding quickly. In this narrative review, analysis of the most recent scientific literature was achieved to understand the nutritional profile, health implications, and the challenges faced by PBMAs. On the positive side, most PBMAs are good sources of dietary fiber, contain phytochemicals, have comparable levels of iron, and are lower in calories, saturated fat, and cholesterol than meat. However, PBMAs frequently contain anti-nutrients, have less protein, iron, and vitamin B12, are lower in protein quality, and also have higher amounts of sodium. Substituting PBMAs for meats may cause iron, vitamin B12, and less likely protein deficiency for these vulnerable population such as women, older adults, and individuals with disorders. PBMAs fall into the category of ultra-processed foods, indicating a need to develop minimally processed, clean-label products. Replacing red meat with healthy plant-based foods is associated with lower risks of cardiovascular diseases, type 2 diabetes, and total mortality. There is a lack of robust, long-term evidence on the role of PBMAs consumption in health. As the nutrient contents of PBMAs can vary, consumers must read nutrition facts labels and ingredient lists to select a product that best fits their nutritional and health objectives.\n",
            "\n",
            "Title: The impact of addition of pearl millet starch-germ complex in white bread on nutritional, textural, structural, and glycaemic response: Single blinded randomized controlled trial in healthy and pre-diabetic participants.\n",
            "Abstract: The rise of pre-diabetes at the global level has created a significant interest in developing low glycaemic index food products. The pearl millet is a cheaper source of starch and its germ contains significant amount of protein and fat. The complexing of pearl millet starch and germ by dry heat treatment (PMSGH) resulted an increase in the resistant starch content upto 45.09 % due to formation of amylose-glutelin-linoleic acid complex. The resulting pearl millet starch germ complex was incorporated into wheat bread at 20, 25, and 30 %. The PMSGH incorporated into bread at 30 % reduced the glycaemic index to 52.31. The PMSGH incorporated bread had significantly (p < 0.05)increased in the hardness with a reduction in springiness and cohesiveness. The structural attributes of the 30 % PMSGH incorporated bread revealed a significant (p < 0.05)increase in 1040/1020 cm-1 ratio and relative crystallinity. The consumption of functional bread incorporated with pearl millet starch germ complex reduced blood glucose levels and in vivo glycaemic index in healthy and pre-diabetic participants when compared to white bread. Hence, the study showed that the incorporation of pearl millet starch-germ complex into food products could be a potential new and healthier approach for improving dietary options in pre-diabetes care.\n",
            "\n",
            "Title: Feasibility and acceptability of a tailored health coaching intervention to improve type 2 diabetes self-management in Saudi Arabia: a mixed-methods randomised feasibility trial.\n",
            "Abstract: Around one-third of the population of Saudi Arabia have been diagnosed with type 2 diabetes, a condition often requiring lifestyle changes. Personalised health coaching, a strategy developed to assist individuals in overcoming challenges to adopt healthy behaviours, has not yet been widely applied in the country.\n",
            "\n",
            "Title: Preferred sources of information on diabetes prevention programmes: a population-based cross-sectional study in Poland.\n",
            "Abstract: This study aimed to analyse preferred sources of information on diabetes prevention programmes and to identify sociodemographic determinants influencing these preferences among adults in Poland.\n",
            "\n",
            "Title: Effect of metformin use on graft and patient survival in kidney transplant recipients with type 2 diabetes: a systematic review protocol.\n",
            "Abstract: Metformin is a first-line antihyperglycaemic agent for type 2 diabetes (T2DM). In addition to glycaemic control, it offers benefits related to cardiovascular health, weight neutrality and metabolic syndrome. However, its benefits in kidney transplant recipients remain unclear as metformin use is controversial in this population due to a lack of evidence and there are recommendations against its use in patients with poor kidney function. Hence, we seek to describe a protocol for a systematic review, which will assess the impact of metformin use on graft survival and mortality in kidney transplant recipients.\n",
            "\n",
            "Title: Recommendations from 'Improving health outcomes of people with diabetes: Target setting for the WHO Global Diabetes Compact' for the Indian context: Laudable but are they achievable?\n",
            "Abstract: \n",
            "\n",
            "Title: Thiamine-responsive megaloblastic anaemia.\n",
            "Abstract: We report a 26-year-old girl who was diagnosed with diabetes mellitus in her childhood and was treated with insulin. With a history of visual disturbances during her childhood and anaemia, which was partially evaluated; the possibility of syndromic diabetes was considered. Genetic analysis was done and revealed a mutation in the SLC19A2 gene, confirming the diagnosis of thiamine-responsive megaloblastic anaemia. She was supplemented with thiamine, which dramatically improved her haemoglobin levels and glucose control. However, her vision could not be salvaged as the rod-cone dystrophy is a permanent damage.\n",
            "\n",
            "Title: Long-Term therapy with CFTR modulators consistently improves glucose metabolism in adolescents and adults with Cystic Fibrosis.\n",
            "Abstract: Impaired glycemic control and the subsequent development of Cystic fibrosis Related Diabetes (CFRD) are prevalent complications, affecting up to 50% of adults with cystic fibrosis (CF). CFTR modulator (CFTRm) therapies improve pulmonary functions, reduce exacerbation rates, increase survival in people with CF (pwCF) and appear to have a positive effect on extrapulmonary manifestations, such as nutritional state, improvements in upper respiratory symptoms, and quality of life. Initial findings indicate that CFTRm may have a positive impact on short-term glycemic control; however, long-term effects remain uncertain at present.\n",
            "\n",
            "Title: Chemo-profiling and exploring Therapeutic Potential of Momordica dioica Roxb. ex Willd. for Managing Metabolic Related Disorders: In-vitro Studies, and Docking based Approach.\n",
            "Abstract: Momordica dioica Roxb. ex Willd. (M. dioica Roxb.) a nutritious and therapeutic property rich crop of Cucurbitaceae plant family. In various folklore medicine including Ayurveda fruits are used to treat several metabolic related disorders i.e., hyperglycemia, hyperlipidemia, diabetes, obesity etc. Furthermore, traditionally it is used to treat fever, inflammation, ulcer, skin diseases, haemorrhoids, hypertension and also employed as cardioprotective, hepatoprotective, analgesic, diuretic.\n",
            "\n",
            "Title: Resmetirom for MASH patients with diabetes: challenges and opportunities in the real world.\n",
            "Abstract: \n",
            "\n",
            "Title: Healing the Diabetic Wound: Unlocking the Secrets of Genes and Pathways.\n",
            "Abstract: Diabetic wounds (DWs) are open sores that can occur anywhere on a diabetic patient's body. They are often complicated by infections, hypoxia, oxidative stress, hyperglycemia, and reduced growth factors and nucleic acids. The healing process involves four phases: homeostasis, inflammation, proliferation, and remodeling, regulated by various cellular and molecular events. Numerous genes and signaling pathways such as VEGF, TGF-β, NF-κB, PPAR-γ, MMPs, IGF, FGF, PDGF, EGF, NOX, TLR, JAK-STAT, PI3K-Akt, MAPK, ERK, JNK, p38, Wnt/β-catenin, Hedgehog, Notch, Hippo, FAK, Integrin, and Src pathways are involved in these events. These pathways and genes are often dysregulated in DWs leading to impaired healing. The present review sheds light on the pathogenesis, healing process, signaling pathways, and genes involved in DW. Further, various therapeutic strategies that target these pathways and genes via nanotechnology are also discussed. Additionally, clinical trials on DW related to gene therapy are also covered in the present review.\n",
            "\n",
            "Title: Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.\n",
            "Abstract: Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised by extremely high plasma LDL cholesterol from birth, causing atherosclerotic cardiovascular disease at a young age. Lipoprotein apheresis in combination with lipid-lowering drugs effectively reduce LDL cholesterol, but long-term health outcomes of such treatment are unknown. We aimed to investigate the long-term cardiovascular outcomes associated with lipoprotein apheresis initiated in childhood or adolescence.\n",
            "\n",
            "Title: Mechanoresponsive ETS1 causes endothelial dysfunction and arterialization in varicose veins via NOTCH4/DLL4 signaling.\n",
            "Abstract: Varicose veins are the most common venous disorder in humans and are characterized by hemodynamic instability due to valvular insufficiency and orthostatic lifestyle factors. It is unclear how changes in biomechanical signals cause aberrant remodeling of the vein wall. Our previous studies suggest that Notch signaling is implicated in varicose vein arterialization. In the arterial system, mechanoresponsive ETS1 is a transcriptional activator of the endothelial Notch, but its involvement in sensing disrupted venous flow and varicose vein formation has not been investigated. Here, we use human varicose veins and cultured human venous endothelial cells to show that disturbed venous shear stress activates ETS1-NOTCH4/DLL4 signaling. Notch components were highly expressed in the neointima, whereas ETS1 was upregulated in all histological layers of varicose veins. In vitro microfluidic flow-based studies demonstrate that even minute changes in venous flow patterns enhance ETS1-NOTCH4/DLL4 signaling. Uniform venous shear stress, albeit an inherently low-flow system, does not induce ETS1 and Notch proteins. ETS1 activation under altered flow was mediated primarily by MEK1/2 and, to a lesser extent, by MEK5 but was independent of p38 MAP kinase. Endothelial cell-specific ETS1 knockdown prevented disturbed flow-induced NOTCH4/DLL4 expression. TK216, an inhibitor of ETS-family, prevented the acquisition of arterial molecular identity and loss of endothelial integrity in cells exposed to the ensuing altered shear stress. We conclude that ETS1 senses blood flow disturbances and may promote venous remodeling by inducing endothelial dysfunction. Targeting ETS1 rather than downstream Notch proteins could be an effective and safe strategy to develop varicose vein therapies.\n",
            "\n",
            "Title: In the heart and beyond: Mitochondrial dysfunction in heart failure with preserved ejection fraction (HFpEF).\n",
            "Abstract: Heart failure with preserved ejection fraction (HFpEF) is a major cardiovascular disorder with increasing prevalence and a limited range of targeted treatment options. While HFpEF can be derived from several different etiologies, much of the current growth in the disease is being driven by metabolic dysfunction (e.g. obesity, diabetes, hypertension). Deleterious changes in mitochondrial energy metabolism are a common feature of HFpEF, and may help to drive the progression of the disease. In this brief article we aim to review various aspects of cardiac mitochondrial dysfunction in HFpEF, discuss the emerging topic of HFpEF-driven mitochondrial dysfunction in tissues beyond the heart, and examine whether supporting mitochondrial function may be a therapeutic approach to arrest or reverse disease development.\n",
            "\n",
            "Title: Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming.\n",
            "Abstract: Vascular calcification is strongly linked to the development of major adverse cardiovascular events, but effective treatments are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging category of oral hypoglycemic drugs that have displayed marked effects on metabolic and cardiovascular diseases, including recently reported vascular medial calcification. However, the roles and underlying mechanisms of SGLT2 inhibitors in vascular calcification have not been fully elucidated. Thus, we aimed to further determine whether SGLT2 inhibitors protect against vascular calcification and to investigate the mechanisms involved.\n",
            "\n",
            "Title: JinLiDa granules alleviates cardiac hypertrophy and inflammation in diabetic cardiomyopathy by regulating TP53.\n",
            "Abstract: JinLiDa granules (JLD) is a traditional Chinese medicine (TCM) used to treat type 2 diabetes mellitus with Qi and Yin deficiency. Clinical evidence has shown that JLD can alleviate diabetic cardiomyopathy, but the exact mechanism is not yet clear.\n",
            "\n",
            "Title: A single-cell profile reveals the transcriptional regulation responded for Abelmoschus manihot (L.) treatment in diabetic kidney disease.\n",
            "Abstract: Huangkui capsule (HKC), as an ethanol extract of Abelmoschus manihot (L.), has a significant efficacy in treatment of the patients with diabetic kidney disease (DKD). The bioactive ingredients of HKC mainly include the flavonoids such as rutin, hyperoside, hibifolin, isoquercetin, myricetin, quercetin and quercetin-3-O-robinobioside.\n",
            "\n",
            "Title: Diagnosis and Management of Periprosthetic Joint Infections After Total Ankle Arthroplasty.\n",
            "Abstract: Periprosthetic joint infection (PJI) after total ankle arthroplasty (TAA) is a dreaded complication that may lead to catastrophic outcomes. Risk factors include a history of surgery on the operated ankle, low preoperative function scores, diabetes, extended surgical time, and postoperative wound-healing problems. Clinical presentation varies and may include increasing ankle pain and swelling, high temperature, local erythema, wound drainage, and dehiscence. The initial diagnostic evaluation should include plain radiographs, erythrocyte sedimentation rate, C-reactive protein levels, and leukocyte count. In suspected cases with elevated erythrocyte sedimentation rate and C-reactive protein, aspiration of the ankle joint for synovial fluid analysis, Gram staining, and culture should be performed. Antibiotic therapy should be based on the pathogen identified, and the surgical strategy should be determined based on the time lines of PJI. Early PJI can be treated with irrigation and débridement with polyethylene exchange. The surgical treatment of choice for late PJI is two-stage revision arthroplasty, which includes removal of the implant, insertion of an antibiotic spacer, and reimplantation of a TAA. In certain chronic PJI cases, permanent articulating antibiotic spacers can be left in place or an ankle arthrodesis can be performed. Below-knee amputation is considered as the final option after limb-sparing procedures have failed.\n",
            "\n",
            "Title: Clinical presentation, antimicrobial resistance, and treatment outcomes of Aeromonas human infections: A 14-year retrospective study and comparative genomics of two isolates from fatal cases.\n",
            "Abstract: Aeromonas virulence may not be entirely dependent on the host immune status. Pathophysiologic determinants of disease progression and severity remain unclear.\n",
            "\n",
            "Title: The effect of calcaneus and metatarsal head offloading insoles on healthy subjects' gait kinematics, kinetics, asymmetry, and the implications for plantar pressure management: A pilot study.\n",
            "Abstract: The global number of people with diabetes is estimated to reach 643 million by 2030 of whom 19-34% will present with diabetic foot ulceration. Insoles which offload high-risk ulcerative regions on the foot, by removing insole material, are the main contemporary conservative treatment to maintain mobility and reduce the likelihood of ulceration. However, their effect on the rest of the foot and relationship with key gait propulsive and balance kinematics and kinetics has not been well researched.\n",
            "\n",
            "Title: Bacteriological analysis and antibiotic resistance in patients with diabetic foot ulcers in Dhaka.\n",
            "Abstract: The primary objective of this study was to isolate bacteria from diabetic foot ulcers and subsequently assess their antibiotic resistance capabilities. Seventy-five patients diagnosed with diabetic foot ulcers were investigated. A number of these patients (97.33%) had type 2 diabetes, with a significant proportion of them having been diagnosed for 1-5 years (29.33%). Notably, a substantial number of these individuals were on insulin usage (78.66%). Among the patients under examination, 49.33% reported having no use of tobacco products, alcohol, or betel leaf. The ulcers analyzed in this study were classified into grades 1-5 according to the Wagner scale. Wagner grade 2 diabetic foot ulcers had the highest number of culture-positive patients, at 33.33%. Pus samples collected from patients were cultured on selective media, and bacterial identity was confirmed by biochemical tests and polymerase chain reaction. A total of 141 isolates were isolated. Among the isolates, 82.97% gram-negative bacteria and 17.02% gram-positive bacteria were detected. Klebsiella pneumoniae was the most common isolate. Proteus spp., Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus were also detected. Approximately 61.33% of the ulcers exhibited were polybacterial. In this study, it was observed that all bacterial isolates, except for Proteus spp., were primarily detected in patients classified under Wagner's grade 2. Moreover, antibiotic susceptibility was also tested on these 141 isolates. Among them, Escherichia coli showed the highest multidrug resistance, 81.81%. Most of the gram-negative bacteria were resistant to ampicillin. All of the gram-negative isolates exhibited high levels of susceptibility to piperacillin-tazobactam, and these levels were Klebsiella pneumoniae (97.56%), Pseudomonas aeruginosa (95.24%), Escherichia coli (81.82%), and Proteus spp. (80%). On the other hand, gram-positive Staphylococcus aureus mostly showed sensitivity towards vancomycin and norfloxacin (79.17%).\n",
            "\n",
            "Title: Electrolyte disturbances in patients hospitalized for COVID-19 infection: An observational study.\n",
            "Abstract: There are multiple mechanisms by which The Coronavirus-19 (COVID-19) infection can cause electrolyte abnormalities, which may not be the case for bacterial causes of pneumonia. This study aimed to assess the differences in electrolyte levels between patients suffering from COVID-19 and bacterial pneumonia. This is an original, retrospective study. Two cohorts of hospitalized patients were included, 1 suffering from COVID-19 and the other from bacterial pneumonia. Their day 1 and day 3 levels of sodium, potassium, magnesium, and phosphorus, as well as their outcomes, were extracted from the charts. Statistical analysis was subsequently performed. Mean admission levels of sodium, potassium, phosphorus, and magnesium were 135.64 ± 6.13, 4.38 ± 0.69, 3.53 ± 0.69, and 2.03 ± 0.51, respectively. The mean day 3 levels of these electrolytes were 138.3 ± 5.06, 4.18 ± 0.59, 3.578 ± 0.59, and 2.11 ± 0.64, respectively. Patients suffering from bacterial pneumonia were significantly older (N = 219, mean = 64.88 ± 15.99) than patients with COVID-19 pneumonia (N = 240, mean = 57.63 ± 17.87). Bacterial pneumonia group had significantly higher serum potassium (N = 211, mean = 4.51 ± 0.76), and magnesium (N = 115, mean = 2.12 ± 0.60) levels compared to COVID-19 group (N = 227, mean = 4.254 ± 0.60 for potassium and N = 118, mean = 1.933 ± 0.38 for magnesium). Only magnesium was significantly higher among day 3 electrolytes in the bacterial pneumonia group. No significant association between electrolyte levels and outcomes was seen. We found that COVID-19 patients had lower potassium and magnesium levels on admission, possibly due to the effect of COVID-19 on the renin-angiotensin-aldosterone system as well as patient characteristics and management. We did not find enough evidence to recommend using electrolyte levels as a determinator of prognosis, but more research is needed.\n",
            "\n",
            "Title: Influence of continuous 4C nursing on quality of life and self-care ability of patients with diabetes retinopathy: An observational study.\n",
            "Abstract: This study aims to investigate the impact of continuous 4C nursing on patients with diabetes retinopathy (DR) and its influence on self-care ability. A total of 100 DR patients admitted to our hospital from October 2020 to October 2022 were randomly divided into a control group and an observation group, with 50 cases in each group. The control group received routine care, while the observation group received continuous 4C care. The nursing effects of both groups were compared. After nursing, the observation group showed a lower self-rating anxiety scale score and a higher self-care ability scale score compared to the control group (P < .05). The SQQL-VI scores for all social activities were also higher in the observation group (P < .05). Additionally, the observation group had lower levels of fasting blood glucose, 2-hour postprandial blood glucose, and glycated hemoglobin than the control group (P < .05). Moreover, the observation group had higher visual acuity and lower intraocular pressure than the control group (P < .05). The visual impairment rate was lower and the overall compliance rate was higher in the observation group compared to the control group (P < .05). After nursing, both groups showed improvements in symptoms, visual function, physical function, psychological and social activity scores, visual acuity, and patient satisfaction scores. The observation group showed greater improvements compared to the control group (P < .05). The application of continuous 4C nursing in DR patients has shown positive effects, including improved patient compliance and satisfaction, enhanced patient quality of life and visual acuity. These findings suggest that continuous 4C nursing should be widely promoted and applied in clinical practice.\n",
            "\n",
            "Title: Regulatory patterns of Chinese patent medicine for lipid metabolism disorders in patients with type 2 diabetes mellitus complicated by ischemic stroke: A systematic review and network meta-analysis.\n",
            "Abstract: To investigate the regulatory patterns of Chinese patent medicine (CPM) interventions on lipid metabolism disorders in patients with type 2 diabetes mellitus (T2DM) complicated by ischemic stroke.\n",
            "\n",
            "Title: Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.\n",
            "Abstract: Incretin-based drugs, a class of Antidiabetic medications (ADMs) used in the treatment of type 2 diabetes, may affect the incidence of prostate cancer (PCa). But real-world evidence for this possible effect is lacking. Therefore, the aim of this study is to assess the effect of incretin-based drugs on the incidence of PCa, including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. We searched PubMed, Embase, and Cochrane Library databases for eligible studies through September 2023. Two independent reviewers performed screening and data extraction. We used the Cochrane Handbook for Systematic Reviews and the Newcastle-Ottawa Scale (NOS) to assess the quality of included randomized controlled trials (RCTs) and cohort studies. We did a meta-analysis of available trial data to calculate overall risk ratios (RRs) for PCa. A total of 1238 articles were identified in our search. After screening for eligibility, 7 high-quality studies met the criteria for meta-analysis, including 2 RCTs and 5 cohort studies, with a total of 1165,738 patients. Compared with the control group, we found that incretin-based drugs reduced the relative risk of PCa by 35% (95% confidence interval (CI), 0.17-0.49; P = .0006). In subgroup analysis, the RR values for GLP-1 receptor agonists and DPP-4 inhibitors were 62% (95% CI, 0.45-0.85; P = .003) and 72% (95% CI, 0.46-1.12; P = .14), respectively. Incretin-based drugs are associated with lower incidence of prostate cancer and may have a preventive effect on prostate cancer in patients with type 2 diabetes.\n",
            "\n",
            "Title: Limb salvage and systemic management of gouty tophi: Case series.\n",
            "Abstract: Gout is a chronic disease characterized by deposition of monosodium urate crystals. Tophi develop in some individuals with untreated or uncontrolled gout, which leads to ulcerations, cosmetic problems, mechanical obstruction of joint movement, joint damage and musculoskeletal disability. Currently, the treatment of gouty tophi is controversial and challenging. Both surgical and internal medical treatments have limitations and require further exploration in clinical practice.\n",
            "\n",
            "Title: Evaluation of adverse reactions induced by anti-tuberculosis drugs among hospitalized patients in Wuhan, China: A retrospective study.\n",
            "Abstract: The study aims to estimate the incidence and risk factors of adverse drug reactions (ADRs) induced by anti-tuberculosis (TB) drugs. A single center retrospective analysis of patients taking anti-TB therapy from January 2016 to December 2018 in the hospital was conducted. Univariate and multivariate logistic regression analysis were used to identify these risk factors of ADRs induced by anti-TB drugs. Among 1430 patients receiving anti-TB therapy, 440 (30.77%) patients showed at least 1 ADR induced by anti-TB drugs. Hyperuricemia was the most common ADR, followed by hepatic function test abnormality, liver damage and gastrointestinal reactions. Significant differences (P < .05) were also seen in diabetes, age, treatment duration, type of TB (extrapulmonary) and some therapeutic regimens between ADR group and non-ADR group, respectively. Multivariate logistic regression analysis showed that treatment duration (OR = 1.029, 95%CI[1.018-1.040], P = .000), type of TB (extrapulmonary, OR = 1.487, 95%CI[1.134-1.952], P = .004) and some therapeutic regimens (HREZ, OR = 1.425, 95%CI[0.922-2.903], P = .001; HRZS, OR = 2.063, 95% CI[1.234-3.449], P = .006; HRZ, OR = 3.623, 95%CI[2.289-5.736], P = .000) were risk factors for ADRs induced by anti-TB drugs. Anti-TB drugs usually induced the occurrence of severe and frequent adverse effects, such as hyperuricemia. Treatment duration, HREZ, HRZS and HRZ regimens, and type of TB (extrapulmonary) should be considered as high-risk factors. Thus, it should be recommended to consider optimum management during anti-TB therapy, particularly hyperuricemia monitoring and hepatic function test.\n",
            "\n",
            "Title: A Comparison of Adverse Short-Term Outcomes After Forefoot Amputation Based on Patient Height.\n",
            "Abstract: The objective of this investigation was to evaluate adverse short-term outcomes after partial forefoot amputation with a specific comparison performed based on patient height.\n",
            "\n",
            "Title: Association of Preulcerative Foot Care and Outcomes of Diabetic Foot Ulceration.\n",
            "Abstract: The purpose of this study was to determine the association of preulcerative foot care and outcomes of diabetic foot ulcerations (DFUs).\n",
            "\n",
            "Title: Effectiveness of Peripheral Nerve Block in Terms of Search for a Standardized Treatment Protocol in Diabetic Foot Patients Using Anticoagulants: A Double-Center Study.\n",
            "Abstract: Lower-extremity amputation for a diabetic foot is mainly performed under general or central neuraxial anesthesia. Ultrasound-guided peripheral nerve block (PNB) can be a good alternative, especially for patients who require continuous anticoagulation treatment and patients with additional comorbidities. We evaluated bleeding due to PNB application in patients with diabetic foot receiving antiplatelet or anticoagulant therapy. Perioperative morbidity and mortality and the need for intensive care hospitalization were analyzed.\n",
            "\n",
            "Title: Postoperative Opioid-Prescribing Practice in Limb Preservation Surgery.\n",
            "Abstract: Limb preservation surgery affects more than 100,000 Americans annually. Current postoperative pain management prescribing practices of podiatric physicians in the United States are understudied. We examined prescribing practices for limb preservation surgery to identify prescriber characteristics' that may be associated with postoperative opioid-prescribing practices.\n",
            "\n",
            "Title: Rate and Location of Reulceration and Reamputation After Partial First-Ray Amputation versus Hallux Amputation in Diabetic and Nondiabetic Populations.\n",
            "Abstract: We sought to determine the rates of reulceration and reamputation in individuals who underwent partial first-ray amputations versus hallux amputations in diabetic and nondiabetic populations.\n",
            "\n",
            "Title: The Utility of Advanced Lower-Extremity Duplex Using Pedal Acceleration Time in the Management of the Threatened Diabetic Foot.\n",
            "Abstract: Patients with diabetes and diffuse infrageniculate arterial disease who present with chronic limb-threatening ischemia require an exact anatomical plan for revascularization. Advanced pedal duplex can be used to define possible routes for revascularization. In addition, pedal acceleration time (PAT) can predict the success or failure of both medical and surgical interventions.\n",
            "\n",
            "Title: Intraretinal Hyper-Reflective Foci Are Almost Universally Present and Co-Localize With Intraretinal Fluid in Diabetic Macular Edema.\n",
            "Abstract: In diabetic macular edema (DME), hyper-reflective foci (HRF) has been linked to disease severity and progression. Using an automated approach, we aimed to investigate the baseline distribution of HRF in DME and their co-localization with cystoid intraretinal fluid (IRF).\n",
            "\n",
            "Title: Improvement in Central Serous Chorioretinopathy Following Multiwavelength Photobiomodulation Treatment - Case Report.\n",
            "Abstract: Central serous chorioretinopathy (CSCR) is a condition where fluid build-up accumulates underneath the retina, resulting in retinal pigment epithelium (RPE) detachment and vision loss. Irreversible retinal functional and anatomical changes are possible consequences. Research into novel strategies to aid in recovery are of interest. Photobiomodulation (PBM) uses light wavelengths to improve cellular function and shows positive effects in several conditions including those with edema.\n",
            "\n",
            "Title: Mitochondria targeted esculetin administration improves insulin resistance and hyperglycemia-induced atherosclerosis in db/db mice.\n",
            "Abstract: The development and progression of hyperglycemia (HG) and HG-associated atherosclerosis are exacerbated by mitochondrial dysfunction due to dysregulated mitochondria-derived ROS generation. We recently synthesized a novel mitochondria-targeted esculetin (Mito-Esc) and tested its dose-response therapeutic efficacy in mitigating HG-induced atherosclerosis in db/db mice. In comparison to simvastatin and pioglitazone, Mito-Esc administration resulted in a considerable reduction in body weights and improved glucose homeostasis, possibly by reducing hepatic gluconeogenesis, as indicated by a reduction in glycogen content, non-esterified free fatty acids (NEFA) levels, and fructose 1,6-bisphosphatase (FBPase) activity. Interestingly, Mito-Esc treatment, by regulating phospho-IRS and phospho-AKT levels, greatly improved palmitate-induced insulin resistance, resulting in enhanced glucose uptake in adipocytes and HepG2 cells. Also, and importantly, Mito-Esc administration prevented HG-induced atheromatous plaque formation and lipid accumulation in the descending aorta. In addition, Mito-Esc administration inhibited the HG-mediated increase in VACM, ICAM, and MAC3 levels in the aortic tissue, as well as reduced the serum pro-inflammatory cytokines and markers of senescence. In line with this, Mito-Esc significantly inhibited monocyte adherence to human aortic endothelial cells (HAECs) treated with high glucose and reduced high glucose-induced premature senescence in HAECs by activating the AMPK-SIRT1 pathway. In contrast, Mito-Esc failed to regulate high glucose-induced endothelial cell senescence under AMPK/SIRT1-depleted conditions. Together, the therapeutic efficacy of Mito-Esc in the mitigation of hyperglycemia-induced insulin resistance and the associated atherosclerosis is in part mediated by potentiating the AMPK-SIRT1 axis. KEY MESSAGES: Mito-Esc administration significantly mitigates diabetes-induced atherosclerosis. Mito-Esc improves hyperglycemia (HG)-associated insulin resistance. Mito-Esc inhibits HG-induced vascular senescence and inflammation in the aorta. Mito-Esc-mediated activation of the AMPK-SIRT1 axis regulates HG-induced endothelial cell senescence.\n",
            "\n",
            "Title: Evaluation of the Factors Influencing Mortality in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Study of 166 Patients.\n",
            "Abstract: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening acute mucocutaneous disorders usually triggered by drugs. In this study, we aimed to evaluate the factors affecting mortality in patients with SJS-TEN.\n",
            "\n",
            "Title: Cardioprotective effects of vaccination in hospitalized patients with COVID-19.\n",
            "Abstract: COVID-19 vaccination has been shown to prevent and reduce the severity of COVID-19 disease. The aim of this study was to explore the cardioprotective effect of COVID-19 vaccination in hospitalized COVID-19 patients. In this retrospective, single-center cohort study, we included hospitalized COVID-19 patients with confirmed vaccination status from July 2021 to February 2022. We assessed outcomes such as acute cardiac events and cardiac biomarker levels through clinical and laboratory data. Our analysis covered 167 patients (69% male, mean age 58 years, 42% being fully vaccinated). After adjustment for confounders, vaccinated hospitalized COVID-19 patients displayed a reduced relative risk for acute cardiac events (RR: 0.33, 95% CI [0.07; 0.75]) and showed diminished troponin T levels (Cohen's d: - 0.52, 95% CI [- 1.01; - 0.14]), compared to their non-vaccinated peers. Type 2 diabetes (OR: 2.99, 95% CI [1.22; 7.35]) and existing cardiac diseases (OR: 4.31, 95% CI [1.83; 10.74]) were identified as significant risk factors for the emergence of acute cardiac events. Our findings suggest that COVID-19 vaccination may confer both direct and indirect cardioprotective effects in hospitalized COVID-19 patients.\n",
            "\n",
            "Title: Psychometric Properties of the Automated Insulin Delivery - Benefits and Burdens Scale (AID-BBS) for Adults with Type 1 Diabetes.\n",
            "Abstract: To evaluate the psychometric properties of a patient-reported outcome measure, The Automated Insulin Delivery - Benefits and Burdens Scale (AID-BBS), which was designed to assess benefits and burdens of AID use in adults with type 1 diabetes (T1D). The measure was hypothesized to have validity, reliability, and clinical utility for predicting likelihood of continued use of an AID system.\n",
            "\n",
            "Title: Performance of subcutaneous continuous glucose monitoring in adult critically ill patients receiving vasopressor therapy.\n",
            "Abstract: Background Subcutaneous continuous glucose monitoring (CGM) may facilitate glucose control in the ICU. We aimed to assess the accuracy of CGM (Dexcom G6) against arterial blood glucose (ABG) in adult critically ill patients receiving intravenous insulin infusion and vasopressor therapy. We also aimed to assess feasibility and tolerability of CGM in this setting. Methods We included ICU patients receiving mechanical ventilation, insulin, and vasopressor therapy. Numerical accuracy was assessed by the mean absolute relative difference (MARD), overall, across arterial glucose strata, over different noradrenaline equivalent infusion rates, and over time since CGM start. MARD below 14% was considered acceptable. Clinical accuracy was assessed using Clarke Error Grid (CEG) analysis. Feasibility outcome included number and duration of interrupted sensor readings due to signal loss. Tolerability outcome included skin reactions related to sensor insertion or sensor adhesives. Results We obtained 2946 paired samples from 40 patients (18 with type 2 diabetes) receiving a median (IQR) maximum noradrenaline equivalent infusion rate of 0.18 (0.08-0.33) µg/kg/min during CGM. Overall, MARD was 12.7 (95% CI 10.7-15.3) % and 99.8% of CGM readings were within CEG zones A and B. MARD values ≥14% were observed when ABG was outside target range (6-10 mmol/l [108-180 mg/dl]) and with noradrenaline equivalent infusion rates above 0.10 µg/kg/min. Accuracy improved with time after CGM start, reaching MARD values below 14% after 36 hours. We observed four episodes of interrupted sensor readings due to signal loss ranging from 5 to 20 minutes. We observed no skin reactions related to sensor insertion or sensor adhesives. Conclusions In our ICU cohort of patients receiving vasopressor infusion, subcutaneous CGM demonstrated acceptable overall numerical and clinical accuracy. However, suboptimal accuracy may occur outside glucose ranges of 6-10 mmol/l (108-180 mg/dl), during higher dose vasopressor infusion, and during the first 36 hours after CGM start.\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import re\n",
        "import nltk\n",
        "from nltk.corpus import stopwords\n",
        "from nltk.tokenize import word_tokenize\n",
        "from nltk.stem import WordNetLemmatizer\n",
        "\n",
        "# Download necessary NLTK data\n",
        "nltk.download('punkt')\n",
        "nltk.download('stopwords')\n",
        "nltk.download('wordnet')\n",
        "\n",
        "def preprocess_text(text):\n",
        "    text = re.sub(r'<.*?>', '', text)\n",
        "    text = re.sub(r'[^a-zA-Z\\s]', '', text)\n",
        "    tokens = word_tokenize(text)\n",
        "    tokens = [word for word in tokens if word.lower() not in stopwords.words('english')]\n",
        "    lemmatizer = WordNetLemmatizer()\n",
        "    tokens = [lemmatizer.lemmatize(word) for word in tokens]\n",
        "    return ' '.join(tokens)\n",
        "\n",
        "preprocessed_articles = [(preprocess_text(title), preprocess_text(abstract)) for title, abstract in parsed_articles]\n",
        "for title, abstract in preprocessed_articles:\n",
        "    print(f\"Title: {title}\\nAbstract: {abstract}\\n\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "IrRKUTyCpXWp",
        "outputId": "7e1eeea1-948e-4df3-9220-f344ab5a91a8"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Unzipping tokenizers/punkt.zip.\n",
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Unzipping corpora/stopwords.zip.\n",
            "[nltk_data] Downloading package wordnet to /root/nltk_data...\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Title: Response semaglutide nondrinker subject type diabetes\n",
            "Abstract: Metabolic dysfunctionassociated Steatotic Liver Disease MASLD display worse prognosis subject type diabetes TD effective treatment far scanty Semaglutide showed efficacy improving steatohepatitis longitudinally observed MASLD cohort TD subject starting semaglutide detect improvement noninvasive surrogate steatosis fibroinflammatory liver involvement evaluating role mild alcohol consumption\n",
            "\n",
            "Title: Characterization gut microbiota polycystic ovary syndrome dyslipidemia\n",
            "Abstract: Polycystic ovary syndrome PCOS endocrinopathy childbearingage female cause many complication diabetes obesity dyslipidemia metabolic disorder patient PCOS linked gut microbial dysbiosis However correlation gut microbial community dyslipidemia PCOS remains unillustrated study elucidated different gut microbiota patient PCOS dyslipidemia PCOSD compared PCOS healthy woman\n",
            "\n",
            "Title: AMPK activation eliminates senescent cell diabetic wound inducing NCOA mediated ferritinophagy\n",
            "Abstract: Diabetic wound one longterm complication diabetes disordered microenvironment diabetic wound easily develop chronic nonhealing wound impose significant burden healthcare diabetic condition senescent cell accumulate wound area suppress wound healing process AMPK molecule related metabolism close relationship aging diabetes purpose study investigate effect AMPK activation wound healing explore underlying mechanism\n",
            "\n",
            "Title: Association lipid accumulation product psoriasis among adult nationally representative crosssectional study\n",
            "Abstract: Lipid accumulation product LAP accessible relatively comprehensive assessment obesity represents anatomical physiological lipid accumulation Obesity psoriasis potentially related according previous research Investigating relationship adult psoriasis LAP index goal study\n",
            "\n",
            "Title: Medical treatment functional pituitary adenoma trial tribulation\n",
            "Abstract: Functioning pituitary adenoma FPAs include frequently prolactinomas somatotroph corticotroph adenoma thyrotroph gonadotroph adenoma rare Despite benign histological nature aggressive tumor rare malignant one exceptional FPAs could cause significant morbidity increased mortality due complication associated hormonal excess syndrome andor mass effect leading compression adjacent structure mini review focus increasing role medical therapy multimodal treatment also includes transsphenoidal surgery TSS radiotherapy\n",
            "\n",
            "Title: TherapyRelated Satisfaction Quality Life Japanese People Diabetes Using RapidActing Insulin Analogs WebBased Survey\n",
            "Abstract: People diabetes require insulin regulate blood glucose BG rapidacting insulin analog RAIA represent one approach BG management New fastacting RAIA administered start meal suppress postprandial BG better conventional RAIA New RAIA expected confer higher treatment satisfaction improved quality life QOL conventional RAIA\n",
            "\n",
            "Title: Association OPRM r HTRB r COMT r polymorphism clinical phenotype among woman fibromyalgia\n",
            "Abstract: investigate association three selected pain polymorphism clinical functional sensoryrelated psychophysical psychological cognitive variable sample woman fibromyalgia FMS One hundred twentythree n woman FMS completed demographic age height weight clinical year pain intensity pain rest daily living activity functional quality life physical function sensoryrelated sensitizationassociated neuropathicassociated symptom psychophysical pressure pain threshold psychological sleep quality depressive anxiety level cognitive pain catastrophizing kinesiophobia variable three genotype OPRM r HTRB r COMT r single nucleotide polymorphism obtained polymerase chain reaction nostimulated whole saliva collection significant difference demographic clinical functional sensoryrelated psychophysical psychological cognitive variable according OPRM r HTRB r COMT r genotype identified sample woman FMS multilevel analysis either reveal significant genetogene interaction OPRM r x HTRB r OPRM r x COMT r HTRB r x COMT r investigated outcome study revealed three single nucleotide polymorphism OPRM r HTRB r COMT r mostly associated chronic pain involved phenotyping feature FMS Potential genetogene interaction association clinical phenotype woman FMS investigated future study including large sample size\n",
            "\n",
            "Title: Comparison HIIT MICT detraining metabolic syndrome asprosin signaling pathway metabolic syndrome model rat\n",
            "Abstract: Physical activity promotes various metabolic benefit balancing pro antiinflammatory adipokines Recent study suggest asprosin might involved progression metabolic syndrome MetS however underlying mechanism understood yet study aimed evaluate effect highintensity interval training HIIT moderateintensity continuous training MICT detraining MetS index insulin resistance serum liver level asprosin AMPactivated protein kinase AMPK pathway menopauseinduced MetS model rat total Wistar rat used study divided eight group Sham OVX ovariectomized Sham OVX OVX HIIT OVX MICT OVX HIIT Det detraining OVX MICT Det Animals performed protocol serum concentration asprosin TNF insulin fasting blood glucose lipid profile TC LDL TG HDL assessed Additionally liver expression asprosin AMPK PAMPK measured western blotting HIIT MICT caused significant decrease weight waist circumference BMI P serum level glucose insulin asprosin P triglyceride total cholesterol lowdensity lipoprotein LDL TNF P increase liver AMPK PAMPK PAMPKAMPK P compared OVX noexercised group MICT superior HIIT reducing serum asprosin TNFa TG LDL P insulin fasting blood glucose HOMAIR QUEKI index P increase liver AMPK pAMPK P Although two month detraining almost index returned pre exercise value P finding suggest MICT effectively alleviates MetS induced menopause least partly activation liver signaling PAMPK reduction asprosin TNF result practical implication development exercise intervention targeting MetS menopausal individual emphasizing potential benefit MICT mitigating MetSrelated complication\n",
            "\n",
            "Title: Extracellular vesicle glioblastoma challenge opportunity\n",
            "Abstract: Glioblastoma highly heterogeneous tumor whose pathophysiological complexity dictate diagnosis disease severity well response therapy Conventional diagnostic tool standard treatment regimen managed achieve limited success management patient suspected glioblastoma Extracellular vesicle emerging liquid biopsy tool shown great promise resolving limitation presented heterogeneous nature glioblastoma discus contrasting yet interdependent dual role extracellular vesicle communication agent contribute progression glioblastoma creating heterogeneous microenvironment liquid biopsy tool providing opportunity accurately identify disease severity progression\n",
            "\n",
            "Title: Development nomogram identifying periodontitis case Denmark\n",
            "Abstract: Although selfreported health outcome importance attempt validate clinical applicable instrument eg nomogram combining sociodemographic selfreported information periodontitis yet performed identify periodontitis case Clinical selfreported periodontitis along sociodemographic data collected adult Akaike information criterion model developed identify periodontitis nomogram developed based regression coefficient discriminatory capability evaluated receiveroperating characteristic curve Decision curve analysis performed Smoking CI poorfair selfrated oral health CI previous periodontal treatment CI tooth loss CI determined higher probability ModerateSevere Periodontitis Age CI low educational level CI poorfair selfrated oral health CI previous periodontal treatment CI determined higher probability Periodontitis nomogram showed excellent discriminatory capability AUC CI CI good calibration slight overestimation high risk underestimation low risk Hence nomogram could help identify periodontitis among adult Denmark\n",
            "\n",
            "Title: novel plantbased meat alternative healthier choice\n",
            "Abstract: global market plantbased meat alternative PBMAs expanding quickly narrative review analysis recent scientific literature achieved understand nutritional profile health implication challenge faced PBMAs positive side PBMAs good source dietary fiber contain phytochemical comparable level iron lower calorie saturated fat cholesterol meat However PBMAs frequently contain antinutrients le protein iron vitamin B lower protein quality also higher amount sodium Substituting PBMAs meat may cause iron vitamin B le likely protein deficiency vulnerable population woman older adult individual disorder PBMAs fall category ultraprocessed food indicating need develop minimally processed cleanlabel product Replacing red meat healthy plantbased food associated lower risk cardiovascular disease type diabetes total mortality lack robust longterm evidence role PBMAs consumption health nutrient content PBMAs vary consumer must read nutrition fact label ingredient list select product best fit nutritional health objective\n",
            "\n",
            "Title: impact addition pearl millet starchgerm complex white bread nutritional textural structural glycaemic response Single blinded randomized controlled trial healthy prediabetic participant\n",
            "Abstract: rise prediabetes global level created significant interest developing low glycaemic index food product pearl millet cheaper source starch germ contains significant amount protein fat complexing pearl millet starch germ dry heat treatment PMSGH resulted increase resistant starch content upto due formation amyloseglutelinlinoleic acid complex resulting pearl millet starch germ complex incorporated wheat bread PMSGH incorporated bread reduced glycaemic index PMSGH incorporated bread significantly p increased hardness reduction springiness cohesiveness structural attribute PMSGH incorporated bread revealed significant p increase cm ratio relative crystallinity consumption functional bread incorporated pearl millet starch germ complex reduced blood glucose level vivo glycaemic index healthy prediabetic participant compared white bread Hence study showed incorporation pearl millet starchgerm complex food product could potential new healthier approach improving dietary option prediabetes care\n",
            "\n",
            "Title: Feasibility acceptability tailored health coaching intervention improve type diabetes selfmanagement Saudi Arabia mixedmethods randomised feasibility trial\n",
            "Abstract: Around onethird population Saudi Arabia diagnosed type diabetes condition often requiring lifestyle change Personalised health coaching strategy developed assist individual overcoming challenge adopt healthy behaviour yet widely applied country\n",
            "\n",
            "Title: Preferred source information diabetes prevention programme populationbased crosssectional study Poland\n",
            "Abstract: study aimed analyse preferred source information diabetes prevention programme identify sociodemographic determinant influencing preference among adult Poland\n",
            "\n",
            "Title: Effect metformin use graft patient survival kidney transplant recipient type diabetes systematic review protocol\n",
            "Abstract: Metformin firstline antihyperglycaemic agent type diabetes TDM addition glycaemic control offer benefit related cardiovascular health weight neutrality metabolic syndrome However benefit kidney transplant recipient remain unclear metformin use controversial population due lack evidence recommendation use patient poor kidney function Hence seek describe protocol systematic review ass impact metformin use graft survival mortality kidney transplant recipient\n",
            "\n",
            "Title: Recommendations Improving health outcome people diabetes Target setting Global Diabetes Compact Indian context Laudable achievable\n",
            "Abstract: \n",
            "\n",
            "Title: Thiamineresponsive megaloblastic anaemia\n",
            "Abstract: report yearold girl diagnosed diabetes mellitus childhood treated insulin history visual disturbance childhood anaemia partially evaluated possibility syndromic diabetes considered Genetic analysis done revealed mutation SLCA gene confirming diagnosis thiamineresponsive megaloblastic anaemia supplemented thiamine dramatically improved haemoglobin level glucose control However vision could salvaged rodcone dystrophy permanent damage\n",
            "\n",
            "Title: LongTerm therapy CFTR modulators consistently improves glucose metabolism adolescent adult Cystic Fibrosis\n",
            "Abstract: Impaired glycemic control subsequent development Cystic fibrosis Related Diabetes CFRD prevalent complication affecting adult cystic fibrosis CF CFTR modulator CFTRm therapy improve pulmonary function reduce exacerbation rate increase survival people CF pwCF appear positive effect extrapulmonary manifestation nutritional state improvement upper respiratory symptom quality life Initial finding indicate CFTRm may positive impact shortterm glycemic control however longterm effect remain uncertain present\n",
            "\n",
            "Title: Chemoprofiling exploring Therapeutic Potential Momordica dioica Roxb ex Willd Managing Metabolic Related Disorders Invitro Studies Docking based Approach\n",
            "Abstract: Momordica dioica Roxb ex Willd dioica Roxb nutritious therapeutic property rich crop Cucurbitaceae plant family various folklore medicine including Ayurveda fruit used treat several metabolic related disorder ie hyperglycemia hyperlipidemia diabetes obesity etc Furthermore traditionally used treat fever inflammation ulcer skin disease haemorrhoid hypertension also employed cardioprotective hepatoprotective analgesic diuretic\n",
            "\n",
            "Title: Resmetirom MASH patient diabetes challenge opportunity real world\n",
            "Abstract: \n",
            "\n",
            "Title: Healing Diabetic Wound Unlocking Secrets Genes Pathways\n",
            "Abstract: Diabetic wound DWs open sore occur anywhere diabetic patient body often complicated infection hypoxia oxidative stress hyperglycemia reduced growth factor nucleic acid healing process involves four phase homeostasis inflammation proliferation remodeling regulated various cellular molecular event Numerous gene signaling pathway VEGF TGF NFB PPAR MMPs IGF FGF PDGF EGF NOX TLR JAKSTAT PIKAkt MAPK ERK JNK p Wntcatenin Hedgehog Notch Hippo FAK Integrin Src pathway involved event pathway gene often dysregulated DWs leading impaired healing present review shed light pathogenesis healing process signaling pathway gene involved DW various therapeutic strategy target pathway gene via nanotechnology also discussed Additionally clinical trial DW related gene therapy also covered present review\n",
            "\n",
            "Title: Cardiovascular outcome patient homozygous familial hypercholesterolaemia lipoprotein apheresis initiated childhood longterm followup international cohort two registry\n",
            "Abstract: Homozygous familial hypercholesterolaemia HoFH rare genetic disease characterised extremely high plasma LDL cholesterol birth causing atherosclerotic cardiovascular disease young age Lipoprotein apheresis combination lipidlowering drug effectively reduce LDL cholesterol longterm health outcome treatment unknown aimed investigate longterm cardiovascular outcome associated lipoprotein apheresis initiated childhood adolescence\n",
            "\n",
            "Title: Mechanoresponsive ETS cause endothelial dysfunction arterialization varicose vein via NOTCHDLL signaling\n",
            "Abstract: Varicose vein common venous disorder human characterized hemodynamic instability due valvular insufficiency orthostatic lifestyle factor unclear change biomechanical signal cause aberrant remodeling vein wall previous study suggest Notch signaling implicated varicose vein arterialization arterial system mechanoresponsive ETS transcriptional activator endothelial Notch involvement sensing disrupted venous flow varicose vein formation investigated use human varicose vein cultured human venous endothelial cell show disturbed venous shear stress activates ETSNOTCHDLL signaling Notch component highly expressed neointima whereas ETS upregulated histological layer varicose vein vitro microfluidic flowbased study demonstrate even minute change venous flow pattern enhance ETSNOTCHDLL signaling Uniform venous shear stress albeit inherently lowflow system induce ETS Notch protein ETS activation altered flow mediated primarily MEK lesser extent MEK independent p MAP kinase Endothelial cellspecific ETS knockdown prevented disturbed flowinduced NOTCHDLL expression TK inhibitor ETSfamily prevented acquisition arterial molecular identity loss endothelial integrity cell exposed ensuing altered shear stress conclude ETS sens blood flow disturbance may promote venous remodeling inducing endothelial dysfunction Targeting ETS rather downstream Notch protein could effective safe strategy develop varicose vein therapy\n",
            "\n",
            "Title: heart beyond Mitochondrial dysfunction heart failure preserved ejection fraction HFpEF\n",
            "Abstract: Heart failure preserved ejection fraction HFpEF major cardiovascular disorder increasing prevalence limited range targeted treatment option HFpEF derived several different etiology much current growth disease driven metabolic dysfunction eg obesity diabetes hypertension Deleterious change mitochondrial energy metabolism common feature HFpEF may help drive progression disease brief article aim review various aspect cardiac mitochondrial dysfunction HFpEF discus emerging topic HFpEFdriven mitochondrial dysfunction tissue beyond heart examine whether supporting mitochondrial function may therapeutic approach arrest reverse disease development\n",
            "\n",
            "Title: Sodiumglucose cotransporter inhibitor attenuate vascular calcification suppressing endoplasmic reticulum protein thioredoxin domain containing dependent osteogenic reprogramming\n",
            "Abstract: Vascular calcification strongly linked development major adverse cardiovascular event effective treatment lacking Sodiumglucose cotransporter SGLT inhibitor emerging category oral hypoglycemic drug displayed marked effect metabolic cardiovascular disease including recently reported vascular medial calcification However role underlying mechanism SGLT inhibitor vascular calcification fully elucidated Thus aimed determine whether SGLT inhibitor protect vascular calcification investigate mechanism involved\n",
            "\n",
            "Title: JinLiDa granule alleviates cardiac hypertrophy inflammation diabetic cardiomyopathy regulating TP\n",
            "Abstract: JinLiDa granule JLD traditional Chinese medicine TCM used treat type diabetes mellitus Qi Yin deficiency Clinical evidence shown JLD alleviate diabetic cardiomyopathy exact mechanism yet clear\n",
            "\n",
            "Title: singlecell profile reveals transcriptional regulation responded Abelmoschus manihot L treatment diabetic kidney disease\n",
            "Abstract: Huangkui capsule HKC ethanol extract Abelmoschus manihot L significant efficacy treatment patient diabetic kidney disease DKD bioactive ingredient HKC mainly include flavonoid rutin hyperoside hibifolin isoquercetin myricetin quercetin quercetinOrobinobioside\n",
            "\n",
            "Title: Diagnosis Management Periprosthetic Joint Infections Total Ankle Arthroplasty\n",
            "Abstract: Periprosthetic joint infection PJI total ankle arthroplasty TAA dreaded complication may lead catastrophic outcome Risk factor include history surgery operated ankle low preoperative function score diabetes extended surgical time postoperative woundhealing problem Clinical presentation varies may include increasing ankle pain swelling high temperature local erythema wound drainage dehiscence initial diagnostic evaluation include plain radiograph erythrocyte sedimentation rate Creactive protein level leukocyte count suspected case elevated erythrocyte sedimentation rate Creactive protein aspiration ankle joint synovial fluid analysis Gram staining culture performed Antibiotic therapy based pathogen identified surgical strategy determined based time line PJI Early PJI treated irrigation dbridement polyethylene exchange surgical treatment choice late PJI twostage revision arthroplasty includes removal implant insertion antibiotic spacer reimplantation TAA certain chronic PJI case permanent articulating antibiotic spacers left place ankle arthrodesis performed Belowknee amputation considered final option limbsparing procedure failed\n",
            "\n",
            "Title: Clinical presentation antimicrobial resistance treatment outcome Aeromonas human infection year retrospective study comparative genomics two isolates fatal case\n",
            "Abstract: Aeromonas virulence may entirely dependent host immune status Pathophysiologic determinant disease progression severity remain unclear\n",
            "\n",
            "Title: effect calcaneus metatarsal head offloading insole healthy subject gait kinematics kinetics asymmetry implication plantar pressure management pilot study\n",
            "Abstract: global number people diabetes estimated reach million present diabetic foot ulceration Insoles offload highrisk ulcerative region foot removing insole material main contemporary conservative treatment maintain mobility reduce likelihood ulceration However effect rest foot relationship key gait propulsive balance kinematics kinetics well researched\n",
            "\n",
            "Title: Bacteriological analysis antibiotic resistance patient diabetic foot ulcer Dhaka\n",
            "Abstract: primary objective study isolate bacteria diabetic foot ulcer subsequently ass antibiotic resistance capability Seventyfive patient diagnosed diabetic foot ulcer investigated number patient type diabetes significant proportion diagnosed year Notably substantial number individual insulin usage Among patient examination reported use tobacco product alcohol betel leaf ulcer analyzed study classified grade according Wagner scale Wagner grade diabetic foot ulcer highest number culturepositive patient Pus sample collected patient cultured selective medium bacterial identity confirmed biochemical test polymerase chain reaction total isolates isolated Among isolates gramnegative bacteria grampositive bacteria detected Klebsiella pneumoniae common isolate Proteus spp Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus also detected Approximately ulcer exhibited polybacterial study observed bacterial isolates except Proteus spp primarily detected patient classified Wagners grade Moreover antibiotic susceptibility also tested isolates Among Escherichia coli showed highest multidrug resistance gramnegative bacteria resistant ampicillin gramnegative isolates exhibited high level susceptibility piperacillintazobactam level Klebsiella pneumoniae Pseudomonas aeruginosa Escherichia coli Proteus spp hand grampositive Staphylococcus aureus mostly showed sensitivity towards vancomycin norfloxacin\n",
            "\n",
            "Title: Electrolyte disturbance patient hospitalized COVID infection observational study\n",
            "Abstract: multiple mechanism Coronavirus COVID infection cause electrolyte abnormality may case bacterial cause pneumonia study aimed ass difference electrolyte level patient suffering COVID bacterial pneumonia original retrospective study Two cohort hospitalized patient included suffering COVID bacterial pneumonia day day level sodium potassium magnesium phosphorus well outcome extracted chart Statistical analysis subsequently performed Mean admission level sodium potassium phosphorus magnesium respectively mean day level electrolyte respectively Patients suffering bacterial pneumonia significantly older N mean patient COVID pneumonia N mean Bacterial pneumonia group significantly higher serum potassium N mean magnesium N mean level compared COVID group N mean potassium N mean magnesium magnesium significantly higher among day electrolyte bacterial pneumonia group significant association electrolyte level outcome seen found COVID patient lower potassium magnesium level admission possibly due effect COVID reninangiotensinaldosterone system well patient characteristic management find enough evidence recommend using electrolyte level determinator prognosis research needed\n",
            "\n",
            "Title: Influence continuous C nursing quality life selfcare ability patient diabetes retinopathy observational study\n",
            "Abstract: study aim investigate impact continuous C nursing patient diabetes retinopathy DR influence selfcare ability total DR patient admitted hospital October October randomly divided control group observation group case group control group received routine care observation group received continuous C care nursing effect group compared nursing observation group showed lower selfrating anxiety scale score higher selfcare ability scale score compared control group P SQQLVI score social activity also higher observation group P Additionally observation group lower level fasting blood glucose hour postprandial blood glucose glycated hemoglobin control group P Moreover observation group higher visual acuity lower intraocular pressure control group P visual impairment rate lower overall compliance rate higher observation group compared control group P nursing group showed improvement symptom visual function physical function psychological social activity score visual acuity patient satisfaction score observation group showed greater improvement compared control group P application continuous C nursing DR patient shown positive effect including improved patient compliance satisfaction enhanced patient quality life visual acuity finding suggest continuous C nursing widely promoted applied clinical practice\n",
            "\n",
            "Title: Regulatory pattern Chinese patent medicine lipid metabolism disorder patient type diabetes mellitus complicated ischemic stroke systematic review network metaanalysis\n",
            "Abstract: investigate regulatory pattern Chinese patent medicine CPM intervention lipid metabolism disorder patient type diabetes mellitus TDM complicated ischemic stroke\n",
            "\n",
            "Title: Incretinbased drug decrease incidence prostate cancer type diabetic poolingup analysis\n",
            "Abstract: Incretinbased drug class Antidiabetic medication ADMs used treatment type diabetes may affect incidence prostate cancer PCa realworld evidence possible effect lacking Therefore aim study ass effect incretinbased drug incidence PCa including glucagonlike peptide GLP receptor agonist dipeptidyl peptidase DPP inhibitor searched PubMed Embase Cochrane Library database eligible study September Two independent reviewer performed screening data extraction used Cochrane Handbook Systematic Reviews NewcastleOttawa Scale NOS ass quality included randomized controlled trial RCTs cohort study metaanalysis available trial data calculate overall risk ratio RRs PCa total article identified search screening eligibility highquality study met criterion metaanalysis including RCTs cohort study total patient Compared control group found incretinbased drug reduced relative risk PCa confidence interval CI P subgroup analysis RR value GLP receptor agonist DPP inhibitor CI P CI P respectively Incretinbased drug associated lower incidence prostate cancer may preventive effect prostate cancer patient type diabetes\n",
            "\n",
            "Title: Limb salvage systemic management gouty tophus Case series\n",
            "Abstract: Gout chronic disease characterized deposition monosodium urate crystal Tophi develop individual untreated uncontrolled gout lead ulceration cosmetic problem mechanical obstruction joint movement joint damage musculoskeletal disability Currently treatment gouty tophus controversial challenging surgical internal medical treatment limitation require exploration clinical practice\n",
            "\n",
            "Title: Evaluation adverse reaction induced antituberculosis drug among hospitalized patient Wuhan China retrospective study\n",
            "Abstract: study aim estimate incidence risk factor adverse drug reaction ADRs induced antituberculosis TB drug single center retrospective analysis patient taking antiTB therapy January December hospital conducted Univariate multivariate logistic regression analysis used identify risk factor ADRs induced antiTB drug Among patient receiving antiTB therapy patient showed least ADR induced antiTB drug Hyperuricemia common ADR followed hepatic function test abnormality liver damage gastrointestinal reaction Significant difference P also seen diabetes age treatment duration type TB extrapulmonary therapeutic regimen ADR group nonADR group respectively Multivariate logistic regression analysis showed treatment duration CI P type TB extrapulmonary CI P therapeutic regimen HREZ CI P HRZS CI P HRZ CI P risk factor ADRs induced antiTB drug AntiTB drug usually induced occurrence severe frequent adverse effect hyperuricemia Treatment duration HREZ HRZS HRZ regimen type TB extrapulmonary considered highrisk factor Thus recommended consider optimum management antiTB therapy particularly hyperuricemia monitoring hepatic function test\n",
            "\n",
            "Title: Comparison Adverse ShortTerm Outcomes Forefoot Amputation Based Patient Height\n",
            "Abstract: objective investigation evaluate adverse shortterm outcome partial forefoot amputation specific comparison performed based patient height\n",
            "\n",
            "Title: Association Preulcerative Foot Care Outcomes Diabetic Foot Ulceration\n",
            "Abstract: purpose study determine association preulcerative foot care outcome diabetic foot ulceration DFUs\n",
            "\n",
            "Title: Effectiveness Peripheral Nerve Block Terms Search Standardized Treatment Protocol Diabetic Foot Patients Using Anticoagulants DoubleCenter Study\n",
            "Abstract: Lowerextremity amputation diabetic foot mainly performed general central neuraxial anesthesia Ultrasoundguided peripheral nerve block PNB good alternative especially patient require continuous anticoagulation treatment patient additional comorbidities evaluated bleeding due PNB application patient diabetic foot receiving antiplatelet anticoagulant therapy Perioperative morbidity mortality need intensive care hospitalization analyzed\n",
            "\n",
            "Title: Postoperative OpioidPrescribing Practice Limb Preservation Surgery\n",
            "Abstract: Limb preservation surgery affect Americans annually Current postoperative pain management prescribing practice podiatric physician United States understudied examined prescribing practice limb preservation surgery identify prescriber characteristic may associated postoperative opioidprescribing practice\n",
            "\n",
            "Title: Rate Location Reulceration Reamputation Partial FirstRay Amputation versus Hallux Amputation Diabetic Nondiabetic Populations\n",
            "Abstract: sought determine rate reulceration reamputation individual underwent partial firstray amputation versus hallux amputation diabetic nondiabetic population\n",
            "\n",
            "Title: Utility Advanced LowerExtremity Duplex Using Pedal Acceleration Time Management Threatened Diabetic Foot\n",
            "Abstract: Patients diabetes diffuse infrageniculate arterial disease present chronic limbthreatening ischemia require exact anatomical plan revascularization Advanced pedal duplex used define possible route revascularization addition pedal acceleration time PAT predict success failure medical surgical intervention\n",
            "\n",
            "Title: Intraretinal HyperReflective Foci Almost Universally Present CoLocalize Intraretinal Fluid Diabetic Macular Edema\n",
            "Abstract: diabetic macular edema DME hyperreflective focus HRF linked disease severity progression Using automated approach aimed investigate baseline distribution HRF DME colocalization cystoid intraretinal fluid IRF\n",
            "\n",
            "Title: Improvement Central Serous Chorioretinopathy Following Multiwavelength Photobiomodulation Treatment Case Report\n",
            "Abstract: Central serous chorioretinopathy CSCR condition fluid buildup accumulates underneath retina resulting retinal pigment epithelium RPE detachment vision loss Irreversible retinal functional anatomical change possible consequence Research novel strategy aid recovery interest Photobiomodulation PBM us light wavelength improve cellular function show positive effect several condition including edema\n",
            "\n",
            "Title: Mitochondria targeted esculetin administration improves insulin resistance hyperglycemiainduced atherosclerosis dbdb mouse\n",
            "Abstract: development progression hyperglycemia HG HGassociated atherosclerosis exacerbated mitochondrial dysfunction due dysregulated mitochondriaderived ROS generation recently synthesized novel mitochondriatargeted esculetin MitoEsc tested doseresponse therapeutic efficacy mitigating HGinduced atherosclerosis dbdb mouse comparison simvastatin pioglitazone MitoEsc administration resulted considerable reduction body weight improved glucose homeostasis possibly reducing hepatic gluconeogenesis indicated reduction glycogen content nonesterified free fatty acid NEFA level fructose bisphosphatase FBPase activity Interestingly MitoEsc treatment regulating phosphoIRS phosphoAKT level greatly improved palmitateinduced insulin resistance resulting enhanced glucose uptake adipocytes HepG cell Also importantly MitoEsc administration prevented HGinduced atheromatous plaque formation lipid accumulation descending aorta addition MitoEsc administration inhibited HGmediated increase VACM ICAM MAC level aortic tissue well reduced serum proinflammatory cytokine marker senescence line MitoEsc significantly inhibited monocyte adherence human aortic endothelial cell HAECs treated high glucose reduced high glucoseinduced premature senescence HAECs activating AMPKSIRT pathway contrast MitoEsc failed regulate high glucoseinduced endothelial cell senescence AMPKSIRTdepleted condition Together therapeutic efficacy MitoEsc mitigation hyperglycemiainduced insulin resistance associated atherosclerosis part mediated potentiating AMPKSIRT axis KEY MESSAGES MitoEsc administration significantly mitigates diabetesinduced atherosclerosis MitoEsc improves hyperglycemia HGassociated insulin resistance MitoEsc inhibits HGinduced vascular senescence inflammation aorta MitoEscmediated activation AMPKSIRT axis regulates HGinduced endothelial cell senescence\n",
            "\n",
            "Title: Evaluation Factors Influencing Mortality Patients StevensJohnson Syndrome Toxic Epidermal Necrolysis Multicenter Study Patients\n",
            "Abstract: StevensJohnson syndrome SJS toxic epidermal necrolysis TEN lifethreatening acute mucocutaneous disorder usually triggered drug study aimed evaluate factor affecting mortality patient SJSTEN\n",
            "\n",
            "Title: Cardioprotective effect vaccination hospitalized patient COVID\n",
            "Abstract: COVID vaccination shown prevent reduce severity COVID disease aim study explore cardioprotective effect COVID vaccination hospitalized COVID patient retrospective singlecenter cohort study included hospitalized COVID patient confirmed vaccination status July February assessed outcome acute cardiac event cardiac biomarker level clinical laboratory data analysis covered patient male mean age year fully vaccinated adjustment confounders vaccinated hospitalized COVID patient displayed reduced relative risk acute cardiac event RR CI showed diminished troponin level Cohens CI compared nonvaccinated peer Type diabetes CI existing cardiac disease CI identified significant risk factor emergence acute cardiac event finding suggest COVID vaccination may confer direct indirect cardioprotective effect hospitalized COVID patient\n",
            "\n",
            "Title: Psychometric Properties Automated Insulin Delivery Benefits Burdens Scale AIDBBS Adults Type Diabetes\n",
            "Abstract: evaluate psychometric property patientreported outcome measure Automated Insulin Delivery Benefits Burdens Scale AIDBBS designed ass benefit burden AID use adult type diabetes TD measure hypothesized validity reliability clinical utility predicting likelihood continued use AID system\n",
            "\n",
            "Title: Performance subcutaneous continuous glucose monitoring adult critically ill patient receiving vasopressor therapy\n",
            "Abstract: Background Subcutaneous continuous glucose monitoring CGM may facilitate glucose control ICU aimed ass accuracy CGM Dexcom G arterial blood glucose ABG adult critically ill patient receiving intravenous insulin infusion vasopressor therapy also aimed ass feasibility tolerability CGM setting Methods included ICU patient receiving mechanical ventilation insulin vasopressor therapy Numerical accuracy assessed mean absolute relative difference MARD overall across arterial glucose stratum different noradrenaline equivalent infusion rate time since CGM start MARD considered acceptable Clinical accuracy assessed using Clarke Error Grid CEG analysis Feasibility outcome included number duration interrupted sensor reading due signal loss Tolerability outcome included skin reaction related sensor insertion sensor adhesive Results obtained paired sample patient type diabetes receiving median IQR maximum noradrenaline equivalent infusion rate gkgmin CGM Overall MARD CI CGM reading within CEG zone B MARD value observed ABG outside target range mmoll mgdl noradrenaline equivalent infusion rate gkgmin Accuracy improved time CGM start reaching MARD value hour observed four episode interrupted sensor reading due signal loss ranging minute observed skin reaction related sensor insertion sensor adhesive Conclusions ICU cohort patient receiving vasopressor infusion subcutaneous CGM demonstrated acceptable overall numerical clinical accuracy However suboptimal accuracy may occur outside glucose range mmoll mgdl higher dose vasopressor infusion first hour CGM start\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.feature_extraction.text import TfidfVectorizer\n",
        "\n",
        "# Combine title and abstract for each article\n",
        "combined_texts = [f\"{title} {abstract}\" for title, abstract in preprocessed_articles]\n",
        "\n",
        "# Create TF-IDF vectorizer\n",
        "vectorizer = TfidfVectorizer()\n",
        "\n",
        "# Fit and transform the combined texts\n",
        "X = vectorizer.fit_transform(combined_texts)\n",
        "\n",
        "# Print the shape of the TF-IDF matrix\n",
        "print(f\"TF-IDF matrix shape: {X.shape}\")\n",
        "\n",
        "# Print feature names (optional, but useful for understanding the feature space)\n",
        "feature_names = vectorizer.get_feature_names_out()\n",
        "print(f\"Number of features: {len(feature_names)}\")\n",
        "print(f\"First 10 features: {feature_names[:10]}\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "BBr0_A24pcPa",
        "outputId": "dcfb2fad-324c-4443-a94b-8d667cc9c8dc"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "TF-IDF matrix shape: (50, 1697)\n",
            "Number of features: 1697\n",
            "First 10 features: ['abelmoschus' 'aberrant' 'abg' 'ability' 'abnormality' 'absolute'\n",
            " 'acceleration' 'acceptability' 'acceptable' 'accessible']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.feature_extraction.text import TfidfVectorizer\n",
        "import pandas as pd\n",
        "\n",
        "# Combine title and abstract for each article\n",
        "combined_texts = [f\"{title} {abstract}\" for title, abstract in preprocessed_articles]\n",
        "\n",
        "# Create TF-IDF vectorizer\n",
        "vectorizer = TfidfVectorizer()\n",
        "\n",
        "# Fit and transform the combined texts\n",
        "X = vectorizer.fit_transform(combined_texts)\n",
        "\n",
        "# Convert the TF-IDF matrix to a DataFrame for better readability\n",
        "tfidf_df = pd.DataFrame(X.toarray(), columns=vectorizer.get_feature_names_out())\n",
        "\n",
        "# Print the shape of the TF-IDF matrix\n",
        "print(f\"TF-IDF matrix shape: {X.shape}\")\n",
        "\n",
        "# Print the entire TF-IDF matrix\n",
        "print(tfidf_df)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gGjNsQX1qP-s",
        "outputId": "a78d1298-5022-4028-da52-d5cb43324c65"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "TF-IDF matrix shape: (50, 1697)\n",
            "    abelmoschus  aberrant       abg   ability  abnormality  absolute  \\\n",
            "0      0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "1      0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "2      0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "3      0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "4      0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "5      0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "6      0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "7      0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "8      0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "9      0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "10     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "11     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "12     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "13     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "14     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "15     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "16     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "17     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "18     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "19     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "20     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "21     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "22     0.000000  0.046816  0.000000  0.000000     0.000000  0.000000   \n",
            "23     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "24     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "25     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "26     0.309889  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "27     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "28     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "29     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "30     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "31     0.000000  0.000000  0.000000  0.000000     0.044556  0.000000   \n",
            "32     0.000000  0.000000  0.000000  0.130088     0.000000  0.000000   \n",
            "33     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "34     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "35     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "36     0.000000  0.000000  0.000000  0.000000     0.051645  0.000000   \n",
            "37     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "38     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "39     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "40     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "41     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "42     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "43     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "44     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "45     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "46     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "47     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "48     0.000000  0.000000  0.000000  0.000000     0.000000  0.000000   \n",
            "49     0.000000  0.000000  0.088631  0.000000     0.000000  0.044316   \n",
            "\n",
            "    acceleration  acceptability  acceptable  accessible  ...    worse  \\\n",
            "0       0.000000       0.000000    0.000000    0.000000  ...  0.13485   \n",
            "1       0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "2       0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "3       0.000000       0.000000    0.000000    0.140046  ...  0.00000   \n",
            "4       0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "5       0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "6       0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "7       0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "8       0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "9       0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "10      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "11      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "12      0.000000       0.150157    0.000000    0.000000  ...  0.00000   \n",
            "13      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "14      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "15      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "16      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "17      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "18      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "19      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "20      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "21      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "22      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "23      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "24      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "25      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "26      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "27      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "28      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "29      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "30      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "31      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "32      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "33      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "34      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "35      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "36      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "37      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "38      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "39      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "40      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "41      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "42      0.278367       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "43      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "44      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "45      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "46      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "47      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "48      0.000000       0.000000    0.000000    0.000000  ...  0.00000   \n",
            "49      0.000000       0.000000    0.088631    0.000000  ...  0.00000   \n",
            "\n",
            "       wound  woundhealing     wuhan      year   yearold       yet       yin  \\\n",
            "0   0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "1   0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "2   0.627713      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "3   0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "4   0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "5   0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "6   0.000000      0.000000  0.000000  0.041714  0.000000  0.000000  0.000000   \n",
            "7   0.000000      0.000000  0.000000  0.000000  0.000000  0.033335  0.000000   \n",
            "8   0.000000      0.000000  0.000000  0.000000  0.000000  0.069292  0.000000   \n",
            "9   0.000000      0.000000  0.000000  0.000000  0.000000  0.045586  0.000000   \n",
            "10  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "11  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "12  0.000000      0.000000  0.000000  0.000000  0.000000  0.111238  0.000000   \n",
            "13  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "14  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "15  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "16  0.000000      0.000000  0.000000  0.000000  0.138281  0.000000  0.000000   \n",
            "17  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "18  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "19  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "20  0.136406      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "21  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "22  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "23  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "24  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "25  0.000000      0.000000  0.000000  0.000000  0.000000  0.122757  0.165706   \n",
            "26  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "27  0.057832      0.069138  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "28  0.000000      0.000000  0.000000  0.155385  0.000000  0.000000  0.000000   \n",
            "29  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "30  0.000000      0.000000  0.000000  0.045561  0.000000  0.000000  0.000000   \n",
            "31  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "32  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "33  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "34  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "35  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "36  0.000000      0.000000  0.057108  0.000000  0.000000  0.000000  0.000000   \n",
            "37  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "38  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "39  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "40  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "41  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "42  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "43  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "44  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "45  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "46  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "47  0.000000      0.000000  0.000000  0.053547  0.000000  0.000000  0.000000   \n",
            "48  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "49  0.000000      0.000000  0.000000  0.000000  0.000000  0.000000  0.000000   \n",
            "\n",
            "     young      zone  \n",
            "0   0.0000  0.000000  \n",
            "1   0.0000  0.000000  \n",
            "2   0.0000  0.000000  \n",
            "3   0.0000  0.000000  \n",
            "4   0.0000  0.000000  \n",
            "5   0.0000  0.000000  \n",
            "6   0.0000  0.000000  \n",
            "7   0.0000  0.000000  \n",
            "8   0.0000  0.000000  \n",
            "9   0.0000  0.000000  \n",
            "10  0.0000  0.000000  \n",
            "11  0.0000  0.000000  \n",
            "12  0.0000  0.000000  \n",
            "13  0.0000  0.000000  \n",
            "14  0.0000  0.000000  \n",
            "15  0.0000  0.000000  \n",
            "16  0.0000  0.000000  \n",
            "17  0.0000  0.000000  \n",
            "18  0.0000  0.000000  \n",
            "19  0.0000  0.000000  \n",
            "20  0.0000  0.000000  \n",
            "21  0.1124  0.000000  \n",
            "22  0.0000  0.000000  \n",
            "23  0.0000  0.000000  \n",
            "24  0.0000  0.000000  \n",
            "25  0.0000  0.000000  \n",
            "26  0.0000  0.000000  \n",
            "27  0.0000  0.000000  \n",
            "28  0.0000  0.000000  \n",
            "29  0.0000  0.000000  \n",
            "30  0.0000  0.000000  \n",
            "31  0.0000  0.000000  \n",
            "32  0.0000  0.000000  \n",
            "33  0.0000  0.000000  \n",
            "34  0.0000  0.000000  \n",
            "35  0.0000  0.000000  \n",
            "36  0.0000  0.000000  \n",
            "37  0.0000  0.000000  \n",
            "38  0.0000  0.000000  \n",
            "39  0.0000  0.000000  \n",
            "40  0.0000  0.000000  \n",
            "41  0.0000  0.000000  \n",
            "42  0.0000  0.000000  \n",
            "43  0.0000  0.000000  \n",
            "44  0.0000  0.000000  \n",
            "45  0.0000  0.000000  \n",
            "46  0.0000  0.000000  \n",
            "47  0.0000  0.000000  \n",
            "48  0.0000  0.000000  \n",
            "49  0.0000  0.044316  \n",
            "\n",
            "[50 rows x 1697 columns]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "7_a6FnRMqgzF"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}